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A systematic review identified limited studies exploring oral formulation-related barriers to 
medicines administration in children. Owing to the lack of licensed medicines suitable for 
use in children, manipulation is often required to deliver a specific dose or to facilitate 
medicines administration. Little is known regarding the prevalence and nature of issues 
encountered when administering medicines to children in the domiciliary setting. 
  
This study adopted a pragmatic approach to determine the nature and prevalence of oral 
formulation-related barriers to medicines administration in children suffering from a range 
of chronic conditions. Problems reported by healthcare professionals, patients and their 
parents/carers were identified to inform future pharmaceutical development and improve 
children’s medicines. 
 
Focus groups (n=4) were conducted with healthcare professionals in the West Midlands and 
semi-structured face-to-face interviews (n=278) were conducted with parents/carers/young 
people at University Hospitals Coventry and Warwickshire. Questions explored barriers to 
medicines administration, refusal and manipulation.  
 
In total, 31% of interview respondents reported medicines refusal. Taste was the most 
commonly reported barrier to medicines administration. Almost one fifth (19%) of medicines 
administered to children were reported to require manipulation. Findings indicate that age-
appropriate medicines are required to provide both suitable dose units and acceptable taste 
for paediatric patients. 
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1 
1 BACKGROUND TO THE THESIS 
Approximately 200 million prescriptions are issued annually for children and young people in 
the UK (Costello et al., 2004). It has been estimated that 5 - 10% of young people worldwide 
suffer from chronic, impairing health conditions (Newacheck et al., 2000).  
Adherence is defined as 
‘the extent to which a person’s behaviour – taking medication, following a diet, and/or 
executing lifestyle changes, corresponds with agreed recommendations from a health care 
provider.’ (WHO, 2003) 
 
There is evidence to suggest that adherence with prescribed medication is lower amongst 
adolescents and children than in adults (Staples and Bravender, 2002). Medication 
adherence rates between 11% and 93% in paediatric patients have been reported (Winnick 
et al., 2005). A median rate of 58% medicine adherence in youth has been estimated 
(Burkhart and Dunbar-Jacob, 2002). 
Adherence is a multi-factorial phenomenon (WHO, 2003) resulting from multiple influencing 
factors. There is little indication of the true prevalence of adherence issues caused by 
inappropriate formulations for children, yet it is a problem that is highlighted by many 
parents and healthcare professionals (Lowey and Jackson, 2008). Several studies have 
investigated medicines adherence in children, however they have not explored all of the 
potential barriers to achieving adherence. A greater understanding of why carers of children 
find some medicines more difficult to administer, and why some are refused is required. 
Children with long-term conditions often need to follow a complex medication regimen. 
They require medicines to be given in accurate dosages often at specific times and/or time 
2 
intervals for critical conditions, using drugs with potentially serious adverse profiles and 
those with a narrow therapeutic index. 
It is well known that many medicines prescribed for children in the UK are used without a 
medicines licence (unlicensed) or outside the terms of a medicines licence (off-label). 
A survey of unlicensed and off-label drug use on paediatric wards across five European 
countries reported that 46% of prescribed medicines were either unlicensed or off-label 
(Conroy et al., 2000). Reports from the primary care setting found that between 10% and 
28.9% of medicines prescribed to children were unlicensed or off-label (Jong et al., 2002, 
Stevenson, 2008).  
Issues with adult formulations used in children including taste and the size of solid unit 
dosage forms have been identified to cause clinical problems (Kendall and Mehta, 2006). 
This often necessitates the use of unsuitable formulations in children which may lead to 
inappropriate modifications to medicines to facilitate medicines administration. The 
manipulation of dosage forms can be the cause of drug errors (Florence, 2008). The 
therapeutic effects of many medicines rely on the integrity of the dosage form  in which they 
are presented, thus altering or damaging these can lead to unexpected or inappropriate 
outcomes e.g. crushing sustained release tablets can cause inappropriate release of large 
amounts of medication. 
Studies have shown how crushing tablets can affect efficacy and compliance (Cornish, 2005). 
Adding medicines to fruit juices or milk in order to mask the flavour can affect the 
bioavailability of a drug (Akinleye et al., 2007). However, limited information is available 
regarding how children and carers adapt various prescribed medicines to increase 
3 
acceptability, and the effects that these actions may have on the drug formulation and its 
pharmacokinetics and pharmacodynamics (Winnick et al., 2005). This may be a decision 
parents, carers and patients make independently or following recommendation from a 
healthcare professional. 
Studies investigating medicine manipulations in children have reported that approximately 
10% of medicines for children are manipulated in a ward environment to administer 
medicines to children (Skwierczynski and Conroy, 2008) and to obtain accurate doses (Richey 
et al., 2011). However, a paucity of evidence is available exploring the prevalence and nature 
of medicines manipulation for the purpose of administering a specific dose or to facilitate 
medicines administration to children in the domiciliary setting. 
Limited data is available regarding the impact of oral formulation properties (i.e. 
organoleptic, taste, texture, smell, colour/appearance and physical, size and difficulties with 
swallowing) of individual medicines on child acceptance. Poor acceptance could lead to child 
resistance or medicines refusal. However, the palatability of paediatric oral medicines is one 
of the most important factors with potential to influence adherence to therapeutic regimens 
and outcomes (Salunke et al., 2011). The importance and great incentive to study 
palatability was discussed in the reflection paper (EMEA, 2006) and endorsed in the latest 
European Paediatric guideline on pharmaceutical development of medicines for paediatric 
use (EMA, 2013). In the Paediatric Investigation Plan (PIP) guidelines, taste-masking and 
palatability are at the forefront in the implemented development of new paediatric 
medicines (European Commission, 2008).  
4 
International studies have explored oral formulation-related barriers to medicines 
administration in specific disease groups (e.g. antiretroviral medicines in Human 
immunodeficiency virus - HIV patients) (Boni et al., 2000, Gibb et al., 2003, Goode et al., 
2003, Marhefka et al., 2004, Pontali et al., 2001, Wrubel et al., 2005). Further studies 
compare the acceptance and flavour preferences of a spectrum of drugs from one class (e.g. 
antibiotics) using a ‘one-off’ taste test method, commonly with the aid of a visual analogue 
scale (VAS) and often in healthy children or adults (Bagger-Sjöbäck and Bondesson, 1989, 
Chan et al., 1997, Cohen et al., 2009, El-Chaar et al., 1996, Samulak et al., 1996, Toscani et 
al., 2000). 
It was necessary to conduct a pragmatic study, exploring oral formulation-related problems 
with individual oral medicines in a large paediatric population suffering from different 
chronic conditions. Determining the nature and prevalence of oral formulation-related 
barriers to medicines administration and their influence on medicines refusal by children 
was needed. 
It was anticipated that study findings would direct drug formulation development with the 
objective of improving future medicines for children, maximising cost-benefit of effort. As 
most of the formulation properties of interest to the present study (i.e. taste, smell, texture, 
volume, size, and swallowing solid dosage forms) relate predominantly to administering oral 
medicines, investigation of oral medicines was pertinent to this study. 
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2 INTRODUCTION 
2.1 Compliance, Adherence and Concordance 
The term compliance is defined as ‘The extent to which the patient’s behaviour matches the 
prescriber’s recommendations’ (Haynes and Sackett, 1979) and involves the patient playing 
a passive role, following the instructions of a medical professional. The term adherence has 
been adopted from compliance, to include the active role of a patient in their health care, in 
which healthcare professional, patient and parent/carer form a partnership. The term 
adherence implies that the patient/parent/carer is free to choose whether they follow the 
advice of a healthcare professional and they should not be blamed if they decide against this 
(Horne et al., 2005). 
Often the terms compliance and adherence are used interchangeably, however this is 
inappropriate as adherence implies that patient, parent/carer, and medical professional are 
collaboratively involved in healthcare decisions unlike compliance (Matsui, 2007b). 
Concordance indicates a consensual agreement about taking medicines formed between 
patient and practitioner in which the beliefs of the patient are of paramount importance 
(Haynes et al., 2008). 
To summarise, the key difference when considering the concepts concordance, compliance 
and adherence, is that adherence involves patients, parents and carers taking an active, 
rather than a passive role in decision-making before following a medication regimen.  By 
defining adherence as a concept that encompasses both elements of concordance and 
compliance, healthcare professionals are able to understand and consider interactions with 
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patients, to provide ways to help patients overcome barriers to their medication regimes 
and to quantify a level of adherence (Lehane and McCarthy, 2009). The term adherence will 
be used throughout this thesis. 
2.2 Medicines adherence  
Adherence is intended to be a statement of fact, and non-judgemental, not to blame 
treatment, prescriber or patient (Haynes et al., 2008). To promote adherence, shared 
decision-making between healthcare professional and parent/carer and child is needed and 
this is not always achieved. To support adherence it is important to ensure effective 
communication between healthcare professionals and parents/carers/patients, that 
parents/carers/patients are involved in decision-making and that patients understand their 
condition/s and treatment and make an informed choice based on this (NICE, 2009). 
Medicines adherence rates in paediatric patients ranging from 11 to 93% have been 
reported (Winnick et al., 2005) with a median rate of 58% (Burkhart and Dunbar-Jacob, 
2002). Rates of medicines adherence in young people and children are generally below 50% 
(Quittner et al., 2008). 
Adherence is a multidimensional phenomenon involving five factors related to the health 
system and healthcare team, condition, patient, therapy, and social/economics (WHO, 
2003). These factors are displayed in Figure 1. 
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Figure 1 The five factors of adherence (WHO, 2003). 
The factors affecting medicines adherence in children and young people are similar to those 
in adults, yet in children, medicines adherence is more complex due to the added dimension 
of a patient’s family (Osterberg and Blaschke, 2005). 
Parents and carers can influence medicines adherence in children as often they are 
responsible for administering medicines until a child begins to take more responsibility. 
Generally parents take full responsibility for a young child, and this changes to a shared 
medication management routine as a child becomes more independent at school age to a 
complete self-management stage at adolescence. However, the age at which a young person 
becomes fully responsible for self-administration varies on an individual basis, and is not 
related to age, rather more maturity (WHO, 2003). 
It is important for healthcare professionals to understand how families manage the 
responsibility of administering medicines as this may influence medicines adherence. 
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Investigating whether parents, carers and young people are independently responsible for 
administering medicines or if the role is shared is vital when exploring medicines adherence. 
Medicines adherence can be affected by varying levels of parental supervision, busy lives 
and dysfunctional families (Matsui, 2007b). Several paediatric studies in patients with 
chronic conditions have indicated that family-related factors can affect medicines adherence 
(Gau et al., 2006, Mackner and Crandall, 2005, Mellins et al., 2004, C.A. Shah, 2007).  
Adherence to medicines can be challenging for young people (Osterberg and Blaschke, 
2005). Factors affecting medicines adherence in young people include cognitive, emotional 
and psychological factors, patient education, family functioning, peer influence, healthcare 
team (i.e. communication style), the healthcare setting, complexity of the therapeutic 
regimen and interference of the treatment with needs and lifestyles of the young person 
(Michaud et al., 2004). Particularly, research on juvenile diabetes, haemophilia and 
rheumatoid arthritis has revealed the potential vulnerability of young people to medication 
non-adherence (WHO, 2003).  
2.2.1 Measuring medicines adherence 
The level of medicines adherence critical for effective disease control varies across different 
chronic conditions, even though optimal adherence is always 100%, except when drug-
plasma levels indicate otherwise. Zelikovsky and co-workers (2008) studying young people 
listed for a renal transplant suggest an 80% - 90% adherence cut-off to classify adherent 
patients. A higher adherence cut-off of 95% has been reported in adult HIV guidelines in 
order to optimise therapeutic outcomes (Carpenter et al., 2000). 
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Adherence can be measured using indirect and direct methods. Drug assays, and body fluid 
levels of drug or markers are examples of direct methods. These produce quantifiable data 
and are objective methods, however there are disadvantages to these such as cost, drug 
interactions (including foodstuff-drug interactions) affecting results, individual drug 
metabolising abilities and drug absorption rates (Riekert and Drotar, 2000). 
Other direct methods include ‘pill counts’ and electronic monitoring. Electronic monitoring 
involves attaching electronic devices to containers of liquids or solid dosage forms, metered 
dose inhalers and nebulisers, which create a record of the time and date each time they are 
opened or used respectively. This data can be evaluated and the level of adherence 
calculated (Butz, 2006). Problems with these exist, for example patients failing to return 
solid dosage forms that they have not taken, or opening containers but discarding the 
contents. In spite of this, electronic monitoring has become the gold standard for measuring 
adherence (Riekert and Drotar, 2000). There are limitations to using this technique in a 
pragmatic study, these include cost, patients being made aware that they are being 
monitored and the inability to provide information on the type of non-adherence behaviour.  
Indirect methods of assessing adherence include self-reports (e.g. face-to-face interviews, 
questionnaires), i.e. questioning whether a patient has taken medicines or not and physician 
rating. These are low cost interventions and easier to perform. Concerns have been raised 
with regard to the validity of indirect methods as adherence may be overestimated because 
of social desirability (i.e. reporting to a clinician ‘what they want to hear’) (Butz, 2006). 
However, findings from studies comparing indirect and direct assessment methods to 
measure adherence have reported similar results when using different methods (Riekert and 
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Drotar, 2000). One example is an adult study by Haynes and co-workers (1980) in which, 75% 
of patients adherent to their anti-hypertensive medication based on tablet counts were 
correctly identified as adherent through direct questioning. In addition, 90% of patients 
reporting that they were non-adherent were non-adherent according to tablet counts 
(Haynes et al., 1980).  
2.2.2 Non-adherence 
Non-adherence can be unintentional or intentional. An explanation of both concepts is 
provided in Figure 2 below. 
   
 
  
 
 
Figure 2 A diagram displaying the factors that influence unintentional and intentional non-
adherence (Adapted from Horne and co-workers (2005)). 
2.2.2.1 Unintentional non-adherence 
Ability and resource barriers may impede adherence, these include forgetfulness, physical 
difficulties with opening containers or using inhalers, not understanding the concept of 
obtaining a repeat prescription and issues with medicines administration affecting normal 
daily activities. Practical aspects causing unintentional non-adherence include administration 
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difficulties such as if the patient is physically unable to swallow solid dosage forms (Horne et 
al., 2005). 
2.2.2.2 Intentional non-adherence 
Intentional non-adherence is a deliberate act, in which a patient may be described as a 
rejector, (i.e. does not take medicines at all) or a modifier (changes the dose or frequency of 
medicines administration) (Horne et al., 2005).  
2.3 Introduction to oral formulation-related barriers to medicines 
administration 
There are many reasons related to drug therapy that could reduce adherence to a prescribed 
treatment plan. Instructions may be misunderstood or misinterpreted, medicines forgotten 
and adverse effects perceived to be worse than the disease itself (notably in the case of 
asymptomatic conditions). Worries about becoming dependent upon medicines, believing 
that medication will not help to improve the condition and denial of the disease itself are all 
potential reasons for sub-optimal adherence (WHO, 2003). 
Oral medicines may be refused by children for a variety of reasons. Reasons for refusing oral 
medicines are displayed in Figure 3 below. 
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Figure 3 Reasons for child refusal of oral medicines. 
Poor child acceptance of medicines may not result in complete omission of a dose of 
medicine, yet delay administration or cause unnecessary stress for parent or carer and child.  
According to the European Medicines Agency (EMA) (EMEA, 2006), the palatability of 
paediatric oral medicines is considered one of the most important factors with potential to 
influence adherence to therapeutic regimens and outcomes. 
In several studies, palatability has been reported to affect acceptance of or adherence to 
medicines in children. However these studies conducted one-off taste-tests with healthy 
children or adult volunteers (Bagger-Sjöbäck and Bondesson, 1989, Chan et al., 1997, Cohen 
et al., 2009, El-Chaar et al., 1996, Samulak et al., 1996, Toscani et al., 2000) or investigated 
problems with organoleptic properties of medicines in specific paediatric populations (e.g. 
children with HIV) (Boni et al., 2000, Gibb et al., 2003, Goode et al., 2003, Marhefka et al., 
2004, Pontali et al., 2001, Wrubel et al., 2005). 
Oral formulation-related barriers: 
organoleptic (e.g. taste, smell, colour) 
and physical (e.g. size and swallowing, 
quantity/volume)  
Perceptive reasons (i.e. side effects, feel 
medicine is not working) 
Too frequent dosing 
Religious, cultural, social views  
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2.4 Licensing of Medicines 
To understand the existence of oral formulation-related barriers to medicines administration 
it is necessary to have a good understanding of the problems associated with the licensing of 
medicines for children. 
European and UK legislation provides marketing authorisation of medicines to ascertain the 
efficacy, safety and quality of medicines. 
A licensed medicine is a medicine that is given a Marketing Authorisation by the Medicines 
and Healthcare products Regulatory Agency (MHRA) once quality, safety and efficacy have 
been assured. For these medicines the manufacturer has responsibility for adverse events 
(Buckham 2010).  
A survey carried out by Neubert and co-workers (2008) confirmed the need for a common 
definition for unlicensed and off-label medicine use which should be incorporated in to 
European legislation. The survey agreed that drugs with a Marketing Authorisation used in 
an unapproved manner should be termed ‘off-label’ and those without a Marketing 
Authorisation termed ‘unlicensed’ (Neubert et al., 2008). 
2.4.1 The prevalence of unlicensed medicines use and off-label prescribing in 
children 
Developing age-appropriate medicines is both time-consuming and technically challenging. 
Stages to drug development include: identifying problematic drugs, using specific 
technologies such as taste-masking, and conducting pharmacokinetic, bioavailability and 
dose-ranging studies (Milne and Bruss, 2008). Additionally, financial and ethical reasons 
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restrict many pharmaceutical companies from performing clinical trials in children (Wong, 
2003).  
The majority of medicines prescribed to children have not been licensed (unlicensed) or are 
medicines used outside of the terms of their licence (off-label) and are commonly adult 
medicines (A. Nunn, 2003).  
Studies conducted in the UK suggest that the use of unlicensed medicines on paediatric 
wards accounts for between 25% and 65% of medicines use (Cuzzolin et al., 2003). 
Unlicensed medicines are also used to treat paediatric patients in general practice. 
Approximately 11% of medicines used in primary care for treating children in the UK are off-
label or unlicensed according to McIntyre and co-workers (2000). 
2.4.2 Specials medicines 
Healthcare professionals may consider it necessary to prescribe or advise the use of an 
unlicensed medicine when no licensed, suitable alternative is available, in which case the 
medicine will often be prepared in a pharmacy by, or under the supervision of a pharmacist 
(extemporaneous medicine) or ordered from a Specials manufacturer (Specials medicine). 
Medicines legislation (specifically, The Medicines for Human Use Marketing Authorisations 
Etc Regulations 1994/SI 3144) states that medicinal products require a licence before they 
are marketed in the UK (MHRA). 
Some patients have special clinical needs that cannot be met by licensed medicinal products 
and therefore, the law allows manufacture and supply of unlicensed medicinal products 
(commonly known as 'Specials') subject to fulfilling the following conditions: 
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 There is a bona fide unsolicited order 
 The product is formulated in accordance with the requirement of a doctor or dentist 
registered in the UK 
 The product is for use by their individual patients on their direct personal 
responsibility. 
A manufacturer's Specials licence issued by the MHRA must be held if a Specials medicine is 
procured in the UK. Advertisement of Specials medicines is not permitted, and a Special 
should not be supplied if an equivalent licensed product is available and suitable. Essential 
records must be kept and serious adverse drug reactions (ADRs) reported to the MHRA 
(MHRA). 
Obstacles to the commercial availability of Specials medicines still prevail. These include 
short shelf-lives and specific storage conditions, creating increased frequency of re-ordering, 
waste medicines, cost and longer time elapses to obtain the medicine from point of ordering 
(Standing and Tuleu, 2005). The inconvenience for parents travelling frequently to and from 
pharmacies and hospitals is a common issue surrounding the supply of Specials medicines. 
When comparing the procurement of Specials and extemporaneous medicines, 
manufacturers of Specials follow quality assurance systems (i.e. record keeping trail and 
tracking of batch numbers, ADR reporting, good manufacturing practice (GMP) and regular 
inspections from legal authorities), to minimise the risk of production errors (Yeung et al., 
2005). Such procedures are not required when dispensing extemporaneously.  
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2.4.3 Extemporaneous medicines 
The compounding of ingredients to prepare an unlicensed medicine for an individual patient 
describes extemporaneous dispensing (A. Nunn, 2003). The preparation of extemporaneous 
medicines does not require a Manufacturer’s Specials licence and can be performed in a 
registered pharmacy (according to section 10 exemption of the Medicines Act) under the 
supervision of a pharmacist (RPS, 2010). 
Extemporaneous medicines are often prepared instead of Specials medicines, owing to 
problems with the supply of Specials medicines. Yeung and co-workers (2005) reported that 
greater than 50% of extemporaneously procured liquids in UK specialist hospitals were 
available to order as Specials. The restrictions on advertising Specials medicines for 
manufacturers (resulting from the lack of regulatory approval on clinical trials regarding 
dosing, efficacy and safety) across the UK make obtaining Specials difficult (Standing and 
Tuleu, 2005). 
It is recognised that children are administered portions of adult doses and tablets crushed or 
capsules opened to ensure that a child receives medicine, although this is inaccurate and 
unsafe practice (WHO, 2009). The manipulation of medicines by parents, carers, young 
people and nurses may be classed as extemporaneous dispensing (Standing and Tuleu, 
2005).   
2.4.4 The problems and risks associated with unlicensed medicines 
Appropriate prescribers are permitted to prescribe unlicensed medicines or medicines off-
label subject to their individual clinical competence, the professional codes and ethics of 
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their statutory bodies, and the prescribing policies of their employers. Additional risks should 
be carefully considered when prescribing an unlicensed medicine or in an off-label manner, 
including: reduced product quality, adverse reactions, inconsistent product information or 
labelling (e.g. absence of Patient Information Leaflets (PILs) and unlicensed imports with 
patient information in a foreign language). Patients and carers can easily become confused 
when a PIL is contradictory with a medicine’s off-label use (MHRA, 2009). 
Unlicensed medicines have a poor quality evidence base in comparison to licensed, 
marketed medicines (Lowey and Jackson, 2008). They may be prepared using a formulation 
in a pharmacopoeia, in other published work or in a local formulary and additionally 
research on chemical, microbiological and physical stability may or may not have been 
carried out (A. Nunn, 2003). The poor evidence base available for extemporaneous 
medicines is associated with risks including the production of non-standardised formulations 
resulting in a lack of uniformity of dosing and possible overdose or underdose (Lowey and 
Jackson, 2008). 
A considerable risk of error exists when preparing extemporaneous medicines. Such errors 
can have serious consequences. One example is the death of a baby following the use of 
concentrated chloroform water by a pre-registration pharmacist (Baby dies after peppermint 
water prescription for colic, 1998). This particular case resulted from the lack of quality 
assurance standards required to prepare medicines extemporaneously. Additionally, 
unsuitable facilities, lack of equipment and materials and the declining expertise of 
pharmacists in pharmaceutics and formulation contribute to risks involved with 
extemporaneous procurement (Lowey and Jackson, 2007). When preparing extemporaneous 
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medicines, calculation errors pose a further risk as units of strength vary (i.e. milligrams, 
micrograms and nanograms) and complex calculations may be needed (Lowey and Jackson, 
2007).  
Both unlicensed and licensed medicines are available in a range of strengths. As unlicensed 
medicines are ordered through specific requests, the variety of strengths is greater. This 
could be perceived as an advantage to administering a specific dose. However, a 10-fold 
difference in available strengths can create confusion and lead to serious dosing errors 
(Koren et al., 1986). One such example involved a child receiving a 10-fold overdose of 
spironolactone following a community pharmacy supplying a formulation ten times stronger 
than a hospital pharmacy (Checking paediatric dosing, 2003).  
Specials production is not a standard reproducible procedure between manufacturers; It 
may vary significantly, so changing suppliers could alter clinical outcomes (Stevenson, 2008). 
Mulla and Co-workers (2007) reviewed captopril liquid formulations used to treat children in 
hospitals and paediatric cardiac centres in the UK. The results indicated that a variety of 
unlicensed liquid captopril formulations were used interchangeably. Concerns regarding the 
bioequivalence of inconsistent captopril liquid formulations and thus the risk of drug toxicity 
were highlighted. Further variations between the formulations were found related to half-
lives, excipients used and solubilities (Mulla et al., 2007). 
Errors occurring during unlicensed medicines administration leading to underdosing or 
overdosing have also been recorded. This could be clinically significant and could cause 
therapeutic failure or toxicity. Liquids prepared extemporaneously or procured as Specials 
come in a variety of strengths (as discussed earlier in this section) which can create 
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confusion for parents. Poor or inconsistent labelling can promote confusion and result in 
errors during medicines administration (Lowey and Jackson, 2008). It should be noted that 
this risk is not confined to the administration of unlicensed medicines. Similar errors can 
occur when administering licensed medicines.  
The risk of experiencing an ADR is higher when using an unlicensed preparation (Turner et 
al., 1999). Often, unlicensed oral medicines are prescribed to patients who are more 
vulnerable to ADRs (i.e. children, infants, premature neonates, and those fitted with 
nasogastric - NG tubes) (Lowey and Jackson, 2007). Close clinical monitoring of ADRs is 
required in such patients who may be unable to alert healthcare professionals of the event 
(Lowey and Jackson, 2007). As there is insufficient evidence for the safety, efficacy and 
quality of unlicensed medicines, the prescriber risks litigation following adverse events 
(Buckham 2010). 
A study conducted with 1,000 members of the public (including 610 parents) in Northern 
Ireland, found that 86% of participants had no previous knowledge of unlicensed medicines 
use in children. The proportion of parents who felt unlicensed medicines were unsafe 
increased from 1.8% to 62.4% after being informed of unlicensed medicine use (Public 
unaware of unlicensed drug use in children, 2009). Parents and carers need to be more 
aware of unlicensed medicine use and alert to the risks associated with this (Public unaware 
of unlicensed drug use in children, 2009). 
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2.4.5 The cost of Specials medicines 
Specials medicines also incur additional costs as they are procured on a ‘produced to order’ 
basis. The limited stability evidence and shortened expiry dates contribute to the medicine 
bill wastage. 
A British Broadcasting Corporation (BBC) report released in September 2010 revealed that 
the cost of Specials to the National Health Service (NHS) increased from £57m to £160.5m in 
four years in England. Data revealed on the inconsistency of pricing showed that 25mg/5mls 
captopril liquid Special had cost Coventry Primary Care Trust between £50 and £1,556. 
Omeprazole liquid Special was reported to cost between £50 and £997. Internal NHS sources 
stated that if each Special had a limit of £75 a saving of almost £72m would be possible 
(Paduano, 2010). 
As of November 2011, changes in reimbursement for Specials medicines ordered to 
pharmacies means that pharmacies are now encouraged to source Specials medicines more 
carefully as those most commonly dispensed are reimbursed based on a Specials tariff 
(NHSBSA, 2011), in attempt to reduce profits. However this will not diminish the problems 
with cost altogether as this does not cover all Specials medicines. 
2.5 Medicines manipulation 
2.5.1 Introduction 
As a result of the lack of appropriate paediatric medicines, healthcare professionals and 
parents often opt to manipulating medicines (T. Shah et al., 2008).  
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Manipulation techniques used to administer medicines are associated with the highest risk 
of errors in extemporaneous dispensing as no compatibility or stability data is available, dose 
bioavailability is unpredictable and they are difficult to monitor (RCPCH, 2004). Medicines 
may be manipulated by nurses at ward level and by parents and carers in the community to 
either facilitate medicines administration (e.g. to improve palatability) or for the purpose of 
administering a specific dose. 
Common examples of manipulation techniques used to administer specific doses of 
medicines to children include diluting concentrated preparations designed for adults and 
segmenting (halving or quartering) tablets (RCPCH, 2004). The limited data that is available 
on manipulating prior to administration is designed for treating geriatric patients or adults 
with difficulties swallowing. The North East Wales NHS Trust (NEWT) guidelines include 
guidance on preparing solid dosage forms for tube administration, however do not report 
evidence for mixing medicines with foodstuffs (Smyth, 2012).  
2.5.2 The prevalence of medicines manipulation 
Skwierczynski and Conroy (2008) investigated drug manipulations performed by nurses on 
paediatric wards in two UK hospitals. They concluded that 9.6% of drugs administered were 
manipulated and 10% of children were administered a manipulated drug. An observational  
study (part of Manipulation Of Drugs In Children - MODRIC study) investigating medicines 
manipulation to obtain accurate doses on wards, revealed that 10.1% of medicine 
administrations required manipulation of a medicine or measurement of a small volume 
(less than 0.2ml) (Richey et al., 2011). 
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An audit conducted in 2001 at Great Ormond Street Hospital in London (GOSH), revealed 
that medicine manipulations (including capsule opening, tablet crushing and cutting) were 
needed to administer 26% of oral doses administered to inpatients (Data unpublished, cited 
by Standing and Tuleu (2005)).  
Tomlin (2007) suggested that parents disguise up to 40% of medicines given to young 
children by putting it in to foods such as jam, honey and yoghurt. However, limited data is 
available on the prevalence and nature of manipulation techniques used to administer 
medicines to children in the domiciliary environment by parents, carers and young people. 
2.5.3 Physicochemical and bioavailability changes associated with medicines 
manipulation 
Manipulating medicines could help to promote adherence, however it could equally 
compromise bioavailability, stability, and safety of a medicine. Several studies have reported 
that splitting, crushing or tampering with solid dosage forms prior to administration can lead 
to inaccurate dosing. 
Teng and co-workers (2002) demonstrated that when a tablet is split, the weight can range 
from 50 to 150% of the desired half-tablet weight. Similarly, Cook and co-workers (2004) 
studied the effects of splitting tablets and found that the fragment weight of unscored 
cyclobenzaprine tablets using a tablet cutter may range between 69.4% and 130.2% of the 
anticipated weight. These examples highlight the risk of unpredictable dosing when 
segmenting tablets which could affect the therapeutic response of a drug. 
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Breitkreutz and co-workers (1999) reported that drug absorption can be affected if tablets 
are crushed. Similarly, crushing tablets was found to increase drug potency in a study by 
Cornish (2005). Additionally, when non-soluble solid dosage forms are dispersed in liquids, 
poor uniformity of the drug in solution can lead to inaccurate dosing resulting from the poor 
solubility of dosage form excipients. 
Certain solid dosage forms should not be manipulated prior to administration, specifically 
controlled release preparations and enteric coated tablets. This can significantly alter drug 
bioavailability and affect clinical response (Lowey and Jackson, 2007). The manipulation of 
solid dosage forms promotes further risks including the inhalation of dusts and powders 
during the process, leading to exposure of parents and carers to potentially harmful 
substances, e.g. carcinogenics (RPS, 2011). 
Although it is known that parents and carers mix medicines with various foodstuffs prior to 
administration to improve child acceptance, it has been acknowledged that for the vast 
majority of substances utilised to increase palatability and medicines adherence, there is no 
data available (Craig et al., 2009). There is limited published data regarding the 
pharmaceutical effects of adding drugs to various foodstuffs (Akinleye et al., 2007, Cacek, 
1986, Carrier et al., 2004, Fay et al., 2005, Johnson et al., 2003, Notterman et al., 1986, T. 
Shah et al., 2008, Wells and Losin, 2008). 
The BNFC provides recommendations on mixing 11 medicines (e.g. topiramate sprinkle 
capsules) with foods (soft foods, honey, yoghurt, apple sauce or jam) and at least 8 
medicines (e.g. Losec MUPS) with fruit juice (BNF for Children, 2011-2012). Additionally, 
some PILs include guidance on mixing with foodstuffs, e.g. Losec MUPS (AstraZeneca, 2011) 
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and also some detailed leaflets, e.g. Movicol paediatric plain (Norgine Pharmaceuticals Ltd, 
2009). To ensure the bioavailability and safety of a manipulated medicine such guidance 
should be supported by robust scientific evidence. A section of the PIP suggests that 
proposed studies for paediatric drug development include those investigating drug stability 
and compatibility when mixed with foodstuffs (European Commission, 2008). 
It is important to recognise that the time elapse from adding a medicine to a foodstuff until 
administration of a dose could increase the drug-foodstuff binding capability and 
pharmacokinetics of the drug; thus drug-foodstuff binding may alter therapeutic response. 
The drug-foodstuff interaction is not the only concern. If a child does not consume the entire 
drug-foodstuff mixture, a reduced dosage will be consumed. Similarly if a child associates 
certain foods or beverages with an adulterated taste as a result of mixing with an 
unpalatable drug, it may discourage a child from consuming the foodstuff used (Cabaleiro, 
2003). 
Altering gastric-transit time in children will also affect the bioavailability of a drug. Studies 
have found that the administration of different liquids causes greater variations in gastric 
emptying time compared to when solids are administered. The reason for this probably 
results from differences in solution parameters including calorific contents, osmolarities and 
viscosities (Bowles et al., 2010). 
Medicines that are administered via NG and percutaneous endoscopic gastrostomy (PEG) 
tubes do not always require manipulation. However, Skwierczynski and Conroy (2008) 
concluded that medicines required manipulation four times more often in children with a 
feeding tube compared to those without. Patients with NG/PEG tubes often have complex 
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dosing regimens including multiple medicine and nutritional formulations. This increases the 
risk of incompatibilities involving drug-drug and drug-nutrient interactions. Sedimentation of 
drugs and electrolytes could lead to caking, which may alter drug uniformity and also the 
pharmacokinetic profile of a drug. This could detrimentally affect therapeutic response. 
There is limited data investigating healthcare professionals’ knowledge of the 
physicochemical effects of mixing medicines with foodstuffs. Akram and Mullen (2012) 
explored the knowledge of 30 paediatric nurses regarding mixing medicines in to foodstuffs 
using a questionnaire. Study findings revealed that mixing medicines with foodstuffs was a 
common activity amongst the nurses, yet over one quarter of the participants did not feel 
sufficiently knowledgeable about problems with drug stability (Akram and Mullen, 2012). 
2.6 Oral formulation-related barriers to medicines administration 
The background and objective section of the reflection paper, Formulations of choice for the 
paediatric population (EMEA, 2006) acknowledged limited data regarding child acceptance 
of dosage forms (in relation to age and developmental status) and also the limited 
availability of licensed medicines suitable for administration to children. 
Formulation work performed so far in pharmaceutical companies has shown that liquids 
appear to be more popular with the younger population (infant age), oral dispersing tablets 
may be favoured by those who are older, and in the adolescent sub-group, tablets and 
capsules may be more appropriate and convenient (T. Nunn and Williams, 2005). These 
findings suggest that a wide range of dosage forms of different pharmaceutical strengths are 
required to suit all paediatric sub-groups (T. Nunn and Williams, 2005). Investigating if 
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factors (e.g. child age) influence dosage form preference across paediatric patients is 
important. 
The palatability of a medicine is one of the most important issues affecting adherence to 
drug regimens (Salunke et al., 2011). This is supported by the PIP guideline which identified 
that taste-masking and palatability information is required when licensing new paediatric 
medicines (European Commission, 2008). 
As the physiological development of children changes markedly with age, they should not be 
regarded as ‘miniature men and women’ (WHO, 2007), therefore involving children in 
studies investigating problems with paediatric medicines is essential. This is supported by 
the Royal College of Paediatrics and Child Health (RCPCH), who suggest that the views of 
children with regard to taste need to be investigated owing to differing perspectives 
between adults and children (RCPCH, 2004).  
Taste is defined as ‘the sensation of flavour perceived in the mouth and throat on contact 
with a substance.’ (Oxford Dictionaries, 2013b) 
 
A food or drink that is described as palatable is ‘pleasant to taste.’ (Oxford Dictionaries, 
2013a) 
 
 
Taste is perceived by humans through taste buds which are concentrated on the top of the 
tongue and found in smaller numbers on the roof of the oral cavity, the larynx and pharynx.  
Taste buds are constituted of taste receptor cells which contain microvilli referred to as taste 
hairs. Protein structures within plasma membranes of taste hairs serve as receptors which 
bind with food molecules once dissolved in water. Receptor cells, followed by sensory nerves 
are stimulated, transmitting impulses from taste buds to the brain (Chiras, 2011). 
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Sweet, salty, sour and bitter are the four basic taste modalities, with a fifth modality 
described more recently as ‘meaty’ ‘substantial’ or ‘delicious’ (Llorens, 2004). The sensation 
of taste is a relatively early development in the foetus (Lawless, 1985). By the seventh or 
eighth week of gestation specialised taste cells are present and by weeks thirteen to fifteen 
taste buds are structurally mature (Lawless, 1985). Flavour preferences vary throughout 
childhood. Sweet-tasting substances are preferred in childhood (Lawless, 1985), whilst taste 
preferences resembling those that predominate in adults are seen in the later adolescent 
years (Liem and Mennella, 2002).  
Reported studies in children have shown that often fruity, sweet formulations are preferred. 
Citrus and red berry flavours are preferred across Europe, liquorice in Scandinavia, whilst 
bubblegum and grape flavours are reported to be preferred in the US (EMEA, 2006). In 
contrast to these general findings, some children may prefer flavours that do not follow the 
general trend. A study by Bennetto and co-workers (2007) acknowledged discrepancies of 
taste preference in autistic children. Personal communication with a parent of an autistic 
child preferring bitter to sweet flavours supports this (Personal communication, Paediatric 
consultant).  
Genetic and cultural effects can also influence taste and flavour preferences (Mennella et al., 
2005). Lipchock and co-workers (2012) reported that children with a bitter-sensitive allele 
were more likely to have experienced solid dosage forms than bitter-insensitive children. 
This suggests that genotype may play a vital role in child acceptance of liquid medicines that 
are bitter tasting. 
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Additionally, taste preferences may be influenced by factors such as religious beliefs, gender 
and diet (Craig et al., 2009).  Some medical treatments can also affect taste recognition. A 
study in oncology patients whom had started chemotherapy treatment identified 
significantly greater taste recognition errors (Matsui, 2007a). Such findings reinforce that all 
healthcare professionals should consider palatability before making any prescribing or 
supply choices to paediatric patients. Although some individuals have very specific taste 
preferences it is not possible to procure medicines that are well-accepted by all children 
universally. However, when prescribing in particular patient groups (e.g. autistic children and 
children receiving chemotherapy) palatability should be at the forefront of prescribing 
decisions. 
Other formulation-related barriers to medicines administration have not been extensively 
studied, and additionally not in relation to child acceptance of a medicine. 
Poor aftertaste of a medicine creates a taste-related problem for which there is a paucity of 
published data. In the European Paediatric Formulation Initiative’s (EuPFI) 2nd conference 
commentary, ‘Formulating better medicines for children’, Dr Menella reported that the 
binding of bitter receptors with bitter agents in the throat could be responsible for the taste 
that occurs after swallowing a medicine and that the dissolution time of a particular drug can 
affect this (Salunke et al., 2011). 
Further organoleptic properties (i.e. smell, texture and colour) of a medicine may alter how 
it is perceived. These properties could affect child acceptance of a medicine and also reduce 
medicines adherence. The RCPCH (2004) suggested that research should be performed to 
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investigate child acceptability of tastes, textures, volumes and colours of medicines to 
promote improved medicines adherence. 
Physical properties (the number of solid dosage forms of an individual drug or volume of a 
liquid or powder required at one dosing interval, the size of or aversion to/difficulty 
swallowing a solid dosage form) may be problems perceived by children resulting in poor 
child acceptance of a medicine. ‘Pill-swallowing’ studies conducted in children and young 
people with HIV have identified that young people fear that solid dosage forms may ‘get 
stuck’ or cause choking (Czyzewski et al., 2000, Garvie et al., 2007). In addition to children 
perceiving that they are not capable of swallowing solid dosage forms, some children may be 
unable to swallow due to physical or mental impairments. In these circumstances they may 
be fitted with an NG/PEG tube. 
This thesis examines some of the problems associated with the administration of oral 
medicines to children suffering from a variety of chronic conditions in the domiciliary setting, 
focussing on the influence of barriers to the administration of oral formulations. 
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3 AIMS AND OBJECTIVES 
3.1 Primary Aims 
 To review literature investigating oral formulation-related barriers to medicines 
administration in paediatric patients suffering from chronic conditions 
 To establish the prevalence and nature of oral formulation-related barriers to 
medicines administration 
 To identify the medicines most commonly associated with oral formulation-related 
barriers to medicines administration, on an individual level and according to drug 
therapeutic class 
 To determine if a relationship exists between oral formulation-related barriers to 
medicines administration and child refusal of medicines 
 To determine the prevalence of medicines manipulation to facilitate medicines 
administration or for the purpose of giving a specific dose, by parents/carers/children  
 To identify the ways that parents/carers/children manipulate oral medicines to 
facilitate medicines administration or for the purpose of giving a specific dose 
3.2 Secondary Aims 
 To explore the problems experienced with oral medicines in paediatric patients from 
the perspectives of medical practitioners, nurses and pharmacists using focus groups 
 To identify additional barriers to medicines administration (i.e. those not directly 
associated with oral formulations). 
31 
3.3 Primary Objectives 
 To perform an international systematic review of literature using relevant sources  
updated on 10th January 2013 
 To conduct semi-structured face-to-face interviews with parents, carers and young 
people to identify the prevalence and nature of: i) oral formulation-related barriers 
to medicines administration ii) manipulations to oral medicines  
 To determine if oral-formulation related barriers to medicines administration 
influence medicines refusal using appropriate statistical analyses.  
3.4 Secondary Objectives 
 To conduct focus groups with medical practitioners, nurses and pharmacists to: 
(i) Inform design of semi-structured face-to-face interviews with parents, carers and 
young people 
(ii) Explore and compare their views on perceived problems associated with oral 
medicines prescribed to paediatric patients  
 To conduct semi-structured face-to-face interviews with parents, carers and young 
people to identify additional barriers to medicines administration that are not 
directly associated with oral formulations. 
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4 SYSTEMATIC REVIEW 
4.1 Introduction to Systematic Review 
There is limited information regarding the prevalence and nature of oral formulation-related 
barriers to medicines administration in children with chronic conditions. 
Personal communication with the Young Persons Group (YPG) at Birmingham Children’s 
hospital (BCH) and the Youth Council at University Hospitals Coventry and Warwickshire 
(UHCW) indicated that some organoleptic and physical properties of medicines may serve as 
barriers to medicines adherence amongst children suffering from chronic conditions (see 
Appendix 1). Healthcare professionals at UHCW during the pre-study period highlighted 
problems with some oral medicines prescribed to paediatric patients (see Appendix 2). 
Palatability has been described as a crucial factor influencing adherence to therapeutic 
regimens and outcomes (Salunke et al., 2011). In the latest guideline developed by the panel 
on antiretroviral therapy and medical management of HIV-infected children, the 
appropriateness (including palatability) and availability of drug formulations were reported 
as important factors to be considered when initiating or changing antiretroviral therapy 
(Panel on Antiretroviral Therapy and Medical Management of HIV-Infected children, 2011).  
Further properties of formulations that may influence child acceptance include: texture, 
colour/appearance and smell (can influence perception of its flavour), volume of a dose 
(typical target dose volumes: less than 5ml for children under 5 years and less than 10ml for 
those 5 years and older (EMEA, 2006)), quantity of solid dosage forms, size of solid dosage 
forms or aversion to/difficulty swallowing medicines. 
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Individuality influences the age at which children are able to swallow intact solid dosage 
forms. In conjunction, support and training from healthcare professionals can influence this, 
and anecdotal evidence suggests that with help, children 6 years and below can learn to 
swallow solid dosage forms (EMEA, 2006). In addition, some children are physically unable to 
swallow as discussed earlier in section 2.6.  
Owing to the limited availability of medicines suitable for use across the paediatric 
spectrum, often medicines require manipulation to facilitate medicines administration or to 
provide a specific dose. 
4.2 Objective of Systematic Review 
The refined review objective was to identify and examine the oral formulation-related 
barriers to medicines administration in paediatric patients suffering from chronic conditions.  
The primary outcome measure was defined as, ‘the influence that oral formulation-related 
barriers to medicines administration have on child acceptance of or adherence to a 
medicine’. 
The secondary outcome of this systematic review was discussion of medicines manipulation 
techniques used to administer oral medicines to paediatric patients. Study inclusion criteria 
(see Table 1) were based on the primary outcome measure. Studies meeting inclusion 
criteria of the review question were further evaluated for reports of medicines 
manipulation.  
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4.3 Methods 
4.3.1 Introduction to methods 
In August 2009, a mind-map was created (see Appendix 3) using guidance from Buzan and 
Buzan (2006). This was developed using themes identified in early literature searches, 
problems with medicines highlighted by children in the YPG at BCH and also healthcare 
professionals at UHCW (see Appendices 1 and 2). The terms in the mind-map were used to 
inform broad searches.  Searches were made on the databases: PubMed (Medline), Science 
Direct, Wiley and Interscience, The Cochrane library and Pharm-line (now part of the 
National electronic Library of Medicines - NeLM). 
These searches retrieved a plethora of studies exploring general medicines adherence in 
children. However, limited literature investigating oral formulation-related barriers to 
medicines administration in children suffering from chronic conditions was retrieved. 
Although providing valuable background information to underpin the study, refinement of 
the search strategy was necessary. 
A systematic review aims to answer a research question by identifying, appraising and 
synthesising all of the empirical evidence that meets the pre-defined eligibility criteria (The 
Cochrane Collaboration, 2013). It was decided that a systematic review would be conducted 
with the purpose of providing more reliable findings that could be used to inform decision 
making (The Cochrane Collaboration, 2013). 
The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist 
as reported by Moher and co-workers (2009) was used to guide the reporting of this review. 
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This was adapted to allow for appropriate reporting of qualitative data and the 
heterogeneity of the quantitative study results in this review. 
4.3.2 Eligibility criteria 
Criteria for inclusion and exclusion of relevant studies were developed using the refined 
review objective: 
 To identify and examine the oral formulation-related barriers to medicines 
administration in paediatric patients suffering from chronic conditions.  
This systematic review considered studies conducted in children of all ages prescribed oral 
medicines for chronic conditions (defined as long-term - at least 4 weeks). This time period 
was chosen to permit the inclusion of families with experience of administering medicines in 
a domiciliary setting and the exclusion of ‘one-off’ taste studies.  This review examined oral 
formulation-related barriers to medicines acceptance or adherence, therefore only studies 
exploring formulation-related problems with orally ingestible medicines were included. 
Reports of children, parents and carers (including parent/carer/child reports documented by 
healthcare professionals) were pertinent to this review.  
The inclusion and exclusion criteria as listed in Table 1 below, were used to screen studies 
retrieved in systematic searches using the refined search strategies provided in sections 
4.3.4.1 - 4.3.4.4, based on Participants, Interventions, Comparisons, Outcomes and Study 
design (PICOS) (Moher et al., 2009). 
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Table 1 Inclusion and exclusion criteria used to screen studies for inclusion in the review 
based on PICOS (Moher et al., 2009). 
Inclusion criteria Exclusion criteria 
Participants: 
 0-<18years (pre-term to adolescent) 
 Outpatients and inpatients 
 All nationalities, demographics, socio-
economic groups, ethnic groups  
Participants:  
 Studies examining issues in 18 years 
(including studies investigating 
paediatric medicines tested in an adult 
population)                                                                                                                                                                                                                                                                                                                                                                                                                                                           
Interventions: 
 Prescribed oral medicine long-term 
(defined as at least four weeks) 
 
Interventions: 
 Short-term treatment (i.e. ‘one-off’ taste 
test  studies) 
 Comparative/medication crossover trial 
Comparisons: 
 Studies with or without a control were 
considered 
Comparisons: 
 Studies were not excluded based on 
absence of a control. 
Outcomes:  
 Investigating oral formulation-related 
barriers to medicines administration 
(organoleptic and physical properties) on 
child acceptance of or adherence to 
medicines. 
Outcomes: 
 No reference to oral formulation-related 
barriers to medicines administration 
 
Study design:  
 Self-report (child 
parent/guardian/caregiver) including such 
data documented by a healthcare 
professional 
Study design:  
 Studies that did not adopt a self-report 
tool i.e. just clinical laboratory results  
 
 
 
4.3.3 Information Sources 
The refined search strategy was conducted using the University of Birmingham e-library and 
databases listed below. These databases were selected to encompass all relevant literature.  
 MEDLINE (includes PubMed (Ovid)) 1946 to 29th May 2012, including also in-process 
and other non-indexed citations (covers life sciences, with a strong focus on 
biomedicine) 
 EMBASE (EMBASE CLASSIC and EMBASE 1947 to 29th May 2012) (a biological and 
pharmacological database, with a strong coverage of drug and pharmaceutical 
research) 
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 CINAHL Plus (EBSCO) (1937 TO 29th  May 2012) (provides nursing and allied health 
literature) 
 NeLM (includes Pharm-line) (includes literature covering pharmacy practice and the 
clinical use of drugs). 
Searches were saved and re-run regularly to ensure up-to-date literature was not omitted. 
Systematic searches were updated as of January 10th 2013 and results are reported in the 
search flow diagram guided by Moher and co-workers (2009), see Figure 4. 
In addition, hand searches within specific journals (Paediatric Drugs, Archives of Disease in 
Childhood and the Pharmaceutical Journal) were performed. 
Further sources of relevant information were also used. This involved checking professional 
and regulatory bodies’ websites, and conference reports. Also, the researcher maintained a 
professional and active role in the field of research and presented at the Royal 
Pharmaceutical Society (RPS) conference 2012 (Venables et al., 2012a). 
Full-texts were obtained through libraries at UHCW, Aston University and University of 
Birmingham. Further sourcing involved inter-library requests and the help of the British 
Library, London. Non-English papers were translated with help from colleagues at the 
University of Birmingham if abstracts were relevant and met inclusion criteria. 
References cited by studies included in this review and additionally those citing the studies 
in this review were retrieved for screening using Science Citation Index (SCI).  
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4.3.4 Search  
Subject headings based on the key search terms were identified for each database searched. 
Free-text terms were also used in the search strategies to maximise the retrieval of relevant 
literature. A systematic search strategy for each database where possible was created based 
on the participants, intervention, problem associated with intervention and outcomes, as 
reported in the inclusion criteria (see Table 1). The search strategies are detailed in sections 
4.3.4.1 - 4.3.4.4 below. 
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4.3.4.1 Search strategy used in OVID EMBASE   
Participants 
exp adolescent/ OR exp child/ OR exp infant/ OR exp Pediatrics/ OR (adolescen* OR child* 
OR teen* OR youth* OR young* OR bab* OR neonat* OR infan* OR pediatric* OR 
paediatric*)  
AND 
Intervention 
("drug formulation" OR "drug manipulation" OR "drug administration" OR "drug adaptation” 
OR medic* formulation" OR "medic* manipulation" OR "medic* adaptation" OR "medic* 
administration") OR drug administration/ OR exp drug dosage form/ OR *drug combination/ 
OR exp drugs, essential/ OR exp drugs, generic/ OR exp nostrums/ OR exp pharmaceutic 
aids/ OR exp adjuvants, pharmaceutic/ OR exp pharmaceutical vehicles/ OR exp 
preservatives, pharmaceutical/ OR *solutions/ OR *hypertonic solutions/ OR *hypotonic 
solutions/ OR *isotonic solutions/ OR exp pharmaceutical solutions/ 
AND 
Problems associated with intervention 
exp organoleptic property/ OR exp swallowing/ OR refus* OR acceptability OR side effect OR 
(preference* OR like OR dislike) OR exp taste/ or exp "smelling and taste"/ OR exp 
palatability/  
AND 
Outcome 
*health behavior/ OR exp patient compliance/ OR exp treatment refusal/ OR (barrier* OR 
"medication adherence" OR "patient compliance" OR "medication compliance" OR "patient   
adherence") OR *health care organization/ 
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4.3.4.2 Search Strategy used in OVID Medline 
Participants 
exp adolescent/ OR exp child/ OR exp infant/ OR exp Pediatrics/ OR (adolescen* OR child* 
OR teen* OR youth* OR young* OR bab* OR neonat* OR infan* OR pediatric* OR 
paediatric*)  
AND 
Intervention 
("drug formulation" OR "drug manipulation" OR "drug administration" OR "drug adaptation” 
or medic* formulation" OR "medic* manipulation" OR "medic* adaptation" OR "medic* 
administration") OR exp dosage forms/ OR *drug combinations/ OR exp drugs, essential/ OR 
exp drugs, generic/ OR exp nostrums/ OR exp pharmaceutic aids/ OR exp adjuvants, 
pharmaceutic/ OR exp pharmaceutical vehicles/ OR exp preservatives, pharmaceutical/ OR 
*solutions/ OR *hypertonic solutions/ OR *hypotonic solutions/ OR *isotonic solutions/ OR 
exp pharmaceutical solutions/  
AND 
Problems associated with intervention 
Organoleptic OR palatability OR exp swallowing/ OR refus* OR acceptability OR side effect 
OR (preference* OR like OR dislike) OR exp taste/ OR exp smell/  
AND 
Outcome 
*health behavior/ OR exp patient compliance/ OR exp treatment refusal/ OR (barrier* OR 
"medication adherence" OR "patient compliance" OR "medication compliance" OR "patient 
adherence") OR health care organization 
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4.3.4.3 Search strategy used in EBSCO CINAHL plus 
Participants 
(MH "Child") OR "child" OR (MH "Adolescence") OR (MH "Infant") OR MJ adolescen* OR 
child* OR teen* OR youth* OR bab* OR infan* OR neonat* OR paediatric* OR pediatric* 
AND 
Intervention 
TX "pharmaceutical preparations" OR "dosage forms" OR "drug combinations" OR "herbal 
drugs" OR "generic drugs" OR "essential drugs" OR "nonprescription drugs" OR 
"investigational drugs" or "nostrums" OR "pharmaceutic* aids" OR "prescription drugs" or 
"pharmaceutical solutions" OR "drug administration" OR "drug formulation" OR "drug 
manipulation" OR "drug adaptation" OR "medicine formulation" OR "medicine 
administration" OR "medicine manipulation" OR "medicine adaptation" OR (MH "Dosage 
Forms+") OR (MH "Drug Combinations+") OR (MM "Drugs, Essential") OR (MM "Drugs, 
Generic") OR (MM "Drugs, Investigational") OR (MM "Drugs, Non-Prescription") OR (MM 
"Drugs, Off-Label") OR (MM "Drugs, Prescription") OR (MM "Prodrugs") OR (MH "Delayed-
Action Preparations+") OR (MH "Powders+") OR (MH "Solutions+") OR (MH "Drug 
Administration+")  
AND 
Problems associated with intervention 
TX ("taste" OR "palatab*" OR "prefer*" OR "accept*" OR "dislike" OR "like" OR "smell*" OR 
"organoleptic" OR "aftertaste*" OR "deglutition" OR "swallow*" OR "side effect*") OR (MM 
"Deglutition") OR (MH "Taste") 
AND 
Outcome 
(MM "Health Behavior") OR (MM "Allied Health Organizations") OR (MH "Patient 
Compliance+") OR (MM "Treatment Refusal") OR TX "health behaviour" OR "patient 
compliance" OR "medic* adherence" OR "treatment refusal" OR "barriers" OR 
"medic*compliance" OR "patient adherence" OR "health care organisation"  
Boolean operators ‘AND’ and ‘OR’ were used to structure the search strategy. An asterisk (*) 
denotes a term searched as a wildcard. Speech marks (“) are used to surround and identify a 
string of terms together. The text ‘exp’ preceding a subject heading term means that the 
term is exploded to retrieve narrower, related terms during the search. 
42 
4.3.4.4 Search strategy for NeLM 
The NeLM database does not permit complex specific searches. Combinations of key terms 
were used to retrieve publications:  child*, infan*, adolescen*, bab*, drug administration, 
dosage form, formulation, manipulation, adaptation, taste, palatab*, swallow*, deglut*, 
flavour, flavor, organoleptic, refuse, adherence, compliance.  
4.3.5 Study Selection 
The citations retrieved from systematic searches were imported in to, and managed using 
the reference manager Endnote X3 (Thomson Reuters). Duplicate studies were identified 
and deleted. Citations of the retrieved studies were screened against the inclusion and 
exclusion criteria listed in Table 1. 
Screening was initially based on title, then abstract and finally full-text. When studies 
seemed to meet inclusion criteria or when a decision to include a study could not be made 
based solely on review of the title or abstract, full-text copies were obtained. The reference 
lists of the included review studies and studies that had cited these were examined to 
identify any further relevant studies as discussed in section 4.3.3. The search flow diagram 
details the rigorous identification process (see Figure 4). 
4.3.6 Data collection process 
Studies identified as potentially eligible for inclusion were validated independently by RV 
and a pharmacist with experience in paediatrics and clinical pharmacy. The decision to 
include the final 27 studies was agreed by consensus.  
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4.3.7 Data outcomes  
For the included review studies, authors, year of publication, study site, medication type, 
study population characteristics (age of child and number and type of interview 
participants), methodology of the study tool of interest, and findings of interest to this 
review were identified and are reported in Table 2. The full content of the review studies 
were critically examined by RV and the pharmacist with experience in paediatrics and clinical 
pharmacy, and themes were derived based on the oral formulation-related barriers explored 
in the studies, following review of the key search terms and review objectives.  The themes 
were categorised and formed the narrative study review. The review studies were assessed 
for quality. Analysis of study outcomes for the narrative review was informed by Pope and 
co-workers (2000). 
4.3.8 Quality assessment and risk of bias in review studies 
Randomised controlled trials are positioned in the top rank of the hierarchy of evidence 
(SIGN, 2008). In this systematic review, it was acknowledged that the methodology of 
included studies used to generate the review outcomes would be considered lower in the 
hierarchy of clinical evidence. Assessing study quality using rigorous methods as reported by 
Moher and co-workers (2009) was not feasible, owing to heterogeneity across 
methodologies and reported outcome measures relevant to this review.   
Quality of the studies was assessed with guidance from the critical appraisal skills 
programme (Public Health Resource Unit, 2006). The studies were critiqued based on the 
following factors: appropriate research design, sampling recruitment strategy met aims of 
research (how participants were selected, why people chose not to participate), defined 
44 
clearly how the data was collected, discussed risk of researcher bias/drug company funding, 
reported rigorous and critical data analysis (considered both arguments and explicitly 
explained how data was analysed) and transparency of findings and value of research linking 
to future research. Critique of the qualitative data was also guided by Mays and Pope (2000). 
4.3.9 Summary measures 
The review outcome measures form the structure of the narrative results section. 
Primary outcome measures:  
 Oral formulation-related barriers to medicines administration 
 The influence of oral formulation-related barriers to medicines administration on 
child acceptance of or adherence to a medicine. 
Secondary outcome measure: 
 Medicines manipulation techniques used to administer oral medicines to paediatric 
patients.  
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4.4 Results 
4.4.1  Study selection 
 
Figure 4 A search flow diagram to show the study screening process, in accordance with 
the PRISMA system (Moher et al. 2009). 
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4.4.2 Study Characteristics 
Table 2 Study characteristics of the 27 studies included in this systematic review. 
Authors 
 
Study title 
Study Setting 
Medication type 
Age of 
children  
Study 
population Method 
Oral formulation-related barriers to medicines 
administration and medicines manipulation 
techniques 
(Shemesh et 
al., 2004) 
Medication 
adherence in 
pediatric and 
adolescent liver 
transplant 
recipients 
A paediatric 
liver 
transplant 
clinic , Mount 
Sinai Medical 
Centre, New 
York, USA 
Liver transplant 
patients (except 
those on 
ciclosporin) 
2 -21y 
 
Analysis of 
81 cases 
Caregivers and children 
questioned independently with 
a 
list of reasons (for non-
adherence) (plus an open 
option for any other reason) 
 
 
Caregivers report Tastes bad: 4.9% (n=4/81). 
 
(Tucker et al., 
2002) 
Associations with 
medication 
adherence among 
ethnically 
different pediatric 
patients with 
renal transplants 
 
 
African 
American and 
European 
American 
patients 
recruited 
from four 
South eastern 
Paediatric 
Nephrology 
Clinics, USA 
Renal transplant 
patients 
6-21y  68 
paediatric 
patients 
(African 
American 
and 
European 
origin) with 
renal 
transplants 
and their 
caregivers 
Primary caregiver and child 
together. Medication aversion 
scale with Likert scale (closed 
questions) 
Neither group of patients agreed that they dislike 
taking their medicines because they tasted bad or may 
make them sick. Neither group agreed that swallowing 
was an issue due to tablet size either. 
 
Among both groups, perceived characteristics of their 
medication regimen, including pill size, pill taste and 
medication complexity, were found to have 
significantly low to moderate associations with 
medication adherence. 
(Zelikovsky et 
al., 2008) 
Perceived barriers 
to adherence 
among 
adolescent renal 
transplant 
candidates 
A large 
transplant 
centre in the 
North East 
USA 
Renal transplant 
patients 
11-18y  
 
56  
Caucasian 
adolescents 
listed for a 
kidney 
transplant, 
and their 
carers 
 
Semi-structured interviews  
‘The Medical Adherence 
Measure (MAM)’ (closed 
questions) 
Approximate results from histogram: 
17% reported taste as a reason for non-adherence 
2% reported ‘hard to swallow.’ 
Those who identified ‘‘hate 
the taste’’ as a barrier missed more doses, 
z = -2.4, p = 0.02 (average ranks 39.81 vs. 
25.36) and took more doses late, z = -2.7, 
p = 0.007 (average ranks 40.44 vs. 24.61). 
Some barriers had a low rate of endorsement (e.g. 
hard to swallow pills) and therefore there was not 
sufficient power to examine the relationship between 
these barriers and adherence. 
47 
Authors 
 
Study title 
Study Setting 
Medication type 
Age of 
children  
Study 
population Method 
Oral formulation-related barriers to medicines 
administration and medicines manipulation 
techniques 
(Christiansen et 
al., 2008) 
Oral 
chemotherapy in 
paediatric 
oncology in the 
UK: problems, 
perceptions and 
information needs 
of parents 
Two 
paediatric 
oncology 
centres: 
Great 
Ormond St 
hospital 
(GOSH) and 
University 
College 
Hospital 
(UCLH) 
London, UK 
Oral 
chemotherapy 
(methotrexate 
and 
mercaptopurine) 
<18y (60%  
younger 
than 7y) 
55 
caregivers 
Semi-structured questionnaire 
via face-to-face interviews with 
primary caregivers (open-ended 
questions) 
75%, (n = 41) faced some kind of problem or difficulty 
when dealing 
with oral chemotherapy: 
Unpleasant taste of the liquid (n=10) 
Capsules dispensed were too big to swallow (n=1). 
 
Approximately one quarter of parents 
(24%, n = 10) had at least at some point during 
treatment crushed tablets prior to administration and 
evidence of dosage form manipulation was evident in 
responses to open-ended questions.  
Breaking capsules in to ice-cream and crushing tablets 
on cornflakes were described by two fathers in the 
study. 
(Ingerski et al., 
2010) 
Barriers to Oral 
Medication 
Adherence for 
Adolescents with 
Inflammatory 
Bowel Disease 
Two 
paediatric 
IBD centres in 
the Northeast 
or Midwest 
regions, USA 
Inflammatory 
bowel disease 
prescribed  
mercaptopurine/ 
azathioprine 
and/or 5-ASA 
13-17y 74 
adolescents 
and their 
primary 
caregivers 
together 
Medical Adherence Measure 
MAM: semi-structured 
interview (closed questions) 
Hate the taste: 10.8% (all reported by Crohn’s patients) 
Hard to swallow: 10.8% (all reported by Crohn’s 
patients). 
 
‘Children resisting, refusing, spitting out drugs 
(because of bad taste?) (32%).’ 
 
(Modi and 
Quittner 2006) 
Barriers to 
Treatment 
Adherence for 
Children with 
Cystic Fibrosis and 
Asthma: What 
Gets in the Way? 
Two 
paediatric 
pulmonary 
clinics in 
Florida, USA 
Oral enzyme 
capsules 
(patients with CF 
or asthma) 
(Review only 
considers oral 
medicines) 
 
6-13y 73 children 
and parents 
separately 
The disease management 
interview-CF (DMI-CF) -  
51-item self-report measure of 
adherence behaviours for 
patients with CF that was 
modified from the treatment 
adherence questionnaire-CF 
(TAQ-CF). 
 
The DMI-Asthma 
is a 28-item questionnaire 
which asks when, how often, 
and how much of each 
medication they took  
(open-ended questions also) 
Barriers to Adherence  
 
Taste was reported as a barrier for taking oral 
antibiotics. Children with CF also identified difficulty 
swallowing solid dosage forms as a key barrier to 
taking oral medications (like oral antibiotics and 
enzymes). 
Barriers to oral enzymes: 
CF Children reports swallowing (13%) 
CF Parent reports of oppositional behaviours (11%) 
Barriers to Nutrition medicines: 
CF Parent reports taste (17%) 
Barriers to Allergy medicines: 
Asthma parent reports (14%) swallowing  
Barriers to oral antibiotics: 
CF parent reports Taste (16%),  Oppositional 
behaviours (11%) 
CF children reports  Swallowing (25%) 
Asthma parent reports Taste (24%). 
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Authors 
 
Study title 
Study Setting 
Medication type 
Age of 
children  
Study 
population Method 
Oral formulation-related barriers to medicines 
administration and medicines manipulation 
techniques 
(Boni et al., 
2000) 
Compliance to 
combination 
antiretroviral 
therapy in HIV-1 
infected children 
Department 
of Infectious 
Diseases, 
University of 
Genoa, Italy 
Antiretroviral 
medicines 
Mean age 
8.2y 
Parents/ 
legal 
guardians of 
25 children  
Questionnaire: Results 
presented as ‘Problems pointed 
out by parents or legal 
guardians in administration of 
antiretroviral treatment’ (open 
questions) 
 
Too many medicines/tablets to take: 36% 
Difficulty swallowing: 32% 
Bad taste: 24% 
Child resists/refuses/spits out medicine 32% (unknown 
reason). 
 
 
 
 
(Buchanan et 
al., 2012) 
Barriers to 
Medication 
Adherence in HIV-
Infected Children 
and Youth Based 
on self- and 
caregiver report 
Multicentre 
USA 
Antiretroviral 
medicines 
8-18y Children/ 
youth with 
perinatally 
acquired 
HIV and 
their 
parents/ 
caregivers 
(n = 120 
dyads) 
Children and their caregivers 
independently: Questionnaire 
about 19 potential barriers to 
adherence to the child’s 
antiretroviral therapy regimen. 
(closed list) 
Barriers to adherence, reasons for missing medicines in 
previous month: 
Child: Taste, can’t get it down, or keep it down (pill or 
liquid) (18%), Child refused (20%) Too much 
medication (9%). 
Adult reports (also reported in bar chart: 
Taste, can’t get it down, or keep it down (pill or liquid) 
(8%), Child refused (12%), Too much medication (2%). 
Significant agreement between child and caregiver 
reports on the barrier of taste/cannot get it down as a 
barrier, based on a kappa statistical test, k = 0.44, 
(P<0.001). 
 
 
 
(Byrne et al.,  
2002) 
Achieving 
Adherence With 
Antiretroviral 
Medications for 
Pediatric HIV 
Disease 
 
The Women 
and Children 
Care Center 
(WCCC) of 
New York 
Presbyterian 
Hospital, USA 
Antiretroviral 
medicines 
4 months 
to 18y 
(average, 
7.5y) 
Primary 
caregivers 
of 42 
children 
The interview guide contained 
48 questions on clinical, family, 
and child factors related to 
adherence drawn from the 
literature on paediatric 
adherence and clinical 
experience with paediatric ARV 
adherence (list of barriers plus 
other open-ended question 
option) 
 
 
 
 
 
In response to specific questions, caregivers reported 
as barriers to adherence: taste (10%), volume of 
medicine (10%). 
 
Strategies related to improving taste or taking away 
unpleasant aftertaste were somewhat more frequently 
reported (29% and 24%, respectively). 
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Authors 
 
Study title 
Study Setting 
Medication 
type 
Age of 
children  
Study 
population Method 
Oral formulation-related barriers to medicines 
administration and medicines manipulation 
techniques 
(Esteban 
Gomez et al., 
2004)  
Influencia de las 
características del 
tratamiento 
antirretroviral en 
la adherencia del 
paciente 
pediátrico 
Servicio de 
Farmacia. Unidad 
de 
Inmunodeficienci
as Pediátricas. 
Hospital 
Universitari, 
Madrid 
Antiretroviral 
medicines 
4-16y 28 
caregivers 
of 32 
paediatric 
patients 
undergoing 
active 
antiretrovir
al therapy 
Subjective numeric scale-based 
questionnaire. 
The questionnaire aimed to 
assess on a scale from 0 (no 
difficulty for adherence) to 5 
(maximal 
difficulty) a number of 
treatment-related factors: a) 
number of 
drugs and dosage regimen; b) 
organoleptic properties of 
drugs; c) 
treatment administration; d) 
adverse events; and e) 
antiretroviral 
therapy effectiveness perceived 
by caregiver. 
(closed questions) 
Caregivers evaluated the following factors as entailing 
moderate to high difficulties for correct adherence: 
number of drugs in the antiretroviral combination, 
organoleptic properties (smell, taste) of protease 
inhibitors (PI), PI-related deglutition problems, and PI-
related immediate gastrointestinal adverse events. 
These factors may be considered potential obstacles 
for adequate adherence to antiretroviral therapy in 
paediatric patients. 
Grading of organoleptic difficulties based on average 
values of scores of carers: 
Syrups and Liquids reverse transcriptase inhibitor, 
protease inhibitor: taste: 0.3, 4.5 smell: 0.3,2.1 
deglutition: 0.1, 2.3  
Solid pharmaceutical forms: taste:0.3, 1.6 deglutition: 
0.75, 1.8 
Mentions texture. The only factor assessed as high 
adherence difficulty was the flavour of the protease 
inhibitors in liquid form. For solid dosage forms, the 
aspects with a highest score (within that none of them 
reached the score corresponding to moderate 
difficulty), were the flavour and the difficulties in 
swallowing of the PI.  
(Farley et al., 
2003) 
Assessment of 
Adherence to 
Antiviral Therapy 
in HIV-Infected 
Children Using the 
Medication Event 
Monitoring 
System, 
Pharmacy Refill, 
Provider 
Assessment, 
Caregiver Self-
Report, 
and Appointment 
Keeping 
 
 
University of 
Maryland School 
of Medicine, 
Baltimore, USA 
Antiretroviral 
medicines  
<13y 
 
 
20 
caregivers 
completed 
the 
Pediatric 
Adherence 
Questionnai
-re (PACTG) 
Caregiver self-report interviews 
completed periodically  
physician/nurse questionnaire 
Paediatric AIDS Clinical Trial 
Group (PACTG) Paediatric 
Adherence Questionnaire 
(list of barriers plus other 
specify open question option) 
 
‘Problems with adherence’  
6 caregivers reported barriers to adherence.  
Taste (n=3/20) 
Child refuses (n=4/20). 
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Authors 
 
Study title 
Study Setting 
Medication type 
Age of 
children  
Study 
population Method 
Oral formulation-related barriers to medicines 
administration and medicines manipulation 
techniques 
(Feingold et al., 
2000) 
Protease Inhibitor 
Therapy in HIV-
Infected Children 
1The 
Children’s 
Regional 
Hospital, 
Camden, New 
Jersey. 
2The 
Children’s 
Hospital of 
Philadelphia, 
Pennsylvania 
 
Protease 
inhibitors 
 
Median 
age 82.9 
months 
(range 5–
204 
months) 
Chart 
review of 70 
children 
A retrospective chart review of 
open-label PI containing 
combination 
therapy 
10 changes were made because of patient preference 
or poor adherence. 
Primary reasons for medicine change 
included medications not being palatable or 
patient’s inability to swallow pills or capsules. 
 
(Hammami et 
al., 2004) 
Integrating 
Adherence to 
Highly Active 
Antiretroviral 
Therapy Into 
Children's Daily 
Lives: A 
Qualitative Study 
 
A Belgian 
paediatric 
acquired 
immune 
deficiency 
syndrome 
referral 
centre 
Antiretroviral 
medicines 
Adherent 
mean age: 
8.5y (0.25-
17.25) 
 
Less 
adherent 
mean age: 
13y (6.70-
18.75) 
 
11 primary 
caregivers 
of 18 
children 
Semi-structured interviews 
about 60 minutes long 
(open questions) 
 
Almost all caregivers mentioned a history of opposition 
from their child as a result of bad taste and side 
effects. 
 
Adherent patients demonstrated creativity in solving 
such problems. One parent discussed offering “nice 
tasting things” at the same time as administering the 
medicine to facilitate child acceptance of the medicine. 
 
 
(Leprevost et 
al., 2006) 
Adherence and 
acceptability of 
once daily 
lamivudine and 
abacavir in human 
immunodeficiency 
virus type-1 
infected children 
Paediatric 
clinic at St. 
Mary’s 
Hospital, 
Paddington 
and 
Great 
Ormond 
Street 
Hospital 
NHS Trust, 
London UK 
 
 
 
 
 
Antiretroviral 
medicines 
(Lamivudine and 
abacavir 
specifically) 
2-13y Caregiver 
reports of 
24 children 
Adherence questionnaire. 
Acceptability was also assessed 
(open questions) 
 
Acceptability questionnaires: 
9/24 (38%) of caregivers commented that taste of 
medications had been a problem for their children 
during the study. 
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Authors 
 
Study title 
Study Setting 
Medication type 
Age of 
children  
Study 
population Method 
Oral formulation-related barriers to medicines 
administration and medicines manipulation 
techniques 
(Marhefka et 
al., 2004) 
Clinical 
assessment of 
medication 
adherence among 
HIV-infected 
children: 
examination of 
the Treatment 
Interview Protocol 
(TIP) 
Urban, public, 
university-
affiliated, 
PACTG 
affiliated 
paediatric 
HIV speciality 
clinics in 
Gainesville, 
Florida, 
Jacksonville, 
Florida, and 
Baltimore, 
Maryland US 
 
Antiretroviral 
medicines 
2-12 y 
(mean=8.7
6 SD=3.06) 
51 
Participants 
(parents or 
primary 
caregivers) 
A new caregiver self-report 
assessment tool (the Treatment 
Interview 
Protocol; TIP)- a caregiver-
completed structured interview 
(open questions) 
Barriers to adherence endorsed: Pills are too big to 
swallow (n=5) 
Medication tastes bad (n=5) 
Child isn’t able to swallow pills (n=1) 
Too many pills (n=3) 
Child doesn’t drink all the medicines (n=1). 
 
Described difficulties experienced by a caregiver when 
preparing a solution. However no more details were 
reported. 
(Paranthaman 
et al., 2009) 
Factors 
influencing 
adherence to anti-
retroviral 
treatment in 
children with 
human 
immunodeficiency 
virus in South 
India- a 
qualitative study 
Non-profit 
medical care 
and 
research 
institution 
based in 
Chennai, 
India 
Antiretroviral 
medicines 
<12y A 
convenienc-
e sample of 
14 
caregivers  
Interview (semi-structured) 
Qualitative in-depth (open-
ended questions) 
Medication related factors that influence adherence 
are mainly associated with side effects, size of tablets, 
Palatability and tablet regime. 
 
Crying because of the ‘bitter taste of the medicines’ 
was reported by a caregiver of a non-adherent child. 
 
“It was difficult to break the tablets into exact doses. 
Once they prescribed 1/3rd of the tablet but it is 
difficult to give. For this, syrup would have been 
better. I feel it is difficult because we are unable to 
break the tablet correctly. I have the feeling that I am 
not giving the correct dosage.” 
 
(Plipat et al., 
2007) 
Evaluation of a 
practical method 
to assess 
antiretroviral 
adherence in HIV-
infected Thai 
children 
 
 
 
 
Siriraj 
Hospital 
Paediatric 
Clinic, 
Bangkok, 
Thailand 
Antiretroviral 
medicines 
<7-14y 
 
137 
caregivers 
PACTG adherence 
questionnaire (list plus open-
ended question option to 
specify additional barriers) 
One hundred and thirty-seven (85%) caregivers 
completed their questionnaires.  
Reasons commonly attributed to poor adherence were 
forgetfulness, bad taste and interruption of the child’s 
rest. 
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Authors 
 
Study title 
Study Setting 
Medication type 
Age of 
children  
Study 
population Method 
Oral formulation-related barriers to medicines 
administration and medicines manipulation 
techniques 
(Pontali et al., 
2001) 
Adherence to 
Combination 
Antiretroviral 
Treatment in 
Children 
Department 
of Infectious 
Diseases, 
University of 
Genoa, 
Genoa, Italy 
Antiretroviral 
medicines 
Mean age 
9.4y 
Caregivers 
of 44 
children 
Questionnaire to caregivers  
(closed question list) 
Problems when administering medicines to children: 
Swallowing (29.5%), Bad taste (20.5%), Child 
resists/refuses/spits out (25%), Too many medicines/ 
pills (34%). List of main problems reported: 
Less than 6 years  
1. Taking medicines at school or out of home 
2. Child resists/refuses/spits out, 2. Child complains of 
bad taste, 2. Food interactions, 2. Vomiting 
From 6 to 10 years 
1. Difficulty swallowing pills 
2. Too many medicines/pills 
3. Child complains of bad taste, 3. Food interactions, 3. 
Change in routine (holidays, weekend) 
More than 10 years 
1. Too many medicines/pills 
2. Food interactions 
3. Difficulty swallowing pills 
4. Taking medicines at school or out of home, 4. 
Running out of medicines. 
(Roberts, 2005) Barriers to 
antiretroviral 
medication 
adherence in 
young HIV-
infected children 
Flyers in 
HIV/AIDS 
clinics and 
community-
based 
organizations 
located 
throughout 
Los Angeles, 
California, 
USA 
Antiretroviral 
medicines 
6-12y 
(mean 
9.5y) 
9 children 
interviewed 
with 
guardians 
and 
guardians 
(alone) of 5 
additional 
children 
Face-to-face in-depth interview 
(open-ended questions) 
As soon as I put them in my mouth, they dissolve and 
taste nasty.” 
“When you put them in your mouth . . . it tastes all 
nasty.” 
 “It’s hard because they’re too big for me. Because 
when it goes down like this, it goes ‘dush, dush, dush.’ 
It hurts my throat.” 
 “He started having problems taking it, like if he looks 
at it or smells it, then he’s just coughing and gagging...” 
Some guardians reported giving their children various 
foods or beverages (e.g., pudding) to make the 
medications more palatable.  
(Wrubel et al., 
2005) 
Pediatric 
adherence: 
Perspectives of 
mothers of 
children 
with HIV 
Multisite USA Antiretroviral 
medicines 
1-18y 
(Range) 
8.3y 
(Mean) 
 
71 
caregivers 
provided 
one or 
more 
accounts  
 
Primary caregivers interviewed 
(open-ended questions) 
The mothers did not present taste a central difficulty, 
but rather as a challenge to be mastered. 
 
32% of the mothers described the ways they 
made the medication palatable as part of the process 
of giving the medication, for example, mixing it with 
some food to disguise the taste, or giving a sweet drink 
immediately after giving the medication. 
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Authors 
 
Study title 
Study Setting 
Medication type 
Age of 
children  
Study 
population Method 
Oral formulation-related barriers to medicines 
administration and medicines manipulation 
techniques 
(Bunupuradah 
et al., 2006) 
Use of taste-
masking product, 
FLAVORx, to 
assist Thai 
children to 
ingest generic 
antiretrovirals 
Thailand Antiretroviral 
medicines  
Mean age 
was 5.2 ± 
SD 1.9y 
(range=1-
9.8y) 
Caregivers 
of 30 
children 
Open label, one arm, cohort 
study – flavour masking. 
 
Children were followed twice, 
one month apart. At each 
visit, the caregivers were asked 
to complete the approved 
Thai version of the NIAID 
Pediatric AIDS Clinical Trial 
Group (PACTG) Standard 
International Questionnaire. 
(barrier list and additional 
open-ended questions) 
“At the first visit, all thirty caregivers answered that 
the child had never missed any antiretroviral 
medicine dose and that they did not experience 
problems with administering the medicine on time 
every day.” 
However, during the interview, most caregivers 
reported that the child disliked taking antiretroviral 
medicines because of the bitter taste especially 
generic AZT syrup, 3TC syrup, ddI powder, NVP 
crushed tablet and EFV opened capsule. 
 
At the final visit, caregivers gave the same answers 
for the PACTG adherence questionnaire with no 
reported problems or occurrence of poor adherence. 
From the interview, 24 caregivers reported that, after 
using FLAVORx, their children had an easier time 
taking antiretroviral medicines with FLAVORx. 
FLAVORx did not affect adherence as full adherence 
was reported in all children despite the problem of 
bitter antiretroviral medicines. 
 
 
 
(Davies et al., 
2008) 
Adherence to 
antiretroviral 
therapy in young 
children in Cape 
Town, South 
Africa, measured 
by medication 
return and 
caregiver 
self-report: a 
prospective 
cohort study 
 
 
 
 
A tertiary 
care 
institution in 
Cape Town, 
South Africa 
Antiretroviral 
medicines 
37 (16-61) 
months at 
start of 
ART 
Caregivers 
of 122 
children 
A questionnaire was 
administered to caregivers 
after 3 months of treatment to 
assess experience with giving 
medication and self-reported 
adherence (PACTG with open-
ended questions element) 
Experience with giving medication: 
Poor palatability of medication was the most 
common problem (21.8% of caregivers), 68% of these 
attributed to ritonavir. 
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Authors 
 
Study title 
Study 
Setting Medication type 
Age of 
children  
Study 
population Method 
Oral formulation-related barriers to medicines 
administration and medicines manipulation 
techniques 
(Gibb et al., 
2003) 
Adherence to 
prescribed 
antiretroviral 
therapy 
in human 
immunodeficiency 
virus-infected 
children in the 
PENTA 5 trial 
Centres in 
Europe and 
Brazil 
Antiretroviral 
medicines 
3 months 
to 16y 
At least one 
caregiver 
questionnair
e returned 
for 108 
children 
Adherence questionnaire to 
caregivers (open-ended 
questions) 
Reasons why a child had difficulty taking medicines 
were given by caregivers of 65 children and could be 
divided into 2 main groups: comments on taste/ 
palatability/volume of drug(s); and social situations. 
 
The largest number of responses (n _ 48) was in the 
first group and included comments on taste/flavour/ 
smell, size of tablets, consistency of medicine, causing 
vomiting/nausea and difficulty in swallowing. 
“Difficulties with unpleasant flavor”; “Taste causes 
nausea”; “Hates the taste and smell”; “Child vomits 
due to taste”; “Bad smell and a big tablet” (referring 
to NFV); and “Difficulties with quantities.” 
 
 
(Goode et al., 
2003) 
Adherence issues in 
children and 
adolescents 
receiving highly 
active 
antiretroviral 
therapy 
Australia Antiretroviral 
medicines 
4-14.5y 
(mean 
7.6y) 
18 parents 
(12 of which 
were also 
treated for 
HIV on 
HAART 
regimens) 
 
Telephone interview (open-
ended questions) 
Qualitative reports indicated overwhelmingly that 
difficulties with administering medicines were due to: 
Taste (44%) 
 
Procedural factors (i.e. mixing and preparation) 
(reported by 28% of respondents). 
 
 
 
 
 
(Lin et al., 
2011) 
Palatability, 
adherence and 
prescribing patterns 
of antiretroviral 
drugs 
for children with 
human 
immunodeficiency 
virus infection in 
Canada† 
 
 
 
HIV clinic 
at the 
Hospital 
for Sick 
Children, 
Toronto, 
Canada 
Antiretroviral 
medicines  
0-18y 119 children Chart review 
Cross-sectional survey of 
physicians caring for the 
children 
Ritonavir was the least palatable drug compared with 
other antiretroviral medicines (p = 0.01); 50% of 
children have refused its consumption because of 
poor taste, and in 27% of children, drug change was 
required. 
 
Authors suggested adding FLAVORx to opened 
capsules to improve palatability. 
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Seven key studies are highlighted in bold font. 
Drug names in Bunupuradah and co-workers (2006) AZT= zidovudine, 3TC= lamivudine, ddI= didanosine, NVP= nevirapine, EFV= efavirenz. 
 
Authors 
 
Study title 
Study 
Setting Medication type 
Age of 
children  
Study 
population Method 
Oral formulation-related barriers to medicines 
administration and medicines manipulation 
techniques 
(Reddington et 
al., 2000) 
Adherence to 
medication 
regimens among 
children with 
human 
immunodeficiency 
virus 
infection 
 
Multisite 
USA 
Antiretroviral 
medicines 
1-14y 
(median 
age 7.9y) 
90 
caregivers 
Caregivers interviewed (79 
face- to-face, 11 telephone) 
(difficulties with medicines 
reported by patients. Open-
ended questions?) 
Better tasting medicines were rated ‘very helpful’ by 
81% of caregivers. 
 
 
Reasons for difficulty in administration were primarily 
the size of the nelfinavir pill, taste and consistency of 
nelfinavir powder and the taste of both the pill and 
liquid form of ritonavir. 
 
 
(Van Dyke et 
al., 2002) 
Reported 
Adherence as a 
Determinant of 
Response to Highly 
Active 
Antiretroviral 
Therapy in Children 
Who Have Human 
Immunodeficiency 
Virus Infection 
 
 
 
 
Multicentr
e USA 
Antiretroviral 
medicines 
4 months-
17y 
125 
children 
PACTG Modules 
Questionnaires of subjects (if 
responsible for medicines) or 
caregivers (list plus other 
open-ended question option) 
The main reasons stated for non-adherence were 
taste (16%) and child refuses (16%) for ritonavir and 
taste (9%) for nelfinavir. 
 
 
‘The large volume and unusual texture of the 
nelfinavir powder is particularly challenging for 
parents to administer.’ 
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4.4.3 Introduction to Results 
In total, 27 studies were retrieved which met the pre-defined review inclusion criteria (see 
Figure 4). In 7 of the included studies, findings were reported on an individual drug level. 
These will be referred to as the 7 ‘key studies’ as reporting of findings was more complete in 
these studies. All 7 ‘key studies’ investigated antiretrovirals. Figure 5 below shows the 
classification of the included review studies according to chronic conditions.  
 
Figure 5 The classification of the 27 included review studies by chronic condition. 
In 25 of the 27 studies an interview or questionnaire was utilised as a self-report tool to 
ascertain potential barriers to medicines administration. In 12 of these 25 studies, a closed 
question approach defining a ‘choice list’ of barriers to medicines acceptance or adherence 
was reported (Buchanan et al., 2012, Byrne et al., 2002, Davies et al., 2008, Esteban Gomez 
et al., 2004, Farley et al., 2003, Ingerski et al., 2010, Plipat et al., 2007, Pontali et al., 2001, 
27 included review studies 
20 studies   
14 HIV studies 
3 organ 
transplant 
studies- liver 
(n=1) renal 
(n=2) 
1 oncology 
study 
1 
inflammatory 
bowel disease 
study 
1 respiratory 
study (patients 
with cystic 
fibrosis- CF or 
asthma)  
7 'key studies' 
reporting 
outcomes on 
an individual 
drug level. 
7 HIV studies  
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Shemesh et al., 2004, Tucker et al., 2002, Van Dyke et al., 2002, Zelikovsky et al., 2008). 
Several of these studies gave an additional option to list a further barrier that was not stated 
in the list.  
The remaining 13/25 studies adopted a more ‘open-ended question’ approach to explore 
barriers to medicines acceptance or adherence in detail, revealing a plethora of qualitative 
data and some individual quotations (Boni et al., 2000, Bunupuradah et al., 2006, 
Christiansen et al., 2008, Gibb et al., 2003, Goode et al., 2003, Hammami et al., 2004, 
LePrevost et al., 2006, Marhefka et al., 2004, Modi and Quittner, 2006, Paranthaman et al., 
2009, Reddington et al., 2000, Roberts, 2005, Wrubel et al., 2005).  
The final 2/27 studies provided results based on review of medical records. As relatively few 
studies have explored oral formulation-related barriers to medicines administration in 
children with chronic conditions, studies reviewing medical records were included in this 
review. Figure 6 below shows the classification of study methodologies across the included 
review studies. 
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Figure 6 The methodological designs of the 27 included review studies. 
4.4.3.1 Introduction to the 7 ‘key studies’ 
Of the 7 ‘key studies’, 3 studies (Bunupuradah et al., 2006, Gibb et al., 2003, Van Dyke et al., 
2002) conducted randomised trials and adopted multi-method design. The interview 
components within these studies revealed relevant data for this review. Randomised 
controlled trials are of higher hierarchical study design quality as discussed earlier (see 
section 4.3.8), however it was the interview and medical record data that was investigated in 
this review. Davies and co-workers (2008) and Lin and co-workers (2011) used multi-method 
design and the questionnaire component and chart review were of interest to this review. 
Goode and co-workers (2003) and Reddington and co-workers (2000) adopted a single-
method design consisting of a telephone survey and interview correspondingly.  
Qualitative, open-ended questions reveal the most detailed and useful data for this review 
as they permit exploration of the obstacles to medicines administration. Of the 7 ‘key 
27 studies 
25 studies used a 
child/parent self-report tool 
12 studies used closed 
questions, majority 
provided option to 
add an additional 
barrier  
13 studies adopted an 
open-ended question 
approach 
2 studies used 
healthcare 
professional 
documentation of 
child/parent self-
report  
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studies’, 3 studies adopted the Pediatric Adherence Clinical Trials Group - PACTG (NIAID) 
questionnaire as the self-report data collection tool (Bunupuradah et al., 2006, Davies et al., 
2008, Van Dyke et al., 2002). This includes closed-style questions with a limited list of 
barriers ending with an option of ‘other’. Gibb and co-workers (2003) and Goode and co-
workers (2003) used open-ended questions in their studies. In the study by Reddington and 
co-workers (2000) the style of all questions could not be interpreted from the study report, 
however results suggest that difficulties with medicines were explored using open-ended 
questions. 
Lin and co-workers (2011) adopted a different methodological approach, involving the 
review of patient records. Data collected from patient records should mirror a retrospective 
recorded qualitative interview format, although it is probable that detail recorded regarding 
problems with medicines may vary. 
4.4.4 Results: A narrative review  
All 27 included review studies were screened for oral formulation-related barriers to 
medicines administration on child acceptance of or adherence to medicines and the relevant 
data was extracted. A thematic analysis approach was adopted by RV, as guided by Pope and 
co-workers (2000). Thematic study findings for primary and secondary outcome measures 
were categorised under the subsequent subheadings: 
 Report on oral formulation-related barriers to medicines administration: Taste 
(including aftertaste), size or swallowing (size of solid dosage form or medicine 
described as difficult to swallow), quantity or volume (of solid dosage forms or 
liquid/powder), texture, smell and colour (including appearance)  
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 Report on the influence of oral formulation-related barriers to medicines 
administration on child acceptance of or adherence to medicines 
 Report on medicines manipulation techniques used to administer medicines. 
In the 7 ‘key studies’, at least one oral formulation-related barrier to medicines 
administration was associated with a specific drug (some with a specific formulation 
reported). Where specified drugs or formulations were associated with a particular oral 
formulation-related barrier these are reported at the end of the appropriate themed 
section. 
4.4.4.1 Taste  
All 27 studies discussed reports of taste and/or aftertaste problems. Taste was identified as a 
key obstacle to medicines administration in 25/27 of the included studies. Data is 
summarised in Table 2. 
Of the 27 studies, 3 studies investigated antiretrovirals and reported data in a qualitative 
manner, revealing participant quotes (Hammami et al., 2004, Paranthaman et al., 2009, 
Roberts, 2005).  
Hammami and co-workers (2004) revealed a taste problem highlighted by a parent, and the 
way that the parent dealt with it, offering ‘nice tasting things’ at the same time as 
administering the medicine to facilitate child acceptance of the medicine. 
Roberts (2005) reported childrens’ views on medicines poorly accepted as a result of 
disliking the taste.  
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Crying because of the ‘bitter taste of the medicines’ was reported by a caregiver of a non-
adherent child according to Paranthaman and co-workers (2009). 
In 2/27 studies, taste was not reported to be a main obstacle to medicines administration. 
Wrubel and co-workers (2005) reported that the mothers of the children in their study did 
not portray taste issues as a “central difficulty,” rather a “challenge to be mastered.” Tucker 
and co-workers (2002) studied results from patients of different ethnic origins (African 
American and European) and found that neither ethnic group disliked taking their medicines 
‘because they tasted bad or may make them sick,’ however properties of their medicines 
including pill taste was found to have low to moderate significant associations with 
adherence measures. 
Caregiver reports of main problems when administering medicines to children were ranked 
based on frequency of reporting and stratified according to age range of the child (<6 years, 
6-10 years and >10 years) in only one of the 27 studies (Pontali et al., 2001). Across the three 
age categories ‘child complains of bad taste’ was the highest rated oral formulation-related 
barrier amongst children younger than 6 years (see Table 2 for ranked results across age 
ranges). 
Buchanan and co-workers (2012) interviewed both children and caregivers independently 
and found significant agreement between their reports of the barrier: ‘taste/cannot keep it 
down (pill/liquid)’ based on a kappa test (k=0.44, (P<0.001)), as reported in Table 2. 
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Frequencies of reported oral formulation-related barriers to child acceptance or medicines 
adherence were not provided in all of the study reports. Where frequency was reported this 
is detailed in Table 2. 
All 7 ‘key studies’ investigated antiretroviral medicines. Taste problems associated with 
ritonavir and/or nelfinavir were highlighted in 6 of these. It was anticipated that 
commonalities would be observed across these studies as they only considered a narrow 
range of medicines. Of the 7 studies, only 3 studies reported the formulation of the drug 
concerned, these are reported in Table 3 below. 
Table 3 ‘Key studies’ reporting taste problems with specific drug formulations. 
Authors Sample size Taste problems with specific drug 
formulations 
Bunupuradah and co-
workers (2006) 
Caregivers of 30 children The reason for a child disliking to take 
their medicines was the bitter tastes of: 
opened efavirenz capsules, crushed 
nevirapine tablets, didanosine powder, 
lamivudine syrup and generic zidovudine 
syrup. 
Reddington and co-workers 
(2000) 
Caregivers of 90 children 
(Tablets 20% of the children (18 
of 90) Liquids 30% (27 of 90) 
combination for 50% (45 of 90)) 
Reasons for difficulties in administration 
were the ‘taste and consistency of 
nelfinavir powder and the taste of both 
the pill and liquid form of ritonavir.’ 
Van Dyke and co-workers 
(2002) 
Caregivers of 125 children 
 
The main reasons reported for non-
adherence: included the bad taste of 
ritonavir liquid, 16% and nelfinavir 
powder/tablets,  9% (note- results for 
nelfinavir powders and tablets were 
pooled). 
 
4.4.4.2 Size or swallowing 
4.4.4.2.1 Size of solid dosage form 
Problems relating to the sizes of solid dosage forms or swallowing medicines were 
investigated in 16/27 studies (Boni et al., 2000, Buchanan et al., 2012, Christiansen et al., 
2008, Esteban Gomez et al., 2004, Feingold et al., 2000, Gibb et al., 2003, Ingerski et al., 
63 
2010, Lin et al., 2011, Marhefka et al., 2004, Modi and Quittner, 2006, Paranthaman et al., 
2009, Pontali et al., 2001, Reddington et al., 2000, Roberts, 2005, Tucker et al., 2002, 
Zelikovsky et al., 2008). 
Frequencies of size or swallowing reports are provided in Tables 4 – 7 for studies in which 
this data is revealed. 
Of the 16 studies, 8 referred to the size of the solid dosage form, as reported in Tables 4 and 
5. The dimensions of the solid dosage forms were not specified in these reports. 
Table 4 Problems reported with the size of solid dosage forms. 
Authors Sample size Reports of problems with the size of 
solid dosage forms 
Buchanan and co-workers (2012) Children/youth with perinatally 
acquired HIV and their 
parents/caregivers (n = 120 
dyads) 
‘Taste, can’t get it down/keep it 
down (pill/liquid)’ reported as a 
barrier to adherence grouped with 
taste (reason for missing medicines 
in previous month). 
Christiansen and co-workers 
(2008) 
55 caregivers ‘Capsules too big to swallow’ was a 
problem or difficulty reported by 1 
parent when dealing with oral 
chemotherapy. 
Marhefka and co-workers (2004) 51 Participants (parents or 
primary caregivers) 
‘Too big to swallow’ reported by 5 
caregivers as a barrier to adherence. 
Paranthaman and co-workers 
(2009) 
A convenience sample of 14 
caregivers 
‘Size of tablets’ was reported as a 
medication related factor influencing 
adherence. 
Roberts (2005) 9 children interviewed with 
guardians and guardians 
(alone) of 5 additional children 
A 7-year-old boy revealed: 
“It’s hard because they’re too big for 
me. Because when it goes down like 
this, it goes ‘dush, dush, dush.’ It 
hurts my throat.” 
 
Tucker and co-workers (2002) 68 paediatric patients with 
renal transplants and their 
caregivers 
No patients agreed that taking their 
pills or medications was difficult 
because of ‘Size.’ 
 
Buchanan and co-workers (2012) indicated that the size of solid dosage forms was a barrier 
to medicines adherence, but this was not clear in the questionnaire methodology and 
therefore was difficult to interpret. The barrier: ‘Taste, can’t get it down or keep it down’ 
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suggests a problem which could be related to the size of a solid dosage form but this was not 
clarified in the study. 
Tucker and co-workers (2002) concluded that neither African Americans nor European 
Americans reported problems swallowing tablets resulting from the size of tablets, however 
this had low to moderate significant associations with adherence measures. 
Data on size problems with individual solid dosage forms was detailed in 2 of the 7 ‘key 
studies’. This is provided in Table 5 below. 
Table 5 Problems reported with the size of individual solid dosage forms in ‘key studies.’ 
Authors Sample size Reports of problems with the size of 
solid dosage forms 
Gibb and co-workers (2003) At least one caregiver 
questionnaire returned for 108 
children 
Large size of nelfinavir tablets reported 
as a reason why a child had difficulty 
with taking medicines grouped with 
other oral formulation-related barriers. 
Reddington and co-workers 
(2000) 
Caregivers of 90 children 
(Tablets 20% of the children (18 
of 90) Liquids 30% (27 of 90) 
combination for 50% (45 of 90)) 
Large size of nelfinavir tablets reported 
as a reason for difficulty with 
administration. 
 
4.4.4.2.2 Difficulties with swallowing medicines 
In 8/16 of the studies, reports on difficulties with or aversion to swallowing medicines were 
provided (see Tables 6 and 7). 
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Table 6 Reported difficulties with swallowing solid dosage forms and liquids. 
Authors Sample size Reports of difficulties with swallowing 
solid dosage forms 
Boni and co-workers (2000) Parents/legal guardians of 25 
children 
‘Difficulty swallowing’ was a problem 
pointed out by 32% of parents or legal 
guardians in administration of 
antiretroviral treatment. 
Esteban Gomez and co-
workers (2004) 
28 caregivers of 32 paediatric 
patients undergoing active 
antiretroviral therapy 
‘Deglutition’ reported as a difficulty with 
adherence. Average scores of 0.1 (low 
difficulty) and 2.3 (moderate difficulty) 
for liquid reverse transcriptase inhibitors 
and protease inhibitors respectively. 
Average scores of 0.75 (low difficulty) 
and 1.8 (low difficulty) for reverse 
transcriptase inhibitors and protease 
inhibitors respectively in solid dosage 
forms. 
Feingold and co-workers 
(2000) 
Chart review of 70 children ‘Inability to swallow pills or capsules’ was 
reported as a reason for changing 
medicines. 
Ingerski and co-workers 
(2010) 
74 adolescents and their 
primary caregivers together 
‘Hard to swallow’ was reported as a 
barrier to adherence by 10.8% of Crohn’s 
patients. 
Modi and Quittner (2006) 73 children and parents 
separately 
‘Swallowing’ reported by 13% and 25% of 
CF children regarding oral enzymes and 
oral antibiotics respectively, and 14% of 
parents of asthmatics regarding allergy 
medicines. 
Pontali and co-workers (2001) Caregivers of 44 children ‘Swallowing’ reported by 29.5% of 
caregivers as a problem when giving 
medicines to their child. 
Zelikovsky and co-workers 
(2008) 
56 adolescents listed for a 
kidney transplant, mean age 
and their carers 
 
‘Hard to swallow pills’ reported by 2% of 
adolescents as a reason for difficulty with 
medicines/ an obstacle that may cause 
non-adherence. 
 
Esteban Gomez and co-workers (2004) reported moderate difficulty with adherence to liquid 
protease inhibitors resulting from child aversion. 
Pontali and co-workers (2001) found that ‘Difficulty swallowing pills’ was a main problem 
with medicines administration reported by caregivers of children over 6 years of age (see 
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Table 2). Caregivers of children less than 6 years did not report difficulty with swallowing 
tablets as a main problem as syrups and suspensions were available (Pontali et al., 2001).  
Zelikovsky and co-workers (2008) reported that the barrier to adherence: ‘hard to swallow 
pills’ had a low rate of endorsement in their study, thus the authors concluded that there 
was insufficient power to examine the relationship between this barrier and adherence.   
In one of the seven ‘key studies’, Lin and co-workers (2011) reported records of ‘cannot 
swallow’ for several antiretroviral drugs (see Table 7 below). The specific formulations were 
not reported, this is a study limitation. 
Table 7 The number of prescriptions refused resulting from documented reports that 
patient ‘cannot swallow’ in the ‘key study’ by Lin and co-workers (2011). 
Authors Sample size Drug and number of prescriptions refused 
Lin and co-
workers (2011) 
Chart review of 119 children Abacavir 1 
Amprenavir 0 
Didanosine 1 
Efavirenz 1 
Indinavir* 
Lamivudine 0 
Lopinavir/ritonavir 0 
Nelfinavir 0 
Nevirapine* 
Ritonavir 1 
Saquinavir* 
Stavudine 1 
Zalcitabine* 
Zidovudine 0 
Total= 5/72 of prescribed medicines refused 
resulted from patient report ‘cannot swallow’ 
as documented in medical records. 
 
*= no medicines refused because of any factors related to palatability. 
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4.4.4.3 Quantity or volume 
4.4.4.3.1 Problems with the quantity of solid dosage forms 
Problems associated with the quantity of solid dosage forms were discussed in 6 of the 27 
studies (see Table 8 below). 
Table 8 Reported problems associated with the quantity of solid dosage forms. 
Authors Sample size Reports of problems with the 
quantity of solid dosage forms 
Boni and co-workers (2000) Parents/legal guardians of 25 
children 
‘Too many medicines/tablets to 
take’ was a problem pointed out 
by 36% of parents or legal 
guardians in administration of 
antiretroviral treatment. 
Buchanan and co-workers (2012) Children/youth with perinatally 
acquired HIV and their 
parents/caregivers (n = 120 dyads) 
‘Too much medication’ reported 
by 9% of children and 2% of 
caregivers (data from reported 
histogram). 
Christiansen and co-workers 
(2008) 
55 caregivers ‘There were a lot of tablets to 
take at once’ reported by 3 
parents as a problem or difficulty 
when dealing with oral 
chemotherapy. 
Gibb and co-workers (2003) At least one caregiver 
questionnaire returned for 108 
children 
“Difficulties with quantities” was 
a reason reported for a child 
having difficulty taking medicines 
grouped with other oral 
formulation-related barriers 
Marhefka and co-workers (2004) 51 participants (parents or primary 
caregivers) 
‘Too many pills’ reported by 3 
caregivers as a barrier to 
adherence. 
Pontali and co-workers (2001) Caregivers of 44 children ‘Too many medicines/pills’ was a 
problem experienced by 34% of 
caregivers when administering 
medicines to children. 
Main problems stratified to age 
ranges <6 years, 6-10 years and > 
10 years. 
Too many medicines/pills was 
listed as a main problem for 
children over 6 years. 
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Gibb and co-workers (2003) did not report the drug formulation/s for which difficulties with 
quantities were reported. Also, the frequency of reports of difficulties with quantities was 
not revealed by Gibb and co-workers (2003). 
4.4.4.3.2 Problems with the volume of liquids or powders 
Comments on the volume of antiretroviral liquids or powders were reported in 3 of the 27 
studies (see Tables 9 and 10 below).  
Table 9 Reported problems associated with the volume of liquids or powders. 
Authors Sample size Reports on the volume of 
antiretroviral formulations 
Byrne and co-workers (2002) Primary caregivers of 44 children 10% of respondents identified 
volume as a barrier to 
administering medicines to 
children. 
Marhefka and co-workers (2004) 51 participants (parents or primary 
caregivers) 
Revealed medicine volume as a 
barrier to adherence, reported by 
a single respondent ‘child doesn’t 
drink all the medicines.’ 
 
In one of the seven ‘key studies’, difficulty with the volume of a drug formulation was 
specified as provided in Table 10 below. 
Table 10 Reported problems associated with the volume of a specific drug formulation in 
the ‘key study’ by Van Dyke and co-workers (2002). 
Authors Sample size Reports of problems with 
volume of a specific drug 
formulation 
Van Dyke et al. (2002) Caregivers of 125 children The ‘large volume’ of nelfinavir 
powder was reported to be 
challenging for parents to 
administer. 
 
It is unclear as to whether the problem reported with the volume of nelfinavir powder was 
an assumption as data from parents was not provided to support this finding. However, the 
discussion reported that an average 6 year old is required to take 25 scoops of nelfinavir 
powder with food twice a day (actual volume not reported) (Van Dyke et al., 2002). 
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4.4.4.4 Texture  
Problems with the texture of medicines were reported in 4 of the 27 studies (Esteban Gomez 
et al., 2004, Gibb et al., 2003, Reddington et al., 2000, Van Dyke et al., 2002). See Tables 11 
and 12 below for reported problems with texture. 
Table 11 Reported problems with the texture of medicines. 
Authors Sample size Reported problems with texture 
Esteban Gomez and co-workers 
(2004) 
28 caregivers of 32 paediatric 
patients undergoing active 
antiretroviral therapy 
Acknowledged the need to 
improve textures of medicines, 
however did not include study 
data on texture to support this. 
Gibb and co-workers (2003) At least one caregiver 
questionnaire returned for 108 
children 
Reported the consistency of 
medicines as a difficulty for 
children taking antiretroviral 
medicines grouped with other oral 
formulation-related barriers. 
 
Of the ‘key studies’, 2/7 reported problems associated with the texture of specific drug 
formulations as provided in Table 12 below. 
Table 12 Reported problems with the texture of specific drug formulations in the ‘key 
studies.’ 
Authors Sample size Reported problems with the texture 
of specific drug formulations 
Reddington and co-workers 
(2000) 
90 caregivers ‘Disliking’ the consistency of nelfinavir 
powder was reported as a reason for 
difficulty with administration. 
Van Dyke and co-workers (2002) 
 
125 children The texture of nelfinavir powder was 
described as unusual and challenging 
for parents. 
 
No frequency data was reported on the impact of texture as a barrier to medicines 
administration. Reported caregiver data was not revealed in the study by Van Dyke and co-
workers (2002), this could be postulation of the authors. 
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4.4.4.5 Smell 
Perceptions regarding the smells of medicines were reported in 4/27 studies (Esteban 
Gomez et al., 2004, Gibb et al., 2003, Lin et al., 2011, Roberts, 2005). 
A quotation describing problems with sensory properties of a medicine was reported by 
Roberts (2005) and is provided in the ‘colour/appearance’ themed section, 4.4.4.6. 
Esteban Gomez and co-workers (2004) reported problems on an average scaled measure 
ranging from 0-5 (0= causing no difficulties 5= causing maximum difficulties with adherence). 
The average smell scores were reported for the liquid: reverse transcriptase inhibitors and 
protease inhibitors as 0.3 and 2.1 respectively. The study found that the smell of protease 
inhibitors caused moderate difficulties with adherence. 
Of the 7 ‘key studies’, 2 studies discussed reports regarding the smells of antiretroviral 
drugs. This is detailed in Table 13 below. 
Table 13 Reports of unfavourable smells associated with specific drugs in the ‘key studies.’ 
Authors Sample size Smell reports associated with specified drug 
Gibb and co-
workers (2003) 
At least one caregiver questionnaire 
returned for 108 children. 
Reports of hating the smell of nelfinavir were 
provided by caregivers as reasons for 
difficulty taking antiretrovirals and grouped 
with other oral formulation-related barriers.  
Lin and co-
workers (2011) 
Chart review of 119 children. Smell was part of the palatability assessment 
of the antiretroviral medicines in their study, 
this was encompassed within the ‘dislike 
taste’ category. The independent effect of 
smell was not reported in this study. 
 
The prevalence of reports of poor acceptance of smell was not provided by the authors. 
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4.4.4.6 Colour/appearance  
Roberts (2005) reported the quotation of a child who perceived the appearance of an 
unspecified antiretroviral medicine negatively:  
“He started having problems taking it, like if he looks at it or smells it, then he’s just coughing 
and gagging...”  
 
4.4.4.7 The influence of oral formulation-related barriers to medicines 
administration on child acceptance of or adherence to medicines  
4.4.4.7.1 The influence of oral formulation-related barriers to medicines administration 
on child acceptance of or adherence to medicines in the non-key studies (n=20)  
The influence of individual oral formulation-related barriers to medicines administration on 
child acceptance of or adherence to medicines was not quantified in 5 of the 20 non-key 
studies (Hammami et al., 2004, Paranthaman et al., 2009, Plipat et al., 2007, Roberts, 2005, 
Wrubel et al., 2005). However, the effects of oral formulation-related barriers to medicines 
administration on child acceptance of or adherence to medicines were implied through the 
qualitative-style reports which included subject quotations (see Table 2). 
The impact of oral formulation-related barriers to medicines administration on child 
acceptance of or adherence to medicines was quantified in 15 of the 20 non-key studies. The 
outcome measures (acceptance or adherence) were heterogeneous across the studies and 
could not be compared. Non-adherence was defined across the studies as omitting doses of 
medicines, delaying administration of doses or changing to an alternative drug formulation 
in several studies. In studies where the adherence measure was not clearly defined, 
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reported outcomes included resisting medicines administration and further factors, as 
reported in Table 2. 
4.4.4.7.2 The influence of oral formulation-related barriers to medicines administration 
on child acceptance of or adherence to medicines for ‘key studies’ (n=7) 
All of the 7 ‘key studies’ investigated oral formulation-related barriers to medicines 
administration on child acceptance of or adherence to medicines. A summary table of 
relevant study findings are reported in Table 14 below. 
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Table 14 Reported oral formulation-related barriers to medicines administration on child acceptance of or adherence to medicines 
across the 7 ‘key studies.’ 
Authors Sample size Reported oral formulation-
related barriers to medicines 
administration  
Correlation to child acceptance of or adherence to 
medicines  
Limitations 
Bunupuradah and 
co-workers (2006) 
Caregivers of 
30 children 
Issues experienced with 
specific antiretroviral 
medicines prior to taste-
masking.  
Adherence was unaffected by taste-masking as all 
participants reported full adherence. 24/30 children said 
that they liked FLAVORx and wanted to carry on using it. Six 
children did not want to continue using FLAVORx; 
caregivers of three children found it too difficult, two 
children (on orange and strawberry flavours) reported 
burning  sensation on the tongue, and one child had 
repeated vomiting immediately after taking FLAVORx 
(strawberry flavour). 
 
 
 
 
 
 
Davies and co-
workers (2002) 
Caregivers of 
122 children 
Experience with giving 
medication: Poor palatability 
was identified as the most 
common issue in this study by 
21.8% of caregivers, 68% of 
these attributed to ritonavir. 
Experiencing problems (including taste) with antiretroviral 
medicines did not affect measured or reported adherence 
in the month in which problems were revealed, however 
was associated with annual adherence measured by 
medication return <90% (OR = 3.07; 95% CI: 0.91 – 
10.38; p = 0.06). 
 
 
 
 
 
 
 
 
The prevalence of 
problems for 
individual drugs was 
not quantified. 
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Authors Sample size Reported oral formulation-
related barriers to medicines 
administration  
Correlation to child acceptance of or adherence to 
medicines  
Limitations 
Gibb and co-
workers (2003) 
At least one 
caregiver 
questionnaire 
returned for 
108 children 
Reported ‘reasons why a child 
had difficulty taking medicines’  
Highlighted the widest variety 
of oral formulation-related 
barriers across the studies: 
comments on 
taste/flavour/smell, size of 
tablets, consistency of 
medicine, causing 
vomiting/nausea and difficulty 
in swallowing were grouped 
and revealed as having the 
largest number of responses 
(n=48). 
Taking nelfinavir powder was not statistically associated 
with poorer adherence, yet reported as having a high 
volume and being hard to dissolve. 
Nearly 80% of children starting nelfinavir powder switched 
to tablets, (majority in the first 8 weeks). There was no 
significant difference reported in adherence between 
placebo and nelfinavir. 
 
Quantitative results 
for the influence of 
independent oral 
formulation-related 
barriers on medicines 
acceptance or 
adherence were not 
provided.  
Goode and co-
workers (2003) 
18 parents (12 
of which were 
also treated 
for HIV on 
HAART 
regimens) 
Taste (44%), side effects (44%) 
and procedural factors (28%)- 
including the mixing and 
preparation of medicines were 
responsible for most 
antiretroviral ‘administration 
difficulties’ in this study. 
Such difficulties administering antiretroviral medicines 
accounted for 50% of children taking nelfinavir or ritonavir 
changing or omitting their medicine. 
The prevalence of 
problems for 
individual drugs was 
not quantified. 
Lin and co-
workers (2011) 
119 children Reasons for medicines refusal 
for individual drugs were 
attributed to each key taste 
issue (dislikes taste, cannot 
swallow, spits out drugs and 
vomits). Results reported 
quantitatively, and directly 
associated with medicines 
refusal and drug changes. 
 
Ritonavir was disliked most with 50% of children refusing it 
because of poor taste, and in 27% of children, ritonavir was 
changed to an alternative drug. 
The prevalence of 
problems for specific 
formulations was not 
reported. 
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Authors Sample size Reported oral formulation-
related barriers to medicines 
administration  
Correlation to child acceptance of or adherence to 
medicines  
Limitations 
Reddington and 
co-workers (2000) 
90 caregivers Reasons for difficulty in 
administration were primarily 
the size of the nelfinavir 
tablets, the consistency and 
taste of nelfinavir powder and 
the taste of ritonavir liquid and 
tablets. 
Sixty-three percent of respondents (57 of 90) reported that 
a particular medication was harder to administer. 
Nelfinavir followed by ritonavir were most difficult to 
administer.  
Missing doses was likely to be due to children refusing 
medicines (reported by 16% of respondents). 
Problems with oral 
formulation-related 
barriers to medicines 
administration were 
reported in a non-
quantitative fashion. 
Further evaluation as 
to why medicines 
were refused was not 
reported. 
 
Van Dyke and co-
workers (2002) 
Caregivers of 
125 children 
Taste of ritonavir liquid and 
nelfinavir (tablets/liquid?) 
 
Difficulty with adherence was more commonly reported for 
the protease inhibitors than for the reverse transcriptase 
inhibitors. A common reason for non-adherence was 
revealed as taste 16%, and 9% for ritonavir liquid and 
nelfinavir (tablets/liquid?) respectively.  
The formulation of 
nelfinavir was unclear 
in the study. 
In addition, Reddington and co-workers (2000) found that 81% of caregivers rated ‘better tasting medicines’ as 'very helpful’ based on a 
question using a Likert scale. This was the highest rated intervention, indicating that palatability was a central issue perceived by 
caregivers.
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4.4.4.8 Secondary outcome: Reports on medicines manipulation techniques 
The 27 included review studies were examined for descriptions of medicines manipulation 
techniques used to facilitate the administration of medicines to children (e.g. to improve 
palatability) or for the purpose of administering a specific dose (e.g. one quarter of a tablet). 
Medicines manipulation techniques may be used by parents, carers or children on their own 
accord or sometimes following the instructions of a healthcare professional. Of the 27 
included studies, 10 discussed manipulation techniques. Of these 10 studies, Bunupuradah 
and co-workers (2006) and Lin and co-workers (2011) discussed manipulation techniques 
instructed by the study teams as opposed to volunteered by parent, carers and children. 
Details of manipulation techniques used by parents and carers to administer medicines to 
children were revealed in 6 of the 10 studies reporting medicines manipulation techniques 
(see Table 15). For 4/10 studies reporting medicines manipulation, details of the techniques 
used were not reported. Details on drugs and formulations manipulated were not specified 
in these studies (see Table 16). Where frequency data was reported this is provided in the 
Tables. 
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Table 15 Reported manipulation techniques used to administer medicines.  
Authors Sample size Reported medicines manipulation techniques  
Bunupuradah and co-workers 
(2006) 
Caregivers of 30 children Discussed FLAVORx addition to antiretroviral medicines in attempt to improve 
palatability. This study considered a uniform approach to taste-masking antiretrovirals 
and found that in 80% of children, masking the bitter taste of antiretroviral medicines 
helped them to take them more easily. Strawberry, orange and grape flavours were the 
most popular. 
Christiansen and co-workers 
(2008). 
55 caregivers An administration problem encountered by parents included having difficulty crushing 
tablets and additionally crushing tablets as liquid was not tolerated. Reports of crushing 
tablets at least once were provided by 24% of parents. 
Breaking capsules in to ice-cream and crushing tablets on cornflakes were described by 
two fathers in the study.  
Lin and co-workers (2011) 119 children Authors suggested adding FLAVORx to opened capsules to improve palatability. There 
was no discussion of administration techniques volunteered by parents/carers or 
children. 
Paranthaman and co-workers 
(2009) 
A convenience sample of 14 
caregivers 
Quotation of an adherent caregiver: “It was difficult to break the tablets into exact doses. 
Once they prescribed 1/3
rd
 of the tablet but it is difficult to give. For this, syrup would 
have been better. I feel it is difficult because we are unable to break the tablet correctly. I 
have the feeling that I am not giving the correct dosage.” 
Roberts (2005) 9 children interviewed with 
guardians and guardians (alone) 
of 5 additional children 
Some guardians reported giving their children various foods or beverages (e.g., pudding) 
to make the medications more palatable. 
 
Wrubel and co-workers (2005) 71 caregivers provided one or 
more accounts 
32% of mothers in the study provided examples of how they improve palatability, mixing 
medicines with some food to disguise the taste, or giving a sweet drink immediately after 
giving medicines. 
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Table 16 Reported non-specific medicines manipulation data across the studies.  
Authors Sample size Non-specific medicines manipulation data 
Byrne and co-workers (2002) Primary caregivers of 42 
children 
Strategies to improve taste or to omit bad aftertaste were frequently reported (29% and 
24%, respectively). 
Goode and co-workers (2003) 18 parents (12 of which were 
also treated for HIV on HAART 
regimens) 
Procedural factors (including the mixing and preparation of medicines) was a difficulty 
reported by 28% of the respondents. 
Hammami and co-workers (2004) 11 primary caregivers of 18 
children 
Parents offering “nice tasting things” as a reward for taking the medicine. 
Marhefka and co-workers (2004) 51 Participants (parents or 
primary caregivers 
Described difficulties experienced by a caregiver when preparing a solution. No more 
details were reported.  
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4.4.5 Quality assessment and risk of bias in review studies 
The participants recruited varied across the included studies (i.e. parents/caregivers versus 
young people). If a child is competent to understand and consent they should be given 
opportunity to participate in a study. However, fewer than one third (8/27 = 30%) of the 
studies (Buchanan et al., 2012, Ingerski et al., 2010, Modi and Quittner., 2006,  Roberts, 
2005, Shemesh et al., 2004, Tucker et al., 2002, Van Dyke et al., 2002, Zelikovsky et al., 2008) 
reported child involvement. In the majority of the studies the young ages of the children 
would make assent impossible. Children may only provide assent to participate in a study if 
they are able to fully understand it. 
It is important to remember that responses of caregivers and children may differ. Modi and 
Quittner (2006) highlighted that swallowing oral enzymes and antibiotics were barriers 
identified by children with Cystic Fibrosis (CF) in addition to those barriers identified by 
parents. In the study by Shemesh and co-workers (2004), bad taste was a barrier reported by 
4.9% of caregivers of children with liver transplants however problems associated with bad 
taste were not reported by these children. 
In paradox to these discrepancies between the reports of caregivers and children, Buchanan 
and co-workers (2012) reported significant agreement for the barrier “taste/cannot get it 
down” (k=0.44, (p<0.001)) when comparing child and caregiver responses relating to HIV 
treatment. As these findings are inconsistent, it seems beneficial to interview child and 
caregiver independently. When this is not possible a family environment would be preferred 
and discrepancies reported. 
80 
Ethical consideration should be at the forefront of studies involving children. Ethical 
approval was not discussed in 9 papers (Boni et al., 2000, Buchanan et al., 2012, Byrne et al., 
2002, Esteban Gomez et al., 2004, Hammami et al., 2004, Paranthaman et al., 2009, Pontali 
et al., 2001, Roberts, 2005, Zelikovsky et al., 2008) and informed consent was not mentioned 
in 5 studies (Christiansen et al., 2008, Goode et al., 2003, Lin et al., 2011, Pontali et al., 2001, 
Shemesh et al., 2004). As the data was collected differently in 2 studies (Feingold et al., 
2000, Lin et al., 2011) the level of ethical approval and consent requirements may have 
differed, however no information on ethics was reported in the studies. 
Studies adopting qualitative methodological approaches are often more time consuming and 
for this reason lower numbers of participants may be recruited.  For 3/12 studies adopting a 
closed-question approach (i.e. a less qualitative nature) sample sizes were relatively low 
(n=20) (n=28) and (n=44) (Esteban Gomez et al., 2004, Farley et al., 2003, Pontali et al., 
2001) given respectively, thus impacting on the power of these studies. Also, it is possible 
that recruitment rate is lower in HIV studies as some parents may choose not to participate 
for fear of disclosing HIV status to their child (Bikaako-Kajura et al., 2006). 
Interviewer bias can arise in interviews or when facilitating questionnaires. For 18/27 studies 
the study personnel are either not disclosed in the text or are recorded as interviewer or 
researcher and no more information is provided (Boni et al., 2000, Buchanan et al., 2012, 
Bunupuradah et al., 2006, Christiansen et al., 2008, Gibb et al., 2003, Goode et al., 2003, 
Ingerski et al., 2010, LePrevost et al., 2006, Marhefka et al., 2004, Modi and Quittner, 2006, 
Plipat et al., 2007, Reddington et al., 2000, Roberts, 2005, Shemesh et al., 2004, Tucker et 
al., 2002, Van Dyke et al., 2002, Wrubel et al., 2005, Zelikovsky et al., 2008). 
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For 3/27 studies, it was implicitly reported that the interviewers were not part of the care 
team (Byrne et al., 2002, Farley et al., 2003, Hammami et al., 2004). However, in 2/27 
studies (Davies et al., 2008, Pontali et al., 2001) the interviewer was known by the 
participants. In the study by Esteban Gomez and co-workers (2004) a pharmacist dispensing 
medicines conducted the research, however it was not stated if they were known to the 
subjects. Paranthaman and co-workers (2009) declared that their interview was conducted 
by the principal investigator (who had no role in clinical care provided). The study conducted 
by Bunupuradah and co-workers (2006) was funded by the FLAVORx Company, and 
therefore the potential risk of bias in this study needs to be highlighted. 
To assess the methodological design of a study, the detailed content of the self-report tool is 
required. For 2/27 studies (Feingold et al., 2000, Lin et al., 2011) reporting data documented 
by healthcare professionals in medical records, specific methodology on how data was 
recorded was not revealed in the study reports. In 9/27 studies, themes explored in 
interviews were discussed although the exact questions were not always reported (Byrne et 
al., 2002, Christiansen et al., 2008, Gibb et al., 2003, Goode et al., 2003, Hammami et al., 
2004, LePrevost et al., 2006, Modi and Quittner, 2006, Paranthaman et al., 2009, Roberts, 
2005). In  8/27 studies the questions constituting the self-report tool were reported 
(Buchanan et al., 2012, Esteban Gomez et al., 2004, Marhefka et al., 2004, Pontali et al., 
2001, Reddington et al., 2000, Shemesh et al., 2004, Tucker et al., 2002, Wrubel et al., 2005).  
The remaining 8/27 studies referenced an existing self-report tool available in the literature: 
Boni and co-workers (2000) referenced questions used by Gross and co-workers (Gross et 
al., 1998), the PACTG tool was referenced by 5 studies (Bunupuradah et al., 2006, Davies et 
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al., 2008, Farley et al., 2003, Plipat et al., 2007, Van Dyke et al., 2002) and the MAM 
referenced by 2 studies (Ingerski et al., 2010, Zelikovsky et al., 2008).  
In several of the studies using a multiple choice closed-question approach, a final option of 
‘other’ was available to enable the interviewee to report an alternative barrier to medicines 
administration. A risk of using closed questions is the ability to direct the interviewee to an 
option, reducing accountability of the response. However, when comparing results of these 
studies to those studies adopting a more qualitative approach, findings were similar.  
Assessment of study quality in this review proved difficult. This required assessment of 
quality of the methodology of interest to the present study (self-report component). The 
self-report tools varied across the studies (i.e. non-standardised interviews and 
questionnaires versus data documented by healthcare professionals). For the majority of 
studies, exploration of oral formulation-related barriers to medicines administration was not 
the main study focus. Limited studies have extensively explored oral formulation-related 
barriers, and generally the quality of reporting was sub-optimal. The impact of individual oral 
formulation-related barriers on specified outcome measures was not reported clearly in the 
studies. 
A systematic literature review titled ‘Effects of the Pharmaceutical Technologic Aspects of 
Oral Pediatric Drugs on Patient-Related Outcomes’ (Van Riet-Nales et al., 2010) similarly 
acknowledged poor quality across study methodologies. They reported that only 2 of their 
94 included studies were of good quality based on Jadad scoring (scores 4 or 5). 
A heterogeneity of patient outcome measures relevant to the research objective (see section 
4.2) existed across the review studies. All 27 studies discussed the influence of oral 
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formulation-related barriers on medicines administration (i.e. reported the nature and/or 
prevalence of such barriers to medicines administration) yet few studies reported the 
individual effects of these barriers on a specific patient outcome. Adherence is multi-
factorial and there is no accepted standard for its measurement, therefore collating and thus 
interpreting data across studies is complex. Additionally, optimal adherence levels are higher 
for some chronic diseases (i.e. HIV adherence is often given a higher adherence cut-off - as 
discussed in section 2.2.1) and therefore comparing adherence levels across different 
chronic conditions is not appropriate. 
For the purpose of determining the influence of oral formulation-related barriers to 
medicines administration on child acceptance, it seems credible to evaluate reports of 
children refusing medicines, as investigated by Lin and co-workers (2011). Reports of refusal, 
resistance and oppositional behaviours (see Table 2) were identified across the review 
studies, yet often the reason for this behaviour was not reported. Such patient outcome 
measures should be fully explored and clearly reported in future studies (i.e. complete 
refusal of a dose reported independently to reports of child resistance to administration) in 
order to avoid ambiguous data interpretation.  
In 3 studies the impact of individual barriers on medicines administration was not revealed 
as quantitative data on oral formulation-related barriers to medicines administration was 
grouped (Buchanan et al., 2012, Gibb et al., 2003, Tucker et al., 2002). 
Wrubel and co-workers (2005) quantified the impact of ‘side effects’ as a barrier for parents 
when administering medicines, however did not reveal the impact of taste. This impedes the 
transparency of data reporting and is a criticism of the study. 
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Reports regarding problems with the quantity of solid dosage forms were unclear across the 
studies. The barrier, ‘too many pills/medicines’ created interpretation difficulties. It could 
not be deciphered whether reference was being made to the number of different solid 
dosage forms administered (polypharmacy) or the number of units of the same solid dosage 
form. It is likely that the term ‘medicines’ was used to refer to liquid formulations. 
Similarly, clarification of specific terminology (i.e. ‘swallowing issues’) and identification of 
patient groups (e.g. patients with NG or PEG tubes) is needed in order to interpret data on 
problems with swallowing and the size of solid dosage forms correctly (i.e. to understand 
whether a child is physically unable to swallow or is averse to/has difficulty swallowing a 
dosage form). Study reports did not necessarily indicate an issue with the medicine 
formulation itself (i.e. difficult size or shape), as problems with swallowing could relate to a 
patient with a physical inability. Clear assumptions cannot be made as this information was 
not provided in the reports.  
Oral formulation-related barriers to medicines administration were not reported for 
individual drugs in 20/27 studies. Of the 7 ‘key studies’ that did report individual drug data, 2 
studies (Davies et al., 2008, Lin et al., 2011) did not specify the actual formulation/s 
concerned. In order to inform future formulation development, knowledge of specific 
formulations is vital, thus more detailed data reporting is needed in future studies. 
A table summarising quality assessment and risk of bias of the included review studies can 
be found in Appendix 4.   
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4.5 Discussion 
4.5.1 Summary of evidence and limitations of review studies 
The search strategy of this systematic review was designed to be rigorous across the 
databases used, however applying the strategy to the NeLM data source proved very 
difficult as a result of its inability to conduct an advanced, detailed search using the refined 
combination of search strings as in sections 4.3.4.1 - 4.3.4.3. This is a limitation of using the 
NeLM for data collection. Multiple searches using search terms from the strategic search 
diagrams were used to retrieve literature in NeLM, see section 4.3.4.4. The NeLM has a 
strong pharmacy input and therefore in addition to retrieving duplicate articles, retrieved 
some studies that had not been identified using the other databases. The NeLM data source 
was used in addition to the other databases in an attempt to minimise the risk of omitting 
any relevant studies in this review. 
This systematic review aimed to explore the influence of oral formulation-related barriers to 
medicines administration on child acceptance of or adherence to medicines. Included in the 
review were a total of 27 studies and the majority (79%) of these, reported findings on 
antiretroviral medicines. Only 7 of the studies (‘key studies’) associated a named drug with 
at least one oral formulation-related barrier to medicines administration (some reporting 
the specific formulation). All of these 7 ‘key studies’ investigated antiretroviral drugs, 
indicating a clear gap in research across paediatric patients suffering from other chronic 
conditions. 
86 
Several studies were retrieved during the systematic search yet excluded from this review as 
study methodology was a one-off taste test of paediatric formulations conducted in adults or 
children. These studies did not focus on problems experienced when administering 
medicines to children suffering from chronic conditions in a domiciliary, natural 
environment. 
Oral formulation-related barriers to medicines administration were identified and then 
categorised for purpose of the narrative review under the following thematic sub-headings: 
Taste, size of solid dosage forms and difficulties with swallowing, volume of powder or liquid 
and quantity of solid dosage forms, texture, smell and colour/appearance (reported in 
descending order of acknowledgement across the studies).  
Results from the review studies indicate that taste is a key oral formulation-related barrier to 
medicines administration in children. Taste featured in each of the 27 studies. However 
where other oral formulation-related barriers (e.g. problems associated with colour, smell, 
texture) were not offered as a choice (i.e. within studies using a list of barriers) this could 
underestimate their impact on child acceptance of a medicine. 
Observations across the 7 ‘key studies’ revealed that: ritonavir liquid, ritonavir tablets, 
nelfinavir powder zidovudine syrup, lamivudine syrup, didanosine powder, crushed 
nevirapine tablets and opened efavirenz capsules were reported to be difficult to administer 
to children because of poor child acceptance of oral formulation characteristics. According to 
current PIP guidelines (European Commission, 2008) there is a mandatory requirement to 
consider palatability when formulating medicines. It is crucial that drug companies are 
adhering to these guidelines when developing new antiretroviral medicines. 
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A finding that contrasted to the general trend of taste problems across the studies was 
reported by Tucker and co-workers (2002). ‘Taste/ taste making them feel sick’ was not 
associated with children disliking to take their medicines. The children in the study were 
taking medicines following renal transplants. Average ages of the African American and 
European American patients were 12.9 and 15.0 years respectively. As these patients were 
older, it could be that tablets as opposed to liquid medicines predominated in their regimes, 
and therefore taste was not perceived as a major barrier to the acceptance of a medicine. 
This data was not reported so is merely a presumption.  
Supporting this finding, Pontali and co-workers (2001) investigating HIV patients reported 
that children over 10 years of age did not identify taste as a main problem when 
administering medicines as reported in Table 2. When film or sugar coats (i.e. in tablet 
formulations) are used, taste is not often perceived to be an issue (EMEA 2006). 
Problems associated with the size of solid dosage forms or swallowing them were 
highlighted in over half (59% 16/27) of the studies. In 2 of these 16 studies, problems with 
size or difficulties with swallowing solid dosage forms was reported to not be an important 
barrier to administering medicines (Tucker et al., 2002, Zelikovsky et al., 2008). These studies 
investigated post renal transplant patients and those requiring a renal transplant. Factors 
such as the older age of these patients or the size of solid dosage forms prescribed to treat 
these patients may have influenced this finding. Supporting this finding, Pontali and co-
workers (2001) did not report difficulty swallowing tablets as a main problem for children 
less than 6 years, yet this was reported as a main problem in children 6 years and older (see 
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Table 2). Nelfinavir in a tablet formulation was reported as ‘too big’ in the study by Gibb and 
co-workers (2003). 
Problems with the volumes of medicines were reported in 3/27 studies. Van Dyke and co-
workers (2002) identified an issue with the volume of ‘nelfinavir powder’. It should be 
acknowledged that child aversion to large volumes of powders and liquids may be influenced 
by palatability also (EMEA, 2006). 
Studies investigating solid dosage forms that are small in size (2mm-3mm), recognised as 
‘Mini-tabs,’ indicate that such formulations may be accepted by children from the age of 6 
months and 2 years respectively (Spomer et al., 2012, Thomson et al., 2009). However, some 
dosage forms exist as a large volume (i.e. powder/liquid) or size (i.e. tablet/capsule) because 
of the characteristics of certain drugs (e.g. powder density, volume of drug, dose required). 
For such dosage forms, improving palatability using standardised manipulation techniques 
based on a robust scientific evidence base should be considered to improve child acceptance 
and medicines adherence. This is discussed in the EMA draft guideline (EMA, 2013). 
Furthermore, education to help children to learn to swallow solid dosage forms should be 
introduced to children requiring solid dosage forms as discussed in previous studies 
(Czyzewski et al., 2000, Garvie et al., 2007). 
Problems with the quantity of solid dosage forms were investigated in 6 of the 27 studies. In 
children aged 6 years and over, the quantity of solid dosage forms was reported as a main 
problem when administering medicines to HIV patients (Pontali et al., 2001).  
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Problems with the texture of medicines were revealed in only 4 of the 27 studies. Esteban 
Gomez and co-workers (2004) commented that texture needs to be improved however did 
not discuss any supporting study data for this statement. Further examination in to such 
issues is needed as this has not been at the forefront of pharmaceutical research to date 
(RCPCH, 2004). In specific patient groups (i.e. those suffering from a learning disability) such 
organoleptic properties may have a significant impact on medicines acceptance. 
Issues with smell and independently colour or appearance of medicines were not as 
frequently reported across the studies. It might be questioned if barriers perceived by 
parents and caregivers when administering medicines to children influence child acceptance. 
Only one of the studies (Roberts, 2005) highlighting such sensory properties mentioned the 
involvement of children during the interview. Children may associate smell and visual 
properties of a medicine with taste. Psychology plays a role in how children and their 
parents and carers perceive medicines. Review findings warrant further research with the 
help of psychologists to investigate the sensory perceptions of parents and children 
regarding medicines. 
Some children may be more sensitive to the organoleptic properties of medicines than 
others. The age of a child may influence the problems experienced with medicines and thus 
the choice of dosage form prescribed. Although dosage form choices may not be dependent 
on the age of a child, a general trend may exist, and this could be related more closely to age 
at diagnosis and familiarity with medicines. Factors that may influence dosage form choices 
of paediatric patients and healthcare professionals need to be investigated in future studies 
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including: age of child, whether a patient has previous experience of taking liquid or solid 
dosage forms, gender, age and ethnicity (FormPIC study REC no 13/NE/0020).  
Early exposure to different tastes and textures has been reported to affect patterns of food 
acceptance in children (Harris, 2008). Also, Northstone and co-workers (2001) found that 
delaying experimentation with lumpy foods at or after 10 months of age increased the 
likelihood of feeding difficulties and more definite likes and dislikes. Encouraging a child 
from an earlier age to experiment with various foodstuffs (different flavours and ‘mouth 
feels’) may improve child acceptance of medicines.  
Owing to the complex, multi-factorial nature of adherence, no accepted, standard measure 
exists. The heterogeneity and lack of clarity of reported patient outcome measures 
(acceptance and adherence) across the studies limited the power of data interpretation in 
this review. Future studies need to improve reporting quality. Patient-related outcome 
measures should be reported clearly, i.e. reports of medicines refusal resulting in dose 
omission versus reports of resistance to administration. This will minimise ambiguity and 
enable data to be compared across studies. 
Lin and co-workers (2011) identified oral formulation-related barriers to medicines 
acceptance for individual drugs and medicines refusal was the reported outcome measure. 
Reporting was better compared to the other review studies as results of palatability 
assessments were revealed for all antiretroviral drugs prescribed to the patient population. 
Lin and co-workers (2011) unveiled important data that should be used to help clinicians 
when prescribing antiretrovirals in order to maximise medicines adherence.  
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Reporting the nature and prevalence of medicines manipulation techniques used in a 
domiciliary environment is important in order to understand the difficulties encountered by 
parents and carers when administering medicines to children on a daily basis. Medicines 
manipulation techniques were reported in 10 studies, yet detail on the techniques used was 
only revealed in 60% of these studies. The medicines concerned and potential risks involved 
were not explored in the study reports.  
The use of medicines manipulation techniques to facilitate medicines administration has the 
potential to affect drug absorption, bioavailability (through drug-foodstuffs binding) and also 
cause degradation reactions which can affect drug stability as discussed in section 2.5.3. It 
would be beneficial for future studies to identify the nature of common medicines 
manipulation techniques used by parents and carers. This data should direct laboratory 
formulation work. This would provide a robust scientific evidence base that could be used to 
inform healthcare professionals and parents, carers and patients on safe and effective 
medicine manipulations. 
It is essential that healthcare professionals involved in prescribing, dispensing and 
administering medicines are fully aware of potential oral formulation-related barriers to the 
administration of medicines to children. In addition parents, carers and patients need to be 
educated on overcoming barriers safely where no alternative therapeutic options are 
available in view of patient safety and drug efficacy. 
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4.6 Conclusion 
This systematic review has identified that taste is the main oral formulation-related barrier 
to medicines administration in paediatric patients. The majority of the studies supporting 
this finding were conducted in children prescribed antiretroviral medicines. 
Current research exploring oral formulation-related barriers to medicines administration is 
limited and has been conducted in narrow patient populations. Future research is required 
in children suffering from a wide range of chronic conditions and prescribed different 
medicines. Exploration of barriers to child acceptance of medicines including taste, size, 
volume of liquid or powder, quantity of solid dosage form, texture, colour, and smell is 
imperative. Such data should influence future pharmaceutical design. Oral formulation-
related barriers are potentially modifiable and overcoming them increases the ability to 
close a gap in difficulties with administration, thus improve medicines adherence in children. 
It is important to remember that adherence is a multi-factorial phenomenon. Adherence 
cannot be compared equivalently across different chronic conditions as optimal adherence 
cut-off levels are inconsistent. Overcoming oral formulation-related barriers to medicines 
administration may reduce the occurrence of paediatric non-adherence through reducing 
medicine refusals, yet further factors are implicated (including forgetting) that are beyond 
the aims of this systematic review. 
Studies need to report problems with specific medicine formulations to inform future 
formulation work, thus prioritise drug development. Medicines manipulation techniques 
adopted by parents, carers and young people to administer medicines in the domiciliary 
setting need to be identified and potential risks investigated in future pharmaceutical work. 
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Healthcare professionals, parents, carers and young people need to be educated on safe and 
effective medicines manipulation techniques. This should be based on robust scientific 
evidence. 
As most of the physical attributes of interest to this study (organoleptic - taste, smell, 
texture, physical – size/swallowing solid dosage forms) relate commonly to administering 
oral medicines, the inclusion criterion for this review was designed to include only oral 
medicines. It would be useful to investigate if such problems influence the administration of 
inhaled formulations in a future study. 
This systematic review informed the overall design of this study. The aim of this review was 
to identify and evaluate literature investigating oral formulation-related barriers to 
medicines administration. This systematic review identified that the studies conducted were 
limited to specific paediatric populations and in the majority of studies, detailed reporting 
was absent. The present study aimed to report detailed data on oral formulation-related 
barriers to the administration of medicines in paediatric patients suffering from a wide range 
of chronic conditions from the perspectives of healthcare professionals (Chapter 5) and 
parents, carers and children (Chapter 6) to inform future formulation work. 
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5 EXPLORING PROBLEMS EXPERIENCED WITH ORAL MEDICINES IN 
PAEDIATRIC PATIENTS FROM THE PERSPECTIVES OF MEDICAL 
PRACTITIONERS, PHARMACISTS AND NURSES 
5.1 Objectives 
The primary objective of the focus groups was to inform design of the semi-structured 
interviews delivered to parents, carers and children (see Chapter 6). The secondary objective 
of the focus groups was to explore and understand the problems experienced when 
prescribing, dispensing and administering oral medicines to children from the perspectives 
of medical practitioners, pharmacists and nurses. The aim of this was to identify common 
and unique themes across healthcare professional groups regarding problems with oral 
medicines prescribed to paediatric patients and furthermore to compare their views with 
those of parents, carers and children. 
5.2 Background and setting 
Problems with children’s medicines may be influenced by many factors. These include issues 
with prescribing and the supply of medicines, unlicensed medicines and medicines used off-
label, difficulties with administering medicines (including manipulation of medicines), 
behaviour around medicine taking (including influence of family, school and life situation), 
adverse effects of medicines and medicine adherence problems in specific patient groups 
(i.e. age groups and chronic conditions). 
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Barriers to medicines adherence have previously been discussed in Chapters 2 and 4. It is 
probable that some healthcare professionals may not be aware of the specific barriers and 
problems that patients and their parents and carers perceive and experience daily when 
administering medicines. Medicines may be manipulated by parents, carers and young 
people for which often there is lack of robust scientific evidence (see section 2.5.3). Parents, 
carers and young people may decide to manipulate medicines of their own accord, 
unbeknown to the responsible medical practitioner. Alternatively medicines manipulation 
may be performed following a recommendation from a healthcare professional.  
There is a paucity of research investigating healthcare professionals’ perceptions of issues 
with medicines used to treat paediatric patients with chronic conditions. Studies that have 
been conducted include an exploration of healthcare providers’ views on HIV adherence in 
paediatric patients (Brackis-Cott et al., 2003), an investigation in to nurses’ knowledge and 
practice of mixing medicines with foodstuffs (Akram and Mullen, 2012) and those 
investigating unlicensed medicines use (Mukattash et al., 2011a, Mukattash et al., 2011b). 
The present study aimed to have a more diverse approach, exploring the perspectives of 
allied healthcare professionals (medical practitioners, nurses and pharmacists) with regard 
to problems with oral medicines prescribed to children. 
Children suffering from chronic conditions often have regular appointments in the secondary 
care setting to review their condition and medicines. In the hospital environment different 
members of the healthcare team are responsible for providing care for patients. This 
multidisciplinary healthcare team includes medical practitioners, nurses and pharmacists of 
varying expertise and with different specialist interests. 
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It was anticipated that the perspectives of medical practitioners, nurses and pharmacists 
regarding problems with children’s medicines would vary owing to their different 
occupational roles. It would be expected that generally medical practitioners would have 
more understanding with regard to prescribing medicines than nurses and pharmacists. 
Pharmacists dispense medicines to patients, and therefore it is probable that they are more 
aware of the problems associated with the supply of medicines. As nurses administer 
medicines to children (on paediatric wards and in the community) they may be more 
knowledgeable on how medicines are administered to children. 
This study was conducted with healthcare professionals at UHCW and BCH. 
5.3 Methodology 
5.3.1 Background work  
Medical practitioners at UHCW were emailed study information and invited to respond to 
the email in order to ascertain if any medical practitioners opposed RV observing clinics. All 
responses that were received were supportive of the study (see Appendix 5). 
Having obtained an honorary contract at UHCW, a variety of paediatric clinics were observed 
between October and December 2009. These clinics included rheumatology, 
gastroenterology, HIV, CF, asthma, endocrinology, renal, and diabetes. This preliminary 
scoping work was used to become familiar with the paediatric clinic environment, the variety 
of clinics and medical practitioners, to observe the patient-healthcare professional 
relationship in clinics, and to inform experimental design. 
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Medical practitioners at UHCW provided case examples of difficulties, highlighted to them by 
parents when administering multiple formulations to their child. Two of these cases can be 
found in Appendix 6. Medical practitioners also revealed problems with children’s medicines 
whilst RV observed paediatric outpatient clinics at UHCW (see Appendix 2). The attitude of 
Medical practitioners at UHCW was positive towards the study.  
During the pre-study period a session was arranged with a paediatric pharmacist in the 
pharmacy department at UHCW to introduce the proposed research. The paediatric 
pharmacist raised issues with the taste of some liquid medicines and highlighted difficult 
medicine regimes (see Appendix 2). Examples of manipulations to medicines were revealed 
and knowledge of risks associated with medicines manipulation was reported. Medicines 
adherence and also difficulties with unlicensed and Specials medicines were discussed by the 
paediatric pharmacist. 
Attending a ‘drug-round’ conducted by paediatric nurses on the paediatric wards at UHCW 
permitted RV to observe nurses administering medicines to children. The pre-study work 
conducted in paediatric outpatient clinics, the pharmacy department and on the wards at 
UHCW gave an insight in to existing knowledge on problems with children’s medicines and 
supported the importance of this study, from the perspectives of healthcare professionals at 
the study setting. 
5.3.2  Introduction to the data collection tool 
Focus groups collate a plethora of information in a short period of time and explore 
attitudes, perceptions and feelings. The group setting provides some security for individuals, 
who might otherwise feel vulnerable to criticism, and encourages them to contribute to the 
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discussions and their direction, when compared to a more structured agenda (Stewart et al., 
2006). 
When conducting a focus group between six and eight participants is optimal (Krueger and 
Casey, 2000). The group should have enough participants to get a wide perspective without 
being too large, and thus disordered or fragmented, (Rabiee, 2004) and should last 1-2 
hours.  
Morse and Field (1995) state that using several combined homogenous groups to provide a 
heterogeneous population enables a wider perception and thus a diversity of views. In 
addition, scoping and exploring the problems associated with a variety of medicines 
prescribed to paediatric patients suffering from chronic conditions was intended. It was 
decided that a more structured research tool (e.g. questionnaire) would not collect the data 
as effectively as a focus group. 
5.3.3 Design of the data collection tool 
Focus groups were used to explore the views of healthcare professionals engaged in the care 
of paediatric patients with chronic conditions. The focus groups were used to develop an in-
depth understanding of problems with oral medicines, as perceived by healthcare 
professionals involved in prescribing, dispensing or administering medicines to children. 
The healthcare professionals that were chosen to participate in the focus groups were 
medical practitioners (specialising in paediatrics), paediatric pharmacists and paediatric 
nurses. It was intended that three focus groups in total would be conducted (one for each 
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healthcare profession). The rationale for the chosen focus group populations is reported in 
Figure 7 below. 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
Figure 7 An algorithm displaying the rationale of conducting individual focus groups with 
medical practitioners, paediatric pharmacists and paediatric nurses. 
Figure 7 above shows the relationship and flow of events leading from the prescribing 
intention of a medical practitioner through to supply of a labelled medicine by a pharmacist 
and finally administration by a nurse. 
Initial ideas generated by RV with the advice of Professor of Clinical Pharmacy and a 
Consultant Paediatrician were informed by healthcare professionals in pre-study hospital 
visits (as described earlier in section 5.3.1) and by study objectives (see Chapter 3). Ideas 
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were used to devise the key topics for exploration in the focus groups. The different 
professional backgrounds of the individuals involved in study design permitted the 
collaboration of a clinical and pharmaceutical input. 
A template plan of topics to explore was formed. The themes for discussion were consistent 
across the focus groups.  
The focus groups were designed to explore the following themes: 
 Problems surrounding prescribing and supply of medicines, highlighting issues around 
individual or particular groups of medicines 
 The use of unlicensed and off-label medicines 
 The process of administering medicines (e.g. measurement of dosage, route, 
organoleptic and physical properties of medicines) 
 Manipulation of medicines to improve child acceptability or for purpose of giving a 
specific dose on wards and in the community (e.g. crushing tablets, mixing with 
foodstuffs) and the difficulties associated with this 
 Behaviour around medicine taking and how this is dealt with 
 Adverse effects (e.g. nausea, vomiting) 
 Groups of patients or drugs with particular medicines adherence issues 
 Factors that affect medicines adherence and how often the regimen is adhered to 
(timing of medicines, effects on family life, school) 
 Patient, parent and carer understanding of medication routine and regimen 
 Positive experiences around taking medicines 
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 Perceptions around the issues of intentional and unintentional non-adherence to 
medicines 
 Ideas for future drug development. 
5.3.4 Identification and Recruitment 
Healthcare professionals were invited to join a focus group by posters (see Appendix 7) 
mounted on walls at UHCW (neonatal unit, paediatric wards and paediatric outpatient 
department). 
Healthcare professionals (UHCW paediatricians, paediatric pharmacists, and paediatric ward 
managers- to disseminate the information to paediatric nurses and community paediatric 
nursing teams) were contacted via the UHCW email system and invited to respond to 
register an interest to participate. In addition, targeted emails were sent to paediatric 
pharmacists in the West Midlands region. An information sheet designed using guidance 
from the NPSA (2009) was distributed with the invitation email (see Appendix 8).  
General Practitioners (GPs) in Coventry and Warwickshire were informed of the study via a 
study summary article in the clinical pharmacology e-newsletter, (edited by a Professor of 
Clinical Pharmacology and Therapeutics) routinely disseminated to all GPs in Coventry and 
Warwickshire. An Invitation to request an information sheet by email or telephone was 
provided.  
It was anticipated that recruitment would not be easy, due to limited free-time during the 
working hours of healthcare professionals. Outpatient clinic commitments made predicting 
recruitment for the medical practitioner group most difficult. Owing to relatively few 
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pharmacists specialising in paediatrics, it was anticipated that the recruitment of paediatric 
pharmacists would also be difficult. 
The dates and times of the focus groups were selected based on the most popular choices 
that were indicated by respondents wishing to participate. A second pharmacist focus group 
was arranged for pharmacists at BCH. These pharmacists had generated interest in the study 
but were unable to attend the UHCW session for logistical reasons.  
Verbal and email reminders were provided to interested participants to encourage 
attendance.  
5.3.5 Ethical issues and informed consent 
All potential participants were given at least 24 hours from receiving information before 
consenting to participate in the study. On arrival, focus group participants were asked to 
sign-in to mark attendance and to provide informed consent for the session to be digitally 
audio-recorded (see Appendix 9) conforming to Good Clinical Practice (GCP training course 
2009 and online 2011 were completed to keep researcher up-to-date). 
5.3.6 Conduct of the focus groups 
Four focus groups were conducted involving nurses, medical practitioners, pharmacists at 
UHCW, and a further group of pharmacists at BCH. The four focus groups were conducted 
between September 2010 and February 2011. It was necessary to create an environment to 
encourage good engagement of the participants. Private rooms were pre-booked within 
UHCW and BCH in locations easily and efficiently accessible for staff, to create a suitable and 
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convenient environment for discussion. Ensuring that participants were relaxed was 
imperative to prompting exchange of ideas, views and feelings (Rabiee, 2004). 
The introduction for each focus group followed the same structure and included a reminder 
about confidentiality issues delivered at the start. The planning and conducting stages of the 
focus group sessions were carried out according to procedures suggested by Krueger and 
Casey (2000). 
The four focus groups were facilitated by RV and assisted by Professor of Clinical 
Pharmacy/Consultant Paediatrician. The groups were digitally audio-recorded using an 
Olympus digital audio-recording device. Complementary notes were taken by the Consultant 
Paediatrician during the sessions. 
Travel expenses (for those who made a special journey to attend the group) and 
refreshments were provided. 
5.3.7 Transcription of the focus group data 
RV transcribed each focus group as soon as was possible after facilitating the group, to 
ensure the ideas and attitudes discussed were ‘fresh in mind’.  
The transcription process from digital audio-recording to verbatim transcript is detailed 
below. This process was followed for all of the four sessions. 
1. Verbatim transcripts were produced in Microsoft Office Word 2007 from the digital 
audio-recordings  
2. Numerical coding was used to identify each participant 
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3. The verbatim text was examined and compared with complementary notes taken 
during each session 
4. Transcription process steps 1 to 3 were repeated to optimise accuracy. 
5.3.8 Analysis of the focus group data 
The verbatim text was copied in to a commercial data content analysis program (QSR NVivo 
8) and thematic content analysis was utilised to analyse the four verbatim files 
independently. The template plan of topics (see section 5.3.3) was used to explore and 
identify the themes revealed in each transcript. Following this, common themes revealed 
across the groups and those unique to each group were identified. 
5.3.8.1 Framework analysis approach 
A framework analysis approach was adopted as this was deemed to be most appropriate 
following development of the research question and early theme derivation. This analytical 
approach is both rigorous and structured and reflects the background work (that is 
inductive) and develops deductively from study aims and objectives (Pope et al., 2000). 
Ritchie and Spencer (1994) defined framework analysis as: 
‘An analytical process which involves a number of distinct though highly interconnected 
stages.’  
 
The five key stages in framework analysis are familiarisation, identifying a thematic 
framework, indexing, charting, mapping and interpretation (Pope et al., 2000). This approach 
allowed themes that arose in the narratives to be derived. The method was designed to 
permit triangulation of data with that obtained in semi-structured interviews (Chapter 6) to 
determine if a paradox existed. 
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The stages of focus groups data analysis followed guidance from Pope and co-workers (2000) 
and are listed below: 
1. Early ideas that were derived from background work with healthcare professionals at 
UHCW as discussed in section 5.3.1, formed an initial list of themes 
2. The verbatim transcript and complementary notes from each focus group were 
explored to identify prevalent, emerging themes. These were added to the original 
list of themes  
3. Short-hand text was inserted in to the margins of the transcript and relevant 
verbatim was highlighted and thematically coded 
4. Each theme was identified as a ‘node’ in QSR NVivo 8 
5. Nodes were linked to form relationships and identify the main thematic groups 
6. Once thematically grouped the verbatim text was examined 
7. Exclusive and overlapping nodes were identified across all focus groups and reported 
systematically.  
5.3.9 Ethical requirements for focus group data 
All focus group data was handled ethically and confidentially. Access to the focus group 
digital audio-recordings and transcribed data was restricted to the direct research team. 
Digital audio-recordings, notes of paper transcripts and verbatim transcription on password 
protected spreadsheets were locked securely in a filing cabinet in a secure University office 
to avoid unauthorised access. The sign-in consent sheets were kept locked in a separate 
locked filing cabinet in a locked University office. 
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The focus group data was transcribed on to password protected spreadsheets from the 
digital audio-recordings, and then analysed confidentially by RV in a secure University office. 
The encrypted laptop was stored securely in a locked cabinet in a secure room at University 
when not being used for data input or analysis during the interview and focus group study 
period. 
Digital audio-recordings on the encrypted laptop were securely destroyed following 
transcription and analysis according to GCP (within twelve months of study completion) 
using the software program, Eraser 6.0.10.  
5.4 Results 
Table 17 below reports the number of participants, the professional statuses of participants, 
dates conducted and locations of the focus groups. 
Table 17 Details of the four focus groups conducted to explore healthcare professionals' 
perspectives of problems with oral medicines in children. 
Focus Group Date 
conducted 
Location Total no. of 
participants 
Professional statuses of participants 
1. Nurses  21
st
 September 
2010 
UHCW 5 Neonatal nurse practitioners (2), a nurse 
with a specialist interest in CF, a 
community-based nurse and a nurse 
practice educator 
2. Medical 
practitioners  
30
th
 September 
2010 
UHCW 8 Paediatric consultants with specialist 
interests (6), a paediatric registrar, and a 
GP (with an interest in paediatrics) 
3. Pharmacists 1 14
th
 October 
2010 
UHCW 2 Paediatric pharmacists 
4. Pharmacists 2 1
st
 February 
2011 
BCH 4 Paediatric pharmacists 
 
The number of participants across the groups varied. The small population of pharmacists 
specialising in paediatrics resulted in lower levels of recruitment as predicted. The 
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pharmacist group conducted at UHCW had a particularly low number of recruits (n=2). This 
focus group tended to be delivered in a more structured manner (interview style), and 
represented a nominal group, as inevitably focus groups do not run optimally when the 
number of participants is low. However, the information gathered from the UHCW focus 
group in collaboration with that obtained in the BCH pharmacist focus group gave an insight 
in to the views of pharmacists from the West Midlands region.  
The nurse and medical practitioner groups were conducted at lunchtime and the pharmacist 
groups took place in allocated study time. It was intended that each session would last 
between 60 and 90 minutes. Groups lasted between 51 and 93 minutes. The exact timings of 
digital audio-recordings are provided in Table 18 below. 
Table 18 The time duration (minutes) of each focus group conducted. 
Focus Group Time duration of group (minutes) 
Nurses 58 
Medical practitioners 51 
Pharmacists 1 (UHCW) 93 
Pharmacists 2 (BCH) 57 
 
5.4.1.1 Observations of the dynamics of the focus groups 
5.4.1.1.1 Nurse focus group 
A total of five participants attended the focus group, CF nurse, children’s community nurse, 
two advanced neonatal nurse practitioners and a nurse practice educator. 
A variety of nurses with differing levels of experience and special interests in caring for 
children with chronic conditions participated, including neonates and general paediatrics, 
those working in hospital, post-admission and (follow-up) home environments. 
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Discussion flowed well across the group. 
5.4.1.1.2 Medical practitioner focus group 
The medical practitioner focus group had the greatest number of participants across the 
groups (n=8). One GP attended. She revealed issues and perspectives from a community 
level with regards to prescribing, Primary Care Trust (PCT) restriction of Specials supply and 
community follow-up of chronic paediatric conditions. The paediatric registrar attendee had 
shown much interest and enthusiasm in this study during the pre-study period (personal 
communication with Consultant Paediatrician). Oncology, HIV, epilepsy, neonatology and 
general paediatrics were included in the specialist interests of the participants. This range of 
specialist interests as well as the general paediatric backgrounds of the medical practitioners 
generated discussion regarding problems with medicines prescribed for different chronic 
conditions. 
Overall, conversation in the group flowed well. Latecomers did not disrupt the flow of the 
focus group. 
5.4.1.1.3 Pharmacist focus group 1 
This group had the lowest recruitment (n=2). The session was more directed and structured 
following the pattern of a nominal group. The scope of ideas and opinions raised during this 
session were relevant to the research.  
5.4.1.1.4 Pharmacist focus group 2  
Four pharmacists consented to take part in the focus group at BCH following much interest 
and enthusiasm for the study. 
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A breadth of experience and knowledge was apparent, owing to the diversity of interests 
and experiences of pharmacists in this group. 
Discussion flowed well between the group members. 
5.4.2 Consent and ethical issues 
No feedback or questions regarding issues with consent or ethics were received. Participants 
all appeared to understand the information and were happy to sign the sign-in consent 
sheet. 
5.4.3 Feedback from focus groups 
An email was sent out to all focus group participants to thank them for their time and 
contributions. Positive feedback was received following the sessions, both verbally and 
electronically.  
5.4.4 Results of the analysis of the focus group data 
Following the framework analysis, a structured thematic coding spine (see Table 19 below) 
was created based on the themes emerging in the focus groups. The coding spine includes 
themes revealed both independently and across the groups. The results of the analysis are 
reported systematically, using the code headings and sub-headings listed in Table 19 below. 
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Table 19 Thematic coding spine detailing code headings and code sub-headings. 
Code headings Code sub-headings 1 Code sub-headings 2 
Oral formulation-related 
barriers to medicines 
administration 
 
 Taste-related problems 
 Problems with texture 
 Problems with colour and smell 
 Problems with size and swallowing 
 Problems with quantity and volume 
 
 
 
 
 
Future medicines for 
children 
 Ideal improvements to medicines 
 Well-accepted medicines 
 
 
Problems related to 
medicines 
administration  
 Administration problems with specific 
medicines 
 Interactions with foodstuffs and sub-
optimal drug absorption 
 Medicines manipulation 
 (The knowledge of 
healthcare professionals 
regarding physicochemical 
effects of medicines 
manipulation, Evidence 
base for medicines 
manipulation) 
Frequent issues 
experienced when 
treating paediatric 
patients 
 Specials medicines, unlicensed medicines 
and off-label administration 
 Omeprazole formulations 
 The knowledge and understanding  of 
medical practitioners, pharmacists and 
parents regarding unlicensed medicine 
 Extemporaneous dispensing 
 
 
(Omeprazole liquid, Losec 
MUPS- licensed 
omeprazole formulation)  
Parental understanding 
of medicines 
 Educating parents and children about 
medicines 
 Social problems and language barriers 
 
 
Medicines adherence 
 
 The relationship between age of child and 
dosage form preference 
 Parental influence on dosage form choice 
and medicines adherence 
 The relationship between age of child, 
disease status, diagnosis, miscellaneous 
variants and medicines adherence 
 Polypharmacy  
 
Adverse effects of 
medicines 
 
 Excipients 
 Adverse effects associated with specific 
medicines 
 
The supply of medicines 
and liquid measuring 
devices 
 Problems with the supply of medicines 
 Problems with the supply of oral syringes 
and the accuracy of measuring liquid 
medicines 
 The parallel importing of medicines 
 
 
Medication errors in 
pharmacies and GP 
practices 
 Standardising the labelling of liquid 
medicines 
 Medicine selection errors at GP practices 
 
Problems with medicines 
at school 
 Problems with medicines at school  
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5.4.4.1 Oral formulation-related barriers to medicines administration 
5.4.4.1.1 Taste-related problems 
Taste was the most common oral formulation-related obstacle to medicines administration 
highlighted across the groups. Flucloxacillin solution was reported to be disliked due to taste 
in all of the focus groups (see Appendix 10 for quotations). 
In the BCH pharmacist group, pharmacist 2 described taste problems associated with 
different flucloxacillin solution brands, stating that children generally prefer taking the 
higher strength solution so that they take less volume. She discussed the consequences of 
prescribing alternate second and third-line antibiotics and addressed the potential risks on 
future antibiotic resistant patterns. 
In addition, nurse 4 reported that flucloxacillin solution had interfered with mother-baby 
bonding in one case and described that parents of children with CF prefer to administer an 
alternative antibiotic: 
“Parents have described feeling like it’s a holiday when administering azithromycin once 
daily compared to flucloxacillin.” (nurse 4) 
The bad taste of prednisolone soluble tablets was highlighted by the medical practitioners 
and nurses, and described as “really really bitter” (nurse 3) “disgusting” (Medical 
Practitioner- MP 2) and “vile.” (MP 3) 
Chloral hydrate solution was described as “vile” by nurses 1 and 2. The UHCW pharmacist 
group in addition identified a disliking to the volume and smell in agreement with the nurses 
“it tastes foul” (UHCW pharmacist 1). 
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Reports from the medical practitioner and nurse focus groups highlighted the poor 
palatability of Movicol oral powder. 
Table 20 below provides additional reports of medicines recognised to have taste issues by 
the healthcare professionals. 
Table 20 Healthcare professional reports of taste problems with medicines. 
Medicines  Reports of healthcare professionals 
Gastrografin solution  Nurse 4 
Oramorph solution  Nurse 1 
Septrin paediatric suspension  Pharmacist 2 UHCW 
Rifampicin suspension  Pharmacist 1 UHCW 
Kaletra solution  MP 7 describes burning sensation 
Nitrofuranotin Special suspension  MP 5 
Clarithromycin suspension  MP 2 
Generic paracetamol suspension Nurse 2 
 
5.4.4.1.2 Problems with texture 
All of the healthcare professional groups highlighted that children experience problems with 
the textures of some medicines. The learning disability population were discussed as a 
problematic patient population across the focus groups when regarding problems with 
texture. 
Specific medicines reported to have problems with texture are listed in Table 21 below. 
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Table 21 Healthcare professional reports of problems with the texture of medicines. 
Medicines  Reports of healthcare professionals 
Ciclosporin solution  UHCW pharmacist 1 described as oily 
Lactulose solution  MP 1 described as oily 
Topiramate sprinkle capsules  MP 1 
Calcichew tablets  MP 2 
Creon Micro gastro-resistant granules Nurse 4 described the inconvenience of 
transporting apple puree to mask the texture 
One pharmacist questioned whether there were any problems with textures of medicines 
(UHCW pharmacist 2). 
5.4.4.1.3 Problems with colour and smell 
A variety of further organoleptic properties of medicines were identified and most 
frequently during the focus group with the nurses. These are reported in Table 22 below. 
Table 22 Healthcare professional reports of problems with further organoleptic properties 
(colour and smell) of individual medicines. 
Medicines   Reports of healthcare professionals 
Rifampicin suspension Colour described as “off putting” (nurse 1) 
Klean-prep oral powder dissolved in liquid “Smell makes you wretch it’s horrible” (nurse 
4) 
Abidec multivitamin drops Bad smell and the colour stains bibs, (nurse 
4), yet described as tolerated 
Feeds (including nutramigen, the pepti-milks and soya 
milks) 
“Horrendous” (nurse 1) and having a smell 
that “pervades everything” (nurse 2) 
 
5.4.4.1.4 Problems with size and swallowing 
All groups acknowledged that children taking antiretroviral tablets experience problems with 
their size and also difficulties when swallowing them. 
“I know probably the older children have problems swallowing the huge tablets.” (nurse 1) 
Medical practitioner 2 in reference to HIV clinic revealed “These little children are expected 
to swallow these enormous tablets.” 
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Kaletra tablets are mentioned specifically and medical practitioner 7 describes these as “big 
bullety” and “like horse pills.” 
Further solid dosage forms identified with problems related to size or swallowing are 
provided in Table 23 below. 
Table 23 Healthcare professional reports of problems with the size or swallowing solid 
dosage forms. 
Solid dosage forms Reports of healthcare professionals 
Slow sodium tablets  “Like an old paracetamol tablet, they’re quite 
sticky to swallow down” (nurse 4) 
Temozolomide capsules (16-21mm ) “I think they’re quite big drugs” (nurse 6) 
Ethambutol tablets Often preferred in multiple small tablets as 
opposed to a single large tablet according to 
UHCW pharmacist 2 
 
5.4.4.1.5 Problems with quantity and volume 
Problems with the volume of medicines were associated with individual medicines or groups 
of patients by a member of each healthcare professional group. These are reported in Table 
24 below. 
Table 24 Healthcare professional reports of problems with the volume of individual 
medicines or medicines prescribed to specific patient groups. 
Medicines  Reports of healthcare professionals 
Movicol oral powder dissolved in liquid (each sachet added 
to 125mls of water) 
BCH Pharmacists in agreement 
Chloral hydrate solution (dose for 1-12 year olds 
approximately 5-20mls ‘well diluted with water’) 
“Huge” volume (UHCW Pharmacist 1) 
Antiretroviral liquids “Liquid volumes are so high” (MP 7) 
Administering considerable volumes of medicines in 
addition to feeds in neonates 
The issue of giving neonates more than their 
recommended total daily volume of fluids 
was voiced by nurse 3 
Approximate volumes from BNF for Children (2011-2012) provided in brackets. 
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5.4.4.2 Future medicines for children 
5.4.4.2.1 Ideal improvements to medicines 
Participants were asked to share their views on key medicine improvements. Improving the 
taste of flucloxacillin solution was reported by pharmacists, nurses and medical practitioners 
(BCH pharmacists 2 and 3, nurse 4 and MPs 3, 4 and 5). Additional suggestions to improving 
medicines were provided in each of the groups. These are reported in Table 25 below. 
Table 25 Ideal improvements to medicines as reported by healthcare professionals. 
Ideal improvements to medicines   Reports of healthcare professionals 
Administering medicines in the smallest volume  Nurses 
The use of neutral flavours Nurse 2 
Improving the taste of chloral hydrate solution and using 
more strawberry and orange flavours 
Nurse 1 
Using neutral or sweet flavours Nurse 5 
Improving the taste of prednisolone soluble tablets MP 2, 3 and 4 
Improving options available for omeprazole in a liquid 
formulation  
UHCW Pharmacist 1 reported concern that 
only some manufacturers supply a Certificate 
of Analysis with Specials medicines 
“A licensed melatonin dispersible tablet or liquid would be 
ideal.” 
BCH pharmacist 1 
 
UHCW Pharmacist 2 gave a pessimistic response with regard to increasing the availability of 
liquid medicines “they’d all be easier if they were in.. It’s not gonna happen.” 
5.4.4.2.2 Well-accepted medicines 
Calpol suspension was idealised as a formulation in three of the four focus groups (nurse, 
medical practitioner and pharmacist group at UHCW) and described as “the panacea of the 
world” by UHCW Pharmacist 1. In addition medical practitioner 6 reported “It’s a shame all 
drugs don’t taste like Calpol.”  
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Medical practitioner 3 stated her appreciation of the well-accepted liquid medicine Calpol, 
and following this discussed concern regarding the risk of Calpol overdoses. Nurse 2 
proposed a contrasting argument, and discussed the risk of potential Calpol overdoses 
resulting from children being too fond of medicine flavours: 
“I think that if it’s nice they’ll drink more is not really a valid answer,” and “Doesn’t matter 
what it is, if it fits with what they want to do they’ll do it.” She also provided the example of 
children opting to drink bleach out of a cupboard. 
 
When compared to its generic equivalents nurse 2 revealed that children have a unanimous 
preference for Calpol suspension and described the poor palatability of generic paracetamol 
suspensions. 
5.4.4.3 Problems related to medicines administration 
5.4.4.3.1 Administration problems with specific medicines  
The groups discussed specific examples of medicines administration issues, these varied 
between the groups. 
Gaviscon for breastfeeding mothers was described as a “challenge” (MP 2).  
Frequency of dosing was an issue highlighted by medical practitioner 2. Prescribing 
amoxicillin three times daily instead of penicillin four times daily was discussed as a way to 
improve adherence.  
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5.4.4.3.2 Interactions with foodstuffs and sub-optimal drug absorption 
The practicality of giving medicines with feeds was discussed by the nurses. The timing of 
ciprofloxacin administration in relation to feeds was queried by nurse 1. The ability of 
phenobarbitone to interact with milk was also highlighted in the nurse group (nurse 5). 
The UHCW pharmacist group discussed feed interactions with phenytoin and ciprofloxacin 
(UHCW pharmacists 1 and 2). 
Medical practitioner 5 addressed his concern regarding mixing medicines with bottle feeds 
resulting in sub-dosing from incomplete dose consumption: 
“Yes yes all crushed in to a bottle of milk or something, you know you may get a bit of you 
know debris in the bottle which never gets taken.” 
 
5.4.4.3.3 Medicines manipulation 
The groups were encouraged to reveal parent, carer and child feedback regarding the 
techniques used to facilitate medicines administration or for purpose of giving a specific 
dose. Additionally, personal advice given to parents on ad hoc manipulation techniques was 
explored. Manipulation techniques reported across the groups are reported in Table 26. 
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Table 26 Manipulation techniques used to facilitate medicines administration or for the purpose of giving a specific dose as reported in 
each focus group. 
Nurses Medical practitioners  UHCW Pharmacists  BCH Pharmacists 
Yoghurt with crushed medicines 
(nurse 1).  
What parents told them: Epi granules 
(epilim chronosphere granules) on jam 
on toast, have in blackcurrant and 
orange juice (medical practitioner 1’s 
personal advice, not to mix with coke 
or fizzy drinks). 
Creon Micro gastro-resistant 
granules with a spoonful of breast 
milk, apple puree or baby rice 
(UHCW pharmacist 1). 
 
 
Losec MUPS with squash and juice 
(provided an appreciation of mixing and 
potential acidic issues on the active 
ingredient when prompted) (BCH 
Pharmacists 2 and 4). 
Creon Micro gastro-resistant 
granules in apple puree to mask 
texture (nurse 4). 
“They’ll sometimes volunteer that they 
put in milk or they put it in orange 
juice or blackcurrant juice or they 
crush it in to jam or yoghurt or 
something like that” (MP 5). 
“Ciclosporin you can mix with stuff” 
(UHCW pharmacist 1). 
Topamax sprinkle on foodstuffs (BCH 
Pharmacists 1 and 3). 
Split doses, e.g. provided with 
antiretrovirals that were making a 
child physically sick (nurse 1). 
Prednisolone soluble tablets mixed 
with neat Ribena (MP 4). 
Grinding tablets and mixing with 
yoghurt or dissolving in water 
(mercaptopurine) 
(UHCW pharmacists 1 and 2). 
Before dispersible tablets came out, 
recommended opening capsules of 
melatonin or dispersing them in yoghurt 
(BCH pharmacist 1). 
Use strong flavours to mask bad 
tastes. Examples given: Gastrografin 
solution masked with Coke (opposing 
argument to MP 1) or Ribena.  
Give a sweet after flucloxacillin (MP 4). 
 
Liquid paraffin and ice-cream 
recommended as a technique to 
numb taste buds (UHCW pharmacist 
1). 
Movicol oral powder advice.. “in apple 
puree and stuff.” Mixing advice is 
provided in drug information sheets, but 
is not referenced (BCH pharmacist 3). 
In reference to Movicol: “People hide 
it in their dinners.. their mash 
potato..” (nurse 5 - reported on what 
parents do). 
Melatonin “I’ll always say yoghurt, the 
advice I would normally give, put it in 
yoghurt and do that immediately 
before you go to bed because it 
denatures before... and don’t use it in 
hot food” (MP 1). 
“Stick in a bit of yogh- put it in a bit 
of banana or something like that you 
can A slip things down if you’ve got 
something that’s a bit harder to 
take” (UHCW pharmacist 1). 
 
“The Movicol rep says you can put it 
in to jellies and things” (nurse 5).  
Methotrexate and mercaptopurine 
tablets “I’m sure they must get 
crushed up those” (MP 4). 
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The medical practitioners and nurses revealed more information on the nature of 
manipulation techniques used by parents to administer medicines to children. When asked if 
specific foodstuffs were mixed with particular medicines, the answers provided by nurses 5 
and 1 were: 
“Not x goes with y, just try whatever the child likes.” (nurse 5) 
“Whatever the child likes.” (repeated by nurse 1) 
In relation to antiretrovirals and mixing with foodstuffs medical practitioner 7 questioned: 
“Would you mix them at all?” and added “I think it’s difficult to mix those HIV ones ‘cos the 
liquid volumes are so high and so disgusting that there’s not much you could mix it with and 
they’re not small tablets that you could hide in yoghurt or something like that.” 
 
5.4.4.3.3.1 The knowledge of healthcare professionals regarding physicochemical effects of 
medicines manipulation  
Awareness of potentially altering the stability of a drug when using administration 
techniques was acknowledged across the groups. 
Concerns regarding pharmacokinetic effects of a drug following medicines manipulation 
were most evident in the UHCW pharmacist group. 
UHCW pharmacist 1 gave her view on mixing with Ribena as an example: 
“You might test it against Ribena but most of the mothers would then actually go and buy 
Asda’s.. .” and “or you know you buy some cheap one that’s just.. whatever flavour and then 
the pHs may be different..” 
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Nurses 1 and 2 discussed their concerns of not knowing what they can safely mix with 
medicines. The instruction of a pharmacist not to mix omeprazole soluble tablets with hot 
water as it could risk altering drug pharmacokinetics was revealed by nurse 1. 
Medical practitioner 1 discussed that melatonin may denature when mixed in to yoghurt and 
left for a period of time. 
5.4.4.3.3.2 Evidence base for medicines manipulation 
The paucity of robust scientific evidence supporting medicines manipulation was revealed by 
a UHCW pharmacist and a medical practitioner.  
UHCW pharmacist 1 discussed the lack of evidence when such manipulation techniques are 
used. She argued that if there is not a known interaction with food, the drug will inevitably 
mix with stomach contents anyway and her attitude was to get the medication down in any 
way possible. Additionally she stated that manipulating medicines prescribed commonly to 
children would not be recommended.  
Medical practitioner 1 acknowledged the lack of evidence for manipulating medicines and 
discussed advising others of medicines manipulation techniques that had been provided to 
her. 
5.4.4.4 Frequent issues experienced when treating paediatric patients 
5.4.4.4.1 Specials medicines, unlicensed medicines and off-label administration 
The issues associated with Specials and unlicensed medicines were discussed in all focus 
groups. The Specials medicines that were discussed are provided in Table 27 below. 
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Table 27 Specials medicines identified by healthcare professionals. 
Specials medicine Reports of healthcare professionals 
Spironolactone liquid Short expiry highlighted in the nurse group. 
Nitrofurantoin suspension, hydroxycarbamide 
(hydroxyurea) liquid and Albright’s solution 
MP 4 
Phenobarbital liquid MP 3 
Clobazam suspension MP 1 
Tacrolimus liquid “Heart sink drug” by BCH pharmacist 2. Problems with 
maintaining continuity of supply and drug bioavailability. 
Captopril liquid, furosemide liquid Various strengths and the risk of inconsistency between 
formulations from different Specials manufacturers (BCH 
pharmacist 3). BCH pharmacists 2 and 4 described such 
risks generally across Specials medicines. 
 
Common issues attributed to the Specials medicines identified by the medical practitioners 
in Table 27 above were related to medicines supply (e.g. waiting for medicines, GPs unwilling 
to prescribe), the variety of strengths availability to order, shortened expiry dates and 
palatability. 
5.4.4.4.2 Omeprazole formulations 
5.4.4.4.2.1 Omeprazole liquid 
Omeprazole liquid Special was mentioned often across the groups. Frequently, the nurses 
described problems associated with omeprazole including those related to cost (nurse 2 and 
3), medicines wastage (nurse 2), medicines supply (nurse 1 and 4) and GPs’ unwilling to 
prescribe (e.g. prescribing often restricted to a named-patient basis) (nurse 5).  
The UHCW pharmacist group discussed Specials issues in more depth and revealed 
shortened expiries and wastage problems. The unavailability of Certificate of Analyses 
(suggesting limited stability evidence) from some suppliers was discussed by UHCW and BCH 
pharmacists. The inconsistency of storage conditions of omeprazole liquid was described by 
the BCH pharmacists. 
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5.4.4.4.2.2 Losec MUPS (licensed omeprazole formulation) 
Losec MUPS blocking feeding tubes (resulting in feeding tube replacements) and the poor 
solubility of the granules in sodium bicarbonate were reported (nurse 1, 2, 4 and 5). Such 
problems were highlighted across the groups (medical practitioner 1, BCH pharmacist 4 and 
UHCW pharmacist 1). 
UHCW pharmacist 1 and BCH pharmacist 2 additionally described the inconvenience of 
administering the Losec MUPS formulation (i.e. the time taken for the granules to dissolve). 
Concerns regarding the high bicarbonate load (UHCW pharmacist 1) and risk of 
administration errors (BCH pharmacist 2) were reported. 
5.4.4.4.3 The knowledge and understanding of medical practitioners, pharmacists and 
parents regarding unlicensed medicines 
UHCW pharmacists described how both medical practitioners and parents often lack 
understanding about Specials medicines, and specifically how medical practitioners do not 
understand the importance of continuity of supply. The BCH pharmacist group shared similar 
views on this topic. However, BCH pharmacist 2 gave an opposing argument that sometimes 
parents are too informed when given a Specials information letter to help their community 
pharmacist to order the Special. An example was provided, where a parent became 
obsessed with maintaining a specific Specials brand of ergocalciferol liquid, which was not 
vital in the professional opinion of BCH pharmacist 2 who discussed the unnecessary 
difficulties with supply that were encountered.  
It was suggested that some community pharmacists “aren’t using their logic” (BCH 
pharmacist 2) when receiving prescriptions for Specials. BCH Pharmacist 4 agreed with this 
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and in addition hypothesised that GPs may be fearful and unwilling to change things 
prescribed by specialists. 
In the medical practitioner focus group, the GP participant (MP 3) described first-hand how 
GPs are advised by PCTs to cut Specials in relation to their budget. Similarly UHCW 
Pharmacist 1 addressed the influence of money shortages from PCT level on the prescribing 
of Specials by GPs. In addition she queried whether pharmacists are acting assertively and 
supplying the readily available licensed products first as often medical practitioners do not 
specify dosage forms. The lack of consistency between Specials, costing reliant on source, 
lack of guidance and GP cost issues (influenced by the drug budget from the local PCT) were 
discussed by the BCH pharmacist group. BCH Pharmacist 3 voiced that multinationals are 
often unwilling to source beyond their Specials supplier. 
As predicted the pharmacists had a strong focus on the problems surrounding Specials 
medicines, and showed particular concern towards risks of error and inaccurate dosing. Both 
pharmacist groups discussed the lack of PILs supplied with Specials medicines (UHCW 
pharmacist 1 and BCH pharmacists 2, 3, and 4). In addition, parental confusion and lack of 
mathematical skills was given as a potential cause of overdosing in paediatric patients (BCH 
Pharmacist 1).   
Licensing problems with medicines administration via feeding tubes and the associated 
accuracy and safety issues were discussed frequently by the BCH pharmacists.  
5.4.4.4.4 Extemporaneous dispensing 
On the topic of extemporaneous dispensing, UHCW pharmacists compared the more 
rigorous approach used in hospital pharmacy to that used in community pharmacy. They 
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perceived that some community pharmacy premises were unsuitable environments for 
dispensing extemporaneously. The influence of economic issues on staffing levels in 
hospitals was highlighted. UHCW pharmacist 1 stated “pressure in the hospitals has turned” 
and revealed that less extemporaneous dispensing is performed in hospital pharmacies.  
The BCH pharmacy group revealed a negative attitude towards extemporaneous dispensing 
in community pharmacies. The view of BCH Pharmacist 3 was that “enough preparations are 
out there without extemps.” Problems addressed by the group included the preparation 
work involved and the lack of quality of ingredients (BCH pharmacist 3). BCH Pharmacist 1 
discussed that a shortage of time and unsuitable work conditions could be detrimental and 
thus increases the risk of errors. Deskilling of the workforce across hospital and community 
pharmacy was identified as a problem by BCH pharmacist 2. BCH Pharmacist 4 spoke about 
the increased prevalence of extemporaneous dispensing in an allied European country, and 
compared the higher level of quality control that is implemented. 
The nurses recognised problems with the supply of extemporaneously dispensed solutions. 
These are reported in Table 28 below. 
Table 28 Healthcare professional reports of extemporaneously dispensed solutions. 
Extemporaneously dispensed medicines  Reports of healthcare professionals 
Sodium phosphate solution Nurses 2, 3, and 5 discussed short expiry resulting in 
inconvenient and frequent hospital journeys. 
Sodium chloride solution “The solution has no preservative in it” and “you have to keep 
ordering it every day. Keeping on top of those prescriptions for 
parents is quite a struggle.” (nurse 4) 
5.4.4.5 Parental understanding of medicines 
All groups discussed concerns regarding parental understanding. The paucity of information 
provided on Specials medicines, parents not reading labels on medicines, the lack of 
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consistency between strengths of formulations ordered from community pharmacies and 
thus the associated risk of error were reported by the focus group participants.  Specific 
examples were highlighted, parents not understanding the difference between strengths of 
drugs (UHCW pharmacist 1) and problems with “parents’ mathematical skills” (BCH 
pharmacist 1).  
Examples were revealed suggesting that some parents are unaware that two different 
medicines can both contain paracetamol: 
“I mean parents don’t even know Calpol is paracetamol” (nurse 5) 
Nurse 2 added “or they give Medised and that’s got paracetamol in it as well.” 
5.4.4.5.1 Educating parents and children about medicines 
In the nurse group, the need for parental education was discussed by nurse 1. Additionally 
Medical practitioner 4 and BCH Pharmacists reinforced the importance of counselling and 
communicating with parents to improve medicines adherence. 
Training and aids used to help children to swallow solid dosage forms were discussed in the 
nurse and pharmacist groups. BCH Pharmacist 2 discussed the “pill-glide administration aid” 
used in some epileptic patients following a ketogenic diet.  BCH Pharmacist 3 queried if this 
compliance aid has a placebo effect, and BCH pharmacist 2 agreed, and additionally 
compared the “pill-glide” cost implication versus the cost of Specials. BCH Pharmacist 1 
described pill-swallowing techniques used for HIV patients by a fellow pharmacist: 
“She gets sweets of the different sizes of ascending order and it’s basically I’ll swallow this if 
you swallow that you know they go up in size, so you start off with a tic-tac or something 
then you sort of go up in size..” 
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BCH Pharmacist 2 identified a “gap” in the care of patients as they are often not trained to 
take medicines orally, and BCH Pharmacist 1 agreed. 
UHCW pharmacist 1 admitted being unaware of who teaches children to swallow tablets, 
and then described her knowledge of training used: 
“I’ve seen you know.. various training aids to teach children how to swallow tablets on..I 
can’t remember whether it was the CF trust or what now.. oncology sites.. or the HIV..” 
Nurse 4 demonstrated her awareness of the training requirements for swallowing solid 
dosage forms in Australia: 
“Well in Australia they all have to go to a swallowing clinic so they can all swallow their 
tablets by the time they start school.” 
 
5.4.4.5.2 Social problems and language barriers 
UHCW Pharmacist 1 recognised “the disorganisational social problems” and children in 
“dreadful circumstances” reporting the example of refugee children. She identified that 
medicines may not be their priority. 
Language was a barrier highlighted in the BCH pharmacist group. BCH Pharmacist 2 
acknowledged that translators are rarely booked at patient discharge to discuss 
management at home. 
5.4.4.6 Medicines adherence 
5.4.4.6.1 The relationship between age of child and dosage form preference 
Pharmacists, medical practitioners and nurses reported that dosage form preference is 
influenced by individual patient choice. 
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BCH pharmacist 2 revealed that dosage form preference (liquid versus capsules) varies 
between individual patients taking itraconazole and this should not be predicted. Similarly 
UHCW pharmacists discussed the variation in dosage form preference across patients, 
providing the example of a child wanting solid dosage forms (UHCW pharmacist 1) and a 16 
year who will only take liquid medicines (UHCW pharmacist 2). 
Medical practitioners 4 and 5 also discussed how dosage form preference is unrelated to the 
age of a child: 
“I’ve got a 17 year old who doesn’t like tablets” and “other children who’d much prefer to 
have a crushed up tablet in some jam than to take any of the syrups” and “it’s really.. 
patients’ difference. I never guess anymore now, I just ask.” (MP 4) 
“It’s not age related really.. a lot of children say they want tablets rather than medicines.” 
(MP 5) 
Medical practitioner 7 discussed the difficulties in administering medicines to HIV positive 
children and particularly getting them to swallow multiple tablets from the age of three. 
5.4.4.6.2 Parental influence on dosage form choice and medicines adherence 
The groups contended that parents can influence dosage form choice and medicines 
adherence in paediatric patients. Reports of parents and carers influencing child adherence 
were frequently addressed in all groups. This included parents not allowing young people 
empowerment and also parents not supporting medicines adherence. 
Examples given in the medical practitioner group included parents concealing the medicines 
of an eleven year old oncology patient in a cupboard (MP 4 and 5), and parents being 
“overprotective,” insisting that a young person still requires liquids, thus demanding a 
specific Specials formulation (MP 2).  
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UHCW pharmacist 1 gave her disapproving view on parents handing medicine responsibility 
to their eleven year old son “he’s just not old enough to do that.”  
Examples of parents altering doses of medication uninstructed were provided in the nurse 
focus group “Yeah parents stop omeprazole I know parents just stop giving it” (nurse 5). 
Nurse 2 revealed how a mother declared that she would stop administering medicines to her 
baby following hospital discharge.  
The BCH pharmacists discussed parents altering doses if they believe that the medicines are 
not working, “they even increase it scary” (BCH pharmacist 4). BCH pharmacist 3 reported 
that a mother with strong opinions regarding her son’s treatment influenced doctors to 
prescribe a different antibiotic drug. 
UHCW pharmacist 1 suggested that adherence may be better when nurses administer 
medicines owing to the child recognising a different relationship with a nurse compared to 
their parent or carer. Her response when questioned about demanding parents was that if 
parents are persistent they get what they want. 
5.4.4.6.3 The relationship between age of child, disease status, diagnosis, miscellaneous 
variants and medicines adherence 
BCH pharmacists discussed the effects that age of child, parental influence, perceived 
severity of chronic condition and an association with perceived disease improvement may 
have on medicines adherence. BCH pharmacist 2 addressed medicines responsibility at 
different ages, “toddlers” relying upon parents and “teenagers” having increased 
responsibility and empowerment for the use of their medicines. She also commented that 
some children with chronic diseases (reporting patients with CF as an example) discontinue 
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medicines administration to see what happens even though they understand the importance 
of taking them. She came to a decision that medicines adherence is likely to be related to the 
treatment goal of the condition being treated. 
BCH pharmacist 4 proposed that non-adherent “teenagers” may be rebelling against 
“normal life.” She anticipated that if an immediate improvement in condition is seen by a 
patient that they are more likely to take medicines. However she ended her view with 
uncertainty on this matter, “I don’t really know.” 
Regarding medicines adherence patterns across paediatric oncology patients, UHCW 
pharmacist 2 perceived that little difference in medicines adherence exists between 
“teenagers” and parents responsible for administering medicines. 
Medical practitioner 4 discussed medicines adherence patterns of different paediatric 
patients, indicating that “toddlers and teenagers” [negative tone] were deemed to be 
problematic.  
Nurse 4 compared drug naïve and CF patients and thus related adherence to acute versus 
chronic patients: 
“Depends how often child takes medication, for example CF as opposed to a child who 
comes in with a pneumonia- they won’t be used to medicines at all whereas our children are 
used to medicines and see the advantages to swallowing a pill rather than having syrup to 
take.” (nurse 4) 
 
UHCW pharmacist 1 hypothesised that an interesting relationship exists between what 
children are familiarised with taking and their adherence to medicines. She gave the 
example of Calpol suspension which may be seen as a “rub and a kiss” by children and 
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implied that when drug-naïve children are prescribed medicines, they experience different 
flavours that they are not used to and this can affect medicines adherence. 
5.4.4.6.4 Polypharmacy 
BCH pharmacist 2 described her views on polypharmacy and rationalising prescribing: 
“I think the other thing you end up with chronic conditions as well is people or children with 
lots of multiple conditions where you get lots of prescribers involved all adding in their own 
individual bit they all want added in prescribed for different conditions so the poor child 
then walks away with massive bag-fulls of drugs and sometimes there’s no rationalisation 
actually could we remove the odd few things to actually encourage them to take it.” 
(pharmacist 2 BCH) 
Medical practitioner 5 proposed that “polypharmacy” patients should be considered. The 
example group of patients reported was CF patients. 
5.4.4.7 Adverse effects of medicines 
5.4.4.7.1 Excipients 
BCH pharmacist 4 addressed concerns regarding liquid medicines as many are adult 
medicines that contain certain excipients which are unsuitable for children. Table 29 below 
details excipients in medicines, identified as problematic by healthcare professionals 
Table 29 Problems with excipients in medicines as reported by healthcare professionals. 
Excipients Reports of healthcare professionals 
Propylene glycol BCH pharmacist 4 
Sorbitol BCH pharmacist 4 described the osmotic effect of sorbitol, causing diarrhoea in patients 
administered medicines through enteral feeding tubes. 
Sugars Causing tooth decay. 
Alcohol Phenobarbital liquid preparation listed in BNFC. 
5.4.4.7.2 Adverse effects associated with specific medicines 
In the nurse group, ciprofloxacin was associated with “terrible diarrhoea” and azithromycin 
with behavioural issues.  
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In the medical practitioner group both Movicol oral powder and nitrofurantoin suspension 
were reported to cause nausea. Additionally, vomiting was an adverse effect highlighted 
following consumption of antiretroviral medicines, similarly reflux or vomiting after taking 
multivitamins. 
5.4.4.8 The supply of medicines and liquid measuring devices 
5.4.4.8.1 Problems with the supply of medicines 
The medical practitioners addressed specific Specials medicines when asked about problems 
with the supply of medicines (as reported in Table 27). Problems with the supply of 
additional medicines are reported in Table 30 below. 
Table 30 Problems with the supply of medicines reported by healthcare professionals.  
Medicines  Reports of healthcare professionals 
Antituberculosis medicines and Gastrografin solution 
 
Nurse 4 (Gastrografin solution specified to be 
difficult to order in community pharmacies). 
Reconstituted erythromycin suspension MP 4 
 
5.4.4.8.2 Problems with the supply of oral syringes and the accuracy of measuring liquid 
medicines 
The nurse focus group highlighted difficulties with obtaining oral syringes for children who 
were not enterally fed. Nurse 5 reported the reluctance of supply by pharmacists, inferring 
that this is a financial problem and additionally discussed her concern of numbers being 
erased from oral syringes as they are frequently re-sterilised. UHCW pharmacist 1 also 
reported that re-sterilising oral syringes is concerning, and acknowledged the associated risk 
of inaccurate dosing. She spoke about the lack of oral syringe sizes available in the Drug 
Tariff “It would be useful if you could get different size syringes on the Drug Tariff though.” 
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This confirmed her awareness that oral syringes of a specific volume can be prescribed on an 
NHS prescription. 
Medical practitioner 3 addressed the disallowance of prescribing oral syringes on an FP10 
prescription and reported her uncertainty as to whether pharmacists are allowed to freely 
provide oral syringes or if it is out of their own goodwill. Nurse 1 also demonstrated 
awareness of the problems with obtaining oral syringes, stating that they have to be 
purchased by parents. 
The risk of inaccurate dosing when using a teaspoon to measure liquid medicines was 
described by UHCW pharmacist 1: 
“If you’ve lost your medicine spoon and use a teaspoon that can vary from 3mls to 8mls 
couldn’t it.” 
 
5.4.4.8.3 The parallel importing of medicines 
The pharmacist focus groups discussed parallel imported medicines. Reports provided by 
pharmacists can be found in Table 31 below. 
Table 31 Parallel imported medicines reported by pharmacists. 
Medicines  Reports of healthcare professionals  
Cephatoxin BCH pharmacists 1 and 2-(American, although manufactured in India) UHCW pharmacist 1-
(imported from Australia).  
Clindamycin BCH Pharmacist 2-(German) UHCW pharmacist 1-(imported from Germany). 
 
Both Pharmacist groups acknowledged protocols for handling parallel imported medicines 
which detailed the need for translation of the PIL. 
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5.4.4.9 Medication errors in pharmacies and GP practices 
5.4.4.9.1 Standardising the labelling of liquid medicines 
The UHCW pharmacist group emphasised the importance of standardising the labelling of 
liquid medicines: 
“It would all be easier if they could formulate it so the calculations were easier so they were 
always 10milligrams in 5ml... 100milligrams in 5ml or something” “and if they were all 
labelled in 5mls or in a ml.” (UHCW pharmacist 1) 
UHCW pharmacist 2 agreed with this suggestion. 
5.4.4.9.2 Medicine selection errors at GP practices 
The risk of medication errors at GP practices associated with untrained staff selecting 
incorrect medicines information on computer systems was addressed by BCH pharmacist 3. 
5.4.4.10 Problems with medicines at school 
Reports of how medicines are dealt with in the school environment were similar across the 
focus groups. Reports are provided in Table 32 below. 
Table 32 Healthcare professional reports of how medicines are dealt with in the school 
environment. 
Comments provided on how medicines are dealt with at school Reporting healthcare professionals 
Medicines should be prescribed where possible to be administered 
outside of the school day. 
UHCW pharmacist 1 and MP 5 
School policy regarding medicines depends on the school concerned 
(i.e. varies between institutions). 
MP 3 and MP 4 
Some schools have refused to allow medicines on the premises. Nurse 2 
Children taking chronic medication would not be denied of their 
medicines at school. Prescribed medicines can be administered during 
school hours if they are labelled and added that schools often expect 
parents to administer medicines during the school day. 
UHCW pharmacist 1 
Schools are not allowed to deny children their medicines and the 
acceptance of medicines is improving in schools. 
Nurse 4 
UHCW pharmacist 1 queried whether teachers have time to give children medicines and also 
questioned whether children requiring antibiotics at regular intervals should attend school.  
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5.5 Discussion 
5.5.1 Oral formulation-related barriers to medicines administration 
Commonly reported oral formulation-related barriers to the acceptance of medicines in 
children across the four focus groups included taste, texture, size of solid dosage form, and 
volume. Taste was the most prevalent oral formulation-related problem highlighted across 
the groups. Flucloxacillin solution was perceived by all healthcare professional groups to be 
disliked by children due to its taste. Baguley and co-workers (2012) similarly reported that 
oral flucloxacillin is often considered unpalatable by children and suggested conducting a 
taste-test with an individual child prior to prescribing flucloxacillin solution. 
Chloral hydrate solution, prednisolone soluble tablets and Movicol oral powder were all 
highlighted with respect to taste in two of the focus groups. Similar findings were reported 
in studies by Chung and co-workers (2000) (oral chloral hydrate), and Lucas-Bouwman and 
co-workers (2001) (taste of prednisolone oral solution superior to crushed tablets).  
However, a study conducted by Pashankar and co-workers (2003) found that Movicol oral 
powder was preferred by children when compared to alternative treatments for chronic 
constipation. 
Gastrografin solution, Oramorph solution, Septrin paediatric suspension, rifampicin 
suspension, Kaletra solution, nitrofurantoin Special suspension, clarithromycin suspension 
and generic paracetamol suspension were all associated with taste problems in an individual 
focus group. Powers (1996) similarly acknowledged the poor palatability of clarithromycin 
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suspension. All medicines reported with taste problems in the focus groups were perceived 
by participants to cause problems with adherence.  
All healthcare professional groups reported texture as a barrier to medicines administration; 
particularly amongst children with learning disabilities. Field and co-workers (2003) defined 
five feeding problems (including one related to the texture of foodstuffs) and explored pre-
disposing factors to these problems. Over one quarter of children suffering from Down’s 
syndrome, autism or cerebral palsy refused to eat food textures that were considered to be 
developmentally appropriate (Field et al., 2003). Feeding problems (including those related 
to texture) should be considered carefully by prescribers prior to making prescribing 
decisions to treat such patients as the consistency of some medicines (including those 
reported in Table 21) may be difficult to ingest.  
The nurses reported the widest variety of oral formulation-related barriers to medicines 
administration including those that affect sensory perceptions (colour and smell). They 
shared an in-depth knowledge on oral formulation-related barriers to medicines 
administration that the medical practitioners and pharmacists did not discuss, highlighting 
the importance of conducting focus groups with different healthcare professionals. This 
plethora of knowledge mirrors the ‘hands-on’ experience that nurses have on administering 
medicines to children. Limited studies have revealed the impact that the appearance and/or 
smell of a medicine may have on medicines acceptance in children as discussed in Chapter 4. 
Across the focus groups, the large sizes of antiretroviral tablets were associated with 
swallowing problems in children. Several studies investigating children suffering from HIV 
support these findings and have reported the negative attitudes of children regarding the 
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size of antiretroviral tablets (Czyzewski et al., 2000, Garvie et al., 2007, Gibb et al., 2003, 
Marhefka et al., 2004, Paranthaman et al., 2009, Reddington et al., 2000, Roberts, 2005). 
Additionally, large dose volumes were perceived to be a barrier to medicines administration 
and examples of formulations with large dose volumes were volunteered across the groups. 
Owing to the paucity of research investigating the variety of oral formulation-related 
barriers to medicines administration, further studies are warranted to explore the 
perspectives of healthcare professionals, parents, carers and children (see Chapter 6). 
5.5.2 Future medicines for children 
Reports of issues with bad-tasting medicines were ubiquitous when probing the participants 
for their views on ideal medicine improvements. Improving the taste of flucloxacillin solution 
was considered important in all of the groups. This finding was anticipated, owing to the 
negative attitudes regarding the taste of flucloxacillin solution in this study and reported in 
literature (as revealed earlier in section 5.5.1). 
The nurses and medical practitioners prioritised the improvement of a variety of bad-tasting 
medicines as reported in section 5.4.4.2.1. However, the pharmacists perceived that an 
improvement to Specials medicines would be ideal. Pharmacists felt that providing 
Certificates of Analyses to assure the safety and stability of Specials medicines and also 
licensing some medicines not commercially available in child appropriate formulations 
should be considered in order to improve medicines for children. Improving Specials 
medicines was not reported as an ideal medicine improvement by the nurses or medical 
practitioners, suggesting that this problem is not such a concern for them. Supporting these 
findings, Elkins-Daukes and co-workers (2005) investigated the opinions of GPs regarding off-
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label prescribing and found that less than 15% of GPs admitted to specific concerns when 
prescribing off-label, including the risk of adverse effects and unevaluated efficacy.  
Calpol suspension was described positively across all groups. Pharmaceutical companies 
should be fully aware of medicines that are generally well-accepted by the paediatric 
population. Although the excipients used to procure Calpol suspension are not suitable for 
taste-masking all drugs, where similar flavourings are appropriate these should be taste-
tested for use in the paediatric population. Alternatively, pharmaceutical companies should 
provide information on safe and effective manipulation techniques (as discussed earlier) 
based on flavours preferred by the general paediatric population when applying to license 
medicines, as is set out in the PIP (European Commission, 2008). 
5.5.3 Problems related to medicines administration 
All groups discussed ad hoc manipulation techniques that had been reported to them by 
parents and carers and also those that they recommend to parents and carers to facilitate 
the administration of medicines to children (see Table 26). Manipulation techniques were 
discussed in detail by the nurses. The nurses gave examples of medicines manipulation on 
wards and also highlighted how parents administer medicines at home.  
The medical practitioners also volunteered information on manipulation techniques. The 
examples were provided by the medical practitioner with a role in the community, 
responsible for children who suffer from delayed learning and physical development. This 
finding suggests that medical practitioners caring for children with delayed learning and 
physical development are more aware of the difficulties associated with administering 
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medicines to this patient population and are more likely to recommend medicine 
manipulation techniques.  
Pharmacists reported the advice that they provide to parents when supplying medicines. 
Often hospital pharmacists will not see follow-up patients as continuation of therapeutic 
treatment is often supplied by community pharmacies. Inevitably, these pharmacists were 
less aware of how parents manipulate medicines to aid medicines administration in a 
domiciliary environment.  
Pharmacists showed more concern with regard to the risks of ad hoc medicines 
manipulation (e.g. mixing medicines with foodstuffs) compared to nurses and medical 
practitioners who demonstrated some awareness of the possible effects of reducing the 
stability of a medicine. Pharmacists demonstrated a better level of understanding than the 
other groups with regard to the risks of medicines manipulation. The potential 
pharmacokinetic effects of manipulating medicines were discussed and examples were 
provided, including the effects of mixing medicines with foodstuffs of differing acidities (i.e. 
Ribena versus supermarkets own equivalent). Although the medical practitioners provided 
less knowledge of the risks of manipulating medicines, the risk of incomplete consumption 
of a dose of medicine when mixed with milk feeds was highlighted.  
Focus group findings indicate that paediatric pharmacists’ knowledge on risks of medicines 
manipulation was better than that of the allied healthcare professionals in this study. This 
suggests that the knowledge of paediatric pharmacists should be used to guide and educate 
healthcare professionals when prescribing or administering medicines in paediatric patients. 
To support this, the knowledge and education of paediatric pharmacists should be addressed 
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to ensure that they have optimal understanding of key scientific properties that may affect 
the dissolution and disintegration of a dosage form, properties including the fat and dairy-
protein content, pH and solubility of foodstuffs (Akram and Mullen, 2012). Such factors, in 
addition to food affecting gastric emptying rate, risk altering the bioavailability of a drug 
(Bowles et al., 2010).  
Findings of the focus groups indicate that the participating healthcare professionals were 
unaware of the level of evidence supporting various ad hoc manipulation techniques (see 
section 5.4.4.3.3.2). Laboratory work is warranted to provide a robust scientific evidence 
base to support safe and effective medicines manipulation. This should be used to inform 
guidelines detailing suitable manipulation techniques for parents and healthcare 
professionals administering medicines to children. User-friendly manipulation guidance 
based on this evidence would be a useful addition to formulation monographs in the BNFC. 
A study by Akram and Mullen (2012) used questionnaires and interviews to explore the 
knowledge and understanding of nurses regarding mixing medicines with foodstuffs. Similar 
to the present study, Akram and Mullen (2012) observed that the majority of nurses were 
unaware of potential drug stability and degradation issues when performing ad hoc 
administration techniques and additionally some nurses were not conscious of a possible 
impact upon clinical outcome. Akram and Mullen (2012) highlighted that further studies are 
needed to investigate the knowledge of healthcare professionals involved in the medical 
care of children. 
The risks of medicines interacting (through binding) with nutritional feeds and the potential 
effects on drug absorption were discussed by the pharmacists and nurses. Nurses declared 
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their uncertainty regarding how and when to administer the calcium binding drug 
ciprofloxacin, highlighting that advice is needed when administering medicines and 
nutritional feeds to optimise therapy. More scientific evidence, based on laboratory work 
investigating interactions between medicines and nutritional feeds (i.e. identifying potential 
insoluble complex formation) should be used to direct and standardise pharmaceutical 
advice. It would be useful to translate this scientific evidence in to appropriate sources for 
nurses and parents and carers to guide the order and timing of administration of medicines 
to children with complex regimens to optimise the therapeutic effects of medicines. 
5.5.4 Frequent issues experienced when treating paediatric patients, the 
supply of medicines and liquid measuring devices 
The problems with Specials medicines and unlicensed medicines were discussed in all groups 
and extensively amongst the pharmacists. Omeprazole liquid Special was frequently 
discussed with regard to several issues including cost. This finding was supported by a BBC 
news article revealing a variety of costs for omeprazole liquid (see section 2.4.5). 
Additionally, with regards to Specials prescribing, cost was mentioned by the nurses, 
pharmacists and the GP with respect to prescribing influence of the PCT. The wide ranging 
costs of Specials medicines have been a major issue. The recent procurement of the new 
Specials Tariff should help to reduce such problems although not all Specials formulations 
are included in this as discussed in introduction chapter, see section 2.4.5. 
Losec MUPS is an omeprazole formulation that is often prescribed instead of omeprazole 
Specials liquid. Reports of Losec MUPS granules blocking NG tubes were highlighted at least 
once in each focus group. This is an issue that needs to be addressed as NG/PEG tube 
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blockages may lead to patient discomfort and additionally, replacements which are costly. 
The prevalence of reported problems with Losec MUPS indicates that an alternative, suitable 
paediatric formulation is required. This finding should direct and prioritise future laboratory 
work in identifying a formulation (i.e. an alternative proton pump inhibitor) that is 
appropriate for administering to children and also those with more complex medical needs 
(e.g. children fitted with an NG or PEG tube).  
Problems with Specials medicines were a main focus of the pharmacist groups. Pharmacists 
demonstrated their increased knowledge, awareness and enthusiasm regarding Specials 
medicines. They discussed a variety of problems surrounding Specials which they frequently 
experienced first-hand (e.g. unpredictable bioequivalence between different Specials 
medicines) compared to the medical practitioners and nurses. The medical practitioners 
seemed to have the least understanding and knowledge of the depth of issues with Specials 
and tended to identify Specials medicines and issues with supply. The medical practitioner 
group suggested that some pharmacists may not be aware that certain medicines can be 
ordered and query whether pharmacists remind patients about the shortened expiries of 
Specials medicines and the need to frequently re-order. The nurses expressed their concern 
towards extemporaneously dispensed products and the inconvenience of frequent journeys 
to hospital pharmacy.  
Several studies have identified differences in the knowledge on Specials medicines between 
allied healthcare professionals. A study at UHCW investigating the Specials knowledge of 
medical practitioners, nurses and hospital pharmacists found that pharmacists had a better 
understanding of Specials terminology than nurses and medical practitioners (Venables et 
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al., 2012b). There was a particularly poor understanding of the term ‘Special’. In total, 50% 
of paediatric consultants were able to define it adequately but no doctor in training was able 
to (see Appendix 11 for published abstract of presented conference poster, reporting key 
study findings). 
Similarly, Mukattash and co-workers (2011a) reported a significant difference between 
healthcare professionals regarding familiarity with unlicensed medicines/prescribing off-
label. Community pharmacists were most familiar with the term unlicensed medicines 
(93.0%) whilst consultant paediatricians were most familiar with the term off-label (83.3%). 
A further study conducted with hospital-based paediatricians demonstrated that although 
over 69% of respondents understood the term off-label, only 28% actually knew when they 
were prescribing off-label (Mukattash et al., 2011b).  
Further investigation is necessary to address the education and support that is needed to 
improve knowledge of unlicensed medicines, Specials and off-label prescribing amongst 
healthcare professionals. Educating doctors and allied healthcare professionals on the 
appropriate use of Specials medicines at degree or equivalent level is fundamental to 
improving their understanding of unlicensed medicines and optimising safe and cost-
effective prescribing practices. Implementing e-learning for healthcare professionals could 
be a useful approach to addressing education and understanding. It is necessary to ensure 
that pharmacists are knowledgeable of all licensed alternatives to Specials medicines and are 
able to support prescribers and reinforce excellent prescribing practice and protocols. 
Additionally, educating healthcare professionals should improve counselling advice provided 
to parents, carers and young people. 
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Regarding Specials medicines, a better understanding of the alternative formulations readily 
available, costing, supply, stability, and accuracy of dosing is required. It is also important 
that the continuity of supply of Specials medicines is monitored as medicines sourced from 
different Specials manufacturers may not be bioequivalent (see section 2.4.4). 
Additionally, the supply of non-Specials medicines needs to be considered and effective 
communication between healthcare professional groups should improve awareness of 
problems that are experienced with the supply of medicines from pharmaceutical 
companies. Feedback to medical practitioners should be delivered in a standardised manner 
by pharmacists and patients should be well-informed of possible delays with medicines 
supply. Results from this study suggest that pharmacists have a greater knowledge on the 
extent of supply problems (including the parallel importing of medicines) compared to allied 
healthcare professionals, therefore increasing the understanding of medical practitioners 
and nurses on the extent of supply problems may be useful to improve medicines supply, 
thus optimise patient care. 
Difficulty in freely obtaining oral syringes on the NHS was highlighted by all of the healthcare 
professional populations. Study findings indicate that the Government should address NHS 
funding in this area. Pharmacists highlighted the risks of using inaccurate measuring devices. 
Household teaspoons can vary between 2ml and 10ml and thus using a teaspoon could 
result in a significant underdose or overdose (McKenzie, 1981). Pharmacists should be 
ensuring that the correct dosing instrument is supplied to all patients and that counselling is 
provided to parents and carers to assure accurate measurement of a dose. 
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5.5.5 Parental understanding of medicines 
Parental influence on medicines adherence and also limited parental understanding of 
medicines featured in all groups. The nurses emphasised the need for parental education, 
whilst the BCH pharmacist group acknowledged the limited time available to counsel 
patients effectively, resulting in their reliance upon nursing staff. Incorporating appropriate 
information in to clinic appointments for parents, carers and children could improve the 
safety and effectiveness of medicines use and also reduce medicines non-adherence. 
Improving time organisation to permit pharmacists to counsel patients effectively could help 
to minimise problems that result from poor parental understanding. Pharmacists identified 
that staff shortages were a barrier to counselling patients. Government funding bodies need 
to consider this when calculating financial budgets available to the NHS. Parental education 
may be valuable in improving general medicines knowledge in order to prevent harm (e.g. 
educating parents on medicines containing paracetamol to minimise paracetamol overdose 
risk). This was discussed by nurses in this study and also identified by the RPS in a recent 
report (RPS, 2012). 
‘Pill-swallowing training’ for groups of patients with specific chronic conditions was 
discussed by the nurses and pharmacists. Mandatory ‘Pill-swallowing training’ for all children 
of a specific age was reported to be implemented in Australia. Several studies investigating 
solid dosage form training have found improvements in swallowing abilities amongst 
children diagnosed with HIV (Czyzewski et al., 2000, Garvie et al., 2007). 
Further investigation is needed to determine if such training may be of significant benefit to 
children suffering from other chronic conditions. This may help to reduce difficulties with 
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tablet size that have been highlighted (e.g. antiretroviral tablets). Additionally, training to 
teach children how to swallow solid dosage forms may support the use of novel 
formulations, (e.g. mini-tabs (Spomer et al., 2012, Thomson et al., 2009)) in paediatric 
patients that would not generally be prescribed a solid dosage form until they are older.  
The UHCW pharmacist group highlighted the plethora of social issues that prevail in the 
domiciliary setting, implying that medicines adherence is not always prioritised in some 
social circumstances. Similarly, studies have found that family circumstances can influence 
medicines adherence in children (see section 2.2).  
5.5.6 Medicines adherence 
Findings from the focus groups suggest that dosage form preference is not correlated to the 
age of a patient, yet based on an individual’s choice. The EMA (EMEA, 2006) reports a matrix 
of general acceptability of different routes and dosage forms in relation to child age, yet 
acknowledges that children of the same age may prefer different dosage forms. Dosage form 
choice of an individual child may be based on several factors including properties of the 
formulation, child’s illness, child’s mood, the influence of their caregivers, cultural and/or 
regional habits (EMEA, 2006). The influence of these factors on choice of dosage form 
requires further investigation. 
Examples of parents influencing medicines adherence were reported across the focus 
groups. These included some parents not allowing young people empowerment over their 
medicines and others not supporting medicines adherence. 
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Study reports of the medical practitioners and pharmacists indicate that within the 
paediatric age spectrum young patients and “teenagers” tend to be less adherent to 
medicines. Several studies have concluded that adolescents are more likely to be non-
adherent than younger children when prescribed medicines to treat HIV, 
immunosuppression (post-transplant), CF and oncology (Beck et al., 1980, Brownbridge and 
Fielding, 1994, Elise et al., 2005, Feinstein et al., 2005, Gudas et al., 1991, Patterson, 1985, 
Reddington et al., 2000, Serrano-Ikkos et al., 1998, S.D. Smith et al., 1979, Tebbi et al., 1986). 
Suggestions that drug naïve patients may be less likely to adhere to medicines than patients 
with chronic conditions were commonly reported across the focus groups. A proposition was 
made by the BCH pharmacist group that if an improvement in a child’s condition is 
perceived, medicines adherence is more likely. The pharmacists voiced their views, implying 
that adherence to medicines may depend upon the specific condition being treated. The 
balance of treatment benefit versus risk on medicines adherence has been similarly 
acknowledged in a study conducted in adults with chronic conditions, including cancer and 
asthma (Horne and Weinman, 1999). 
The value of rationalising medicines in children who are prescribed multiple medicines 
(polypharmacy) was proposed by a medical practitioner and BCH pharmacist. Polypharmacy 
was investigated further in the semi-structured interviews conducted with parents, carers 
and young people in section 6.7.5. 
To improve childrens’ understanding of chronic conditions and the importance of adhering 
to medicines regularly, encouraging and promoting the participation of children at groups 
such as the YPG at BCH may be useful. The BCH YPG encourages young people to interact 
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and learn about medicines and chronic conditions. Participation in the group gives young 
people the opportunity to ask questions about medicines they are taking and what adverse 
effects they may experience.  
The importance of medicines adherence should be thoroughly explained to parents and 
children especially in circumstances where an improvement of a chronic condition is not 
apparent. This may help to discourage parents, carers and young people from discontinuing 
medicines without consulting healthcare professionals and through this improve medicines 
adherence. A cross-sectional survey of parents of 622 children with asthma found an 
association between parental beliefs about medicines and adherence, thus supports the 
need for parental education to promote adherence (Conn et al., 2007). 
5.5.7 Adverse effects of medicines 
The medical practitioners and nurses identified key adverse effects of medicines with which 
they were familiar. Future work should investigate whether incorporating education for 
parents, carers and young people within clinic sessions, on common and minor adverse 
effects of medicines to support patients and manage their expectations of medicines has the 
potential to improve adherence. 
Concerns regarding the safety of excipients were at the forefront of the BCH pharmacist 
session, with specific reference to propylene glycol, alcohol, sweeteners and sugars. The 
draft guideline on pharmaceutical development of medicines for paediatric use (EMA, 2013) 
reinforced the requirement for pharmaceutical companies to carefully select excipients 
when formulating medicines for children. The final decision to include an excipient should be 
evaluated using a benefit to risk ratio of the end pharmaceutical product (GRIP, 2013).  
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Often, the concentrations of excipients included in a medicine are not explicitly provided by 
pharmaceutical companies. Several studies have investigated the risks of using propylene 
glycol in intravenous formulations administered to neonates, but there is a paucity of 
research on the potential risks that flavouring agents (containing excipients such as 
propylene glycol) added to oral medicines may have on paediatric patients (GRIP, 2013).  
Protocols should be in place to alert healthcare professionals to excipients that could be 
harmful to the paediatric population when consumed in large quantities. This should 
additionally highlight medicines containing excipients that are inappropriate for regular 
administration to children and also direct healthcare professionals to alternative, safer 
choices. Where such alternative options are not currently available for a specific drug, 
pharmaceutical companies should prioritise the development of novel, age-appropriate 
formulations or provide robust evidence supporting mixing medicines with foodstuffs as 
discussed in the EMA (2013) draft guideline. 
5.5.8 Medication errors in pharmacies and GP practices 
The UHCW pharmacists perceived that the labelling of liquid medicines should be 
standardised, for example, labelling all liquid medicines as the weight of drug in the same 
volume (i.e. Xmg in 1ml). Both healthcare professionals and parents can become confused 
when different strengths are printed on medicine labels and examples of this were provided 
by the UHCW pharmacists. Through standardising the labelling of liquid medicines it may be 
possible to minimise some dosing errors. Studies are required to investigate if standardising 
the labelling of liquid medicines could significantly improve patient safety. It is prudent that 
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medicines labelling guidance provided to pharmaceutical companies when applying for a 
Marketing Authorisation is addressed imminently.  
The risk of medication selection errors at GP practices was identified in the UHCW 
pharmacist focus group. This finding suggests that safeguarding measures and staff training 
need to be addressed across GP practices.  
5.5.9   Problems with medicines at school 
Problems with medicines at school were reported across the groups. Unanimous reports 
suggested that medicines should be prescribed to be administered outside of the school day 
(where this is possible). Reports of some schools refusing to accept responsibility for 
medicines suggests that medicines policies are not adopted uniformly across schools. The 
National Service Framework for Children, Young People and Maternity Services 2004 (DOH, 
2004) reinforced the need to support children requiring medicines in schools. The 
requirement for school staff to receive adequate support, advice and training regarding 
medicines was reported. Additionally the framework emphasised the need for policies to 
guide safe storage, supply and administration of medicines in schools (DOH, 2004).  
Several studies have investigated medicine policies in schools. A survey of London primary 
school head teachers by Wong and co-workers (2004) found that 95% of participants 
reported having a medication policy for young people in school. However an earlier study by 
Pugh and co-workers (1995) reported that only 40% of primary schools and all secondary 
schools had a policy in place for asthma treatment.  
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Medicines adherence during school hours may be sub-optimal if schools do not support 
medicines administration. Omitting doses of medicines during the school day could have a 
significant impact on clinical outcome, therefore it is critical that medicines administration is 
addressed correctly in schools. This is especially important for paediatric patients suffering 
with chronic conditions and those requiring vital acute medicines.  
5.5.10  Discussion of limitations 
Recruitment to focus groups was conducted in a structured manner. Logistics created the 
greatest problem when recruiting participants. Time constraints resulting from staff 
shortages restricted the availability of healthcare professionals and affected study 
recruitment. A weakness of the focus group study was the low recruitment rate in the UHCW 
pharmacist group, as inevitably a focus group does not run correctly when only two 
participants are present. This focus group represented more a nominal group. However the 
information gathered from the UHCW pharmacist focus group in collaboration with the BCH 
pharmacist group widened the scope of pharmacist views in this study. Pharmacists from 
these institutions are required to meet the same standards with regards to training and it 
was not anticipated that the practice of pharmacy would differ significantly between BCH 
and UHCW. 
Although latecomers have the potential to disrupt the flow of a focus group, this did not 
cause a problem in this study as discussion was not interrupted. Supplementary data was 
collected from those attending late because of clinic commitments. 
The perspectives of healthcare professionals with experience in community and hospital 
settings were explored across the focus groups. It was necessary to investigate the issues 
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encountered in domiciliary and hospital environments in order to understand the scope of 
problems that present when prescribing, dispensing and administering medicines to 
paediatric patients. It would be useful in future studies to explore the perspectives of further 
hospital doctors, nurses and pharmacists and additionally those working solely in the 
community sector to gather a wider perspective. This would increase the validity of views 
across the healthcare sectors.  
The varied specialist interests and level of expertise of healthcare professionals in each 
group was advantageous to this study and permitted the collaboration of both common and 
unique data within and between the groups. The study aimed to investigate problems with 
oral medicines prescribed for many different chronic conditions, thus the variety of specialist 
interests of participating healthcare professionals was pertinent to this study. 
Inevitably some healthcare professionals participating from the same institution were known 
to each other. This could be seen as a potential limitation as it is thought that participants 
may be more inclined to speak in a ‘socially accepted’ manner (i.e. less honestly) (Rabiee, 
2004). As the nature of this focus group study was not perceived to be threatening, it is 
unlikely that participants would have contributed in this way. 
The study was conducted at two sites in the West Midlands, therefore it cannot be 
generalised and viewed as a nationwide perspective. The focus groups were used to scope 
the research and inform design of the semi-structured interviews with parents, carers and 
young people (Chapter 6). 
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5.6 Conclusion 
In summary, this focus group study has identified a large number of issues perceived by 
some healthcare professionals to cause problems when administering oral medicines to 
children that are not always considered when using medicines in children. 
Some of the problems highlighted with children’s medicines had been anticipated, including 
those surrounding poor palatability, however some problems were more novel. These 
included the limited awareness of medical practitioners with regard to risks associated with 
medicines manipulation (e.g. mixing medicines with foodstuffs) and issues surrounding 
Specials medicines. 
Collaboration between doctors, nurses and pharmacists is essential to optimise patient care. 
Communication is crucial and each healthcare professional group should be utilised for the 
wealth of their knowledge, for example it may be beneficial for medical practitioners and 
nurses to seek advice from hospital pharmacists on drug-foodstuff incompatibilities as 
findings suggest that their knowledge is greater. However, the findings of this study suggest 
that a paucity of scientific evidence is available to support the many ad hoc manipulation 
techniques regularly used. Review of medicines manipulation data available in literature 
confirmed that a robust scientific evidence base is lacking. 
It is evident that medical practitioners require more information when prescribing medicines 
to ensure supply, clinical effectiveness and to maximise cost efficiency. This information 
should include guidance on Specials prescribing, supported by a small-scale study on 
knowledge of Specials at UHCW which found that in particular, the existing knowledge of 
junior doctors regarding Specials medicines requires attention (Venables et al., 2012b). 
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Addressing the education of healthcare professionals involved in prescribing, dispensing and 
administering oral medicines to children and additionally counselling provided to parents, 
carers and paediatric patients will be invaluable to improving the therapeutic treatment of 
paediatric patients. Protocols detailing best practice guidance need to be developed based 
on the problems identified in this study.  
An understanding of problems with oral medicines from the perspectives of key healthcare 
professionals involved in the supply and administration of medicines to children was 
required prior to exploring problems perceived by parents, carers and children to inform 
interview design. It was anticipated that the focus groups would reveal if a paradox exists 
between problems with oral medicines reported by healthcare professionals, and parents, 
carers and young people. The views of parents, carers and children are reported in the 
consecutive Chapter, 6.  
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6 DETERMINING BARRIERS TO ADMINISTERING ORAL MEDICINES 
TO PAEDIATRIC PATIENTS FROM THE PERSPECTIVES OF 
PARENTS, CARERS AND PATIENTS 
6.1 Objectives 
The primary aims of this study were to identify the prevalence and nature of oral 
formulation-related barriers to medicines administration and in addition, ad hoc 
manipulation techniques used to administer medicines to children in the domiciliary setting. 
The primary outcomes of this study were to identify medicines commonly associated with 
reports of oral formulation-related barriers to administration and to establish if correlations 
exist between oral formulation-related barriers to medicines administration and child refusal 
of medicines. 
6.2 Background  
Structured discussions through West Midlands Medicines for Children Research Network 
(WM-MCRN) activities with parents and carers of children of differing social and ethnic 
backgrounds and suffering from chronic conditions, generated positive feedback regarding 
the importance of examining problems with medicines (see Appendix 1). 
Chapter 4 identified that limited studies have investigated oral formulation-related barriers 
to medicines administration across chronic conditions in paediatric patients. Systematic 
review included studies that were conducted in children prescribed a narrow spectrum of 
medications. The methodological tools used across these studies included the Medical 
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Adherence Measure (MAM) adherence interview (Ingerski et al., 2010, Zelikovsky et al., 
2008), Treatment Interview Protocol (TIP) (Marhefka et al., 2004), and Pediatric Acquired 
immuno-deficiency syndrome Clinical Trials Group (PACTG) questionnaire (NIAID). Detailed 
reporting of results of oral-formulation related barriers to medicines adherence in the 
included review studies was generally limited.  
The focus groups with healthcare professionals (see Chapter 5) highlighted obstacles to 
medicines administration and adherence in children. This warranted further exploration in to 
these problems from the perspectives of children and their parents/carers.  
Manipulation techniques used by nurses to administer medicines to children have been 
investigated as discussed earlier in section 2.5.2 (Akram and Mullen, 2012, Richey et al., 
2011, Skwierczynski and Conroy, 2008). However, studies have not explored the prevalence 
of manipulation of medicines performed by parents, carers and young people in the 
domiciliary environment. 
6.3 Setting 
UHCW was the chosen study setting for conducting this research. UHCW is a large teaching 
hospital offering a wide range of secondary and tertiary paediatric services. The hospital 
covers a child population of 66000, with approximately 3866 new paediatric patients seen in 
paediatric clinics each year and 8035 paediatric patients having ongoing follow-up in 
paediatric outpatient clinics (statistics based on 2011-2012 data). The catchment area covers 
inner city Coventry and rural Warwickshire, thus a diverse ethnic and socio-economic patient 
group attends the hospital.  
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6.4 Data collection technique 
Malim and Birch (1996) state that the balance and compromise for research is to maximise 
information gained with ease of analysis. A semi-structured interview tool was selected for 
this study to obtain the appropriate balance in data collection and subsequent analysis. 
A semi-structured interview approach allows the interviewer to initially define the area to be 
explored, and then diversify to pursue a response in more detail if necessary (Pope and 
Mays, 1999). The sequence of questions can be changed as required, whilst facilitating data 
collection in a reproducible fashion. Both quantitative and qualitative data can be collected 
within semi-structured interviews. 
During a semi-structured interview, the interviewer is able to show empathy and alter 
phrasing of questions in order to elicit detailed and considered responses from participants. 
These benefits have been previously shown to provide more detailed outputs (Gillham, 
2000) and an increased response rate (Chambers, 2000) compared to paper-based 
questionnaires. A criticism of using an interview as a collection tool is the phenomenon of 
patients telling the interviewer what they want to hear, i.e. what they think would be 
socially acceptable as a response and hence there is risk of collection of ‘false’ data (Butz, 
2006).  
Successful interviewing techniques were reviewed. Techniques included listening and not 
asking too many questions else the interviewee may expect the interviewer to take lead, not 
asking more than one question at once (to avoid confusion), not to be nervous, to wait for a 
response (give time) and not to interrupt or teach (Morse and Field, 1995). In addition it was 
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important to conduct the research in a safe setting and to obtain a good interaction with 
interviewee to maximise interview effectiveness (Chirban, 1996). 
Green and Thorogood (2004) suggest an order for the interview: introduce interviewer by 
name, discuss the aims of the interview, provide a reminder that interviewee can stop at any 
point without penalty and offer an opportunity to ask any questions. Special care and 
consideration is required when collecting more sensitive (i.e. background and ethics) data to 
avoid recording information not required for analysis. It was deemed most appropriate to 
ask sensitive questions towards the end of the interview, proceeding questions that could be 
answered more easily (Pope and Mays, 1999).  
Inviting a wide variety of participants with different backgrounds is vital to minimise bias. 
Interviewer bias also requires consideration as the social and ethnic characteristics of the 
interviewer could affect responses (Chambers, 2000). 
6.5 Methods 
Semi-structured face-to-face interviews with parents/carers and young people were 
designed to explore oral formulation-related barriers to medicines administration, and 
identify the influence of barriers on child acceptance of paediatric medicines, thus 
adherence. 
6.5.1 Design of semi-structured interview 
The aims and objectives of this study (see Chapter 3) were used to inform template design of 
the interview questions to provide the relevant output. A copy of the semi-structured 
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interview prompt sheet for parent/guardian can be found in Appendix 12.  These were 
modified appropriately for young people. 
6.5.1.1 Barriers to medicines administration 
The study questions were designed based on methodological tools used in previous studies: 
MAM (Ingerski et al., 2010, Zelikovsky et al., 2008), TIP (Marhefka et al., 2004) and PACTG 
(NIAID) to identify the oral formulation-related barriers to medicines administration. 
The medication module in the MAM adherence interview explored ‘obstacles that could 
result in non-adherence (e.g. forgetting, refuse, hard to swallow, etc.)’ This methodology 
was used in a study of 56 young people aged between 11 and 18 years on a renal transplant 
list (Zelikovsky et al., 2008) and also in a study by Ingerski and co-workers (2010) conducted 
in 74 young people aged between 13 and 17 years diagnosed with either Crohn’s disease or 
ulcerative colitis and their carers. Marhefka and co-workers (2004) designed the TIP to 
identify regimen knowledge, potential adherence barriers and adherence problems. The TIP 
was completed by 51 primary carers of HIV-infected children aged between 2 and 12 years. 
The National Institute of Allergy and Infectious diseases (NIAID) PACTG developed a 
structured questionnaire exploring general barriers to adherence to antiretroviral regimens, 
adapted for different age groups. In the PACTG questionnaire a Likert scale was used to 
provide a greater range of options than a simple yes or no response. For example, 0= never a 
problem 1= hardly ever a problem (1 - 2x a month) 2= frequent problem (1 - 2x a week) 3= 
almost always a problem (more than 3x a week). The PACTG tool has been used in several 
studies (Bunupuradah et al., 2006, Davies et al., 2008, Farley et al., 2003, Plipat et al., 2007, 
Van Dyke et al., 2002) as reported in Table 2. 
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The MAM adherence interview (Ingerski et al., 2010, Zelikovsky et al., 2008) and TIP 
(Marhefka et al., 2004) elicit qualitative responses, whilst the PACTG questionnaire (NIAID) is 
more structured and includes a checklist of barriers. A limitation of asking open-ended 
questions revolves around phrasing of the questions on barriers to adherence. In the 
methodology of the TIP (Marhefka et al., 2004), example barriers are provided to the 
interviewee when delivering the question, this could influence bias. Such methodological 
tools have only been used in narrow patient populations (transplant patients and HIV-
infected patients) and not across different chronic conditions.  
Methodological tools used to collect data on the obstacles to medicines administration 
(MAM (Ingerski et al., 2010, Zelikovsky et al., 2008), TIP (Marhefka et al., 2004) and PACTG 
(NIAID)) informed design of the explorative, open-ended questions within the interview of 
the present study. Questions were asked for each medicine to detect oral formulation-
related issues. This approach to data collection enabled detailed information about barriers 
to medicines administration to be determined.  
In addition to determining barriers to medicines administration, in order to understand non-
adherence behaviours it was decided that an estimation of respondents revealing full 
adherence and also intentional versus unintentional non-adherence behaviours would be 
calculated. Paediatric adherence studies have utilised modified adult adherence measures 
that have not been validated for use in children. Morisky and co-workers (1986) validated a 
structured four-item self-reported adherence measure of blood pressure control in adults 
which they concluded can be easily included in clinic visits; this was developed further to an 
eight item scale with improved sensitivity (Morisky et al., 2008). 
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The Morisky questions (Morisky et al., 2008, Morisky et al., 1986) were designed to be asked 
generally across a group of medicines (i.e. patients taking blood pressure medicines) and to 
give a composite score. In isolation, these closed questions were insufficient to meet the 
aims of the present study as they do not explore the obstacles to medicines administration. 
For example, Morisky and co-workers (1986) did not ask about the refusal of specific 
medicines, but used the question, ‘Are you careless at times about taking your medicine?’ 
this question would not provide sufficient information within this study. However, 
adaptation of the Morisky questions directed the design of the questions on adherence. 
Questions (1 - 5) used to detect barriers to medicines adherence in this study are reported 
below. The questions were designed to be delivered to parents and carers (and were re-
worded appropriately when delivered to 12-18 year olds): 
1. Have you ever forgotten to give this medicine? Yes/No  
2. Has the child in your care ever refused (chosen not) to take the medicine? Yes/No  
3. When the child in your care is feeling better do you stop giving this medicine? Yes/No  
4. If the child in your care is feeling worse do you stop giving the medicine? Yes/No 
5. Is there any other reason that your child is unable to take this medicine? Yes/No (a 
positive response led to the question, for what reason/s?). 
In a self-reported adherence study conducted in 260 HIV infected adults, Pratt and co-
workers (2001) found that self-reporting accuracy improved when reporting missed doses as 
opposed to doses taken and also when patients were asked about time periods of less than 
one month. A further study conducted in 34 HIV infected adults found that the number of 
doses omitted in the preceding three days (self-reported) was correlated to missed doses 
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measured by electronic medication monitoring and pill-count (Bangsberg et al., 2000). Doses 
omitted in the preceding three days (Van Dyke et al., 2002) and up to three weeks (Goode et 
al., 2003) have been used in paediatric studies investigating oral formulation-related barriers 
to medicines administration.  
The present study interview was designed to record if doses were missed in the week prior 
to interview. This time period was chosen as it was decided to be sufficient to detect if a 
once weekly medication was missed with the intention of also maintaining accurate memory 
recall. Appropriate questions were designed to collect this information, and further 
questions investigating when a medicine was last missed were also used (see sections 
6.5.1.1.3 and 6.5.1.1.5). 
Although general adherence behaviour was explored, reports of children refusing a dose of 
medicine were of primary importance in scope of the present project aims. Forgetting to 
administer a dose of medicine (leading to dose omission) and other reasons for missing 
medicines were considered, but were secondary outcomes of this study.  
Open-ended questions were placed between the closed questions on adherence when 
designing the interview prompt sheets (see Appendix 12) to make the participants feel at 
ease, in order to optimise the accuracy of information collected. 
The interview prompt sheets were used as a guide to elicit data on medicines administered 
to a child, name, formulation type, route, dose, frequency, problems with interrupting daily 
lives, forgetting, any manipulations made to the medicine to facilitate medicines 
administration or for purpose of dosing, problems with acceptance attributed to the 
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properties of oral formulations, how happily the child takes the medicine and medicines 
refusal, any adverse effects experienced, further barriers to adherence, problems with the 
supply of medicines and with PILs. In addition, general problems with medicines at school 
and techniques used for reminding to administer medicines were investigated. 
The questions delivered to parents and carers are provided within the themed sections 
reported below. These questions were re-worded appropriately for young people (12-18 
years) participating in the study. Questions using Likert scales were also designed based on 
those within the PACTG module 2 questionnaire (NIAID) so that parents/carers/young 
people could rate their responses to some questions. 
6.5.1.1.1 Oral formulation-related barriers to medicines administration 
The open-ended questions listed below were designed to identify obstacles to the 
administration of oral medicines to children (including unfavourable organoleptic and 
physical properties):  
 If you could change one thing about this medicine, or how child takes it what would 
this be? 
A prompt was delivered to participant: 
 How would you like it (the medicine) to be changed if you could decide?  
Where children were too young to verbally describe problems i.e. with the taste, parental 
judgement was used. Behavioural descriptions including wry face, shrugging shoulders, 
vomiting or spitting the medicine out, were used as indicators of unfavourable organoleptic 
properties (EMEA 2006). 
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6.5.1.1.2 Medicines Manipulation 
The ad hoc manipulation of a medicine was defined by consensus of RV with a Professor of 
Clinical Pharmacy and a Consultant Paediatrician. Relevant definitions for terminology used 
to design the interview tool are listed below.  
 Gold standard = medicine delivered to the route of administration without 
manipulation  
 Manipulation of a medicine = medicine physically adapted to facilitate medicines 
administration or for the purpose of giving a specific dose. 
The study defined terminology related to gold standard administration and the manipulation 
of medicines were not explained to study participants as it was anticipated that this may 
reduce reporting accuracy and underestimate the prevalence of medicines manipulation 
across the study population. 
The questions on manipulation of a medicine are reported below: 
 Do you give medicine in a different way? Prompt used, mix with food or juice, Crush 
or cut tablet or open capsule or dilute medication? Yes/No 
 Prompt used: how do you get the child in your care to take this once you get it 
home? Prompt used, exactly like it is or does it need to be dissolved? 
 If yes, how often? 1= Always 2= most of the time 3= not sure 4= rarely  
6.5.1.1.3 Medicines Refusal 
It was necessary to investigate medicines refusal to determine if oral formulation-related 
barriers influenced medicines refusal by children. 
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Refusal of a medicine was defined for the purpose of this study as complete omission of a 
dose by intent on at least one occasion, including spitting the dose back out, and/or closing 
the mouth. The questions asked:  
 Has the child in your care ever refused (chosen not) to take the medicine? Yes/No  
 If yes, how many times in last week? 1 2 3 4 5 6 7 
 When was the last time they refused to take the medicine?  
Resisting the administration of a medicine was not considered to be refusal. Disliking a 
medicine as a result of oral formulation properties (i.e. organoleptic or physical) may not 
necessarily cause refusal, but instead poor acceptability and may result in child resistance. 
This often requires increased parent or carer persuasion and persistence in order to prevent 
dose omissions. Interruption of a dosing schedule may result from child resistance. Dosing at 
precise time intervals may be crucial for some regimens and delaying doses may have 
significant implications on the clinical response of a drug. 
6.5.1.1.4 Child acceptance of medicines 
An indication of how well children accept medicines was explored based on a Likert scale 
assessment: 
 How often is child happy to take this medicine? 1= Always 2= most of the time 3= not 
sure 4= rarely 5= never. 
6.5.1.1.5 Forgetting to administer medicines 
Forgetting to administer a medicine was defined as complete omission of a dose on at least 
one occasion, resulting from unintentional memory lapse at the time of administration. The 
questions designed are listed below: 
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 Have you ever forgotten to give this medicine? Yes/No 
 If yes, how many times in last week? 1 2 3 4 5 6 7 
 When was the last time you forgot? Yesterday, 2 days ago, 3 days ago etc. 
Forgetting to administer a dose of a medicine resulting in delayed administration was not 
considered a missed dose for the purpose of this study, providing that the delayed dose was 
administered before the next dose was due to be administered. 
6.5.1.1.6 Reminding systems for administering medicines 
Reminding techniques are often useful to help parents/carers and young people to 
administer medicines regularly and also at the correct dosing times. The following question 
was designed to prompt participants to report techniques used to remember to administer 
medicines: 
 How do you remember to administer medicines? 
Prompt was delivered: 
 What reminding system do you use?  
6.5.1.1.7 Intentional discontinuation of medicines 
Parents, carers or children may choose to discontinue the administration of medicines 
unilaterally (i.e. without the advice of a healthcare professional). Medicines may be 
discontinued when a child is feeling better or worse, or when parents or carers perceive this. 
The questions that were used are listed below: 
 When the child in your care is feeling better do you stop giving the medicine? Yes/No 
 If the child in your care is feeling worse do you stop giving the medicine? Yes/No. 
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6.5.1.1.8 Adverse effects and treatment effectiveness of medicines 
Adverse effects of medicines may contribute to treatment discontinuation. A question was 
designed to determine the prevalence and nature of adverse effects of medicines 
experienced by children: 
 Does/has the child in your care experienced side effects? Yes/No. 
 Can you please describe to me.. Prompt with sickness, headache, pain, rash? 
A further question with a Likert scale response was designed to evaluate the perceptions of 
parents, carers regarding treatment effectiveness of medicines.   
 How often do you feel that the medicine makes the child in your care better?           
1= Always 2=most of the time 3=not sure 4=rarely 5=never. 
6.5.1.1.9 Additional barriers to medicines adherence and medicines adherence status 
Barriers to medicines adherence were defined as reasons for omitting doses of medicines.  
To identify barriers to medicines adherence in addition to refusing, forgetting and 
discontinuing medicines, the following question was used: 
 Is there any other reason that your child is unable to take this medicine? Yes/No 
 If yes, for what reason/s? 
An indication of participants reporting unintentional and intentional barriers to adherence 
was determined from reports of refusing, forgetting, discontinuing and additional reasons 
for omitting doses of medicines. 
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6.5.1.1.10  Issues surrounding the supply of medicines 
It was necessary to explore any problems experienced by parents, carers and young people 
when obtaining medicines in order to develop a detailed understanding of the range and 
extent of problems encountered. The questions that were delivered are reported below: 
 Do you have any problems getting this medicine in hospital/community pharmacies? 
Yes/No 
 If yes, what problems? 
6.5.1.1.11  Problems with PILs 
The information provided in PILs corresponds to the licensed use of a medicine. A question 
was designed to investigate how well parents, carers and young people use and understand 
PILs: 
 Do you feel that the information you get is in plain English and clear/easy to 
understand? Yes/No 
Appropriate terminology was used to obtain participant understanding. Prompts to the 
“leaflet in the medicine box” were provided by RV. It was anticipated that participants may 
report on other sources of information (e.g. information provided by healthcare 
professionals). 
6.5.1.1.12  Problems with medicines at school 
In order to explore how well medicines are accepted in schools, the following questions 
were asked: 
 Do you have any problems with medicines at school? Yes/No 
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 Prompt used, are teachers happy to store medicines safely and give out medicines?  
A further question to evaluate if participants perceived that teachers and social staff require 
more information on medicines was asked: 
 Do you think that teachers and other school staff should be given more information 
on medicines? Yes/No. 
6.5.2 Ethical approval to conduct semi-structured interviews with patients 
and their parents 
Once the initial design was complete, information sheets, consent forms, posters and 
supporting documents were produced (including a detailed research protocol and simplified 
flowchart - see Appendix 13). 
The development of all study information sheets involved active consultation with the 
UHCW Youth Council with representation from age-appropriate individuals and parents and 
carers. The assent and consent forms were designed using template examples provided in 
NPSA (2009) guidance and ethically approved MCRN trials.  
An application was made to the Research Ethics Committee (REC) through the Integrated 
Research Application System (IRAS). The submission to the South Birmingham REC was 
completed on the 14th May 2010. An appointment was allocated by the South Birmingham 
REC on the 15th June 2010 to review the study application. Ethical approval was granted on 
the 8th July 2010 (REC no 10/H1207/47), see Appendix 14. 
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6.5.3 Delivery of the semi-structured interview 
It was necessary to ensure that questions were delivered using a layman approach, (Gillham, 
2000) thus collaboration with the consumer liaison team was crucial in the early design 
stages. The YPG at BCH provided positive, constructive feedback when asked to review the 
drafted interview questions in a pilot session using qualitative focus groups on the 14th 
November 2009. During the session the children were split in to small groups according to 
age range (under 9 years, 9-12 years and over 12 years), and asked questions from the age-
appropriate drafted template in order to gather their views on this study. Their views and 
feedback were incorporated in to the final study documents. 
Empathy from the interviewer was an important aspect within this study to provide 
reassurance to parents, carers and patients that their responses would not affect their 
clinical care. Statements to reassure participants that they could answer honestly without 
fear of blame were delivered by RV during the interview. Such statements included that RV 
would not “report back to doctors that medicines have not been taken as instructed” and 
also “everyone is human and humans sometimes forget.” However, study participants were 
informed that if a dangerous practice was identified that could put someone at harm this 
would be reported confidentially to the medical practitioner responsible for treating the 
child. 
6.5.3.1 Study populations 
Interview strategies were developed for :  
1. Parents and carers of children taking long-term medication for a chronic condition 
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2. Young people aged between 12-18 years taking long-term medication  for a chronic 
condition. 
Study interviews were conducted with parents or carers (if legal guardians) of children or 
young people. The opportunity to assent and participate alone was given to 12-16 year olds 
providing parent or carer consent was also obtained. Young people over 16 years of age 
were permitted to consent alone and encouraged to discuss the study with a parent or legal 
guardian before providing consent.  
6.5.4 Identification and recruitment to participate in semi-structured 
interviews 
Target recruitment was 300 children taking long-term medicines for a chronic condition. The 
aim was to sample approximately 100 parents or carers of children or young people in each 
age group (0-4 years, 5-11 years, and 12-18 years) in order to examine how results vary in 
relation to age of a child. As no other study has investigated oral formulation-related barriers 
to medicines administration in a paediatric population suffering from various chronic 
conditions, this sample size was calculated based on detecting the difference in medicines 
adherence between the three age groups. The study was powered to detect a difference of 
20 percentage points between the three age groups with alpha of 5% and power of 80% (see 
Appendix 15 for statistical advice from Research Design Service - RDS). For the purpose of 
the power calculation it was assumed that similar power would be achieved for the other 
outcomes and factors in this study. 
It was intended that the children would have a variety of chronic conditions (e.g. epilepsy, 
CF, neoplasms, cardiac disorders, endocrine disorders, tuberculosis, HIV, renal diseases, 
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rheumatological diseases and survivors of neonatal intensive care). It was anticipated that 
some of the children would have specific problems related to their route of medicines 
administration e.g. fitted with an NG or PEG tube. 
Many of the children were attending specialist paediatric outpatient clinics at UHCW. There 
was a scheduled approach to accessing patients at these clinics on a rotating basis to ensure 
wide coverage of the target patient population. Inpatients with chronic conditions were also 
recruited to this study to minimise the risk of missing patients who were hospitalised during 
the study period. 
Attendance at UHCW outpatient sessions was planned at least two weeks in advance. Lists 
of follow-up patients due to attend identified clinics were retrieved using the hospital 
patient booking information system in order to identify all patients potentially eligible for 
study inclusion. A letter of invitation (see Appendix 16) to participate in the study was 
posted out to potential participants, to arrive at least 24 hours prior to their outpatient 
appointment, (generally one week before). The invitation letter also contained age-
appropriate information sheets (see Appendix 16 for parent/guardian version) explaining the 
present study. On arrival at outpatient department, families were asked if they had received 
the study information and whether they would be interested in participating.  
Inpatient participants were identified on the morning after being admitted on to a paediatric 
ward, providing that they met the defined inclusion criteria (see Table 33). Appropriate 
information sheets were provided and a minimum of 24 hours was allowed for the potential 
participants to decide whether they wished to participate.  
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Following agreement to participate and checks to ensure that the study inclusion criteria 
were met, the consent and assent forms (see Appendix 17) were completed as defined in 
GCP. Written consent was witnessed by RV.  
Following a positive consent/assent process, the interview was conducted by RV. The 
responses were recorded on the data recording template sheets (see Appendix 18 for 
parent/guardian version). The data recording template sheets included patient hospital 
numbers and were held confidentially and securely at UHCW. Hospital numbers were added 
to a database in order to reduce the risk of duplicating interviews at UHCW. 
Interviews conducted with inpatients were identical to those conducted in the outpatient 
department. All Interviews took a maximum of 45 minutes to complete and were conducted 
in a private room in the paediatric outpatient department or behind a curtained bay on the 
wards, to maximise participant confidentiality and create a comfortable environment. 
Outpatient interviews were conducted either before or after outpatient appointments, 
ensuring minimal disruption to the running of clinics. The option to arrange a mutually 
agreeable alternative date was offered to families for whom participating at outpatient 
appointment was inconvenient.  
6.5.4.1 Inclusion and exclusion criteria for recruiting participants  
Studies included in Chapter 4 investigated patients prescribed a narrow spectrum of 
medicines. The inclusion criteria for this study (as provided in Table 33 below) included a 
more widened target population as children were not recruited based on a specific chronic 
condition. 
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Table 33 Inclusion and exclusion criteria for recruiting participants to the study. 
Inclusion Exclusion 
0-<18years (pre-term to young person) 18 years 
Parents/carers of children ranging from pre-term up 
to 18 years 
Parent/carer unable or unwilling to give consent 
 
If 12-17 years must also agree to take part. Must 
read and sign assent form once read and understood 
information 
Young person unable or unwilling to give consent 
(unless unable to consent and parent/carer provides 
consent) 
Chronic condition classed as any state requiring long 
term (study defined as > 1 month) therapy with 
medicines 
Had chronic condition likely to be long term for < 1 
month  
Diagnosed with condition at least one month 
previous to inclusion 
A short completed  illness lasting less than one 
month 
Receiving at least one medicinal product Where not receiving at least one medicinal product 
(e.g. just having physiotherapy but not taking 
medicines) 
Outpatients and Inpatients Patients who do not have follow-up appointments in 
a secondary care environment, and only utilise the 
primary care service 
 
Main carer/ parent/young person (whichever may 
be completing) needs to read and understand and 
speak English or have someone with them to 
translate (Generally, patients/parents/carers 
requiring a translator are booked one for whilst at 
outpatient clinic or during hospitalisation, we would 
endeavour to utilise this translator).   
 
Where main carer/parent/young person does not 
read and understand and speak English and has no-
one with them to translate. 
 
Where carer is reported, s/he must have legal guardian status. 
6.5.5 Data analysis 
6.5.5.1 Introduction to data analysis and software 
The collated quantitative data was analysed using a statistical program (IBM SPSS 20). All 
data was analysed confidentially, and the outcomes of the analyses reported anonymously.  
Qualitative data arising from the interviews was coded and analysed thematically with the 
aid of QSR NVivo 8, applying the same strategy used to analyse the Focus Groups (see 
section 5.3.8). 
174 
6.5.5.2 Qualitative data analysis 
Utilising a simple frame-work analysis approach, themes were defined and formed a coding 
spine analogous to that described in section 5.3.8.1.  
This frame-work analysis approach was used to code the qualitative responses retrieved 
from open-ended questions investigating oral formulation-related barriers to medicines 
administration (including unfavourable properties of oral formulations), other formulation 
and administration-related problems, ad hoc manipulation techniques used to administer 
medicines and also for reports of additional barriers to medicines adherence. 
6.5.5.3 Statistical data analysis 
Review of the initial aims and objectives of this study (see Chapter 3) identified five key 
binary outcomes: 
 Reporting manipulation of a medicine  
 Reporting refusal of a dose of medicine on at least one occasion  
 Reporting refusal of a dose of medicine within 6 months prior to interview 
 Reporting forgetting to administer a dose of medicine on at least one occasion 
 Reporting forgetting to administer a dose of medicine within 6 months prior to 
interview 
Quantitative analysis based on these five key binary outcomes for medicines administered 
by the participants in the study was proposed. The methods of data analysis used required 
that, for each category of a factor under consideration, there was at least one positive, and 
one negative outcome. For example, when considering the effect of gender on forgetting 
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doses, there needed to be at least one male patient who had reported forgetting a dose, and 
one who had not. Where this was not the case, then it was not possible to calculate odds 
ratios, and any statistical models produced would not converge, resulting in unreliable 
results. For this reason, the reports of forgetting and refusing doses of medicines in the week 
prior to interview were not included in the statistical analysis, due to the small frequency at 
which they were recorded.  
Results of forgetting and refusing to administer doses of medicines in the previous six 
months were derived from the open-ended questions enquiring when a medicine was last 
forgotten or refused (see sections 6.5.1.1.3 and 6.5.1.1.5). An assumption was made that a 
six month period would not alter the age range in which the patient was stratified at the 
time of interview. 
All data was entered in to IBM SPSS 20 so that both patient and medicine-specific variables 
could be converted into categorical variables. Patient data was stratified according to the 
patient and participant variables and medicine-specific variables listed in Tables 34 and 35 
below. 
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Table 34 Stratification of patient and participant variables into categories. 
Patient and participant variables Categories 
Age band of patient at time of interview 0-4y, 5-11y, 12-18y, split according to pre-school, 
primary school and secondary school age ranges. 
Type of patient Inpatient or Outpatient 
Gender  Male or Female 
Health-related need of guardian (included medical 
conditions, problems with eyesight, hearing) 
yes, no, not applicable (n/a) (n/a category was 
excluded for this analysis) 
English first language  yes, no 
Additional Educational needs of child 
 
yes, no, n/a (n/a category was excluded for this 
analysis) 
Attendance at mainstream school  
 
yes, no, n/a (n/a category was excluded for this 
analysis) 
Ethnicity  
 
Regrouped and coded into two categories, white and 
any other ethnic group 
Age band at diagnosis Regrouped according to BNFC recognised prescribing 
age bands, less than 1 month, 1 month- 2 years, 2 
years -12 years, 12 years -18 years 
Number of current prescribed oral medicines 1, 2, ≥3 
Multiple health conditions yes, no 
Other health-related need of patient (additional to 
medical condition including feeding problems, 
problems with eyesight, physical/mental 
impairment) 
yes, no 
Patient had PEG/NG tube fitted yes, no 
Who is responsible for administering medicines Recoded into groups with individual responsibility 
and shared responsibility: child, child plus 
parent/guardian/other, parent/guardian/other 
The Index of Multiple Deprivation (IMD) score 2010   
 
Variable grouped based on the quartiles in the data: 
<11.5, 11.5-19.8, 19.9-31.9, 32+ 
Logistic models require at least one positive and negative response within each categorical variable otherwise 
it is not possible to fit such a model. As a result of this, variables were grouped and recoded accordingly. Re-
grouping was also used for variables with too many categorical groups of uneven proportions. 
The Index of Multiple Deprivation 2010 (IMD 2010) score is a measure of multiple deprivation. This value 
encompasses 38 indicators that cover a range of economic, social and housing issues, giving a single 
deprivation score for each lower super output area (LSOA)  in England. Each area can be related to another 
according to deprivation score (Lad, 2011). The higher the IMD 2010 score, the greater the deprivation. 
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Table 35 Stratification of medicine-specific variables into categories. 
Medicine-specific variables Categories 
Formulation type of medicine  Regrouped to liquid, tablet or capsule, and other- 
granules, powders, soluble tabs and melts as too 
many categories with small numbers were present 
for analysis to run correctly. 
BNFC Chapter Chapters 1-6, 8, 9, omitting chapter 7, 10 and 
medicines not featuring in any of the BNFC chapters 
as small samples would not permit model to run. For 
BNFC chapters (see Appendix 19). 
 
Specials medicine yes/no. 
Oral formulation-related barriers to medicines 
administration: 
Taste (taste, aftertaste/lack of taste)  
Size of solid dosage form or aversion to/difficulty 
swallowing  
Texture (texture, consistency, thickness)  
Volume or quantity  
Colour/appearance  
Smell 
Other formulation and administration problems 
yes/no. 
Frequency of dosing Regrouped to less than once daily- i.e. 
monthly/weekly/alternate daily, once daily, twice 
daily, three times or more daily (omitting ‘when 
required’ medicines). 
Logistic models require at least one positive and negative response within each categorical variable otherwise 
it is not possible to fit such a model. As a result of this, variables were grouped and recoded accordingly. Re-
grouping was also used for variables with too many categorical groups of uneven proportions. 
 
Binary logistic models were employed with each of the five key binary outcomes reported 
earlier in this section. These were set as dependent variables. Data analysis was performed 
on an individual medicine level, thus allowed for each medicine taken by a patient to be 
analysed separately, rather than just considering their response to medicines as a whole. It 
also allowed comparisons to be made between medicine-specific variables (e.g. different 
medicine groups and forms), which are not possible on a patient level. However, it also 
raised the issue of non-independence in the data, since there were likely to be inter-
correlations between the responses to medicines taken by an individual patient (i.e. if they 
refuse one medicine, then they are more likely to refuse another). 
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In order to account for this, univariable generalised estimating equations were used. These 
are statistical models which adjust for inter-correlation within outcomes from the same 
subject. The univariable analysis did not control for potential relationships between variable 
factors, therefore multivariable analysis was conducted using the combination of variable 
factors found to be significant (p<0.05) for the five key binary outcomes in the univariable 
models. The variables used to form the multivariable logistic regression are highlighted in 
Appendix 20. 
Throughout the results section, the multivariable analysis results are reported. Some 
variables had to be recoded to enable some multivariable models to run as analysis is only 
possible if there is at least one positive and one negative outcome for each category of an 
independent variable. Where recoding was necessary this information is provided in the 
appropriate results sections.  
6.5.5.3.1 Spearman’s correlation test 
It was hypothesised that properties of oral formulations including taste, texture, volume or 
quantity colour and smell could be interrelated. A Spearman’s correlation test was used to 
identify relationships between these properties based on the interview reports. 
6.5.6 Ethical requirements of semi-structured interview data 
6.5.6.1 Ethical storage of semi-structured interview data 
Access to consent forms, assent forms and paper-based data recording templates were 
restricted to the immediate research team at all times and stored in designated locked filing 
cabinets in a locked MCRN office at UHCW. Consent and assent forms were stored 
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separately to paper-based data recording template sheets in a separate, locked filing 
cabinet. 
All information transferred on to the designated study encrypted laptop had restricted 
password protected access and was only available to the immediate research team. Data 
transfer on to the study laptop was completed in a secure office at UHCW. The data was 
analysed by RV at University on the same encrypted laptop on which the data was recorded. 
The laptop was retained securely in a locked office, within a locked cabinet at University 
when not in use. The key was kept securely by RV. 
6.5.6.2 Confidentiality and ethical issues 
All information was held confidentially by the research team. It was hypothesised that the 
interview would not be disturbing or contentious, but participants were reminded to put 
forward any questions or concerns before or after the interview. Participants were able to 
freely withdraw from the study at any point in time, and were advised before opting to 
consent that a decision to withdraw from the study would not affect their care.  
6.6 Results of semi-structured interviews 
6.6.1 Identification and recruitment to semi-structured interviews 
A total of 1559 study invitation letters were sent out by post (1448/1559) or handed out on 
the paediatric wards (111/1559) to potential recruits during the study period, between 
November 2010 and February 2012. Table 36 below reports the frequency of clinics targeted 
for this study (n=191). 
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Table 36 Frequency of clinics targeted during November 2010 and February 2012. 
Clinic Frequency of clinics targeted during study period 
Allergy 1 
Asthma/ respiratory  13 
Cardiology 4  
Cystic Fibrosis 9 
Diabetes 5  
Endocrinology 14 
Epilepsy 12 
Gastroenterology 18 
HIV 4  
Oncology 10 
General paediatrics  48 
Neonatal  32  
Orthopaedic 3  
Renal 7 
Rheumatology 9 
Sickle cell anaemia 2  
 
In total, 280 participants consented to the study. There were 483 patients that did not meet 
study criteria (majority not prescribed medicines for at least one month) and 47 subjects 
declined to participate in the study. Reasons for choosing not to participate included a 
parent who did not want to fill out personal information on the consent form, a family with 
social issues, difficulty with an autistic young person in clinic and a parent who could not 
read or write in English so had not understood the study information sheet. The majority of 
participants opting not to participate in the study did not provide a reason and were mostly 
young people. 
The remaining 749 patients included: 
 Patients that ‘did not attend’ (DNA) clinic  
 Parents who had phoned before clinic appointment to cancel a patient’s 
appointment and classed as ‘unable to attend’ (UTA) clinic 
 Patients that were missed whilst interviewing other subjects or restricted by time 
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  Those requiring more time to read study information properly and decide (postal 
mail was delayed in some cases). 
Two planned clinic days were missed due to unforeseen circumstances. 
Of the 280 subjects that consented to this study, 278/280 participants (211 parents/carers 
and 67 adolescents) completed the study. One young person decided to discontinue 
participation in the study and one parent did not complete any questions on medicines 
administration. Of the medicines currently prescribed at the time of interview, 79% 
(542/682) were oral medicines, and 8% (41/542) of these were identified as Specials 
medicines. 
The information collected on currently prescribed oral medicines was most valuable and 
relevant to the present study as formulation-related barriers pertinent to this study were 
those associated with oral medicines. For 91% (252/278) of children in this study, an orally-
ingestible medicine was prescribed. The remaining 26 patients were not prescribed any 
orally-ingestible medicines. Data collected from these 26 patients has been excluded from 
subsequent analyses. 
In the results and discussion sections of this chapter, young people, parents and carers 
answering each question are reported as respondents.  
6.6.2 Demographic results of 252 children 
6.6.2.1 Participant response rates for patient data 
Figure 8 below shows participant response rates for patient data. 
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Figure 8 A histogram displaying participant response rates for patient data.  
Uncoloured sections of bars represent missing data.
Male, 48% Female, 52% 
0-4 Years, 37% 5-11 Years, 37% 12-18 Years, 27% 
< 1month , 23% 1m-2y, 23% 2y-12y, 43% 12y-18y, 11% 
White, 76% Asian, 9% Mixed race, 8% 
Black, 5% 
Other 
2% 
<11.5, 20% 11.5-19.8, 21% 19.9-31.9, 24% 32+, 22% 
Inpatient, 12% Outpatient, 88% 
Single medical condition, 56% Multiple medical conditions, 44% 
Other health-related needs, 34% No  other health-related needs, 66% 
Attending school/higher education, 62% 
Too young to attend school or completed 
education, 35% 
Mainstream, 54% 
Extra-needs 
4% 
Private, 2% 
Home-schooled 
1% 
Too young to attend school or completed 
education, 35% 
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Gender 
Age (Interview) 
Age (Diagnosis) 
Ethnicity 
IMD 2010 quartile 
Type of Patient 
Multiple medical conditions 
Other health-related needs of child 
Child in education 
Type of schooling/higher education  
Participant response rate (%) 
(136/252) 
(10/252) (2/252) 
(5/252) 
(87/252) 
(156/252) 
(87/252) 
(85/252) (167/252) 
(140/252) (112/252) 
(29/252) (223/252) 
(51/252) (52/252) (61/252) (55/252) 
(191/252) 
(23/252) (20/252) 
(12/252) (4/252) 
(92/252) (93/252) (67/252) 
(121/252) (131/252) 
(57/252) (57/252) (108/252) 
(28/252) 
183 
6.6.2.1.1 Patients with NG or PEG tubes 
Nine patients utilised NG tubes (either for feeds or medicines) and five patients had PEG 
tubes fitted at the time of study participation. 
6.6.2.2 Main chronic condition  
The frequency of children with each main condition is provided in Table 37 below. 
Table 37 The frequency of children diagnosed with the main chronic conditions listed. 
Main chronic condition  Frequency of children 
Gastro-intestinal disorder (chronic constipation, 
Crohn’s, celiac disease, colitis, vomiting) 
44 
Neoplasm (sarcomas, lymphomas, metastatic 
disease) 
15 
Epilepsy 43 
Cerebral palsy 3 
Chronic allergies 8 
Oesophageal Reflux  10 
Cystic Fibrosis 13 
Systemic Lupus Erythrematosus (SLE)  and uveitis 14 
HIV 4 
Growth problems 5 
Thyroid condition 19 
Blood related disorder 18 
Other genetic disorders 2 
Asthma 15 
Renal disease  27 
Cardiac 4 
Diabetes Type 1 1 
Chronic fatigue Syndrome 2 
Chronic migraine 2 
Other (autism, scleroderma, chronic 
dermatological condition).  
3 
 
6.6.2.3 Participant response rates for participant data 
Figure 9 below displays participant response rates to questions regarding participant data. 
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Figure 9 A histogram displaying participant response rates for participant data.  
Uncoloured sections of bars represent missing data.
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6.6.3 Medicines data for 252 children 
The frequency of medicines prescribed and purchased (i.e. over the counter – OTC 
medicines, herbal medicines, vitamins, minerals and dietary supplements) were identified 
and then stratified according to age range of child at interview. The total number of 
medicines taken by the 252 patients was calculated. The results are reported in Table 38 
below. 
Table 38 The frequency of medicines prescribed and purchased stratified by child age 
range (0-4, 5-11 and 12-18 years). 
Age group 0-4y 
(n=92) 
5-11y 
(n=93) 
12-18y 
(n=67) 
Total in 252 
patients 
Total number of currently 
prescribed medicines 
(including feeds, thickening 
agents, vitamins etc) 
228 236 174 638 
Total number of OTC 
medicines administered 
75 77 46 198 
Total number of vitamins, 
minerals and supplements 
purchased 
9 16 7 32 
Total number of herbal 
medicines purchased 
1 0 1 2 
Total number of dietary 
supplements purchased 
0 1 0 1 
Total number of medicines, 
vitamins, minerals and 
supplements taken 
313 330 228 871 
 
Of the medicines currently prescribed, 85% (542/638) were oral medicines. The frequency of 
oral formulation types prescribed across child age ranges at interview is provided in Table 39 
below. 
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Table 39 The frequency of oral formulation types prescribed across child age ranges (0-4y, 
5-11y, 12-18y). 
Age group 0-4y 
(n=92) 
5-11y 
(n=93) 
12-18y 
(n=67) 
Total in 252 
patients 
Liquids  130 86 36 252 
Tablets or capsules 20 61 96 177 
Other (granules, 
powders, soluble 
tablets and melts) 
49 47 17 113 
Totals 199 194 149 542 
 
6.6.3.1 Response rates for interview questions 
Owing to the nature of the semi-structured flexible design and also restricted time to 
interview participants in the clinic environment, not all study questions were delivered to all 
participants or asked for all oral medicines prescribed to each patient (see Figures 10 and 11 
below for missing data, represented by uncoloured sections of bars). This applies throughout 
the results, analysis and discussion sections of this chapter. 
Response rates for questions are reported appropriately (i.e. on a participant/individual 
medicine level or both) according to the nature of the question. Question response rates for 
participants and medicines are reported in Figures 10 and 11 below. The narrative that 
follows, discusses the response rates shown in these Figures. 
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Figure 10 Question response rates for participants.  
Uncoloured sections of bars represent missing data.  
N/A= where question is not applicable, see narrative that follows for discussion of this. 
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Figure 11 Question response rates for individual medicines.  
Uncoloured sections of bars represent missing data. 
N/A= where question is not applicable, see narrative that follows for discussion of this. 
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6.6.3.1.1 Oral formulation-related barriers to medicines administration 
All 252 participants answered this question for all 542 medicines prescribed. 
6.6.3.1.2 Medicines manipulation 
All 252 participants answered the question regarding how exactly medicines are 
administered for the majority (499/542) of medicines prescribed. 
6.6.3.1.3 Medicines refusal 
The majority (232/252) of participants answered the question regarding the refusal of 
medicines, this resulted in data concerning 436/542 of medicines. 
For 10/252 of patients taking a total of 42 medicines this question did not apply as these 
patients were administered medicines only via NG or PEG tubes and formulations could not 
be refused via the current route of administration. For a further patient administered 2 
medicines via an NG tube the refusal question was asked as one medicine was administered 
orally. In total, 8% (44/542) of medicines were administered via NG or PEG tubes and 
medicine refusal was not possible. Data on medicine refusals was absent for these 44 
medicines. 
6.6.3.1.4 Child acceptance of medicines 
The question used to understand child acceptance of medicines was asked for 437/542 of 
the medicines prescribed. For 44/542 medicines this question was not applicable as they 
were administered via NG or PEG tubes. 
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6.6.3.1.5 Forgetting to administer medicines 
The majority (240/252) of participants answered questions on forgetting medicines for at 
least one medicine, this resulted in data regarding 462/542 of medicines. 
Questions on forgetting medicines were not applicable for 6/252 participants. The medicines 
prescribed for these children were instructed to be taken ‘when required,’ and according to 
disease symptoms. In total, 47/542 of medicines were administered on a ‘when required’ 
basis and therefore questions on forgetting were not applicable. 
6.6.3.1.6 Reminding systems for administering medicines 
A total of 208/252 participants answered the question regarding reminding systems used to 
remember to administer medicines.  
6.6.3.1.7 Intentional discontinuation of medicines 
Of the participants, the majority, 238/252 and 239/252 answered the question regarding 
stopping medicines unilaterally (i.e. without the advice of a healthcare professional) if a child 
was feeling worse or better respectively. 
For 6 children these questions were not applicable as medicines were prescribed to be taken 
on a ‘when required basis’. 
6.6.3.1.8 Adverse effects and treatment effectiveness of medicines 
For 481/542 of the medicines, a question was asked to investigate if adverse effects had 
been experienced. 
For 476/542 of the medicines, a question was delivered to ascertain whether they were 
perceived by respondents to be effective. 
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6.6.3.1.9 Additional barriers to medicines adherence and medicines adherence status 
The question exploring additional barriers to adherence was delivered to the majority 
(242/252) of participants, resulting in data for 469/542 of the medicines prescribed.  
Of the participants, 245/252 provided a valid response for at least one of the barriers to 
adherence questions (see sections 6.5.1.1.3, 6.5.1.1.5, 6.5.1.1.7 and 6.5.1.1.9 for questions 
on refusing, forgetting, discontinuing and additional reasons).  
6.6.3.1.10  Issues surrounding the supply of medicines 
In total, 241/252 of participants answered this question, resulting in data for 472/542 of 
medicines, of which 8% (38/472) were Specials medicines. 
6.6.3.1.11  Problems with PILs 
Data on problems with PILs was collected for 456/542 of medicines. 
6.6.3.1.12  Problems with medicines at school 
In total, 153/252 of participants responded to the question: Do you have any problems with 
medicines at school? This question was not applicable for 87/252 of children as it was 
reported that they were not receiving education (were either below school age or had 
completed education).  
In total, 154/252 of participants responded to the question: Do you think that teachers and 
social staff should be given more information on medicines? For 87/252 participants this 
question was not applicable as it was reported that they were not receiving education (were 
either below school age or had completed education). 
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6.6.4 Results of semi-structured interviews with parents, carers and young 
people 
6.6.4.1 Oral formulation-related barriers to medicines administration 
Study participants were asked to report barriers to administering medicines, as detailed in 
section 6.5.1.1.1. 
Reported obstacles to medicines administration were grouped into oral formulation-related 
barriers, derived using thematic analysis (guided by Pope and co-workers (2000), and 
detailed in section 5.3.8.1): taste-related (taste, lack of taste, aftertaste), texture-related 
(texture, thickness or consistency), quantity or volume (of solid dosage forms or 
liquid/powder), size or aversion to/difficulty swallowing (size of solid dosage form or solid 
dosage form described as difficult to swallow), smell and colour/appearance. A further group 
‘other formulation and administration problems’ was created which encompassed problems 
not directly related to oral formulations (e.g. storage of medicine and frequency of dosing). 
Oral formulation-related problems identified with individual medicines in this study are 
reported in relation to: 
 Prescribing frequency of individual medicines 
 Prescribing frequency across different drug therapeutic classes (based on BNFC 
chapter classification, see Appendix 19). An additional category ‘other’ was used to 
categorise medicines that did not feature in the main BNFC chapters. 
Following data observation, a cut-off prescribing frequency of n=6 was used for fair 
representation of the data on individual medicines. Individual medicines are reported 
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generically, yet include their proprietary equivalents. An exception is paracetamol liquid, this 
includes Parapaed and generic versions, yet excludes Medinol and Calpol as no oral 
formulation-related barriers were reported for these formulations. 
6.6.4.1.1 Taste-related problems 
For 35% (188/542) of the medicines prescribed, taste-related problems were reported (see 
Appendix 21 for quotations). Frequencies of taste-related problems associated with 
individual medicines and across drug therapeutic classes are shown in Figures 12 and 13 
below. 
 
 
Figure 12 A histogram displaying the frequency of taste-related problems reported across 
drug therapeutic classes (based on BNFC chapter classification). 
CNS = Central Nervous System. 
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Taste-related barriers to medicines administration were reported for at least 20% of 
medicines prescribed from each BNFC chapter (see Figure 12). 
 
Figure 13 A histogram displaying the frequency of taste-related problems reported for 
individual medicines (prescribing frequency cut-off of n=6). 
pred = prednisolone, lq = liquid, tabs = tablets.  
Figure 13 above shows that ranitidine liquid (82%), prednisolone soluble tablets (81%) and 
trimethoprim liquid (75%) were most commonly reported to have taste problems. 
6.6.4.1.2 Texture problems 
Of the medicines prescribed, 8% (42/542) were reported to have an unfavourable texture 
(see Appendix 21 for quotations). Figures 14 and 15 below show the prevalence of problems 
with texture associated with medicines in different drug therapeutic classes and amongst 
individual medicines. 
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Figure 14 A histogram displaying the frequency of problems related to texture reported 
across drug therapeutic classes (based on BNFC chapter classification). 
CNS = Central Nervous System. 
The highest frequency of texture problems (14%) were reported for medicines prescribed 
from chapter 8 of BNFC (i.e. drugs used to treat malignant diseases and 
immunosuppressants) as shown above in Figure 14. 
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Figure 15 A histogram displaying the frequency of problems related to texture reported for 
individual medicines (prescribing frequency cut-off n=6). 
pred = prednisolone lq = liquid, tabs = tablets. 
Co-trimoxazole liquid (38%), omeprazole soluble tablets (33%) and lactulose liquid (25%) 
were most commonly reported to have texture-related problems (see Figure 15 above). 
6.6.4.1.3 Quantity and volume problems 
Of the medicines prescribed, 5% (29/542) were reported to have ‘too large’ a volume or ‘too 
many’ solid dosage units to be administered at one dosing interval (see Appendix 21 for 
quotations). The frequency of reported problems associated with quantity and volume are 
displayed in relation to drug therapeutic class and individual medicines in Figure 16 and 
Table 40 below. 
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Figure 16 A histogram displaying the frequency of reported problems associated with 
quantity or volume across drug therapeutic classes (based on BNFC chapter classification). 
CNS = Central Nervous System. 
Problems associated with quantities or volumes of medicines were most commonly reported 
for medicines featuring in the gastro-intestinal chapter of BNFC (BNFC chapter 1) as shown 
in Figure 16 above. 
Table 40 The frequency of reported problems associated with the volume or quantity of 
individual medicines (prescribing frequency cut-off n=6). 
Medicines most commonly reported with 
quantity or volume problems 
Frequency of quantity or volume reports (prescribing 
frequency cut-off n=6) 
Pancrealipase capsules (5/8)= 63% 
Macrogol 3350 oral powder (12/30)= 40% 
Prednisolone soluble tablets (3/16)=19% 
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Almost two thirds of patients prescribed pancrealipase capsules reported problems with too 
many unit doses at one dosing interval (see Table 40 above). 
6.6.4.1.4 Problems with size and aversion to or difficulty with swallowing 
Problems related to i) the size of a solid dosage form or ii) aversion to or difficulty 
swallowing a solid dosage form was associated with 5% (28/542) of the total medicines 
prescribed (16% if only solid dosage forms considered), see Appendix 21 for quotations. 
For 16% (28/177) of solid dosage forms prescribed to patients, problems experienced either 
with the size of a solid dosage form or where children were averse to/reported difficulties 
swallowing a dosage form were reported. Problems specifically related to the sizes of 
particular solid dosage forms were reported for 68% (19/28) of these medicines, and 
aversion to, or difficulty swallowing solid dosage forms was reported for the remaining 32% 
(9/28) of medicines (see Figure 17 below). It should be noted that these patients were not 
physically unable to swallow (i.e. not patients fitted with an NG or PEG tube). 
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Figure 17 A diagram displaying the proportion of reports regarding problems with the size 
of a solid dosage form and aversion to or difficulty swallowing a solid dosage form. 
 
Problems reported with the size of a solid dosage form and aversion to or difficulty 
swallowing, were grouped for the purpose of statistical analyses. Figure 18 below shows the 
proportion of medicines from each therapeutic class identified with a problem related to the 
size of a solid dosage form or aversion to or difficulty swallowing a solid dosage form. 
Problems related to the size of a 
solid dosage form or aversion to 
or difficulty swallowing a dosage 
form were reported for 16% 
(28/177) of solid dosage forms 
prescribed 
68% (19/28) of 
reports were problems with the 
size of a solid dosage form 
32% (9/28) of 
reports were related to aversion 
to or difficulty swallowing a solid 
dosage form 
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Figure 18 A histogram displaying the frequency of problems reported with the size of, 
aversion to or difficulty swallowing solid dosage forms across drug therapeutic classes 
(based on BNFC chapter classification). 
CNS = Central Nervous System. 
Over 20% of medicines prescribed from BNFC chapter 5 - infections (antibiotics, antivirals 
and antifungals) were reported to be too big or difficult to swallow. 
The most commonly reported medicine with regard to size or aversion to/difficulty 
swallowing was the tablet formulation of co-trimoxazole. The majority (7/8= 88%) of 
patients prescribed co-trimoxazole tablets reported a problem with their size or difficulty 
swallowing them. 
6.6.4.1.5 Colour/appearance and smell problems 
An unfavourable colour/appearance was associated with 2% (11/542) of medicines 
prescribed (see Appendix 21 for quotations). 
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For 11% (2/18) of children prescribed sodium valproate liquid its ‘alarming colour’ was 
highlighted. Similarly, 11% (1/9) of patients prescribed paracetamol liquid described its 
unappealing colour. 
In addition, 2% (11/542) of medicines prescribed were identified as having ‘off-putting’ 
smells (see Appendix 21 for quotations). 
For 25% (2/8) of children prescribed trimethoprim liquid, an unfavourable smell was 
described. 
6.6.4.1.6 Spearman’s correlation statistical test 
Spearman’s correlation coefficients were calculated to test for correlations between the 
organoleptic and physical properties of medicines. The results are reported in Table 41.
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Table 41 A table displaying the results of a Spearman's correlation test investigating the correlation between organoleptic and physical 
properties of medicines. 
  Taste Texture 
Volume or 
quantity 
Size or aversion 
to/difficulty 
swallowing Smell Colour 
Taste   
0.151 (P<0.001) 0.102 (P=0.017) -0.030 (P=0.486) 0.143 (P=0.001) 0.033 (P=0.449) 
Texture 
0.151 (P<0.001)  0.054 (P=0.212) -0.005 (P=0.992) 0.007 (P=0.867) 0.007 (P=0.867) 
Volume or quantity 
0.102 (P=0.017) 0.054 (P=0.212)  0.019 (P=0.666) -0.034 (P=0.427) -0.034 (P=0.427) 
Size or aversion to/ difficulty 
swallowing 
-0.030 (P=0.486) -0.005 (P=0.992) 0.019 (P=0.666)  -0.034 (P=0.435) -0.034 (P=0.435) 
Smell 
0.143 (P=0.001) 0.007 (P=0.867) -0.034 (P=0.427) -0.034 (P=0.435)  0.072 (P=0.094) 
Colour 
0.033 (P=0.449) 0.007 (P=0.867) -0.034 (P=0.427) -0.034 (P=0.435) 0.072 (P=0.094)  
Results are based on a 2-tailed Spearman’s correlation test. For significant results, Spearman’s correlation coefficients and associated p values are reported in bold 
font.  
 
The Spearman’s statistical test found a weak, yet significant positive correlation between reported taste-related issues and texture, smell 
and volume/quantity, with correlation coefficients 0.151 (p<0.001), 0.143 (p=0.001) and 0.102 (p=0.017) respectively.
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6.6.4.1.7 Other formulation and administration problems  
Of the medicines prescribed, 12% (63/542) were associated with ‘other formulation or 
administration problems’ (i.e. those not associated directly with oral formulations). 
Problems reported in this study included frequency of dosing, difficulty with or dislike of the 
route of medicine administration, children fearing syringes, medicines blocking NG and PEG 
tubes, difficult storage conditions and short expiries. 
6.6.4.1.8 Well-accepted medicines 
The positive attributes of some medicines were reported in the present study (see Table 42 
below). 
Table 42 The frequency of medicines identified with positive oral formulation properties. 
Oral formulation properties reported in a positive 
manner  
The frequency of medicines associated with 
positive reports regarding oral formulation 
properties 
Taste 4% (24/542) 
Texture  <1% (3/542) 
Smell <1% (1/542) 
Size <1% (1/542) 
6.6.4.2 Medicines manipulation 
For this study ‘Gold standard’ administration of a medicine was defined as: ‘a medicine 
delivered to the route of administration without manipulation’. 
A medicine manipulation was defined as: ‘a medicine physically adapted to facilitate 
medicines administration or for the purpose of giving a specific dose’. 
Responses to questions on how medicines were administered to/taken by children were 
analysed using a thematic approach (see section 6.5.5.2). 
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All 252 study participants were asked to describe the process of medicines administration 
for at least one of their medicines.  
Although not classed as medicine manipulations, some dosage forms were reported to be 
administered at the same time as various foodstuffs (e.g. with a drink other than water, 
followed or preceded by biscuits or sweets). In addition, 8% (38/499) of medicines were 
administered via NG or PEG tubes in their existing form. Patients who were administered 
medicines via NG or PEG tubes are discussed as a subgroup of the population in section 
6.6.4.2.1. 
A total of 71% (178/252) of respondents reported administering medicines in a ‘gold 
standard’ manner accounting for the administration of 82% (405/499) of medicines. 
Almost one third of respondents 29% (74/252) reported manipulating medicines. 
In total, 19% (94/499) of medicines were manipulated. Of these, 87/94 medicines were 
reported to be manipulated always (i.e. prior to every dose administration), 4/94 most of the 
time, 1/94 rarely. For the remaining 2/94 medicines, an ‘unsure’ response was provided 
regarding the frequency of medicines manipulation. 
Thematic analysis of the reported data derived two thematic groups:  
 Medicines manipulated for the purpose of administering a specific dose 
 Medicines manipulated to facilitate administration. 
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Manipulation techniques that were reported in the study interviews were used to generate 
thematic sub-groups. A coding spine was developed based on the thematic groups and sub-
groups (see Table 43 below). 
Table 43 Thematic coding spine for medicines manipulation. 
Medicines manipulation thematic groups Medicines manipulation thematic sub-groups 
For the purpose of administering a specific dose  Measuring part volumes of solution 
following dissolving a soluble 
tablet/crushing a tablet 
 Segmenting tablets and splitting sachets of 
powder or granules. 
To facilitate medicines administration  Mixing sachets/soluble tablets/ liquids with 
foodstuffs (including dairy products, acidic 
juices, warm drinks, breakfast cereal)  
 Mixing non-soluble tablets with diluents 
 Opening capsules and mixing powder or 
granules with foodstuffs 
 Crushing/segmenting tablets. 
 
The proportion of medicines classified into each thematic group is reported in Figure 19. 
Four medicines were manipulated for both reasons (e.g. tablet crushed, and then added to 
orange juice). Such physical adaptations were categorised into both thematic groups and is 
the reason for percentages exceeding 100% in Figure 19 below. 
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Figure 19 A diagram displaying the proportion of medicines manipulated for the purpose 
of administering a specific dose, to facilitate medicines administration and for both 
reasons. 
 
Reports of physical adaptations of medicines for the purpose of administering a specific dose 
and to facilitate medicines administration are reported in Tables 44 and 45 below 
respectively. 
  
19% (94/499) of 
medicines manipulated 
26% (24/94) of medicines 
manipulated for the 
purpose of administering 
a specific dose 
79% (74/94) of medicines 
manipulated to facilitate 
medicines administration 
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Table 44 Medicines manipulated for the purpose of administering a specific dose. 
Medicine BNFC chapter Medicine Manipulation 
Amlodipine tablets 2 Mixed with xmls of water and 
xmls measured 
Aspirin soluble tablets (n=2) 10 Mixed with xmls of water and 
xmls measured 
Azathioprine tablets* 8 Halved, mixed with water and 
swirled 
Co-trimoxazole tablets 5 Quartered 
Gaviscon infant oral powder 1 Quartered 
Hydrocortisone tablets 6 Crushed, mixed with water and 
xmls measured 
Lansoprazole soluble tablets 1 Dissolved in xmls of water and 
xmls measured 
Macrogol 3350 oral powder (n=2) 1 Halved/dissolved in xmls of water 
and xmls measured 
Mercaptopurine tablets 8 Halved 
Mycophenolate mofetil tablets* 8 Halved 
Nifedipine tablets 2 Halved 
Omeprazole soluble tablets 
*(n=5) 
1 Halved/dissolved in xmls of water 
and xmls measured 
Ondansetron melts 4 Halved 
Piroxicam tablets 10 Cut one quarter out 
Prednisolone tablets 6 Halved 
Prednisolone soluble tablets 6 Dissolved in xmls of water and 
xmls measured 
Ranitidine tablets 1 Halved 
Tranexamic acid tablets*  2 Crushed and mixed with 
squash/water and xmls measured 
*Identifies medicines manipulated for both reasons. n=1 unless other otherwise stated. 
Table 45 Medicines manipulated to facilitate medicines administration. 
Medicine  BNFC chapter Medicine Manipulation 
Azathioprine tablets* 8 Halved then added to water and 
swirled 
Calcium liquid (n=2) 9 Added to yoghurt/hot chocolate 
Co-codamol soluble tablets 4 Mixed with blackcurrant squash 
Co-trimoxazole tablets (n=3) 5 Administered in two 
halves/administered in three 
segments 
Fludrocortisone tablets 8 Crushed and mixed with water 
Hydroxychloroquine tablets 10 Crushed 
Lactulose liquid 1 Added to bottle of milk 
Levetiracetam liquid 4 Added to breakfast cereal 
Lamotrigine soluble tablets 4 Crushed and added to meals 
Levothyroxine tablets (n=5) 6 Segmented before 
administration/added to pureed 
fruit/crushed and added to water 
Loperamide capsules 1 Opened and contents mixed with 
water 
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Medicine  BNFC Chapter Medicine Manipulation 
Macrogol 3350 oral powder (n=20) 1 Added to orange juice/blackcurrant 
juice/pure apple juice/pure orange 
juice/apple and blackcurrant 
juice/warm hot chocolate/cup of 
tea/milk/breakfast cereal/warm water 
Melatonin capsules (n=2) 4 Opened, contents added to lemonade 
and stirred/ yoghurt 
Mercaptopurine tablets (n=2) 8 Mixed with water/crunched prior to 
swallowing 
Metformin liquid 6 Added to orange or blackcurrant 
squash 
Methotrexate tablets (n=2) 8 Crushed prior to swallowing/added to 
blackcurrant juice 
Montelukast sodium granules 3 Mixed with yoghurt 
Mycophenolate mofetil tablets* 8 Administered in two halves in squash 
Omeprazole capsules 1 Contents added to squash 
Omeprazole soluble tablets* (n=3) 1 Mixed with apple juice and xmls 
measured/pineapple juice/mixed with 
breakfast cereal 
Ondansetron liquid 4 Added to yoghurt 
Pancrealipase Micro gastro-resistant 
granules (n=3) 
1 Added to bottle of milk/fruit puree 
Prednisolone soluble tablets (n=5) 6 Added to orange juice/strawberry 
squash or summer fruits 
squash/blackcurrant squash 
n=2/Ribena 
Procarbazine capsules 8 Contents added to yoghurt 
Rifinamide tablets 5 Crushed and added to meals 
Setraline tablets 4 Administered in two halves 
Sodium chloride liquid (n=3) 9 Added to bottle of milk/squash and 
‘everything’ 
Sodium valproate liquid (n=2) 4 Added to breakfast cereal/glass of 
milk 
Topirimate capsules 4 Contents added to every meal as 
didn’t mask taste in juices 
Tranexamic acid tablets* 2 Crushed and mixed with squash/water 
and xmls measured 
Trimethoprim liquid 5 Added to bottle of milk 
Zinc soluble tablets (n=3) 9 Added to warm water (dissolves 
quicker)/blackcurrant squash/squash 
*Identifies medicines manipulated for both reasons. n=1 unless other otherwise stated. 
 
For medicines with a prescribing frequency of n=6, rates of medicines manipulation were 
calculated to determine which medicines were most commonly reported to be manipulated 
(see Figure 20 below). 
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Figure 20 A histogram displaying the frequency of individual medicines reported to be 
manipulated (prescribing frequency cut-off n=6). 
pred = prednisolone, lq = liquid, tabs = tablets. 
 
Omeprazole soluble tablets (7/9 78%), macrogol 3350 oral powder (22/30 73%) and co-
trimoxazole tablets (4/8 50%) were most commonly reported to be manipulated by 
respondents, as shown in Figure 20 above. 
6.6.4.2.1 Patients with NG/PEG tubes 
In total, 8% (44/542) of orally ingestible medicines were administered non-orally to 79% 
(11/14) of children with NG or PEG tubes. The remaining 3 patients with NG or PEG tubes 
fitted did not have any medicines administered via this route. 
Over one third (36% (4/11)) of participants administering medicines via the NG/PEG tube 
route had to manipulate at least one medicine prior to administration. Figure 21 below 
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shows the breakdown of children with NG/PEG tubes requiring medicines to be 
manipulated.  
 
Figure 21 A diagram displaying medicines administration and manipulation in children 
fitted with NG or PEG tubes. 
 
In total, 14% (6/44) of medicines administered via NG or PEG tubes were manipulated and 
are included in the multivariable analysis. The remaining 38/44 medicines were administered 
unadulterated.  
Over one quarter (26%) of medicines prescribed for patients fitted with NG or PEG tubes 
were Specials medicines, compared to only 5% of medicines prescribed to patients without 
NG or PEG tubes fitted. 
14 children with NG/PEG tubes 
79% (11/14) of children administered at least one 
medicine via NG/PEG route 
Medicines manipulation was 
required to administer 
medicines to 36% (4/11) of 
children administered 
medicines via NG/PEG tubes 
Medicines manipulation was 
not required to administer 
medicines to 64% (7/11) of 
children administered 
medicines via NG/PEG tubes 
21% (3/14) of children 
not administered 
medicines via NG/PEG 
route 
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6.6.4.2.2 Multivariable analysis  
To identify which factors significantly influenced the manipulation of medicines, binary 
logistic regression using multivariable models was used to analyse the data as discussed in 
section 6.5.5.3. Variable factors that required adjustment for the statistical model to 
converge are reported in Appendix 22. The results of the multivariable analysis are reported 
in Table 46 below. Odds ratios with 95% confidence intervals and associated p values are 
reported for the variables used in the analysis. 
Table 46 Multivariable analysis results: Reports of medicines manipulation.  
  
Odds Ratio (95% 
CI) P Value 
Age of child at Interview   0.005* 
0-4 years 1  
5-11 years 0.29 (0.13-0.67) 0.004* 
12-18 years 0.18 (0.06-0.59) 0.005* 
Is English first language of participant   0.085 
Yes 1  
No 0.26 (0.06-1.20) 0.085 
Formulation type   <0.001* 
Liquid 1  
Tablets and Capsules 9.66 (3.48-26.87) <0.001* 
Other 23.97 (9.14-62.84) <0.001* 
Problem with size of dosage form or aversion 
to/difficulty swallowing dosage form    0.013* 
No 1  
Yes 4.52 (1.37-14.90) 0.013* 
Problem with texture   0.006* 
No 1  
Yes 3.15 (1.39-7.14) 0.006* 
Problem related to other formulation and 
administration problems   0.206 
No 1  
Yes 1.89 (0.70-5.08) 0.206 
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BNFC Chapter in which medicine is classified    0.075 
1 1   
2 0.85 (0.14-5.06)  0.855 
3 0.07 (0.01-0.51) 0.008 
4 0.79 (0.27-2.26)  0.656 
5 0.42 (0.15-1.17)  0.097 
6 1.07 (0.38-3.02)  0.895 
8 2.04 (0.65-6.38) 0.222 
9 0.54 (0.16-1.87) 0.335 
Other 0.76 (0.25-2.29) 0.625 
Who is responsible for medicines administration   0.049* 
Parent/Guardian 1  
Child plus Parent/Guardian 0.28 (0.10-0.81) 0.019* 
Child 0.22 (0.02-1.94) 0.171 
Problem with volume or quantity   0.157 
No 1   
Yes 2.17 (0.74-6.35) 0.157 
Frequency of dosing   0.404 
1x daily 1   
2x daily 0.70 (0.34-1.45) 0.345 
≥3x daily 0.20 (0.03-1.46) 0.113 
<1x daily (not including medicines prescribed on a 
‘when required’ basis)  0.76 (0.23-2.46) 0.647 
p values marked with * identify statistically significant results (p<0.05).  
The ‘other’ group includes medicines from chapters 7, 10 and those medicines not featuring in BNFC. 
6.6.4.3 Medicines refusal 
Refusal of a medicine was defined in this study as: ‘complete omission of a dose by intent on 
at least one occasion, including spitting the dose back out, and/or closing the mouth’. 
Questions on refusal are reported in 6.5.1.1.3. 
Almost one third 31% (71/232) of respondents reported medicines refusal on at least one 
occasion, 9% (20/232) of respondents reported medicines refusal in the six months prior to 
interview and 6% (15/232) of respondents reported medicines refusal in the week prior to 
interview.  
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The frequency of medicines reported to be refused on at least one occasion, within one 
week and six months prior to interview are displayed in Figure 22 below. 
 
Figure 22 A histogram displaying the reported frequency of medicines refusal on at least 
one occasion, within one week and six months prior to interview. 
 
Refusing a medicine on at least one occasion was reported for 19% (85/436) of medicines in 
total. In the six months prior to interview, 6% (24/436) of medicines were reported to be 
refused and in the week prior to interview, 4% (16/436) of medicines. 
6.6.4.3.1 Patients with NG or PEG tubes 
Children who were administered all oral medicines non-orally (via an NG or PEG tube) were 
treated as a sub-group of the population, as medicines could not be refused via the current 
route of administration. These are reported as N/A in Figure 10. 
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Over half (52% (23/44)) of the medicines administered via these routes at the time of 
interview were reported to have been refused orally prior to changing to PEG or NG tube 
administration. 
6.6.4.3.2 Multivariable analysis 
Binary logistic regression using multivariable models was used to analyse reported medicines 
refusal on at least one occasion and in the six months prior to interview, as discussed in 
section 6.5.5.3. The multivariable analysis results for reporting medicines refusal are 
provided in Tables 47 and 48 below. Odds ratios with 95% confidence intervals and 
associated p values are reported for the variables used in the analysis. 
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Table 47 Multivariable analysis results: Reports of medicines refusal on at least one 
occasion.  
  Odds Ratio (95% CI) p Value 
Age of child at Interview   0.016* 
0-4 years 1  
5-11 years 0.42 (0.19 - 0.89) 0.024* 
12-18 years 1.31 (0.54 - 3.20) 0.554 
IMD 2010 score   0.002* 
<11.5 1   
11.5-19.8 1.32 (0.49-3.51) 0.584 
19.9-31.9 3.19 (1.37-7.43) 0.007* 
32+ 4.75 (2.02-11.18) <0.001* 
Formulation type   0.336 
Liquid 1   
Capsules and Tablets 0.59 (0.27-1.30) 0.193 
Other 0.64 (0.30-1.38) 0.254 
Problem with taste   <0.001* 
No 1   
Yes 3.82 (2.11-6.92) <0.001* 
Problem with texture   0.017* 
No 1   
Yes 3.38 (1.24-9.22) 0.017* 
Problem with volume or 
quantity    <0.001* 
No 1   
Yes 12.79 (4.41-37.12) <0.001* 
Problem with smell   0.776 
No 1  
Yes 1.24 (0.28-5.46) 0.776 
p values marked with * identify statistically significant results (p<0.05).  
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Table 48 Multivariable analysis results: Reports of medicines refusal during the six months 
prior to interview.  
  Odds Ratio (95% CI) p Value 
Age of child at 
Interview   0.017* 
0-4 years 1   
5-11 years 0.06 (0.01-0.48) 0.009* 
12-18 years 0.35 (0.07-1.69) 0.191 
Age of child at 
diagnosis   0.030* 
<1m 1   
1m-2y 0.91 (0.23-3.56) 0.890 
2-12y 0.46 (0.11-1.98) 0.300 
12-18y 5.37 (0.74-39.03) 0.097 
Problem with 
taste   0.021* 
No 1   
Yes 2.66 (1.16-6.07) 0.021* 
Problem with 
texture   0.021* 
No 1   
Yes 3.34 (1.20-9.32) 0.021* 
Problem with volume or quantity 0.043* 
No 1   
Yes 4.44 (1.05-18.82) 0.043* 
p values marked with * identify statistically significant results (p<0.05). 
 
6.6.4.4 Child acceptance of medicines 
Descriptions of children being rarely or never happy to take a medicine were reported for 
51% (43/85) of medicines reported to be refused on at least one occasion.  
For 35% (30/85) of medicines claimed to be refused on at least one occasion, children were 
reported to be ‘never happy to take’. 
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6.6.4.5 Forgetting to administer medicines 
Forgetting a medicine was defined in this study as: ‘complete omission of a dose on at least 
one occasion resulting from unintentional memory lapse at time of administration’. The 
questions delivered to respondents are reported in section 6.5.1.1.5. 
Of the respondents, 64% (153/240) reported forgetting medicines on at least one occasion. 
A total of 35% (85/240) of respondents reported forgetting to administer medicines in the 
six months prior to interview and 23% (55/240) in the week prior to interview.  
The frequency of medicines reported to be forgotten on at least one occasion, within six 
months and one week prior to interview are displayed in Figure 23 below. 
 
Figure 23 A histogram displaying the frequency of medicines reported to be forgotten on 
at least one occasion, within one week and six months prior to interview. 
 
Forgetting to administer medicines on at least one occasion was reported for 47% (215/462) 
of medicines in total. In the six months prior to interview, 23% (106/462) of medicines were 
reported to be forgotten and in the week prior to interview, 15% (67/462) of medicines. 
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6.6.4.5.1 Multivariable analysis 
To identify which factors significantly influenced forgetting medicines, binary logistic 
regression using multivariable models were used to analyse reports as discussed in section 
6.5.5.3. Variable factors that required adjustment for the statistical model to converge are 
reported in Appendix 22. The results of the multivariable analysis on forgetting medicines on 
at least one occasion and within six months prior to interview are reported in Tables 49 and 
50 below. Odds ratios with 95% confidence intervals and associated p values are reported 
for the variables used in the analysis. 
Table 49 Multivariable analysis results: Reports of forgetting to administer medicines on at 
least one occasion.  
  Odds Ratio (95% CI) p Value 
Age of child at Interview   0.026* 
0-4 years 1   
5-11 years 1.67 (0.93-2.99)                        0.086 
12-18 years 2.98 (1.32-6.74) 0.009* 
Number of prescribed oral medicines <0.001* 
      
1 1   
2 0.74 (0.40-1.36) 0.334 
≥3 0.28 (0.15-0.51) <0.001* 
Who is responsible for 
medicines administration   0.150 
Parent/Guardian 1   
Child plus Parent/Guardian 1.22 (0.56-2.61) 0.618 
Child  8.30 (0.98-69.97) 0.052 
p values marked with * identify statistically significant results (p<0.05).  
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Table 50 Multivariable analysis results: Reports of forgetting to administer medicines 
within the six months prior to interview.  
  Odds Ratio (95% CI) p Value 
Age of child at Interview   0.069 
0-4 years 1   
5-11 years 0.67 (0.24-1.89) 0.449 
12-18 years 1.82 (0.59-5.58) 0.297 
Number of prescribed oral medicines 0.003* 
1 1   
2 0.58 (0.28-1.18)                            0.132 
≥3 0.27 (0.13-0.57) 0.001* 
Who is responsible for 
medicines administration   0.286 
Parent/Guardian 1   
Child plus Parent/Guardian 2.05 (0.84-5.03) 0.116 
Child  1.77 (0.41-7.60) 0.444 
Additional educational help   0.018* 
No 1   
Yes 0.40 (0.17-0.95) 0.039* 
N/A 0.38 (0.16-0.94) 0.036* 
 
   
Other health-related need of 
patient   0.869 
No 1   
Yes 0.94(0.45-1.95) 0.869 
BNFC Chapter in which 
medicine is classified    0.013* 
1 1   
2 0.73 (0.22-0.39) 0.606 
3 0.20 (0.05-0.85) 0.029* 
4 0.67 (0.37-1.21) 0.180 
5 1.13 (0.52-2.47) 0.761 
6 0.30 (0.13-0.69) 0.004* 
8 0.26 (0.11-0.61) 0.002* 
9 0.66 (0.33-1.33) 0.244 
Other 0.54 (0.24-1.22) 0.139 
p values marked with * identify statistically significant results (p<0.05).  
The ‘other’ group includes medicines from chapters 7, 10 and those medicines not featuring in BNFC. 
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The unadjusted reported frequencies of medicines forgotten from each BNFC chapter are 
displayed in Figure 24 below. 
 
Figure 24 Unadjusted reported frequencies of medicines forgotten from each BNFC chapter 
in the previous six months. 
 
Figure 24 above shows that medicines in BNFC chapters 8 (drugs used to treat malignant 
diseases and immunosuppressants), 3 (respiratory drugs) and 6 (drugs used to treat the 
endocrine system) were least likely to be reported as forgotten in the six months prior to 
interview. 
6.6.4.6 Reminding systems for administering medicines 
When asked about reminding systems used to help parents, carers and young people to 
remember to administer medicines (see section 6.5.1.1.6), the majority (170/208) of 
respondents reported that they relied on the familiarity of daily routine or medicines. Some 
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parents provided additional comments that familiarity of their child’s disabilities also 
reminded them to administer medicines. 
One parent reported using disease symptoms to help to remember medicines 
administration. The use of alarms (on clocks and phones), written instructions (on 
cupboards, fridges, charts and in calendars, diaries, nursery day books), and medicine 
organisation boxes were reported as systems used to prompt medicines administration. The 
results of the question regarding reminding systems are displayed in Figure 25 below for the 
valid responses. 
 
Figure 25 A histogram displaying valid responses to the questions: How do you remember 
to administer medicines? What reminding system do you use? 
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6.6.4.7 Reports of intentional discontinuation of medicines  
The questions designed to reveal if parents, carers or children discontinued medicines 
unilaterally (i.e. without the advice of a healthcare professional) are provided in section 
6.5.1.1.7. 
When examining if medicines were discontinued, only 8% (20/238) of respondents reported 
that they had discontinued a medicine without consulting a healthcare professional if it was 
perceived to have made a child feel worse. The majority of respondents stated that they 
would seek the advice of a healthcare professional before discontinuing medicines 
administration (responses included phoning a nurse or GP). 
Similarly, a minority of respondents, 2% (5/239) reported that if a child seemed better they 
had discontinued medicines administration unilaterally. 
These questions were not applicable to all medicines as 47/542 medicines were prescribed 
to be taken ‘when required’ as displayed in Figure 11. For these medicines, participants 
frequently revealed that they had been advised by a medical practitioner to stop or adjust 
the prescribed dose based on clinical response. 
6.6.4.8 Reported adverse effects and treatment effectiveness of medicines 
The questions delivered to parents, carers and young people regarding their experience of 
adverse effects of medicines can be found in section 6.5.1.1.8. 
Over one quarter, 26% (123/481) of medicines were reported to cause adverse effects. For 
less than 1% (3/481) of medicines, respondents reported being unsure as to whether a 
perceived adverse effect was instead associated with a child’s disease state.  
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A question was delivered to parents, carers and young people to explore their views on the 
effectiveness of medicines (see section 6.5.1.1.8). Of the valid responses, 38% (180/476) of 
medicines were perceived to always be effective (Likert score = 1), whilst only 5% (24/476) 
of medicines were perceived to rarely or never make a child better (based on reports of 
Likert scale scores 4 or 5). 
6.6.4.9 Additional barriers to medicines adherence and medicines adherence status 
Barriers to medicines adherence were defined for the purpose of this study as reasons for 
dose omissions. 
The question used to identify reasons for omitting a dose of medicine in addition to refusing, 
forgetting, and discontinuing medicines is provided in section 6.5.1.1.9. Independently, 
additional barriers to medicines adherence were not reported by sufficient respondents to 
conduct statistical analyses. Also, the additional barriers reported were not specific 
properties of oral formulations and therefore were not a focus of the present study.  
All reported reasons for non-adherence were grouped into two themes, unintentional and 
intentional barriers to medicines adherence. 
Reports of unintentional barriers to medicines adherence included parents not re-ordering 
medicines on time and thus omitting doses, delays in obtaining medicines from pharmacies 
(e.g. stock problems), delays in obtaining prescriptions from GP surgeries, forgetting to take 
medicines out (e.g. when children stayed with other parent, at sleepovers or on holiday), 
and not administering when child is ill or sleeping. These included reports of forgetting to 
administer medicines from section 6.6.4.5. 
224 
Intentional barriers to adherence included concerns of the stigma associated with medicine 
taking (e.g. choosing not to take to sleepovers or for weekend activities), parents choosing 
not to administer for additional reasons (e.g. feel that medicine is not working). These 
included reports of children refusing medicines and parents/young people discontinuing 
medicines administration from section 6.6.4.3 and 6.6.4.7 respectively. 
Any reason reported for omitting a dose of medicine classed a child as not fully adherent in 
this study. 
In total, 21% (51/245) of respondents did not report missing any doses of medicines. 
Of the respondents, 79% (194/245) reported at least one reason (i.e. forgetting, refusing, 
discontinuing if it was perceived that child felt worse or better or an additional reason) for 
omitting a dose of a medicine. These 194 respondents were categorised according to the 
type of non-adherence behaviour/s reported; 56% (108/194) were classified as 
unintentionally non-adherent, 10% (19/194) intentionally non-adherent and 35% (67/194) 
both unintentionally and intentionally non-adherent. The categorisation of respondents 
reporting non-adherent behaviour is displayed in Figure 26 below. 
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Figure 26 A diagram displaying the categorisation of respondents reporting unintentional 
and intentional non-adherent behaviours.  
Reason for percentages exceeding 100% is due to rounding up results. 
 
6.6.4.10 Reported issues surrounding the supply of medicines 
Participants were asked if they had encountered problems when obtaining medicines from 
pharmacies (see section 6.5.1.1.10).  
When investigating problems encountered by parents, carers and young people when 
obtaining medicines, over one third (36% (86/241)) of respondents claimed to have 
experienced issues with a total of 23% (110/472) of medicines.  
Supplementary comments were provided by two participants, concerning difficulties with 
obtaining oral syringes and the problems with re-sterilising them (i.e. numbers erasing). 
6.6.4.10.1  Obtaining Specials medicines 
One quarter (25% (27/110)) of problems reported with medicines supply were associated 
with Specials medicines. 
79% (194/245) of 
respondents reported NON-
ADHERENCE 
56% (108/194) of 
respondents: 
UNINTENTIONALLY NON-
ADHERENT 
35% (67/194) of 
respondents: BOTH 
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Almost three quarters (71% (27/38)) of Specials medicines with a valid response for the 
question regarding obtaining were described as difficult to obtain. 
Difficulties reported by respondents regarding the supply of Specials medicines included 
shortened expiries i.e. frequent re-ordering, GPs unhappy to prescribe (or not prescribing 
quantities requested by specialists), delays at GP surgeries and pharmacies (time periods of 
24 hours to one week for pharmacies to obtain medicines from Specials suppliers).  
6.6.4.10.2  Obtaining non-Specials medicines 
Problems obtaining non-Specials medicines were reported and included insufficient 
medicines stock in pharmacies, delays at pharmacies (e.g. when ordering specific brands of 
medicines, pharmacists querying off-label prescribing), delays in receiving prescriptions from 
consultants, waiting times in pharmacies and short medicine expiries resulting in frequent 
pharmacy visits (flucloxacillin solution was provided as an example). 
6.6.4.11 Problems with PILs 
The question designed to explore problems experienced with PILs is provided in section 
6.5.1.1.11. 
Data regarding problems experienced with PILs is reported in Figure 27 below for the valid 
responses (see Figure 11 for missing data). 
227 
 
Figure 27 A histogram displaying valid responses to the question: Do you feel that the 
information you get is in plain English and clear/easy to understand? 
  
Problems were reported for 7% (33/456) of medicines and included conflicting information 
provided by healthcare professionals and printed in PILs (e.g. PILs stating that a medicine is 
not to be administered to children), PILs described as ‘complicated’ and ‘difficult’, 
discrepancies between doses on labels of medicines and in PILs, PILs in non-English 
language, and difficulties with the English language written in PILs. 
For 4% (20/456) of medicines it was reported that no PIL was received. For the remaining 
medicines either no problems were reported (77% (351/456)) or respondents could not 
recall reading the PIL so were unable to answer the question (11% (52/456)). 
6.6.4.12 Reports of problems with medicines at school 
Questions regarding medicines administration in schools (see section 6.5.1.1.12) were 
delivered to participants if children were receiving education (see Figure 10 for missing 
data). 
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The responses provided regarding problems with medicines at school for children in 
education are displayed in Figure 28 below. 
 
 
Figure 28 A histogram displaying valid responses to the questions: Do you have any 
problems with medicines at school?  and Do you think that teachers and social staff should 
be given more information on medicines? 
Uncoloured sections of bars represent missing data. 
Whilst nearly half (45%) of the respondents did not report any problems with medicines 
administration at school, 28% of the respondents reported such problems. Issues included 
teachers and school staff refusing to administer medicines, teachers and social staff not 
permitting children to take medicines at school, parents expected to administer medicines at 
school, too much paperwork (i.e. parental permission required) and schools not willing to 
manage medicines. 
Yes, 28% No, 45% Unsure, 26% 
Yes, 46% No, 26% Unsure, 28% 
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Where problems were not reported, often parents praised the support offered by teaching 
staff at specialist educational institutions for children with delayed development. 
Almost half (46%) of the respondents perceived that it would be beneficial for teachers and 
social staff to be better educated regarding medicines management at school, however, 26% 
felt that teachers and social staff did not require more information. Some parents reported 
that schools were good with managing medicines and felt that administering medicines was 
beyond teachers’ responsibilities. 
For some children, medicines were not required during the school day. This was the most 
common reason highlighted by respondents reporting indifferent (‘unsure’) responses to the 
questions regarding problems with medicines at school. 
6.7 Discussion 
6.7.1 Oral formulation-related barriers to medicines administration 
This study uniquely identified the prevalence and nature of oral formulation-related barriers 
to medicines administration across various chronic conditions in a large population of 
paediatric patients. No other study has investigated this (see Chapter 4). 
Study findings indicate that problems with the properties of oral formulations are those 
associated with the taste, texture, quantity or volume, size or aversion to or difficulty 
swallowing, colour/appearance and smell in descending order of reported prevalence. 
Issues that were grouped to form ‘other formulation and administration problems’ revealed 
obstacles to administration (e.g. frequent daily dosing) that were not associated with the 
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specific properties of oral medicines. Such barriers to medicines administration are beyond 
the current project aims and require further exploration in future studies.  
Oral formulation-related barriers to medicines administration were observed across 
individual medicines and across drug therapeutic classes (based on BNFC chapter 
classification). This study identified that at least 20% of medicines prescribed from each 
BNFC chapter were reported to have taste problems. Medicines featuring in BNFC chapters 5 
(antibiotics antivirals and antifungals), 6 (drugs used to treat the endocrine system) and 1 
(gastro-intestinal drugs) were reported to have the largest proportion of taste problems in 
descending order. 
Taste problems highlighted with some medicines had been anticipated in the early stages of 
this research through personal communication with healthcare professionals and the YPG. 
However some findings were more surprising; anecdotally iron formulations have been 
perceived to be unpalatable, however in this study, taste problems were reported for only 
one quarter of children prescribed a liquid iron preparation.  
The most prevalent taste problems were reported amongst children prescribed ranitidine 
liquid, prednisolone soluble tablets and trimethoprim liquid in order of descending 
prevalence. These findings warrant further investigation to determine if similar problems are 
experienced by patients suffering from acute conditions, as these medicines are often 
prescribed.  
Prednisolone soluble tablets were commonly identified with taste, texture and quantity 
problems. This medicine is frequently prescribed to treat acute asthma flare-ups in the 
primary setting, therefore it is of paramount importance that this formulation is addressed. 
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Such findings need to be used to direct healthcare professionals when prescribing medicines, 
and pharmaceutical companies when designing medicines for children.  
In this study, oral formulation-related barriers to medicines administration, texture, volume 
or quantity, size or aversion to/difficulty swallowing, colour and smell were reported across 
fewer medicines compared to taste, however such properties of oral formulations should 
not be ignored. Statistical results (see spearman’s correlation test, Table 41) found that a 
weak, yet significant positive correlation existed between taste reports and texture, smell, 
volume/quantity, (correlation coefficients 0.151 (p<0.001), 0.143 (p=0.001) and 0.102 
(p=0.017) respectively). This suggests that although significant correlation exists between 
taste and other oral formulation-related barriers to medicines administration, further 
investigation in future studies is needed as the correlation is weak.  
Prescribers need to be alert with regard to oral formulation properties when prescribing 
medicines for children. Based on study findings, problems with texture were commonly 
associated with medicines used to treat malignant diseases and immunosuppressants 
(chapter 8 of BNFC) and also co-trimoxazole liquid, omeprazole soluble tablets and lactulose 
liquid. Problems reported with the quantity of solid dosage forms or volume of 
liquids/powders were most prevalent across medicines prescribed for gastro-intestinal 
disorders (BNFC chapter 1). The quantity of pancrealipase capsules and the volume of 
macrogol 3350 oral powder and prednisolone soluble tablets (when added to liquids) were 
highlighted most commonly by respondents reporting problems with the volume or quantity 
of medicines. 
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The size and ease of swallowing of solid dosage forms also need to be carefully considered. 
Over one fifth (21%) of antibiotics, antivirals and antifungals (from BNFC chapter 5) 
prescribed were identified as being too large or difficult to swallow through reports. Co-
trimoxazole tablets were most frequently reported by participants with respect to problems 
with their size. 
Colour/appearance and smell were not reported to serve as obstacles to medicines 
administration as frequently as the other oral formulation-related problems discussed. 
Administering colourless medicines through an NG tube was reported to cause confusion for 
one mother. She perceived coloured medicines to be most useful for remembering which 
medicines had been administered.  
Parents or carers may influence child acceptance of a medicine. If parents or carers perceive 
that a property of an oral formulation (e.g. smell, colour) is unfavourable this could reduce 
child acceptance. When recording parent or carer reports of unfavourable oral formulation 
properties, respondents were asked to provide details to support the problems experienced 
by children as reported in section 6.5.1.1.1. This was performed to optimise the accuracy of 
parental reports. 
The plethora of oral formulation-related barriers to medicines administration reported in 
this study warrant further exploration in future studies. Problems identified with the oral 
formulation properties of individual medicines in this study need to be addressed by 
pharmaceutical companies and also carefully considered by prescribers when prescribing 
medicines for children. The overarching aim will be to help to improve medicines for children 
in the future and through this improve adherence to medicines. 
233 
6.7.2 Medicines manipulation 
It has been documented that many medicines administered to paediatric patients are not 
age-appropriate, as a consequence of this some parents or carers (either on their own 
accord or following the advice of a healthcare professional/information provided in a PIL) 
manipulate medicines. Reports of parents, carers and young people mixing medicines with 
different foodstuffs were provided in the interviews. The limited awareness of parents, 
carers and young people regarding potential consequences of medicines manipulation was 
observed during the interviews.  
Reassuringly, 82% (405/499) of medicines were reported to be administered in a manner 
defined as ‘gold standard’. However, this study identified that almost one third (29%) of 
participants reported medicines manipulation for the purpose of giving a specific dose or to 
facilitate medicines administration. Several studies conducted in HIV and oncology patients 
included in Chapter 4, reported similar findings to the present study. Manipulation strategies 
used to administer medicines to children were highlighted by between 24% and 32% of 
parents or carers (Byrne et al., 2002, Christiansen et al., 2008, Goode et al., 2003, Wrubel et 
al., 2005) (see Table 2). 
The qualitative analysis of reported administration techniques identified several examples of 
medicine manipulations (see Tables 44 and 45) that could affect drug bioavailability and thus 
therapeutic response. The potential physicochemical effects of these manipulations are 
reported in Table 51 below. 
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Table 51 Potential physicochemical effects of medicines manipulation. 
Manipulation technique Potential physicochemical effects 
 Splitting tablets or sachets manually Inaccurate segmentation resulting in administration 
of inaccurate dose (underdose versus overdose) 
Mixing non-soluble tablets with liquids  Non-uniform dosing, aggregation and sedimentation 
of insoluble drug particles 
Milling tablets  Thermal degradation 
Mixing with foodstuffs  Fruit juices (altering pH), drug binding to dairy 
proteins, formation of insoluble complexes 
 
Drug-foodstuff incompatibilities and effects on drug absorption were previously discussed in 
section 2.5.3. It is well documented that the tetracycline antibiotics form an insoluble 
complex with calcium and thus drug absorption can be reduced by between 50 - 80% if taken 
with milk or other dairy products (Baxter, 2010). The binding of calcium with levothyroxine is 
less well appreciated than binding with the tetracyclines (Baxter, 2010). A young person in 
this study reported swallowing levothyroxine tablets with a large glass of milk, and although 
this was not classed as a medicine manipulation, drug bioavailability may be altered as a 
result of drug-foodstuff binding. Sub-optimal clinical response of a drug could be the 
outcome. 
However, it is probable that the extent of drug-foodstuffs binding is lesser when solid dosage 
forms are swallowed immediately with foodstuffs, compared to when mixed with foodstuffs 
and in contact for a period of time prior to administration (cf medicines manipulation). 
Whilst it could be argued that for some reports of medicines administration with foodstuffs, 
only a negligible effect on drug absorption may present, for some medicines such as those 
with a narrow therapeutic index, this may be of clinical significance. In addition, 
administering medicines with foodstuffs affects gastric transit time and this can also 
influence drug bioavailability (Bowles et al., 2010). 
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Limited evidence is available on the effects of mixing drugs with various foodstuffs prior to 
medicines administration (see section 2.5.3). Prolonging the contact time of a drug with a 
foodstuff is likely to increase the binding capability of foodstuff to drug and therefore may 
risk reducing drug bioavailability, thus affect therapeutic response. 
Additionally, if a drug-foodstuff mixture is not consumed in its entirety, the desired dose will 
not be administered. Examples of parents adding medicines to bottles of milk and breakfast 
cereals are reported in Table 45. In addition, children may associate certain foodstuffs with 
the administration of unpalatable medicines and refuse to consume these foods. 
Informal recommendations on how to manipulate medicines were retrieved from the BNFC 
and other sources as reported in section 2.5.3 (AstraZeneca, 2011, BNF for Children, 2011-
2012, Norgine Pharmaceuticals Ltd, 2009). Also, the Great Ormond Street Hospital website 
(GOSH, 2010) and Medicines for children website (Medicines for Children, 2011a, b) offer 
advice for administering medicines to children. However, the data retrieved was not largely 
supported by a robust scientific evidence base. 
Statistical results of this study have identified that medicine manipulations were significantly 
less likely to be reported for children aged 5-11 years and 12-18 years, compared to children 
aged 0-4 years in this study, with odds ratios 0.29 (95% CI 0.13-0.67) (p=0.004) and 0.18 
(95% CI 0.06-0.59) (p=0.005) respectively. See Table 46 for multivariable analysis results for 
medicines manipulation discussed in this section. 
It is probable that younger children have less experience with different flavours and ‘mouth-
feels’ and therefore may be more likely to resist medicines administration or refuse to take 
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medicines in the study defined ‘gold standard’ manner (i.e. in their existing form). It was 
discussed earlier (section 4.5) how similarly, delaying feeding infants lumpy foods can 
influence acceptance of foodstuffs (Northstone et al., 2001). 
The person/s responsible for administering medicines significantly influenced reports of 
medicines manipulation (p=0.049) in this study. When the responsibility of administering 
medicines involved children, the likelihood of reporting medicine manipulations was 
significantly lower compared to when parents or carers had sole responsibility with an odds 
ratio of 0.28 (95% CI 0.10-0.81) (p=0.019). These findings are supported by interview reports 
of parents and carers revealing manipulation techniques that had been mastered, including 
reports of parents concealing medicines in various foodstuffs unbeknown to their child. 
Some ad hoc administration techniques were whispered to RV by parents and carers. 
Medicine manipulations were significantly more likely to be reported for ‘other’ medicine 
formulations (encompassing granules, powders, soluble tablets, chewable tablets and melts) 
and also solid dosage forms (tablets and capsules) compared to liquids, with odds ratios of 
23.97 (95% CI 9.14-62.84) (p<0.001) and 9.66 (95% CI 3.48-26.87) (p<0.001) respectively. As 
granules, powders and soluble tablets often need to be dissolved in water prior to 
administration, manipulation techniques, e.g. adding dosage forms to various fruit juices or 
foodstuffs or measuring specific volumes of medicines (see Tables 44 and 45) are more likely 
to be adopted. As dissolvable formulations have varying solubilities this may influence 
parents and carers to mix these with various foodstuffs (sometimes at different 
temperatures) to mask unfamiliar textures, tastes and/or reduce dissolution time (e.g. 
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reports of macrogol 3350 oral powder added to hot chocolate and zinc soluble tablets added 
to warm water were provided, see Table 45). 
Tablets and capsules are pre-measured solid dosage forms. Tablets may need to be 
segmented or capsules opened either to measure commercially unavailable doses or to 
facilitate medicines administration. Splitting tablets or measuring the powder or granules 
within capsules poses the risk of administering an inaccurate dose and could contribute to a 
medicine overdose or underdose. A minor dosing error could have a significant clinical effect 
if the drug concerned has a narrow therapeutic index.  
Tablets may require milling prior to administration where there is no equivalent liquid 
formulation available to administer a required dose and/or swallowing a solid dosage form is 
an obstacle to administration. The majority (21/24) of medicines that were manipulated for 
purpose of administering a specific dose in this study were tablets, soluble tablets or melts 
(see Table 44). Richey and co-workers (2011) similarly found that tablets were more likely to 
be manipulated to administer a specific dose compared to other dosage forms.  However, 
Richey and co-workers (2011) investigated the practices of nursing staff administering 
medicines in a ward environment, not parents, carers and young people in the domiciliary 
setting as in the present study. 
Statistical results indicate that medicines identified with size problems or child aversion 
to/difficulty swallowing are significantly more likely to be manipulated compared to those 
not associated with such problems (odds ratio of 4.52 (95% CI 1.37-14.90) (p=0.013). This 
study finding was anticipated as such difficulties are associated with solid dosage forms, e.g. 
tablets were segmented or crushed and capsules were opened and contents mixed with 
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various foodstuffs to facilitate administration and/or to improve child acceptance. This can 
affect the integrity of the dosage form and risks altering the pharmacokinetic profile of a 
drug. Modified release preparations in particular should not be crushed (Lowey and Jackson, 
2007).  
Statistical results of the present study showed that the likelihood of reporting medicine 
manipulations was significantly increased for medicines identified with unfavourable 
textures with an odds ratio of 3.15 (95% CI 1.39-7.14) (p=0.006). Ad hoc administration 
techniques were reported in circumstances where the consistency of a medicine was a 
barrier to administration. Mixing pancrealipase Micro gastro-resistant granules with pureed 
fruit was one example provided in an interview by a parent (see Table 45). This 
administration technique was used in an attempt to minimise the gritty texture of the 
granules, to improve child acceptance.  
It is evident that many available medicines are inappropriate for children, therefore parents 
are often left with little choice except to manipulate medicines to administer a specific dose 
or to facilitate medicines administration. This can pose risks including inaccurate dosing and 
altered drug bioavailability as a result of drug-foodstuffs binding. 
As there is a paucity of evidence regarding the safety and efficacy of such manipulation 
techniques, laboratory investigation (involving stability tests) beyond the scope of the 
present study is required to provide a scientific evidence base to support manipulations. This 
robust, evidence-based approach is warranted to inform guidelines on safe and effective 
medicine manipulation techniques to optimise drug therapy in paediatric patients. 
Administration techniques reported in this study should be used as case examples to guide 
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pharmaceutical companies in designing future paediatric formulations. Addressing 
medicines commonly reported to be manipulated in this study should be a priority (i.e. 
omeprazole soluble tablets, macrogol 3350 oral powder and co-trimoxazole tablets, see 
Figure 20). 
Future formulation work needs to be implemented to develop age-appropriate medicines 
that are accepted by paediatric patients and also available in appropriate unit doses. Ideally, 
medicines for paediatric patients should be available in pre-measured dosage units covering 
child dosing ranges and be small enough to taper doses accurately. 
Dosage form technologies such as mini-tabs as reported in two studies (Spomer et al., 2012, 
Thomson et al., 2009) may help to reduce medicines manipulation through minimising 
barriers that were found in this study to be significantly associated with physical adaptation, 
i.e. tablet size and texture of medicine. Dosing with mini-tabs can easily be adjusted and in 
addition the dosing counter device provides a more accurate dosing method compared to 
manipulation techniques (Thomson et al., 2009). However, it should be acknowledged that 
for some medicines, it may be more feasible for practical and economical reasons to use safe 
and effective manipulation techniques. 
Also, it would be useful for future studies to investigate if education to help children with 
chronic conditions to learn to swallow tablets could improve medicines adherence. 
Encouraging children to accept solid dosage forms from a younger age may be beneficial, 
supported by studies investigating infant acceptance of different tastes and textures of 
foodstuffs as discussed earlier in section 4.5.1. This could reduce child aversion to some 
medicines and also reduce unnecessary medicine manipulations.  
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The majority (79%) of patients with NG or PEG tubes fitted were administered medicines via 
these routes. For this group of patients, solid dosage forms needed to be crushed where 
liquids were unavailable and part volumes of liquids measured following the dispersion of 
tablets/granules. Personal communication with parents and carers revealed that much time 
is spent, and many problems and concerns encountered when administering medicines via 
NG or PEG tubes. It is vital that the healthcare team responsible for the care of a child fitted 
with an NG or PEG tube understand the complex issues that surround these routes of 
administration. Administering medicines through NG and PEG tubes potentiates 
pharmaceutical risks including sedimentation and caking of drug particles.  
Medicines manipulation was not as high (14%) as anticipated for patients administering 
medicines via NG or PEG tubes. This is likely to be related to the increased prescribing of 
Special liquid formulations in these patients. In the present study, prescribing of Specials was 
found to be five times more prevalent in patients with NG or PEG tubes fitted. A cascaded 
prescribing process should always be followed to ensure that commercially available 
products are prescribed where possible. Rigorous implementation of a prescribing cascade 
for administering oral medicines to children both orally and via the NG/PEG tube route may 
help to achieve a nationally standardised, safe and cost-effective prescribing practice. 
Nonetheless, to supply some drugs it may be justified to order a Specials medicine, for 
example if the equivalent licensed medicine formulation poses a risk such as blocking an NG 
or PEG tube. An example reported by parents in this study involved Losec MUPS granules 
blocking NG/PEG tubes. Such administration difficulties highlighted by parents of children 
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with complex health needs should be used to direct formulation work, and have highlighted 
a niche for extemporaneous dispensing. 
6.7.3 Medicines refusal 
Statistical results of this study indicate that medicine refusals at some point or in the six 
months prior to interview were significantly less likely to be reported for 5-11 year olds than 
for 0-4 year olds with odds ratios of 0.42 (95% CI 0.19-0.89) (p=0.024) and 0.06 (95% CI 0.01-
0.48) (p=0.009) respectively. See Tables 47 and 48 for multivariable analysis results for 
medicines refusal discussed in this section. 
A possible explanation for this finding could be associated with the increased understanding 
of children regarding medicines as they enter school age. They may begin to understand why 
they need to take medicines and the importance of medicines adherence. It should be 
remembered that parental or carer guidance and persuasion may also be more feasible with 
5-11 year olds as generally they are more developed compared to 0-4 year olds.  
The rate of reporting medicine refusals in the six months prior to interview significantly 
differed across the child age ranges at diagnosis (p=0.030). Although not reaching statistical 
significance between each age group and the youngest age group (less than one month old), 
the findings of this study suggest that when paediatric patients are diagnosed with chronic 
conditions later in childhood (12-18 years), medicines are more likely to be refused. Young 
people with limited knowledge of their chronic condition may be striving for autonomy and 
left by parents or carers to be fully responsible for medicines administration (Michaud et al., 
2004) thus may be more vulnerable to poor medicines adherence. A study conducted by 
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Shemesh and co-workers (2004) found that young people were left responsible for 
medicines administration from an average age of 12 years. 
It is likely that young people recently diagnosed with a chronic condition will be less familiar 
with regular medicines administration compared to children diagnosed with a chronic 
condition at a younger age. This finding supports the need to increase education in young 
people recently diagnosed with chronic conditions in order to improve their understanding 
of the importance of adhering to medicine regimes. A study conducted by Clarke and co-
workers (2005) concluded that amongst oncology children, those with more information on 
their disease had improved understanding of the importance of adhering to medicines. 
Regarding adherence, paediatric studies conducted in CF and oncology have found that 
patients have a tendency to be less adherent to medicine regimes if they are less 
knowledgeable of their disease and treatment (Gudas et al., 1991, Tebbi et al., 1986). 
However, a further study by Beck and co-workers (1980) found no association between 
medicines adherence and patient knowledge in children with renal disease. It is 
acknowledged that refusal is only one factor influencing medicines adherence, however 
these study findings on adherence support findings of the multivariable analysis results 
regarding medicines refusal in this study. 
Results of multivariable analysis suggest that reporting medicine refusals is more likely for 
patients living in more deprived areas (higher IMD 2010 scores) than those living in less 
deprived areas with odds ratios 3.19 (95% CI 1.37-7.43) (p=0.007) and 4.75 (95% CI 2.02-
11.18) (p<0.001) in ascending order of IMD 2010 score for the two uppermost quartiles. It is 
likely that this finding is related to lower educated parents and carers living in more deprived 
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areas. It is probable that parents and carers living in more deprived areas have a poorer 
understanding regarding the importance of medicines adherence.  
In more deprived areas there may be a higher prevalence of poorer health and parents or 
carers with learning disabilities, increased social difficulties, and poorer housing and living 
conditions (more inhabitants per household, more children and potentially less one-to-one 
care) based on IMD 2010 scoring (see footnote to Table 34). Inevitably in such circumstances 
adherence to medicines may not be the number one priority in life. Additionally, it is likely 
that more immigrants and ethnic groups live in more deprived areas, therefore cultural, 
social and language issues may act as barriers to medicines administration. 
Several studies have found associations between low socioeconomic status (including low 
level of parent education) and non-adherence, in child populations suffering from renal 
disease, HIV, CF and Juvenile Rheumatoid Arthritis (JRA) (Brownbridge and Fielding, 1994, 
Davies et al., 2008, Patterson, 1985, Rapoff et al., 2005). The education and knowledge 
regarding medicines administration and the importance of medicines adherence amongst 
parents living in more deprived areas needs to be addressed. 
Problems identified with taste (odds ratios 3.82 (95% CI 2.11-6.92) (p<0.001) and 2.66 (95% 
CI 1.16-6.07) (p=0.021)), texture (odds ratios 3.38 (95% CI 1.24-9.22) (p=0.017) and 3.34 
(95% CI 1.20-9.32) (p=0.021)), volume/quantity (odds ratios 12.79 (95% CI 4.41-37.12) 
(p<0.001) and 4.44 (95% CI 1.05-18.82) (p=0.043)) all significantly increased the rate of 
reported medicine refusals on at least one occasion and in the six months prior to interview 
(odds ratios and p values reported respectively). 
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When examining the influence of reports of poor palatability on reported medicine refusals, 
taste-related problems were associated with 64% (54/85) of medicines that were refused. 
Supporting the findings of the present study, Zelikovsky and co-workers (2008) conducted a 
study in 56 young people listed for a renal transplant and found that participants reporting 
‘hate the taste’ as a barrier, missed more doses of medicines (p=0.02), see Table 2. 
The type of formulation (e.g. liquid versus solid dosage form versus other) was not 
significantly correlated with reports of medicine refusals in this study (p=0.336). This finding 
suggests that medicine refusal is not related to the type of formulation prescribed. 
Van Dyke and co-workers (2002) reported lower medicines adherence rates in children 
suffering from HIV who were administered tablets compared to those administered liquid 
medicines. However, this study was conducted in a narrow patient population prescribed 
antiretrovirals and it is widely accepted that the size of antiretroviral tablets are 
troublesome for children (Van Dyke et al., 2002). The present study was conducted in 
children with different chronic conditions therefore limited comparisons can be drawn with 
findings from studies conducted in narrow patient populations. 
A further study (FormPIC- REC no 13/NE/0020) previously discussed in section 4.5.1, 
evaluates which specific factors influence healthcare professionals when choosing to 
prescribe, dispense or administer a particular dosage form. Additionally, determining the 
factors perceived as important by children, parents and carers when choosing a liquid or 
tablet formulation will be crucial. 
245 
6.7.4 Child acceptance 
When examining the influence of reports of child acceptance of medicines, children were 
reported to be rarely or never happy to take over half of the medicines reported to be 
refused on at least one occasion. Child acceptance of medicines could influence child refusal, 
thus further studies in children are warranted to explore the obstacles to medicines 
administration. 
Not all medicines that were disliked in this study were reported to be refused. For some 
medicines, dose administration was delayed. Resisting medicines administration was 
commonly reported in the interviews and described as time consuming and often distressing 
for parents and carers. Additionally, for some medicines with critical dosing intervals this 
could result in sub-optimal therapy. 
6.7.5 Forgetting to administer medicines  
In this study, rates of forgetting to administer medicines on at least one occasion were found 
to differ significantly across child age ranges at interview (0-4, 5-11 and 12-18 years) 
(p=0.026). A history of omitting medicines through forgetfulness was significantly more likely 
to be reported for young people (12-18 years) compared to 0-4 year olds with an odds ratio 
of 2.98 (95% CI 1.32-6.74) (p=0.009), see Tables 49 and 50 for multivariable analysis results 
for forgetting to administer medicines discussed in this section. 
Forgetting to administer a dose of medicine is one barrier to medicines adherence. Other 
reasons can contribute to non-adherence. Several studies have reported that young people 
are more likely to be non-adherent than younger children when prescribed medicines to 
treat HIV, immunosuppression (post-transplant), CF and oncology (Beck et al., 1980, 
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Brownbridge and Fielding, 1994, Elise et al., 2005, Feinstein et al., 2005, Gudas et al., 1991, 
Patterson, 1985, Reddington et al., 2000, Serrano-Ikkos et al., 1998, S.D. Smith et al., 1979, 
Tebbi et al., 1986). The results from the multivariable analysis of forgetting a dose of 
medicine are supported by these previous study findings on non-adherence conducted in 
specific patient populations. 
In contrast to these findings, Gibb and co-workers (2003) found that HIV-infected children 
over 10 years of age were more likely to be adherent to antiretroviral medicines than those 
younger than 10 years, however a small patient population (19/128) aged less than 10 years 
may have influenced these results (Gibb et al., 2003). In two further studies no significant 
difference was found in adherence to medicines between children and young people 
suffering from HIV (Davies et al., 2008) and JRA (Litt and Cuskey, 1981). 
Findings of the present study suggest that medicines administration is not always a priority 
in the day-to-day life of a young person. As a child matures in to adolescence, generally 
reduced parental guidance and supervision is observed. It has been discussed earlier (in 
section 2.2) that young people begin to desire independence and empowerment over their 
medicines. Often, parents become less responsible for administering medicines and also 
reminding their child to administer medicines as the child gets older (WHO, 2003). 
The majority of young people strive to lead a stereotypical ‘teenage life’ and are likely to 
undergo peer pressure, and feel the stigma associated with administering medicines (e.g. 
when attending social events) (Michaud et al., 2004). The desire to answer in a socially 
acceptable manner may have encouraged some young people in this study to report 
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medicine taking behaviour inaccurately (Butz, 2006). For example, some reports of 
‘forgetting’ medicines may represent intentional medicine omissions.  
Statistically significant findings of this study indicate that forgetting to administer medicines 
was less likely to be reported for children prescribed three or more medicines (i.e. 
polypharmacy based on prescribed oral medicines) compared to children prescribed one 
medicine (odds ratio 0.28 (95% CI 0.15-0.51) (p<0.001)) and similarly within the six months 
prior to interview (odds ratio 0.27 (95% CI 0.13-0.57) (p=0.001)). 
A study in HIV patients conducted by Reddington and co-workers (2000) concluded that 
children taking three to four medicines were more likely to be adherent than those taking 
fewer (one to two) and also those taking more (five to seven) medications (study details 
reported in Table 2). A further study conducted to validate medication adherence scales in 
78 young people with organ transplants, found that parents provided more prompts to 
remind young people to administer medicines when a greater number of medicines were 
prescribed (Simons and Blount, 2007). However, in contrast to the present study which 
included children with various chronic conditions these studies were conducted in narrow 
patient groups. 
It is probable that when patients are prescribed multiple medicines, routine and familiarity 
of medicines reduce the risk of forgetting to administer doses. Also, parents, carers and 
children may recognise the synergistic effect of different medicines on therapeutic response 
when prescribed multiple medicines to treat a chronic condition. In addition, polypharmacy 
may indicate that a child is suffering from multiple conditions, this could promote increased 
parental concern towards adhering to medicines. 
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Reports of parents using drug charts on kitchen walls for children with complex therapeutic 
regimes were recorded in the interviews. Drug charts were not discussed by any young 
people. Encouraging parents, carers and young people to use reminding systems as 
discussed later (see section 6.7.6), irrespective of the number of medicines that they are 
prescribed may help them to remember to administer medicines throughout the day and 
thus improve medicines adherence. 
Forgetting to administer medicines within the six months prior to interview was significantly 
less likely to be reported for children requiring additional educational help compared to 
those children not requiring additional educational help, with an odds ratio of 0.38 (95% CI 
0.16-0.94) (p=0.036). This finding suggests that parents and carers accept more 
responsibility with regard to medicines administration in circumstances where children 
require additional educational help. 
Parents and carers may have more concern towards their child’s health if s/he requires 
additional support at school, suggesting that they are more likely to understand the 
importance of adhering to medicine regimes. A general observation from data on medicines 
at school (see section 6.6.4.12) was that specialist schools for children with learning 
difficulties dealt better with medicines administration during the school day compared to 
non-specialist institutions. 
Reports of forgetting to administer medicines in the six months prior to interview were 
significantly associated with drug therapeutic class (based on BNFC chapter) (p=0.013). The 
unadjusted rates of forgetting doses of medicines across drug therapeutic classes were 
calculated and followed a similar pattern to the multivariable model. Medicines featuring in 
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chapters 8 (drugs used to treat malignant diseases and immunosuppressants), 3 (respiratory 
drugs) and 6 (drugs used to treat the endocrine system) were least likely to be reported as 
forgotten (in descending order) in the six months prior to interview, see Figure 24. 
Medicines featuring in chapter 8 of the BNFC include those used to treat malignant diseases. 
This finding suggests that remembering to administer medicines is more likely when the 
condition treated is perceived to be of a more serious nature. A review of adherence rates 
across chronic disease regimens in children reported higher adherence to medication 
regimes used to treat paediatric patients with HIV/Acquired Immune Deficiency Syndrome 
(AIDS) (Rapoff, 2010). The results of the present study support the finding of Rapoff and co-
workers (2010) in terms of linking adherence with illness. 
It also should be noted that medicines adherence may be influenced by how patients 
perceive the benefits and risks of their medication. A study conducted in adults suffering 
from different chronic conditions concluded that significant differences in beliefs and 
reported adherence between illness groups existed, with cardiac and asthma patients more 
likely to perceive that concerns regarding their medication outweighed the benefits 
compared to oncology or dialysis patients (Horne and Weinman, 1999).  
When considering reports of forgetting to administer medicines in the six months prior to 
interview, the influence of additional educational help and other health-related need of a 
child followed a similar pattern, although other health-related need did not reach statistical 
significance (p=0.869). There are limitations to the factor other health-related need as this 
covered a wide range of problems including visual-related and multiple needs associated 
with chronic physical and/or mental impairment. 
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6.7.6 Reminding systems for administering medicines 
Encouraging and reinforcing effective reminding systems may be useful for parents, carers 
and young people administering medicines in the domiciliary environment. The majority 
(82%) of respondents reported remembering to administer medicines as being part of ‘daily 
routine’, yet 64%, reported forgetting to administer medicines on at least one occasion. 
During the interviews, young people who reported forgetting to take medicines were 
counselled (if appropriate) to use devices with alarms (e.g. mobile phones); such 
technological methods may be effective. Parents using medication charts in the domiciliary 
environment reported positive feedback regarding their value. Families struggling with 
complex regimes should be encouraged to use a medication chart. 
Reminding systems used to remind parents and young people to administer medicines 
should not be overlooked as they can prompt accurate and timely dose administration. 
Prescribers and other healthcare professionals need to ensure that such systems are in place 
to aid medicines adherence where remembering to administer doses is difficult. In addition 
reminding systems should be considered for children who are prescribed complex regimens 
and those prescribed medicines requiring medicines to be administered at critical dose 
intervals. Further investigation in to the effectiveness of medicine reminding systems is 
required that is beyond the scope of this study. 
6.7.7 Intentional discontinuation, adverse effects and treatment 
effectiveness of medicines 
Reassuringly, less than 10% of respondents claimed that they had discontinued medicines 
without the instruction of or in agreement with a healthcare professional if it was perceived 
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that a child was worse (i.e. adverse effects were experienced). Even fewer respondents (2%), 
reported that they had discontinued a medicine if a child seemed better. Reports suggest 
that the majority of parents, carers and young people understood that medicines prescribed 
to treat chronic conditions should not be discontinued without professional guidance. 
Comments were provided by respondents to support this (see section 6.6.4.7). 
Education plays a key role in developing the knowledge of parents, carers and young people 
regarding a chronic condition and the importance of regular and accurate timing of 
medicines administration. Discouraging patients from discontinuing medicines is critical to 
achieve full adherence, thus it is essential that allied healthcare professionals are educated 
to counsel patients and their carers effectively. Healthcare professionals ought to discuss 
common adverse effects of medicines thoroughly with parents, carers and young people so 
that they are able to deal with them safely and effectively. This may help to minimise 
parental stress and negative attitudes towards medicines. 
The importance of taking medicines with a preventative value and taking medicines when 
not feeling unwell is not always understood by children up to the age of 11 years (Sanz, 
2003). In addition, several studies have reported that medicines adherence can reduce over 
time (Lancaster et al., 1997, Tebbi et al., 1986), indicating that close, regular monitoring is 
required post-diagnosis. 
If parents, carers and young people were provided with a better understanding of how 
individual medicines work this could improve medicines adherence. For example parents, 
carers and young people should be advised of the time period that exists before clinical 
effects of a medicine ought to be experienced. Similarly for medicines where clinical effects 
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are not expected to be seen or experienced by patients this information should be provided 
to patients and their carers.  
6.7.8 Additional barriers to medicines adherence and medicines adherence 
status 
This study identified barriers to medicines adherence. Over half (56%) of the respondents 
reported unintentional non-adherence behaviours. Only one tenth (10%) of respondents 
reporting non-adherence behaviours reported solely intentional barriers, however over one 
third (35%) of respondents reported a combination of unintentional and intentional reasons 
for omitting doses of medicines, see Figure 26. 
Medicines adherence in children is more complex than in adults as reasons for unintentional 
and intentional non-adherence behaviours can be influenced by parents/carers and/or 
children (e.g. parents may choose not to administer medicines and/or children may refuse 
medicines). Adherence is a complex multi-factorial phenomenon, therefore these findings 
provide a general insight in to overall medicines adherence patterns in this study, yet are not 
particularly useful alone. It is evident that in order to understand how to improve medicines 
adherence, healthcare professionals need to explore the obstacles experienced by individual 
patients and their parents or carers. Education needs to be addressed accordingly with the 
aim of minimising barriers to medicines adherence where this is possible.  
6.7.9 Issues surrounding the supply of medicines 
This study identified that issues with medicines supply were reported for almost three 
quarters (71%) of Specials medicines that were prescribed. When medical practitioners are 
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prescribing for children, it is not only crucial that they choose a suitable formulation; they 
also need to be vigilant with regard to potential problems surrounding medicines supply.   
Prescribing protocols need to be addressed to ensure that healthcare professionals have the 
necessary resources to prescribe effectively. Healthcare professionals (especially prescribers 
and pharmacists) need to work collaboratively to ensure that a prescribing cascade is 
followed. This should direct prescribers to select medicine formulations commercially 
available before choosing unlicensed products as previously discussed in sections 5.5.4 and 
6.7.2.  
Communication between hospital prescribers and GPs is crucial in promoting the 
continuation of drug treatment in a smooth, unaffected manner following patient discharge 
from hospital. Optimisation of patient safety, satisfaction of therapeutic treatment 
(including ease of obtaining) and reduction in the drugs bill is the overarching aim. 
6.7.10  Problems with PILs 
Community law requires that for all medicinal products placed on the ‘community market’ a 
PIL is provided to enable safe and appropriate use of a medicinal product (European 
Commission, 2009). Guidance on presentation of patient information is also provided in the 
guideline (European Commission, 2009). 
The majority (77%) of respondents claimed to be happy with the information provided in 
PILs. When prescribing a medicine off-label (outside of the terms of the product licence), it is 
essential that effective counselling is provided by healthcare professionals to ensure that 
parents, carers and young people are happy to administer it. It is crucial to alleviate any 
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unnecessary concerns, for example parents reading information suggesting that a particular 
medicine should not be administered to children (prescribed off-label), as this could result in 
non-adherence. 
For 4% of medicines prescribed, it was reported that no PIL had been provided. In 
circumstances where unlicensed medicines are prescribed, often there is no PIL available. It 
is necessary for prescribers to reassure parents, carers and young people of their personal 
expertise in prescribing the unlicensed medicine concerned and where possible to provide 
them with alternative sources of medicines information. 
6.7.11  Problems with medicines at school 
Observations of the present study data indicate that medicines administration and 
responsibility in the school environment varies across different schools. Over one quarter of 
respondents revealed that they had experienced difficulties with medicines at school. 
Similarly, a study exploring family perceptions of medicines administration at school 
concluded that between 15% and 50% of children taking medicines for asthma, diabetes and 
ADHD experienced problems (Clay et al., 2008). 
Almost half of the respondents in the present study agreed that teaching/social staff require 
more information on children’s medicines and chronic conditions. A variety of views 
regarding the medicines management support of teaching and social staff was reported by 
parents, carers and young people (see section 6.6.4.12). F.J. Smith and co-workers (2008) 
examined the experiences and concerns of 27 young people and their parents and carers 
regarding medicines management at school and similarly reported wide variations in support 
with medicines management at school. They found that over one third (10/27) of 
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parents/young people reported negative attitudes regarding the support received from 
school staff (F.J. Smith et al., 2008). These findings are supported by a study promoting the 
collaborative work of pharmacists and nurses to educate teaching staff personnel (Clay et 
al., 2008). 
6.8 General limitations and ethical issues 
The ethical nature of the study recruitment process involved posting study invitation letters 
to all patients on the selected outpatient lists. It was anticipated that a significant proportion 
of children attending clinics would not be eligible for study participation (e.g. child not 
prescribed medicine for at least one month). However, only a minority, (3% (47/1559)) of 
the invited population declined to take part in the study.  
Prior to providing consent, some parents clarified with RV that their child’s medication 
would not be changed as a result of this study. Further parents sought reassurance that their 
personal information would be held confidentially and would not be disclosed when 
reporting results. Two parents sought to ensure that there was no follow-up to the study 
before providing consent. 
During the study period, language barriers and parental concern regarding the exposure of 
personal information impeded the consent of some participants. However, interpreters were 
utilised where possible. One interview was conducted utilising an interpreter. Parental 
consent to participate in the study was obtained for ten young people who were unable to 
provide consent as it was perceived that they were not Gillick competent.  
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Time was an impending factor for parents and carers when asked to provide consent. Some 
parents had work commitments or had to return children to school so were unable to 
participate at the time of appointment. Owing to consultation with a multidisciplinary team, 
the increased duration of HIV and CF clinics affected recruitment in these patient groups as 
parents and young people did not want to stay at hospital any longer than was necessary. 
Further problems were encountered when a parent or carer (with legal guardian status) was 
not present at the clinic appointment. In such circumstances, RV advised that a parent or 
carer could choose to arrange a mutually convenient time in the future. Seven participants 
did not have time to answer any questions on barriers to medicines adherence, however 
data on medicines manipulation and oral formulation-related barriers to medicines 
administration was collected.  
Differences in the number of patients on specific clinic lists and the frequency of specific 
clinics affected the numbers of individual clinics targeted. Recruitment rate was lower in 
some clinics. A cardiologist informed RV that recruitment would be low in cardiology clinic as 
only few patients are prescribed medicines. Observation during diabetic clinics revealed that 
the majority of children were not prescribed oral medicines. As oral medicines were 
pertinent to the present study fewer diabetic clinics were targeted. Recruitment rates across 
orthopaedic clinics were low as the majority of patients were not prescribed oral medicines 
for at least one month. Specialist HIV and sickle cell anaemia clinics were conducted less 
frequently (monthly) and additionally there were many repeat visits, reducing the potential 
recruitment population.  
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A limitation of using a self-report tool is the risk of inaccurate reporting, as acknowledged in 
section 2.2.1, and discussed in section 6.7.5. Interview design attempted to minimise this as 
far as possible. Questions were designed to not be threatening and prior to conducting 
interviews, participants were advised that responses would not be reported back to 
clinicians unless something dangerous was revealed, see section 6.5.3. Also, as the 
researcher (RV) was not a member of the clinical care team it was not anticipated that false 
reports would limit this study. 
The number of participants reporting forgetting or refusing medicines within one week or six 
months was small. It is not known whether this was the result of underreporting or 
indicative of the true behaviour of the participants. It is important to also understand that 
some reports of forgetting medicines may represent medicine refusals. Underreporting of 
medicines refusal may be represented by some ‘forgetting’ results as participants could be 
more likely to report an unintentional reason for not taking medicines, (i.e. it may be that a 
participant chooses to answer in a more socially acceptable manner and fears blame) (Butz, 
2006).  
Irrespective of the causes of low reporting, this resulted in a paucity of positive outcomes on 
which to perform statistical analyses. As a consequence of this, statistical tests involving 
these variables had limited statistical power within these time frames (i.e. one week and six 
months prior to interview). This resulted in the minimal detectable differences in the 
analyses being very large, hence factors that may have had small but genuine effects on 
these variables may not have been identified. 
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In this study, one mother reported that medicines had not been omitted, however the young 
person in her care provided an opposing report. This finding reinforces the need for future 
studies to investigate parent and teenager reports independently. In the present study, 
there was insufficient time and resources for parents and young people to be interviewed 
independently and the study was designed to be pragmatic, thus reflect a family 
environment. A study by Buchanan and co-workers (2012) (see Table 2) found significant 
similarity between independent reports of ‘taste/cannot get it down’ (p<0.001), forgetting 
(p<0.001), and also refusing doses (p=0.01) amongst young people with HIV and their carers. 
These findings suggest that reporting of such outcomes is fairly consistent between carers 
and young people, however this is only one study, conducted in children with HIV.  
Optimising the accuracy of parent/carer reports was important as some children were too 
young to describe problems experienced with medicines. When exploring reports of oral 
formulation-related barriers to administering medicines to babies and young children, RV 
asked parents/carers to describe the child’s reaction to medicine administration. Parents 
and carers described how some medicines were easier to administer than others and 
provided examples to support poor palatability of a medicine (including wry face, shrugging 
shoulders). 
6.9 Direct patient benefit of interview 
The interview process itself had a direct patient benefit as RV was able to utilise her 
professional role as a pharmacist in circumstances where it was necessary. Advice was 
provided to parents and young people with regard to optimising medicines management 
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(i.e. patient benefit, clinical benefit, and safety). Examples of advice provided by RV can be 
found in Appendix 23. 
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7 FINAL DISCUSSION 
7.1 Introduction 
Perspectives of parents, carers, children and healthcare professionals were explored in this 
study to develop a thorough understanding of the problems that prevail when administering 
oral medicines to the paediatric population. This study has examined the prevalence and 
nature of oral formulation-related barriers to medicines administration and also medicines 
manipulation in a large population of paediatric patients suffering from chronic conditions. 
The data collected in the interviews and focus groups of this study has provided new 
information, adding to the published literature to date. 
7.2 Oral formulation-related barriers to medicines administration 
The present study has expanded the pre-existing, narrowly focussed literature and identified 
the prevalence and nature of oral formulation-related barriers to medicines administration 
in children suffering from various chronic conditions. In the literature to date, no study has 
explored problems experienced in the domiciliary environment across such a wide patient 
population. 
Taste was the most prevalent oral formulation-related barrier to medicines administration 
reported in the systematic review (Chapter 4), and similarly in the present study interviews 
and focus groups. In the majority (93%) of review studies (see Table 2) taste was identified 
as a central obstacle to medicines administration, and additionally associated with a drug or 
specific formulation in the key 7 (antiretroviral) studies. In the present study interviews over 
one third (35%) of currently prescribed oral medicines were associated with taste-related 
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(taste, aftertaste and lack of taste) problems. Taste was reported as a barrier to medicines 
administration for almost two thirds (64%) of currently prescribed oral medicines that were 
refused. In addition to medicines refusal, resisting medicines administration was described in 
cases where medicines were poorly accepted and caused unnecessary parental stress, yet 
still taken by children. 
Findings from the interviews in this study indicate that at least 20% of medicines prescribed 
from each BNFC chapter are associated with taste-related problems. Antibiotics, antivirals 
and antifungals (BNFC chapter 5), endocrine drugs (BNFC chapter 6) and gastro-intestinal 
drugs (BNFC chapter 1) in descending order were associated with the largest proportion of 
taste issues. When considering individual medicines, ranitidine liquid (82%), prednisolone 
soluble tablets (81%) and trimethoprim liquid (75%) were identified as having the highest 
proportion of taste issues in descending order (see Figure 13 for further results).  
It has been documented that fruity, sweet formulations are preferred and in general citrus 
and red berry flavours are favoured across Europe (EMEA, 2006). The present study results 
support this evidence. Positive attitudes towards Strawberry flavoured Calpol suspension 
were revealed across the healthcare professional focus groups and also by interview 
participants in the present study. Findings from study interviews show that flavours 
including mint (e.g. ranitidine liquid), ‘bitter’ flavoured prednisolone soluble tablets and 
aniseed (e.g. trimethoprim liquid) are disliked largely across a paediatric population suffering 
from chronic conditions.  
Discussion in the UHCW pharmacist focus group supports the argument that poor medicines 
acceptance may result from unfamiliar flavours. Strawberry Calpol suspension was a 
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medicine reported to be better accepted than flavours perceived to be more ‘unusual’. This 
concept may similarly apply to further organoleptic properties of medicines (e.g. poor 
acceptance of textures amongst children as reported in section 6.6.4.1.2). 
A plethora of further oral formulation-related barriers to medicines administration, texture, 
quantity or volume, size or aversion to/difficulty swallowing, colour and smell were 
endorsed across the present study interviews and focus groups. In particular, problems with 
the texture of lactulose liquid and the volume of macrogol 3350 oral powder (in liquid) were 
reported in focus groups and interviews. Such barriers were reported less frequently than 
taste, however significant correlation was found with some of these properties and 
unfavourable taste, thus they should not be overlooked. Taste problems were found to be 
correlated with texture, smell and also volume or quantity in the study interview reports 
(see Spearman’s correlation test of interview responses, Table 41) and also across the focus 
groups. The relationship between medicine volume and taste has been previously reported 
in the reflection paper (EMEA, 2006). These findings warrant that pharmaceutical companies 
consider oral formulation-related barriers carefully when designing medicines. 
Prednisolone soluble tablets were commonly identified as problematic to administer across 
the focus groups and interviews in the present study. The reasons reported for this included 
taste, texture and volume. Administering bitter tasting soluble prednisolone tablets in 
minimal volume was advised in the medical practitioners group to improve child acceptance. 
It is of paramount importance that further investigation of this specific formulation is 
prioritised. Prednisolone is commonly prescribed to children to treat acute asthma flare-ups 
in the community setting. Investigating if similar problems are experienced by children 
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treated in primary care would complement the present study. Such findings should be 
considered carefully by prescribers and institutions in all healthcare settings. 
There is a potential opportunity to use key findings to reduce medicines wastage and 
improve cost-benefit. The positive economic impact of changing prednisolone soluble tablets 
to prednisolone tablets for general use in children was calculated. It is estimated that this 
will generate a cost improvement saving of £5000 per annum at UHCW (personal 
communication, UHCW healthcare professionals).  
It should be noted that some organoleptic properties (e.g. colour and smell) may be 
considered unfavourable by parents, and therefore these should be dealt with very carefully 
as this may or may not influence child acceptance. Problems related to the colours or smells 
of medicines need to be explored to ensure that their impact is fully understood. Psychology 
assistance is warranted, to investigate such perceptions further.  
Feedback directly in to formulation development work is critical to improve children’s 
medicines of the future. Findings of this study should help pharmaceutical companies to 
prioritise formulation work. Formulation teams should be advised to review organoleptic 
and physical properties of medicines that are generally well-accepted across a paediatric 
population to direct the procurement of future medicines that are better suited to children. 
This could decrease the economic cost of medicine wastage in the future. 
Following literature searches conducted in the present study it was evident that the majority 
of studies used taste-tests which had been conducted in specific patient populations and 
often in healthy children or adults (see Chapter 1). Taste-tests investigating flavour 
preferences across the paediatric population are warranted and are detailed in PIP guidance 
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(European Commission, 2008). It is vital that such studies consider paediatric patients 
suffering from various chronic conditions so that factors with potential to influence taste 
preference in specific patient groups can be considered (e.g. oncology patients may have 
increased taste-recognition errors) (Matsui, 2007a). 
However, it is appreciated that taste-masking certain drug flavours can be troublesome, and 
more pharmaceutical drive to overcome this is needed as a matter of urgency. When 
formulating medicines for children, pharmaceutical companies need to be vigilant regarding 
the safety of excipients used. Concerns related to the safety of excipients when prescribing 
in children were raised in the pharmacist focus groups (see section 5.5.7). Supporting this, 
the EMA draft Guideline on pharmaceutical development of medicines for paediatric use 
provides guidance on the selection of excipients (EMA, 2013). 
7.3 Medicines manipulation 
The lack of appropriate paediatric formulations creates a barrier to safe and effective 
medicines administration. The systematic review (see Chapter 4) identified some examples 
of medicines manipulation reported in literature. In the majority of studies reporting such 
techniques there was a paucity of detail. Additionally, no scientific evidence base was 
referenced to support these medicines manipulation techniques in the review studies.  
Findings from the present study interviews with parents, carers and patients have shown 
that nearly one third of respondents (29%) reported manipulating medicines. Almost one 
fifth (19%) of medicines were manipulated. A variety of reasons for manipulating medicines 
was reported across the interviews. Over one quarter (26%) of medicine manipulations were 
performed to administer a specific dose, however, the majority (79%) were carried out to 
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facilitate medicines administration (e.g. to mask unfavourable formulation properties, to 
improve child acceptance). 
The present study has uniquely focussed on the prevalence and nature of manipulations to 
medicines performed by parents, carers and patients in a domiciliary environment. 
Complementing the findings of the current study, two investigations (Richey et al., 2011, 
Skwierczynski and Conroy, 2008) as discussed earlier in section 2.5.2 identified the nature 
and frequency of manipulations to medicines administered to children on paediatric wards.  
The risks of dosing inaccuracy (resulting in under or overdosing) are concerning and 
especially when the dosage required is not commercially available in a pre-measured unit. 
Amongst the reported medicines manipulation techniques, parents described having to 
measure fractions of powders or solid dosage forms. Human error may result in inaccurate 
doses being measured. The therapeutic response of a drug may be altered as a result of 
inaccurate dosing. This could cause a fatal dosing error if the drug concerned has a narrow 
therapeutic index, for example digoxin. 
The medicines manipulated for the purpose of administering a specific dose, as identified in 
the study interviews (see Table 44), highlighted drugs for which age-appropriate 
formulations may not be commercially available. This should direct future paediatric 
formulation work.  
Paradoxically, it is important that the MHRA are vigilant regarding the potential risks, e.g. 
parental confusion and dosing errors associated with licensing too many different strengths 
of the same drug formulation. The variety of dose units available need to be carefully 
rationalised in view of patient safety and risks associated with overdose, as has been done 
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with warfarin, where the number of tablet strengths are limited (BNF for Children, 2011-
2012). Similarly, the unlimited variety of strengths of Specials formulations needs to be 
acknowledged. This was a concern highlighted in the focus groups and interviews. 
Additionally, to increase safety through prevention of prescribing, dispensing or 
administration errors, it would be sensible if strengths of liquid formulations were provided 
in a standardised fashion where possible (e.g. Xmg in 1ml) as discussed by pharmacists in 
this study (see section 5.5.8). 
Qualitative analyses of medicines manipulation techniques (e.g. adding doses of 
levetiracetam liquid and sodium valproate liquid to breakfast cereal - see Table 45) used to 
facilitate administration reported in study interviews, revealed potential physicochemical 
effects that could alter drug bioavailability and additionally therapeutic response (see Table 
51). Drug-dairy protein binding may occur when milk is added to breakfast cereal. Prolonging 
contact time of drugs with foodstuffs prior to dose administration increases the drug-
foodstuff binding capability and therefore has the potential to reduce drug absorption, 
bioavailability and affect therapeutic response.  
Although it is universally acknowledged that tetracyclines chelate calcium ions in dairy 
products as discussed in section 6.7.2, for the majority of medicines manipulation 
techniques the potential effects on pharmacokinetic responses are unknown. Limited data is 
available regarding the safety and efficacy of mixing medicines with foodstuffs, yet this study 
has shown that medicines manipulation is a common occurrence for the families 
interviewed. When parents or carers add medicines to meals or bottles of milk it is 
additionally concerning as incomplete consumption of a dose may result which could lead to 
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an altered therapeutic response.  This was a concern raised in the focus group with medical 
practitioners. 
An understanding of medicines manipulation is needed by all healthcare professionals 
involved in the care of an individual. Education of healthcare professionals to ensure that 
they fully understand the potential risks of medicines manipulation on therapeutic response 
is essential. This should guide them to prescribe the most appropriate formulation to attain 
accurate dosing, efficacy and patient safety. Collaboration between a multidisciplinary team 
of pharmacists, medical practitioners and nurses is crucial to achieve best patient care in 
more complex cases. 
To minimise unnecessary medicines manipulation it is essential that medical practitioners 
prescribe the most suitable dosage form for a patient. It is important that they consider age-
appropriateness, the type of formulation (in relation to patient acceptability and ease of 
administration), swallowing problems and patient capability to swallow tablets according to 
size, and also whether the individual has difficulty with various textures. These factors were 
found to significantly influence medicines manipulation in statistical analysis of the interview 
responses in this study (see Table 46, for odds ratios and associated p values).  
Findings from the present study have directed the design of further research to determine 
which factors influence dosage form selection (FormPIC study REC no 13/NE/0020) as 
discussed in section 4.5.1. Such parameters need to be at the forefront of the prescribing 
process in an attempt to minimise inappropriate modifications of medicines. Furthermore, it 
is necessary to address the benefits of implementing training courses to help children to 
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learn to swallow solid dosage forms from a younger age, as discussed in the focus groups 
and published studies, see section 5.5.5.  
It is appreciated that for some drugs, procuring a medicine that is well-accepted by 
paediatric patients is difficult, therefore medicine manipulations are inevitable. However, 
the lack of knowledge regarding the scientific evidence for medicines manipulation was 
evident across the healthcare professional focus groups. This was similarly reported in a 
study by Akram and Mullen (2012) which explored nurses’ knowledge of mixing medicines 
with foodstuffs. These findings were anticipated owing to the limited scientific data 
available.  
It is therefore vital that laboratory work is conducted to support the safety and efficacy of 
commonly used medicines manipulation techniques. This would provide a robust scientific 
evidence base to inform standardised protocols that could be used nationally. Suitable 
medicines manipulation techniques should be clearly referenced in commonly used 
reference sources (e.g. BNFC, PIL, Summary of Product Characteristics - SmPC). This is 
supported in the EMA draft guideline (EMA, 2013) which states that information on mixing 
medicines safely with food should be provided by pharmaceutical companies. 
Medicines commonly reported to be manipulated in the study interviews were omeprazole 
soluble tablets, macrogol 3350 oral powders and co-trimoxazole tablets in descending order 
of endorsement (see Figure 20). Focus group participants highlighted similar manipulation 
techniques used to administer omeprazole soluble tables and macrogol 3350 oral powder 
(see Table 26). Reported examples of medicines manipulation provided in the study 
interviews, focus groups and the systematic review support the need for further laboratory 
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investigation and thus should feed in to pharmaceutical development work. In addition this 
may reduce time for preparation of medicines, medicines wastage and through this, cost. 
Optimisation of the education of both consumers of healthcare and those involved in the 
prescribing, dispensing or administration process is critical. 
7.3.1 Patients with NG or PEG tubes 
In addition to medicines manipulation, reports of parents administering medicines via 
unlicensed routes (e.g. NG or PEG tubes) were provided. Parents that needed to administer 
medicines via such routes described difficulties. The time taken to prepare and administer 
medicines plays a huge role in the day-to-day life of a parent, carer and patient. Personal 
communication with paediatric consultants at the start of this project identified difficult 
patient cases that had been highlighted to them by parents with complex dosing regimens 
(see patient cases in Appendix 6). 
Across the present study interviews, reports of problems with feeding and medicines 
administration via NG and PEG tubes were prevalent. Losec MUPS granules blocking feeding 
tubes were discussed in the study focus groups and interviews, highlighting a problem to be 
considered carefully by pharmaceutical companies. 
Nurses and pharmacists in the present study focus groups reported interactions between 
specific formulations (e.g. ciprofloxacin) and feeds when administered together via NG or 
PEG tubes, unlike the medical practitioners, who did not discuss the extent of problems 
encountered when administering medicines via these routes. This finding suggests that the 
medical practitioners were unaware of the scope of issues associated with NG/PEG tube 
administration. Parents additionally reported their concerns regarding the accuracy of 
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dosing following the preparation/manipulation of medicines for NG or PEG tube 
administration. 
Guidance informed by a scientific evidence base would be especially useful to advise 
healthcare professionals, parents and carers on optimal and safe medicines administration in 
children with complex needs (e.g. where multiple medicines need to be administered via an 
NG or PEG tube, see Appendix 6). This should minimise current concerns of healthcare 
professionals, parents and carers regarding inefficacy of dosing through potential drug-food 
(including drug-nutrient) and drug-drug interactions.  
7.4 Problems with Specials medicines 
Specials medicines created many problems from the perspectives of parents, carers, young 
people and healthcare professionals in the interviews and focus groups of this study. Of the 
oral medicines prescribed to the children in the present study, 8% were identified as 
Specials.  
For almost three quarters (71%) of Specials medicines prescribed, problems with medicines 
supply were revealed including shortened expiries e.g. frequent re-ordering, GPs unhappy to 
prescribe (and not prescribing quantities requested by specialists), delays at GP surgeries 
and pharmacies (medicines supply taking between 24 hours and one week in pharmacies). 
Prescribing of Specials medicines was five times higher in study patients with NG or PEG 
tubes compared to patients not fitted with NG or PEG tubes. This increased Specials 
prescribing could be the reason for medicines manipulation not being as high as may be 
expected amongst this patient group. Future formulation work needs to target commonly 
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identified Specials medicines that were reported to cause difficulties across the focus groups 
and interviews e.g. omeprazole liquid. Increasing the practice of extemporaneous dispensing 
in pharmacy premises may help to reduce Specials prescribing (i.e. decrease expenditure on 
paediatric drugs), however, focus groups with pharmacists indicated that the suitability of 
pharmacy premises, staffing and quality assurance need to be addressed (see section 
5.4.4.4.4). Portugal is an example where there are significant state controls on 
compounding. In Portugal, every community pharmacy must have a compounding 
laboratory and its dimensions are specified by law (Carvalho et al., 2008, INFARMED, 2007). 
It may be beneficial to introduce similar regulations in the UK and across Europe. This 
requires further investigation. 
The medical practitioners seemed to have the least understanding and knowledge of the 
depth of issues with Specials and referred to fewer, more specific Specials medicines in 
comparison to the nurses and pharmacists whom reported an array of issues. The lack of 
credible evidence supporting efficacy and safety supplied with some Specials medicines (i.e. 
Certificate of Analyses) and absence of PILs were reported by the pharmacists. These issues 
clearly need to be addressed by pharmaceutical companies. To assure the safety and efficacy 
of Specials medicines, supporting scientific evidence should be provided in a standardised 
fashion. 
Following analysis of focus group data it was evident that the knowledge of Specials 
medicines varied amongst healthcare professionals. The flow of events from prescribing 
intentions of medical practitioners through to interpretation and conversion in to a labelled 
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medicine by pharmacists (see Figure 7) will not be achieved if flow is interrupted by lack of 
awareness of medicine categorisation. 
If a medical practitioner does not understand the implications of prescribing certain 
medicines (e.g. if s/he prescribes an unlicensed formulation which is ordered from a Specials 
manufacturer) this will affect the patient who will not be aware of the impending issues until 
they visit a pharmacy. Reports of parents experiencing unexpected problems with the supply 
of medicines were provided in the study interviews (see section 6.6.4.10). Supply problems 
were also associated with non-Specials medicines and liquid measuring devices (e.g. oral 
syringes) in parent interviews and across focus groups. The reported problems regarding 
difficulty in obtaining oral syringes through the NHS need to be addressed by Government 
funding bodies. 
It is fundamental to ensure that healthcare professionals are educated to understand the 
importance of continuity of medicines supply. Communication between secondary and 
primary care must be improved to try to ensure smooth, continuous medicines supply at 
patient level. Furthermore, the cost of Specials procurement may not be considered during 
the prescribing process, this will have an impact on the economics of national drug costs. It is 
necessary to minimise Specials prescribing as far as is possible using a cascaded prescribing 
process to ensure that all commercially available products are primarily considered (as 
previously discussed in sections 5.5.4 and 6.7.2). Although the education of prescribers 
should be a primary focus, it is prudent to also address the knowledge of other healthcare 
professionals involved in supplying and administering medicines.  
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It is vital that parents, carers and young people are educated by healthcare professionals 
when prescribed unlicensed medicines or medicines in an off-label manner. This will aim to 
reduce confusion and concern when patient information is not provided (as discussed in 
pharmacist focus groups) or contradicting information is found in PILs (e.g. ‘not suitable for 
children’). 
Although the absence of PILs with Specials medicines was commonly acknowledged in this 
study, problems reported with PILs by interview respondents were not confined to Specials 
medicines. For 4% of medicines, it was reported that no PILs were provided and for 7% of 
medicines, problems with PILs were reported (see section 6.6.4.11). The translation 
requirements for patient information supplied with parallel imported medicines were 
reported in the pharmacist focus groups. It is essential that patient information is provided 
with prescribed medicines, following guidance from the European Commission (2009). 
Furthermore, pharmacists should be extra cautious when supplying parallel imported 
medicines or unlicensed medicines. They need to ensure that protocols are in place and 
adhered to, regarding the provision of suitable and comprehensive patient information.     
When prescribed unlicensed medicines or medicines in an off-label manner, it is important 
that parents understand the exact dose to be administered owing to varying strengths of 
formulations (as discussed in section 2.4.4). Also, it is essential that parents are counselled 
appropriately so that they understand when receiving the same brand of a formulation is not 
essential. Effective collaboration is needed between medical practitioners and pharmacists 
to improve prescribing practice and to increase patient understanding and satisfaction of 
care.  
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7.5 Medicines refusal 
Refusal of medicines by children was an outcome influencing adherence, pertinent to the 
present study. It was necessary to investigate the proportion of subjects that had refused 
medicines and also the factors influencing medicines refusal. Reports of forgetting medicines 
and other reasons for poor adherence were also identified so that an overall indication of 
non-adherence (i.e. unintentional versus intentional versus both) could be ascertained. 
However, this was not a primary focus of this study. 
In total, 31% of interview respondents reported medicines refusal on at least one occasion, 
accounting for the refusal of 19% of medicines prescribed. Medicines associated with the 
oral formulation-related barriers: taste, texture, volume or quantity were significantly more 
likely to be refused by paediatric patients in the present study (for odds ratios and 
associated p values see Tables 47 and 48). Across the focus groups these oral formulation-
related barriers were also frequently reported to influence medicines adherence. Similarly, 
the systematic review highlighted these obstacles to acceptance of or adherence to 
medicines, albeit in narrow patient populations (see Chapter 4); however, only one study 
linked taste to child refusal (Lin et al., 2011). It would be beneficial for future studies to 
correlate oral formulation-related barriers with medicines refusal in order to identify if 
significant relationships exist. 
The type of formulation prescribed was not associated significantly with history of medicines 
refusal in the multivariable analysis of the interview data in this study. This finding is 
supported by focus group reports which suggest that formulation choice varies between 
individual patients. Examples of adolescents insisting that they were prescribed liquids and 
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younger children preferring tablets were provided across the interviews and focus groups in 
this study. The relationship between influential factors and dosage form choice will be 
investigated in the study, FormPIC (REC no 13/NE/0020) as discussed earlier. 
Statistical results of the interviews suggest that children 5-11 years are less likely to refuse 
medicines than those younger (for odds ratios and associated p values see Tables 47 and 48). 
Focus group reports support this finding. As far as medicines adherence is concerned, 
suggestions that toddlers and teenagers are problematic and also children who are less 
familiarised with different flavours and textures were reported in the groups.  
It is probable that from school-age, children begin to experiment with more textures and 
flavours, thus they may be more likely to accept medicines that may be perceived by a pre-
school infant to be ‘unusual’. Additionally, children from school-age begin to learn and 
therefore may understand the importance of taking medicines regularly. Supporting this, 
Birch (1998) discussed the importance of early experience on children’s developing food 
acceptance patterns and also reported how the quantity and quality of children’s 
experiences with food influence food intake patterns and food preferences. Parental 
influence may play a role in medicines refusal and the suggestion that parents may influence 
medicines adherence was reported across the study focus groups.  
The introduction of education for teenagers, parents and carers at clinic appointments may 
help to improve their understanding of a chronic condition and thus the importance of 
adhering to medicine regimens. It may be beneficial to introduce educational counselling at 
the point of diagnosis and also periodically during clinic appointments. The aim of this would 
be to identify any problems encountered at an early stage. Once identified, potential 
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solutions to barriers should be proposed and an agreement reached between healthcare 
professional and parent/patient. The overarching aim is to minimise medicines refusal, thus 
improve adherence to medicines. 
Children living in increased poverty may be more likely to refuse medicines, this is supported 
by the statistical findings of the present study interviews (for odds ratios and associated p 
values of IMD 2010 score, see Table 47). There may be issues with large families and also 
poor understanding due to a lower level of parental education. Several studies as discussed 
earlier (see section 6.7.3) have reported associations between low socioeconomic status 
(including low level of parent education) and non-adherence. Issues with ‘disorganisational 
social problems’ were reported in the UHCW pharmacist focus group with regard to 
medicines not necessarily being a priority in complex life circumstances. 
Patient, parent and carer education needs to be targeted to try to improve medicines 
adherence in families of lower socioeconomic status. Supplementary advice and support 
should be provided to such families to ensure that they understand the importance of 
adhering to therapeutic regimes.  
7.6 Additional barriers to medicines administration (i.e. those not 
directly associated with oral formulations) for future work 
7.6.1 Forgetting to administer medicines 
Forgetting to administer medicines on at least one occasion was reported by 64% of 
interview respondents. Almost half (47%) of the medicines prescribed were reported to have 
been forgotten on at least one occasion.  
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Statistical findings suggest that young people (12-18 years) compared to 0-4 year olds were 
more likely to forget medicines (see odds ratios and associated p values in Table 49). In 
addition, for children prescribed three or more oral medicines, statistical results indicate 
that forgetting medicines is less likely (see Tables 49 and 50 for odds ratios and associated p 
values). When taking multiple medicines: routine, familiarity of medicines, synergistic effects 
of medicines and increased parental concern (e.g. if child has multiple chronic conditions) 
may reduce the likelihood of forgetting medicines. In contrast to these findings, discussions 
in the BCH pharmacist and medical practitioner focus groups suggested that rationalising 
prescribing in patients prescribed several medicines may help to improve medicines 
adherence. This requires further investigation. 
Statistical results from forgetting medicines in the six months prior to interview (see odds 
ratio and associated p value in Table 50) suggest that for children requiring additional 
educational help, medicines are less likely to be forgotten compared to those not requiring 
educational help. These children may require more parental support than their peers in all 
areas of their life and so parents are more used to providing additional support. 
Medicines in BNFC chapters 8 (drugs used to treat malignant diseases and 
immunosuppressants), 3 (respiratory drugs) and 6 (drugs used to treat the endocrine 
system) were significantly less likely to be reported as forgotten in the previous six months 
based on the multivariable model (see Table 50 for odds ratios and associated p values). The 
unadjusted rates of forgetting medicines in the previous six months as displayed in  
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Figure 24, similarly showed that medicines in these groups were reported to be forgotten 
less frequently. Also, reports of forgetting antibiotics, antivirals and antifungals, gastro-
intestinal drugs and cardiac drugs were higher (see Figure 24). 
Perceived severity of disease may affect medicines adherence as discussed in section 6.7.5. 
Also, the perceived balance of risk and benefit of a medicine may affect adherence (see 
sections 5.5.6 and 6.7.5). Prescribers need to be aware of factors that may affect adherence 
when prescribing medicines to children. These findings should also highlight to prescribers, 
particular patient groups that may require extra help to support medicines adherence. 
Study interview data revealed that the majority of respondents (82%) reported that daily 
routine helped them to remember to administer medicines. As almost half of medicines 
prescribed were reported to be forgotten on at least one occasion, it seems evident that 
reminding systems (e.g. phone alarms and wall calendars) need to be implemented to 
remind parents, carers and young people to administer medicines throughout the day. 
Counselling parents, carers and young people on the importance of regular and correct 
timing of doses is crucial for some medicines, especially those with a short half-life and a 
narrow therapeutic index. 
7.6.2 Intentional discontinuation, adverse effects and treatment 
effectiveness of medicines  
Although interview reports in the present study suggest that the majority of interview 
respondents did not discontinue medicines without guidance from a healthcare professional 
(see section 6.6.4.7), a minority reported stopping medicines if the child seemed worse or 
better (8% and 2% respectively). It is prudent that patients are closely monitored post-
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diagnosis. This should help parents/carers and children to develop a better understanding of 
the importance of adhering to medicines. 
A thorough understanding of pharmacology and adverse effects of medicines is required by 
healthcare professionals in order to counsel parents, carers and young people effectively. 
This should help to improve their understanding of the therapeutic responses that should be 
expected and also highlight key adverse effects of medicines and how to deal with them, 
thus to discourage medicines non-adherence. Ideally, counselling should be performed by 
pharmacists when dispensing medicines. Time was reported to be an obstacle to effective 
counselling of parents in the pharmacist focus groups. Time constraints owing to staff 
shortages within the NHS were acknowledged in this study and need to be urgently 
addressed by Government funding bodies. 
7.6.3   Problems with medicines at school 
Reports on problems with medicines administration at school varied across the interviews 
and focus groups. For over one quarter (26%) of children in full-time education, problems 
with taking medicines at school were reported. Almost half (46%) of respondents voiced that 
teachers and social staff require more information on chronic conditions and medicines. 
Across the focus groups, inconsistent reports regarding the acceptance of children’s 
medicines at school were provided, indicating variation in the adoption of medicines policies 
between different schools. Further reports from the focus groups suggested that prescribing 
for school-aged children should be carefully considered, and where possible, formulations 
allowing dosing outside of the school day should be prescribed. Prescribing doses outside of 
the school day was similarly reported to be beneficial by some parents in the interviews.  
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Present study data on problems with medicines administration at school should be used to 
reinforce the standardisation of and adherence to policies regarding medicines in the school 
environment. Addressing the education of teaching staff with regard to treatment of chronic 
conditions is necessary to improve their acceptance and understanding of medicines. The 
values on ‘roles and attitudes of staff’ reported in a study by F.J. Smith and co-workers 
(2008) reflect the views on teaching and social staff reported in the present study interviews, 
as discussed in section 6.7.11. It may be useful to explore the specific role of school nurses in 
a further study. 
The goal of investigating medicines management within the school environment is to 
support and direct the standardisation of care provided to children suffering from chronic 
conditions at school, in line with the National Service Framework for Children, Young People 
and Maternity Services (DOH, 2004). 
7.7 Medicines adherence 
Medicines adherence remains a multi-factorial phenomenon, which is more complex in 
children owing to the additional influence of a patient’s family (Osterberg and Blaschke, 
2005). An inconsistency of outcome reporting was observed across the included review 
studies (see section 4.4.4.7.1), although oral formulation properties were described as, or 
implied to be barriers to medicines adherence. 
The present study identified that 79% of interview respondents reported a reason for 
missing at least one oral medicine on an occasion. Over one third (35%) of these non-
adherent respondents reported both intentional and unintentional reasons for missing doses 
of medicines (see Figure 26). To address ways to improve adherence this information alone 
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is inadequate. Future studies need to design methodology similar to that adopted in the 
present study to explore the specific factors that compromise medicines adherence when 
administering medicines to children. 
Additional barriers to medicines adherence were identified, yet are beyond the scope of the 
present study as they were not specifically related to oral formulations (see section 6.6.4.9, 
e.g. parents not re-ordering medicines on time and stock problems in pharmacies). These 
need to be investigated further in future research. 
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8 CONCLUSION 
Owing to its explorative (inductive) yet consumer informed (deductive) design this was a 
unique and multi-perspective study investigating oral formulation-related barriers to 
medicines administration across paediatric patients suffering from various chronic 
conditions. This pragmatic study has filled the research gap that existed through 
investigating such problems in a large sample of paediatric patients in a domiciliary 
environment. Identification of the difficulties experienced by families when administering 
medicines to children is essential for directing future formulation development work. It was 
necessary to ask children and their parents/carers the right questions to obtain the answers 
needed to fulfil the original project aims, thus parent, carer and patient involvement has 
played a fundamental role throughout this study. 
In total, 31% of interview respondents reported medicines refusal on at least one occasion, 
accounting for the refusal of 19% of medicines prescribed. Medicines refusal was found to 
be significantly influenced by age of child, socioeconomic status (IMD 2010 score), taste, 
texture and volume (of liquid/powder) or quantity (of solid dosage form). 
This study found that taste was the main oral formulation-related barrier to medicines 
administration; associated with 35% of medicines prescribed and 64% of medicines that 
were refused. 
Out of the interview respondents, 29% reported manipulating medicines. In total, 19% of 
medicines were manipulated, of which 26% were performed to administer a specific dose. 
However, the majority (79%) were carried out to facilitate medicines administration. Factors 
found to significantly influence medicines manipulation were: age of child, type of 
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formulation prescribed, size of solid dosage form or aversion to/difficulty with swallowing, 
texture and the person responsible for medicines administration. 
The initial study objectives are supported by PIP guidance, which states that paediatric 
formulation studies should include ‘palatability and taste-masking’ and data on 
‘compatibility and stability in the presence of relevant common foods and drinks particularly 
if food is used to facilitate administration of the dosage form’ (European Commission, 2008). 
The project findings should be used to inform and direct future paediatric medicines 
formulation design. This will assist with the development of age-appropriate formulations to 
provide suitable dose units and improve child acceptance. 
8.1 Future Work 
 
The key five findings from this thesis that require further exploration are: 
(i) Almost one third (31%) of oral medicines were reported to have been refused by children 
suffering from chronic conditions. This demonstrates that a significant number of children 
with chronic conditions are refusing medicines. It is crucial that healthcare professionals are 
asking parents, carers and young people non-threatening questions regarding adherence, to 
identify any difficulties experienced with medicines. This will prompt prescribers to ensure 
that they are prescribing the most appropriate formulation for a patient. The education of 
healthcare professionals with regard to effective parent/carer counselling needs to be 
addressed in future studies. 
In addition, it is appreciated that a significant proportion of medicines prescribed to children 
do not meet their needs and it is crucial that pharmaceutical companies prioritise paediatric 
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formulation work based on current study findings, which have identified factors related to 
oral formulations that are significantly associated with medicines refusal: taste; texture and 
volume (of liquid/powder) or quantity (of solid dosage form). Additional factors found to be 
significantly associated with medicines refusal were child age and socioeconomic status (IMD 
2010 score). These factors need to be explored in future studies. 
(ii) Almost one third (29%) of oral medicines administered to children suffering from chronic 
conditions were reported to have been manipulated. Age-appropriate formulations should 
be developed to provide both suitable dose units and acceptable palatability for paediatric 
patients. Additionally, pharmaceutical companies should undertake further laboratory work 
based on the findings of this study to provide robust scientific evidence to support medicines 
manipulation techniques suitable for parents, carers and young people to use in the 
domiciliary environment - with attention to patient safety and maintaining drug efficacy. 
Such guidance should be referenced and available to healthcare professionals and parents, 
carers and young people in clear, appropriate formats (e.g. within BNFC monographs and 
PILs respectively). Healthcare professionals should advise parents, carers and young people 
based on this guidance. 
In addition, healthcare professionals should carefully consider factors found to be 
significantly associated with medicines manipulation when making prescribing decisions, 
especially those related to palatability and ability to swallow. 
(iii) Findings from focus groups with healthcare professionals suggest that the knowledge 
and understanding of such professionals regarding prescribing, dispensing and administering 
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medicines to children with chronic conditions needs to be investigated and addressed in 
future studies. It would be useful to explore this in both a community and hospital setting. 
(iv) This study has reported barriers to administering oral medicines to children suffering 
from chronic conditions in the domiciliary environment. Further studies should investigate if 
similar problems are encountered by parents, carers and children prescribed oral medicines 
for acute conditions in a primary care setting. 
(v) This study has identified that there are significant problems experienced by parents, 
carers and children when administering oral medicines to children, thus further studies 
should determine the prevalence and nature of barriers to administering non-oral medicines 
to children. 
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Appendix 1 Views of West-Midlands Young people, parents and carers 
regarding medicines 
This present study has developed with the support of the Consumer Liaison Team for the 
WM-MCRN who have  facilitated focus groups to provide a lay perspective to inform 
research undertaken by MCRN. This work has brought to light the issues that children and 
young people have with the type of medication that they are prescribed. This research 
project evolved through public involvement and user involvement was utilised throughout 
this study. The initial design of this study was influenced using feedback from work 
conducted by the team with young people in the Birmingham and Coventry area to 
investigate young peoples’ perceptions on what medicine studies should address. 
The ideas surrounding this research was initially discussed during different activities with 
consumers (parent support groups, school visits, MCRN consumer liason work). Feedback 
revealed a vast amount of support from consumers of all ages, with different conditions and 
from different ethnic and social groups. Consumers felt that patients will benefit directly as 
lay individuals will have had a role in future drug developments. Information about 
medicines adherence, especially for individuals with chronic conditions and of a vulnerable 
age group is perceived as very helpful. 
Consultation has also taken place at UHCW’s Youth Council comprising members aged 11-18 
years, of mixed ethnicity, with a range of medical conditions. Members consulted about this 
project agreed that this research was important and felt that those involved in medicinal 
developments need to listen to the views of both the individuals taking problematic 
medication and their parents/carers who support their adherence. The group were 
delegated the task of designing posters to publicise the project and formulated the top 5 
questions that they think should be asked in questionnaires to aid experimental design of 
the template interview sheet. The responses given were: side effects, taste, formulation, 
forgetting medicines and issues at school.  
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Side effects quotations 
“I had mood swings so I stopped taking that medication.” 
“Steroids for colitis, my sister has to take 20 tablets a day. This had an effect on her immune 
system and now she can’t go swimming at schools which she was really upset about.” 
“Steroids make you pale- appearance and social issues especially when you’re a teenager it 
affects your confidence. They also make you gain weight.” 
Taste of medicines quotations 
“Horrible taste of some medicines.” 
“I had to take protein drinks and it was meant to be blackberry flavour but it tasted of salt 
still. Another young person had the same experience of this.” 
Formulation quotations 
“I can’t take tablets- my parents always crush my paracetamol.” 
Forgetting medicines quotations 
“I forget a lot to take my long-term medication.” 
“My sister’s school always forget to give her medication at lunchtime. She is only 10. Now 
my mom has to put stickers in her lunch box to remind her to ask.” 
Issues with medicines at school quotations 
“Social staff on school trips aren’t informed enough about medicines!” 
“It’s a big worry for teachers.” 
“More information is needed for teachers as we have to explain how to give our medicines.” 
(Consumer liaison personal communication) 
General opinions from public involvement 
The young people were asked what they thought about the study, and they all agreed it was 
worthwhile and would be happy to take part if they thought that improvements may be 
made. 
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Consumer Liaison Officer for the WM-MCRN team has confirmed that parents, carers and 
young people have expressed strong requests for research on paediatric medicines. This has 
influenced the need for the study. An anonymous quotation from a parent: 
“We aren’t asked about the medicines.” (Consumer liaison personal communication) 
  
306 
Appendix 2 Personal communication with healthcare professionals at UHCW 
The attitudes of many paediatricians towards this study were very positive. A Paediatric 
Consultant with specialist interests in neonatology and general paediatrics reported personal 
interest: 
“Issues with the taste of Kaletra”- a commonly prescribed antiretroviral combination 
formulation in HIV paediatric patients. 
A discussion with a Rheumatology Consultant with regard to her perception of issues with 
paediatric medicines took place. The consultant’s response: 
“Methotrexate tablets are commonly complained about by patients.”  
Consultation with a paediatric pharmacist raised some issues with specific medicines: Taste 
issues associated with the following liquid medicines: rifampicin, chloral hydrate, 
cephalosporins and osetalmavir 
Regimes identified as problematic by the paediatric pharmacist: Antiretrovirals and 
tuberculosis regimes - described as “intense.” 
The Paediatric pharmacist was asked to reveal any advice given to parents administering 
medicines to children. The advice that was given: 
“Avoid too much disruption to drug” – an example provided was to add hydrocortisone 
tablets to minimal water and swirl around as crushing may generate energy and influence 
molecular characteristics of the drug, thus potentially affecting activity and effectiveness. 
Further points identified by the paediatric pharmacist: Drug naïve patients seem to be less 
compliant with taking medicines, i.e. for short-term, acute conditions such as infections, 
whereas chronic patients are less likely to spit out/refuse medicine as parents/carers will 
have developed their own specific way of administering medication to their child. 
She queried: “Firstly, how are dosage forms adapted to make them palatable and secondly 
are they still effective in this form?”  
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Further laboratory study required beyond the scope of the current project was proposed by 
the pharmacist.  
Consultation with the paediatric pharmacist with regard to the use of unlicensed medicines 
at UHCW clarified the order and procurement process followed. Normally unlicensed 
medicines prescribed in hospital are ordered from a specials manufacturer. The orders to 
specials manufacturing units are usually performed consistently (i.e. the same 
manufacturers are used when ordering specific medicines) to try to ensure homogeneity and 
maintain continuity for patients. Usually two main specials manufacturing units are used. 
When there is difficulty, other specials units are used, this inevitably alters consistency of 
formulations obtained. 
The pharmacist revealed that sometimes medicines that are assumed to be specials prove 
too difficult to procure, and in these cases hospital best practice guidance is followed and a 
specific formulary is utilised. Unfortunately a seven day expiry exists with most 
extemporaneous medicines due to lack of preservative, and thus can create inconvenience 
and wastage. Following hospital best practice, ‘Novo diluents’ are often used at UHCW, 
(diluents A and C). A reference list showing compatibility of the diluents with various drugs is 
available. The diluent: C is flavoured, but this does not always mask drug taste.  
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Appendix 3 A mind-map of key search terms guided by Buzan and Buzan (2006) 
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Appendix 4 Summary of quality assessment and risk of bias in included review studies 
Authors 
 
Study title 
Was the 
recruitment 
strategy 
appropriate to 
meet the aims of 
the research? 
Participants 
recruited: child 
involvement is 
discussed in 
study Ethical approval 
discussed 
Informed 
consent 
discussed 
Details on 
interview 
personnel 
reported in 
study (including 
if interviewer is 
a member of 
patient’s care 
team and/or 
their role) 
Transparency of 
content 
(questions) of 
self-report tool 
(UNCLEAR –
indicates where 
themes were 
discussed but 
not specific 
questions) 
Detail of 
reporting 
relevant findings 
(oral 
formulation-
related barrier/s 
associated with 
drug/specific 
formulation) 
Reporting 
influence of oral 
formulation-
related barrier/s 
on acceptance of 
or adherence to 
medicines 
(quantitatively) 
(Shemesh et al., 
2004) 
Medication 
adherence in 
pediatric and 
adolescent liver 
transplant 
recipients 
YES YES YES NO NO YES NO 
 
YES 
 
(Tucker et al., 
2002) 
Associations with 
medication 
adherence 
among ethnically 
different 
pediatric patients 
with renal 
transplants 
YES YES YES YES NO YES NO YES 
(Zelikovsky et al., 
2008) 
Perceived 
barriers to 
adherence 
among 
adolescent renal 
transplant 
candidates 
YES YES NO YES NO Reference to an 
existing self-
report tool 
(MAM) 
 
NO YES 
(Christiansen et 
al., 2008) 
Oral 
chemotherapy in 
paediatric 
oncology in the 
UK: problems, 
perceptions and 
information 
needs of parents 
YES NO YES NO NO UNCLEAR NO YES 
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Authors 
 
Study title 
Was the 
recruitment 
strategy 
appropriate to 
meet the aims of 
the research? 
Participants 
recruited: child 
involvement is 
discussed in 
study Ethical approval 
discussed 
Informed 
consent 
discussed 
Details on 
interview 
personnel 
reported in 
study (including 
if interviewer is 
a member of 
patient’s care 
team and/or 
their role) 
Transparency of 
content 
(questions) of 
self-report tool 
(UNCLEAR –
indicates where 
themes were 
discussed but 
not specific 
questions) 
Detail of 
reporting 
relevant findings 
(oral 
formulation-
related barrier/s 
associated with 
drug/specific 
formulation) 
Reporting 
influence of oral 
formulation-
related barrier/s 
on acceptance of 
or adherence to 
medicines 
(quantitatively) 
(Ingerski et al., 
2010) 
Barriers to Oral 
Medication 
Adherence for 
Adolescents with 
Inflammatory 
Bowel Disease 
YES YES YES YES NO Reference to an 
existing self-
report tool 
(MAM) 
NO YES 
(Modi and 
Quittner 2006) 
Barriers to 
Treatment 
Adherence for 
Children with 
Cystic Fibrosis 
and Asthma: 
What Gets in the 
Way? 
YES YES YES YES NO UNCLEAR   
(Boni et al., 
2000) 
Compliance to 
combination 
antiretroviral 
therapy in HIV-1 
infected children 
UNCLEAR NO NO YES NO Reference to an 
existing self-
report tool (used 
by Gross and co-
workers 1998) 
NO 
 
YES 
 
 
 
(Buchanan et al., 
2012) 
Barriers to 
Medication 
Adherence in 
HIV-Infected 
Children and 
Youth Based on 
self- and 
caregiver report 
 
YES- refers to a 
longitudinal 
study of a 
multicenter 
cohort study 
(random 
recruitment from 
multicenter 
study 
population) 
YES NO YES NO YES NO YES 
(Byrne et al.,  
2002) 
Achieving 
Adherence With 
Antiretroviral 
Medications for 
Pediatric HIV 
Disease 
 
YES NO NO YES YES (reported 
that interviewer 
was not part of 
care team) 
UNCLEAR NO 
 
 
 
YES 
311 
Authors 
 
Study title 
Was the 
recruitment 
strategy 
appropriate to 
meet the aims of 
the research? 
Participants 
recruited: child 
involvement is 
discussed in 
study Ethical approval 
discussed 
Informed 
consent 
discussed 
Details on 
interview 
personnel 
reported in 
study (including 
if interviewer is 
a member of 
patient’s care 
team and/or 
their role) 
Transparency of 
content 
(questions) of 
self-report tool 
(UNCLEAR –
indicates where 
themes were 
discussed but 
not specific 
questions) 
Detail of 
reporting 
relevant findings 
(oral 
formulation-
related barrier/s 
associated with 
drug/specific 
formulation) 
Reporting 
influence of oral 
formulation-
related barrier/s 
on acceptance of 
or adherence to 
medicines 
(quantitatively) 
(Esteban Gomez 
et al., 2004)  
Influencia de las 
características 
del tratamiento 
antirretroviral en 
la adherencia del 
paciente 
pediátrico 
YES NO NO YES YES (Pharmacist 
dispensing 
medicines – 
unclear if known 
to respondents) 
YES NO  YES 
(Farley et al., 
2003) 
Assessment of 
Adherence to 
Antiviral Therapy 
in HIV-Infected 
Children Using 
the Medication 
Event Monitoring 
System, 
Pharmacy Refill, 
Provider 
Assessment, 
Caregiver Self-
Report, 
and Appointment 
Keeping 
UNCLEAR NO YES YES YES (reported 
that interviewer 
was not part of 
care team) 
 
Reference to an 
existing self-
report tool 
(PACTG) 
 
NO 
YES 
(Feingold et al., 
2000) 
Protease 
Inhibitor Therapy 
in HIV-Infected 
Children 
YES NO NO (different 
requirements 
considered as 
review of patient 
medical records) 
NO (different 
requirements 
considered as 
review of patient 
medical records) 
N/A UNCLEAR (no 
information on 
methodology for 
reporting in 
medical records) 
NO YES 
(Hammami et al., 
2004) 
Integrating 
Adherence to 
Highly Active 
Antiretroviral 
Therapy Into 
Children's Daily 
Lives: A 
Qualitative Study 
 
YES  NO NO YES YES (reported 
that interviewer 
was not part of 
care team) 
UNCLEAR NO NO  (all 
qualitative 
reporting) 
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Authors 
 
Study title 
Was the 
recruitment 
strategy 
appropriate to 
meet the aims of 
the research? 
Participants 
recruited: child 
involvement is 
discussed in 
study Ethical approval 
discussed 
Informed 
consent 
discussed 
Details on 
interview 
personnel 
reported in 
study (including 
if interviewer is 
a member of 
patient’s care 
team and/or 
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Transparency of 
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(questions) of 
self-report tool 
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themes were 
discussed but 
not specific 
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Detail of 
reporting 
relevant findings 
(oral 
formulation-
related barrier/s 
associated with 
drug/specific 
formulation) 
Reporting 
influence of oral 
formulation-
related barrier/s 
on acceptance of 
or adherence to 
medicines 
(quantitatively) 
(Leprevost et al., 
2006) 
Adherence and 
acceptability of 
once daily 
lamivudine and 
abacavir in 
human 
immunodeficienc
y virus type-1 
infected children 
YES NO 
 
 
 
YES YES NO UNCLEAR NO YES 
(Marhefka et al., 
2004) 
Clinical 
assessment of 
medication 
adherence 
among HIV-
infected children: 
examination of 
the Treatment 
Interview 
Protocol (TIP) 
YES NO YES YES NO YES NO YES 
(Paranthaman et 
al., 2009) 
Factors 
influencing 
adherence to 
anti-retroviral 
treatment in 
children with 
human 
immunodeficienc
y virus in South 
India- a 
qualitative study 
NOT IDEAL – 
convenience 
sample 
NO    NO YES YES (interviewer 
reported to be 
principal 
investigator, not 
part of care 
team) 
UNCLEAR NO  NO (all 
qualitative 
reporting)           
 (Plipat et al., 
2007)                   
Evaluation of a 
practical method 
to assess 
antiretroviral 
adherence in 
HIV-infected Thai 
YES NO                                                                                         YES YES  NO                                                                         
 
Reference to an 
existing self-
report tool 
(PACTG) 
NO  NO (all 
qualitative 
reporting) 
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Was the 
recruitment 
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appropriate to 
meet the aims of 
the research? 
Participants 
recruited: child 
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study Ethical approval 
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Informed 
consent 
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Details on 
interview 
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reported in 
study (including 
if interviewer is 
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drug/specific 
formulation) 
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influence of oral 
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or adherence to 
medicines 
(quantitatively) 
(Pontali et al., 
2001) 
Adherence to 
Combination 
Antiretroviral 
Treatment in 
Children 
 
YES NO NO NO YES (interviewer 
known to 
respondents) 
YES NO YES 
(Roberts, 2005) Barriers to 
antiretroviral 
medication 
adherence in 
young HIV-
infected children 
 
YES YES NO YES NO UNCLEAR NO  NO (all 
qualitative 
reporting) 
(Wrubel et al., 
2005) 
Pediatric 
adherence: 
Perspectives of 
mothers of 
children 
with HIV 
 
NOT IDEAL - 
Convenience 
sample 
NO YES YES NO YES NO NO (all 
qualitative 
reporting) 
(Bunupuradah et 
al., 2006) 
Use of taste-
masking 
product, 
FLAVORx, to 
assist Thai 
children to 
ingest generic 
antiretrovirals 
 
UNCLEAR NO YES YES NO (potential 
risk highlighted 
as study was 
reported to be 
conducted by 
FLAVORx 
company) 
Reference to an 
existing self-
report tool 
(PACTG) 
YES YES 
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Authors 
 
Study title 
Was the 
recruitment 
strategy 
appropriate to 
meet the aims of 
the research? 
Participants 
recruited: child 
involvement is 
discussed in 
study 
Ethical approval 
discussed 
Informed 
consent 
discussed 
Details on 
interview 
personnel 
reported in 
study (including 
if interviewer is 
a member of 
patient’s care 
team and/or 
their role) 
Transparency of 
content 
(questions) of 
self-report tool 
(UNCLEAR –
indicates where 
themes were 
discussed but 
not specific 
questions) 
Detail of 
reporting 
relevant findings 
(oral 
formulation-
related barrier/s 
associated with 
drug/specific 
formulation) 
Reporting 
influence of oral 
formulation-
related barrier/s 
on acceptance of 
or adherence to 
medicines 
(quantitatively) 
(Davies et al., 
2008) 
Adherence to 
antiretroviral 
therapy in young 
children in Cape 
Town, South 
Africa, measured 
by medication 
return and 
caregiver 
self-report: a 
prospective 
cohort study 
YES NO YES YES YES (interviewer 
known to 
respondents) 
Reference to an 
existing self-
report tool 
(PACTG) 
YES (did not 
specify specific 
formulation) 
YES (the 
prevalence of 
problems for 
individual drugs 
was not 
reported 
quantitatively) 
(Gibb et al., 
2003) 
Adherence to 
prescribed 
antiretroviral 
therapy 
in human 
immunodeficien
cy virus-infected 
children in the 
PENTA 5 trial 
YES  NO YES YES NO UNCLEAR YES YES (the 
influence of 
individual oral 
formulation-
related barriers 
was not 
reported 
quantitatively) 
(Goode et al., 
2003) 
Adherence 
issues in children 
and 
adolescents 
receiving highly 
active 
antiretroviral 
therapy 
YES NO YES NO NO UNCLEAR YES YES (the 
prevalence of 
problems for 
individual drugs 
was not 
reported 
quantitatively) 
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antiretroviral 
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YES NO NO (different 
requirements 
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review of patient 
medical records) 
NO (different 
requirements 
considered as 
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N/A UNCLEAR (no 
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methodology for 
reporting in 
medical records) 
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specify specific 
formulation) 
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(Reddington et 
al., 2000) 
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medication 
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children with 
human 
immunodeficien
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YES NO YES YES NO YES YES NO (all 
qualitative 
reporting) 
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reported in 
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Appendix 5 Email sent to Medical Practitioners at UHCW 
Dear All  
We are really fortunate to have the opportunity to work with John Marriott from Aston 
University and the MCRN in a very patient-orientated formulation project. We have funding 
for a PhD research fellow and Rebecca Venables will be starting in July. I have already spoken 
to some of you about this and we have been very encouraged by the support and 
enthusiasm for the study so far. 
She is a pharmacy graduate and will be looking at the ways patients and carers 
alter/adapt/disguise or otherwise manipulate medications to encourage the children to take 
them (or otherwise). The aim is to inform and direct future formulation work at Aston. She 
will initially be based at Aston, but once her honorary contract, CRB checks etc come 
through will be spending significant amounts of time here.  
Rebecca and I would like your help in 2 ways please: 
1. Initially she would like to sit in on some outpatient sessions – as she is a pharmacy 
graduate she would like to develop some more knowledge of how we work in outpatients, 
doctors and patients expectations at a consultation etc. She may well approach you and ask 
if she can join you at a clinic. Please can you let me know if you would NOT be happy if she 
approaches you to join in a clinic. 
2. Once we have the patient questionnaires finalised and through ethics etc we would like to 
know if you would NOT be happy for her to approach your patients in out patients or on the 
wards.  
The questionnaire will be facilitated by Rebecca, will be relatively brief and will not delay the 
running of your clinics!! 
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We envisage the questionnaire will be anonymous but will be offering the patients the 
opportunity of Rebecca feeding back information about drugs/formulations to the relevant 
clinician if the families would like this.  
Also if she picks up any potentially dangerous usages of medications this will be fed back to 
you. 
PLEASE would you let me know if you wish to opt out– if I do not here from you I will assume 
it is OK!! 
Thanks and best wishes 
Heather Stirling Consultant Paediatrician 
Responses from Medical practitioners: 
“I am happy to help in any way.” 
“I'm sure my rheumatology patients would be very happy to help!!” 
“I have no objection to Rebecca sitting in clinics – as long as parents agree. Also no 
objections to her questioning parents about medication.”   
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Appendix 6 Complex patient cases highlighted by parents to paediatric 
consultants 
“Children and parents bring specific medicines related questions to paediatric consultations 
which require clear pharmaceutical advice- is there any evidence for what how they should 
administer cocktails of medicines safely and effectively?” (Personal communication with 
paediatric consultant). 
The following patient cases were highlighted by parents to paediatric consultants. Cases are 
included with parental permission. 
Patient Case 1: 
A 3yr old boy with congenital adrenal hyperplasia, autism, significant feeding difficulties 
(dependent on NG tube), and gastro-oesophageal reflux with frequent vomiting was 
receiving a complex medication regimen administered via NG. 
Drug regimen: 
Hydrocortisone 4mg tds  
Fludrocortisone 100mcg od 
Sodium Chloride (NaCl) (1mmol/ml) 1ml three times daily (tds) and reducing – previously on 
6 mls tds  
Calcium Sandoz (liquid) – mum unsure of dose 
Dalivit vitamin drops 
Feeds: 
Nutrini Peptisorb 275mls four times a day (qds) 
Mum also gives “thickened water” (not sure what she thickens it with - Nestargel or similar – 
to clarify) 
This involved a complex time consuming daily routine:  
Daily Routine: 
07.00   275mls Nutrini feed over 45 minutes (given via NG tube with a pump) 
07.45    Dissolves 10mg hydrocortisone in 10 mls sterile water – gives 4mls (?crushes tablets)  
 Fludrocortisone:  crushes tablet and mixes and gives in a small amount of water 
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 NaCl – prepared by pharmacy 1mmol/ml 
Always gives HC, FC and salt at end of feed. Sometimes vomits. 
If vomits up to 30mins after drugs, mum repeats them 
Mid morning at nursery: thickened water – prepared by mum and sent into nursery with 
child 
13.00  275mls Nutrini feed  
  Hydrocortisone and NaCl (as above) 
1600  275mls Nutrini feed 
1900-2000 275mls Nutrini feed 
  Hydrocortisone and NaCl (as above) 
Each feed takes 45 minutes to go through, plus the time to give the drugs. 
The mother’s concerns centred around the time it took to prepare and give the drugs in the 
morning prior to nursery, what to do if the child vomited some/all of the medication and 
was there anything she could do (e.g. order of giving the medication) to minimise the 
chances of vomiting. The child was dependent on arranged transport to take him to nursery 
and if he was not ready on time then he would not be able to go to. 
The flow charts that follow display preliminary evaluation of patient case 1. 
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Preliminary evaluation of Case Study 1 
 
A flow chart to show preliminary evaluation of case study 1, issue 1: recurrent vomiting 
 
 
 
 
 
 
 
 
 
 
 
 
Issue 1: Recurrent vomiting 
Are feeds and salts given too 
closely together? (Spacing may 
compromise normal daily activities 
as feed alone takes 45 minutes). 
To sought pharmaceutical advice 
on timing and order of feeds, 
sodium chloride and 
corticosteroids. 
Has vomiting improved since 
reduction of sodium chloride 
dose to 1ml tds? 
Alternative, clinical reasons: 
*Gastroesophageal reflux 
disease (GORDS)              
*Anxiety                                  
*Food intolerance (residual 
lactose present in Nutrini 
Peptisorb)                              
*Side effect of drug 
Query with parent to find 
out pattern of vomiting. 
Clinical 
investigations 
to diagnose/ 
eliminate. 
Non-therapeutic 
approach: Socialising 
in parent-child groups 
to increase social 
interaction. Keep 
behaviour diary at 
nursery to monitor 
anxiety.  
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A flow chart to show preliminary evaluation of case study 1, issue 2: Hydrocortisone and 
fludrocortisone administration. 
 
Issue 2: Hydrocortisone (HC) and 
fludrocortisone administration 
How are tablets 
crushed? (Literature 
supports that 
hydrocortisone tablets 
are insoluble, but can be 
crushed finely and mixed 
with water and 
fludrocortisone tablets 
dissolve in water. N.B. 
There should be minimal 
disruption as crushing 
may produce heat and 
thus could cause some 
denaturation).  
Is the water used to dissolve the drug 
sterile, if so how- i.e. boiled and cooled? 
 
What 
technique/equipment is 
used to measure the 
4mls of the HC ‘solution’ 
that is procured (is 
patient receiving an 
accurate dose of 4mg at 
the stage of 
administration?) 
Is remaining HC 
‘solution’ discarded and 
procured freshly for 
each administration?  
 
 
In vitro stability testing of 
denaturation/degradation of 
hydrocortisone at time intervals 
In vitro stability testing of 
denaturation/degradation of 
fludrocortisone at time intervals. 
 
Clinician to clarify queries with 
parent 
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A flow chart to show preliminary evaluation of case study 1, issue 3: Interactions between 
drugs and Nutrini Peptisorb? 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Issue 3: Interactions between 
drugs and Nutrini Peptisorb? 
In vitro testing of sodium chloride, 
hydrocortisone and fludrocortisone 
with Nutrini Peptisorb at the time 
elapse (investigate binding, 
bioavailability and efficacy?) 
Laboratory investigations are needed 
to determine stability, degradation 
and the result of potential 
interactions between the drug 
formulations administered and 
nutritional formulations. 
In vitro testing with calcium and Dalivit 
(investigate binding and effect on 
bioavailability thus efficacy) 
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A flow chart to show preliminary evaluation of case study 1, issue 4: General administration 
and surrounding problems 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Issue 4: General administration and 
surrounding problems  
Sodium chloride solution is 
ordered from specials 
manufacturers (may cause 
potential problems with 
strength/formulation 
continuity if collected from 
multiple community 
pharmacies/hospitals and 
also a time wait).   
 
Is nasogastric (NG) tube cleaned 
correctly and regularly to prevent 
drug/nutritional particles sticking to 
tube? 
Are nursery nurses 
trained to administer 
doses during hours that 
patient is at nursery? 
Do nursery nurses follow 
a protocol when 
administering 
medicines? 
Do they follow the 
guidance provided by a 
healthcare professional 
that if patient is sick 
within half an hour of 
receiving doses, they are 
repeated? 
 
Counsel parent to ensure sodium 
chloride is ordered from same 
pharmacy and always checks labels on 
bottles to clarify how much she is giving, 
as change in concentration will mean 
the volume to administer will alter 
accordingly.  It is important to query 
how the sodium chloride dose is 
measured. 
Clinician to clarify queries with 
parent 
Review of literature: HC is readily 
absorbed from the 
gastrointestinal tract and peak 
blood concentrations are attained 
in approximately one hour. 
Advise to repeat dose if child 
vomits within one hour of 
receiving HC.  
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Patient Case 2:  
A six year old Afro-Caribbean old girl with Ornithine transcarbamylase (OTC) deficiency had 
recently received a liver transplant. 
Post transplant her oral feeding was supplemented with nasogastric feeds of Nutrini Fibre 
twice daily (morning and pre-bed) 
She had developed steroid – induced diabetes and had been established on sc glargine with 
Novorapid as necessary, and as well as medicines administration the mother was now 
checking the child’s blood glucose four times daily. 
She had a complex regimen of medication (anti-rejection and gastro-intestinal) involving 10 
oral medications in addition to sc insulin (see medication charts provided below) involving 
up to 26 episodes of medicine administration per day, several of which had to be 
prepared/manipulated prior to administration. 
Her mother described the burden of care this posed – particularly in terms of time in the 
morning whilst getting the child to school efficiently, and particular difficulties with specific 
medications. On review of the medication charts she freely admitted that some doses were 
missed or refused because of these constraints. 
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Appendix 7 A poster inviting healthcare professionals to participate in focus 
groups 
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Appendix 8 Invite letter and information sheet for focus groups with 
healthcare professionals 
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Appendix 9 Sign-in consent sheet for focus groups  
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Appendix 10 Additional taste quotations regarding flucloxacillin from focus 
groups 
Description from nurses group referring to the bad aftertaste: ‘‘cos I’ve tasted it you taste it 
and you think that’s not too ergh, and there’s a sort of after..” (Nurse 4) 
MP 4: “flucloxacillin it’s got a really bitter aftertaste, and if they’ve got to take it four times in 
a day and it tastes horrible and they have a challenge to do that,” 
MP 5: “yep fluclox is disgusting” 
MP 3: “flucloxacillin, avoid if I possibly can.” 
  
334 
Appendix 11 Results from study on Specials prescribing  
Healthcare professionals’ understanding of children’s medicines 
(Venables, R., Marriott, J. and Stirling, H. (2012b) Poster 0073 Healthcare professionals’ 
understanding of children’s medicines. International Journal of Pharmacy Practice, 20: 
(Supplement 2): 68-69). 
 
Focal points  
 The study aimed to determine just how much (or how little) paediatric healthcare 
professionals understand about medicines they are prescribing or administering. 
 The study identified significant gaps in the knowledge of paediatric healthcare 
professionals. 
 Further education of healthcare professionals (especially junior doctors in training) about 
prescribed formulations is required to ensure clinical effectiveness and cost-efficiency of 
paediatric prescribing. 
 
Introduction 
Approximately 200 million paediatric prescriptions are issued annually in the UK and many 
are used outside of the terms of their medicine licence. One in ten prescriptions for children 
in primary care is for an unlicensed or off-label medicine which can lead to an unsuitable 
formulation. Manufacture of “specials” is a major issue with significant cost implications. 
Doctors and health care professionals at all levels of training are often unaware of the 
licensing requirements for paediatric drugs and the implications of these on how they 
prescribe medication for children, but there is little information assessing their knowledge. 
This study was designed to determine the level of understanding of paediatric healthcare 
professionals about the legal status of medicines that they are prescribing or administering. 
 
Methods 
Health care professionals attending a paediatric continuing professional development 
afternoon on paediatric research were invited to complete a questionnaire at the start of the 
session. The participants were asked to provide five definitions related to the prescribing of 
children’s medicines: 1) Off-licence, 2) Off-label 3) “Specials”, 4) NICE approved and 5) 
Marketing authorisation. Answers were evaluated as correct, partly correct or 
incorrect/unknown according to standard definitions. The local ethics body indicated that 
approval was not necessary given anonymity of responses. 
 
Results 
36 questionnaires were distributed and 32 (89%) were returned from 12 paediatric 
consultants, 9 paediatric trainee doctors, 4 senior paediatric nurses and 7 pharmacists. 
Participants were asked to provide 5 definitions each, giving a total of 160 potentially correct 
answers. 64/160 (40%) were defined correctly, with 28/160 (17.5%) being partially correct 
and 68/160 (42.5%) incorrect or unknown. There were significant differences between the 
groups (Chi squared p<0.01). 
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    Correct                  Partially correct  Incorrect/unknown 
Paediatric consultants   33/60 (55%)   9/60 (15%)  18/60 (30%) 
Paediatric trainees     3/45 (7%)   7/45 (16%)  35/45 (77%) 
Paediatric nurses     5/20 (25%)   5/20 (25%)  10/20 (50%) 
Pharmacists   23/35 (66%)   7/35 (20%)    5/35 (14%) 
 
There were also significant differences in the ability to define the definitions (Chi squared 
p<0.01). 
 
                                                                     Correct    Partially correct  Incorrect/unknown 
Off- licence   17/32 (53%)     3/32 (9%)  12/32 (38%) 
Off- label    15/32 (47%)     1/32 (3%)  16/32 (50%) 
“Special”    13/32 (41%)     1/32 (3%)  18/32 (56%) 
NICE approved   13/32 (41%)   13/32 (41%)    6/32 (18%) 
Marketing authorisation    6/32 (18%)   10/32 (32%)  16/32 (50%) 
 
There was particularly poor understanding of the term “Special”. 50% consultants were able 
to define it adequately but no doctor in training was able to. The pharmacists had the best 
understanding of “Specials”.  
 
Discussion 
All levels of paediatric doctors (in particular, Juniors), appear to have a poor understanding 
about the legal status of medicines (off -label or off- licence drugs), hence may be ignorant 
of their prescribing responsibilities. Many would not be aware when prescribing a “special” 
and could also be unaware of the possible supply problems, variations in formulations’ 
pharmacokinetics, and their costs. Paediatric consultants fared slightly better, but have gaps 
in understanding which if addressed could lead to more effective and cost efficient 
prescribing. Further detailed studies are required to establish the effect of doctors’ lack of 
knowledge re paediatric prescribing on practice outcomes and the potential beneficial 
effects of utilising paediatric pharmacists’ knowledge in improving the prescribing process. 
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Appendix 12 Semi-structured interview prompt sheets for parents/guardians  
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Appendix 13 Research protocol flow chart 
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Appendix 15 Sample size calculations based on medicine adherence rates for 
children with long-term conditions 
A sample size calculation is carried out for the comparison of adherence rates between three 
pre-defined age groups. The adherence rate is denoted p1 for age group one, p2 for age 
group two and p3 for age group three.  An adherence rate 1 0.6p  means that 60% of the 
children in this age group comply with the prescription. 100 children are supposed to be 
followed up in each age group, giving a total sample size of n=300. The usual significance 
level of 0.05  is used throughout. 
In order to investigate whether the adherence rates differ between the three groups a 2 -
test is conducted. This statistical test is readily available in SPSS. It tests the hypothesis that 
the three adherence rates are all equal and if this hypothesis is rejected (i.e. the test gives a 
p value of less than 0.05), it can be concluded that the rates are not all the same. The test 
does not inform which groups are significantly different from each other. A multiple testing 
procedure for pair-wise comparisons would have to be used to investigate differences 
between pairs of age groups. This more complicated procedure is not discussed here. 
The following table shows the power to detect an overall difference for 10 combinations of 
adherence rates. Usually a power of 80% or 90% is desirable. The power for detecting a 
difference if one rate is 60% and the other two are 50% is only 29.1%. This means that it is 
very unlikely to be picked up. The power is 86.1% if one rate is 70% whilst the others are 
50%, i.e. the study is sufficiently powered to detect this difference. For a doubling of the 
adherence rate from 30% to 60% in one group the power would be almost 100%.  
 
 
  
345 
p1 p2 p3 Power 
0.5 0.5 0.5 5.0% 
0.5 0.5 0.6 29.1% 
0.5 0.5 0.7 86.1% 
0.5 0.5 0.9 100% 
0.5 0.6 0.6 2.5% 
0.7 0.7 0.9 97.0% 
0.5 0.45 0.55 22.5% 
0.5 0.4 0.6 72.1% 
0.5 0.3 0.7 99.9% 
0.3 0.3 0.6 99.6% 
 
Another way of examining the adequacy of the sample size is to consider the precision with 
which the adherence rate (for each group separately) can be estimated from the sample. 
Usually statistical analysis programs give confidence intervals (CI) for estimated parameters. 
A narrower interval is desirable. The following 95% CIs are calculated using a normal 
approximation which should be fairly good for the anticipated sample size.  
Assuming that the adherence rate is 50% the confidence limits would be approximately
1
ˆ 0.098p  . So if the estimate were 50%, the confidence limits would be roughly 40% and 
60% adherence. Similarly, if the adherence rate were 80% for one group, the confidence 
limits would be approximately 72% and 88%. 
If on the other hand a CI with a width of 10% is requested, for example ranging from 45% to 
55%, a sample size of 385 children per age group would be necessary. 
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Appendix 16 Parent/guardian invite letter and information sheet 
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Appendix 17 16-18 year olds consent form, parent/guardian consent form 
and young persons assent form 
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Appendix 18 Data recording template sheet for parent/guardian 
 
355 
 
356 
 
 
 
357 
 
 
358 
 
 
 
 
359 
 
360 
 
361 
Appendix 19 List of drug therapeutic groups featuring in BNFC chapters  
BNFC Chapter number Classification of medicines to BNFC Chapters 
1 Gastro-intestinal system 
2 Cardiovascular system 
3 Respiratory system 
4 Central nervous system 
5 Infections 
6 Endocrine system 
7 Obstetrics, gynaecology, and urinary-tract disorders 
8 Malignant disease and immunosuppression 
9 Nutrition and blood 
10 Musculoskeletal and joint diseases 
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Appendix 20 Results of univariable analysis  
  
Medicines 
refusal 
(p value) 
Medicines 
refusal in 
previous 6 
months 
(p value) 
Forgetting 
to 
administer 
medicines 
(p value) 
Forgetting 
to 
administer 
medicines in 
previous 6 
months 
(p value) 
Medicines 
manipulation 
(p value) 
Age band of patient at 
time of interview 0.003 0.016 <0.001 0.003 0.003 
Type of patient 0.223 0.724 0.061 0.053 0.618 
Gender 0.757 0.898 0.925 0.961 0.606 
Health-related need of 
guardian  0.291 0.901 0.879 0.557 0.294 
English first language 0.691 NC 0.699 0.721 0.017 
Additional educational 
needs of child 0.105 NC 0.847 0.036 0.934 
Attendance at mainstream 
school 0.888 0.874 0.961 0.329 0.242 
Ethnicity 0.373 0.496 0.557 0.917 0.478 
Age band at diagnosis 0.652 0.027 0.129 0.060 0.626 
No of current prescribed 
oral medicines 0.139 0.842 <0.001 0.009 0.368 
Multiple health conditions 0.811 0.811 0.545 0.783 0.478 
Other health-related need 
of patient 0.180 0.489 0.106 0.045 0.497 
Patient had PEG/NG tube 
fitted 0.833 NC  0.088 0.314 0.760 
Who is responsible for 
administering medicines 0.979 0.411 0.002 0.002 0.025 
IMD 2010 score 0.026 0.229 0.385 0.538 0.806 
Formulation, type of 
medicine 0.036 0.328 0.238 0.522 <0.001 
BNFC Chapter (missing 
chap 7) 0.101 NC 0.132 0.048 <0.001 
Specials medicine 0.680 0.488 0.946 0.661 0.809 
Size or aversion 
to/difficulty swallowing 0.326 0.946 0.202 0.101 0.048 
Taste <0.001 0.023 0.574 0.334 0.293 
Texture <0.001 0.012 0.887 0.882 <0.001 
Volume or quantity <0.001 0.014 0.949 0.466 0.004 
Colour/appearance 0.455 NC  0.621 0.244  NC 
Smell 0.049 0.287 0.846 0.299 0.582 
Other formulation and 
administration problems 0.142 0.203 0.889 0.198 <0.001 
Frequency of dosing 0.165 0.556 0.149 0.191 0.037 
NC= Not calculable as there were insufficient numbers of positive and negative outcomes to calculate an odds 
ratio.  
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Appendix 21 Quotations of parents, carers and young people participating in 
semi-structured interviews  
Taste: 
‘Tinney’ ‘like a rusty nail’ ‘bitter’ ‘sour’ ‘acid taste’ ‘salty’ ‘like beer’ ‘like leaves’ ‘burnt throat’ 
‘horrible’ ‘foul’ ‘yacky’ ‘yucky’ ‘horrid’ ‘disgusting.’ 
Texture: 
‘Foams up’ ‘gloopy’ ‘chalky’ ‘clumps’ ‘too thick’ ‘all bits makes her gag’ ‘like grit’ ‘thick 
gelatinous texture’ ‘oily’ ‘powdery’ ‘gooey paste’ ‘fizzy’ ‘weird texture’ ‘crystallises, bitty 
texture.’ 
Quantity/volume: 
‘Large volume’ ‘too many tablets’ ‘quantity’ ‘taste is worse when more sachets’ ‘large 
volume - issue if doesn’t finish milk’ ‘volume when on 13 soluble tablets’ ‘large quantity 
when lower strength capsules taken’ ‘if higher volume vomits.’ 
Size or aversion to/difficulty swallowing: 
‘huge tablet’ ‘swallowing’ ‘too large’ ‘too big’ ‘size too big’ ‘big, got stuck in throat’ ‘hard to 
swallow’ ‘difficult to swallow’ ‘doesn’t like to swallow it.’ 
Colour: 
‘Off-putting as bright red’ ‘colour red is alarming’ ‘bright orange, alarming colour and stains’ 
‘yellow turns green if put in liquid’  ‘doesn’t like yellow coloured liquid.’ 
Smell: 
‘Sickly smell’ ‘strong aniseed smell’ ‘smells bad’ ‘smells horrible’ ‘smells of acid.’ 
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Appendix 22 Recoded variable factors for multivariable analysis models 
  
Medicines manipulation: 
 
Forgetting to administer medicines in the six months prior to interview: 
 
Variable Categories 
BNFC Chapter 7 and 10 (smallest numbers of medicines in these 
chapters) and also formulations not featuring in 
any of the BNFC chapters were grouped into a 
chapter labelled ‘other’. 
Additional educational help The N/A response for the question was included in 
this analysis in order to decrease the number of 
cases omitted from the model. The results were 
not greatly affected with the inclusion of the N/A 
category. 
 
 
 
 
 
  
Variable Categories 
BNFC Chapter 7 and 10 (smallest numbers of medicines in these 
chapters) and also formulations not featuring in 
any of the BNFC chapters were grouped into a 
chapter labelled ‘other’. 
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Appendix 23 Direct patient benefit of interviews 
Counselling points were provided to parents and young people with regard to helping 
remembering medicines, these included: using alarms, calendars, diaries, daily medication 
organisers for those who reported struggling with multiple medicines and a drug chart for 
one particular patient with a complex medication regime.  
Additional counselling points were provided to parents, carers and young people to optimise 
patient care (clinical benefit and/or safety). Advice that was provided to participants 
included: avoiding administering milk at the same time as levothyroxine tablets (due to 
pharmacokinetic effects reducing levothyroxine absorption), omitting ibuprofen doses on 
the day that methotrexate is administered if child is experiencing nausea (to minimise risk of 
increasing the levels of methotrexate, thus to avoid drug toxicity) and avoiding hot drinks (to 
avoid altering drug pharmacokinetics). RV also advised patients to discuss alternative 
formulations commercially available in BNF for Children (2011-2012) where difficulties with 
specific medicine formulations arose. One example of this was the recommendation of 
mycophenolate mofetil 250mg capsules to a parent struggling to halve 500mg tablets 
accurately.  
One parent was encountering difficulties when administering omeprazole Losec Mups to an 
infant. RV used guidance from BNF for Children (2011-2012) and advised the parent to mix 
the dosage form in a small amount of yoghurt and administer immediately. However, it 
should be noted that no reference to scientific evidence was provided in BNFC to support 
this administration technique (BNF for Children 2011-2012). 
Signposting participants to medical professionals and alternative sources was also necessary 
in some circumstances. An example of a parent signposted by RV was a child prescribed 
sertraline, and administered regular ibuprofen over the counter by her parent. When an 
NSAID is administered to a patient taking an SSRI there is an increased risk of a stomach 
ulcer developing (BNF for Children, 2011-2012), and therefore in circumstances where an 
NSAID is required, this should ideally be prescribed and monitored by the medical 
practitioner responsible for the child’s care. A parent concerned with side effects unreported 
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in the BNFC was directed to speak to the responsible consultant and report the adverse 
events via the yellow card scheme. 
A parent on a paediatric ward approached RV and queried mixing Carobel thickener and 
other Cow and Gate products with antiepileptics. She had been advised by consultants to 
mix Carobel with vigabatrin liquid against the recommendations of a pharmacist. RV advised 
the mother to contact Cow and Gate, who said that this had not been studied and that 
before laboratory investigation could be carried out, instruction of the prescriber was 
required. The mother in question was concerned about risk of drug-thickener binding, 
resulting in an altered antiepileptic dose being absorbed. RV referred the mother to the 
consultant responsible for her daughter’s care. 
 
 
